id	sid	tid	token	lemma	pos
fnp-4675	1	1	multiple	multiple	ADJ
fnp-4675	1	2	sclerosis	sclerosis	NOUN
fnp-4675	1	3	:	:	PUNCT
fnp-4675	1	4	2023	2023	NUM
fnp-4675	1	5	update	update	NOUN
fnp-4675	1	6	feel	feel	VERB
fnp-4675	1	7	free	free	ADJ
fnp-4675	1	8	to	to	PART
fnp-4675	1	9	add	add	VERB
fnp-4675	1	10	comments	comment	NOUN
fnp-4675	1	11	by	by	ADP
fnp-4675	1	12	clicking	click	VERB
fnp-4675	1	13	these	these	DET
fnp-4675	1	14	icons	icon	NOUN
fnp-4675	1	15	on	on	ADP
fnp-4675	1	16	the	the	DET
fnp-4675	1	17	sidebar	sidebar	NOUN
fnp-4675	1	18	free	free	ADJ
fnp-4675	1	19	neuropathology	neuropathology	NOUN
fnp-4675	1	20	4:3	4:3	NUM
fnp-4675	1	21	(	(	PUNCT
fnp-4675	1	22	2023	2023	NUM
fnp-4675	1	23	)	)	PUNCT
fnp-4675	1	24	review	review	VERB
fnp-4675	1	25	multiple	multiple	ADJ
fnp-4675	1	26	sclerosis	sclerosis	NOUN
fnp-4675	1	27	:	:	PUNCT
fnp-4675	1	28	2023	2023	NUM
fnp-4675	1	29	update	update	NOUN
fnp-4675	1	30	tanja	tanja	NOUN
fnp-4675	1	31	kuhlmann1,2	kuhlmann1,2	PROPN
fnp-4675	1	32	,	,	PUNCT
fnp-4675	1	33	jack	jack	PROPN
fnp-4675	1	34	antel2	antel2	PROPN
fnp-4675	1	35	1	1	NUM
fnp-4675	1	36	institute	institute	NOUN
fnp-4675	1	37	of	of	ADP
fnp-4675	1	38	neuropathology	neuropathology	NOUN
fnp-4675	1	39	,	,	PUNCT
fnp-4675	1	40	university	university	NOUN
fnp-4675	1	41	hospital	hospital	NOUN
fnp-4675	1	42	münster	münster	NOUN
fnp-4675	1	43	,	,	PUNCT
fnp-4675	1	44	48149	48149	NUM
fnp-4675	1	45	münster	münster	NOUN
fnp-4675	1	46	,	,	PUNCT
fnp-4675	1	47	germany	germany	PROPN
fnp-4675	1	48	2	2	NUM
fnp-4675	1	49	neuroimmunology	neuroimmunology	NOUN
fnp-4675	1	50	unit	unit	NOUN
fnp-4675	1	51	,	,	PUNCT
fnp-4675	1	52	montreal	montreal	PROPN
fnp-4675	1	53	neurological	neurological	PROPN
fnp-4675	1	54	institute	institute	PROPN
fnp-4675	1	55	,	,	PUNCT
fnp-4675	1	56	mcgill	mcgill	PROPN
fnp-4675	1	57	university	university	PROPN
fnp-4675	1	58	,	,	PUNCT
fnp-4675	1	59	3801	3801	NUM
fnp-4675	1	60	québec	québec	PROPN
fnp-4675	1	61	,	,	PUNCT
fnp-4675	1	62	canada	canada	PROPN
fnp-4675	1	63	corresponding	corresponding	PROPN
fnp-4675	1	64	author	author	NOUN
fnp-4675	1	65	:	:	PUNCT
fnp-4675	1	66	tanja	tanja	PROPN
fnp-4675	1	67	kuhlmann	kuhlmann	PROPN
fnp-4675	1	68	·	·	PUNCT
fnp-4675	1	69	institute	institute	PROPN
fnp-4675	1	70	of	of	ADP
fnp-4675	1	71	neuropathology	neuropathology	PROPN
fnp-4675	1	72	·	·	PUNCT
fnp-4675	1	73	university	university	NOUN
fnp-4675	1	74	hospital	hospital	NOUN
fnp-4675	1	75	münster	münster	NOUN
fnp-4675	1	76	·	·	PUNCT
fnp-4675	1	77	pottkamp	pottkamp	VERB
fnp-4675	1	78	2	2	NUM
fnp-4675	1	79	·	·	SYM
fnp-4675	1	80	48149	48149	NUM
fnp-4675	1	81	münster	münster	NOUN
fnp-4675	1	82	·	·	PUNCT
fnp-4675	1	83	germany	germany	PROPN
fnp-4675	1	84	tanja.kuhlmann@ukmuenster.de	tanja.kuhlmann@ukmuenster.de	PROPN
fnp-4675	1	85	submitted	submit	VERB
fnp-4675	1	86	:	:	PUNCT
fnp-4675	1	87	02	02	NUM
fnp-4675	1	88	february	february	NOUN
fnp-4675	1	89	2023	2023	NUM
fnp-4675	1	90	accepted	accept	VERB
fnp-4675	1	91	:	:	PUNCT
fnp-4675	1	92	01	01	NUM
fnp-4675	1	93	march	march	PROPN
fnp-4675	1	94	2023	2023	NUM
fnp-4675	1	95	copyedited	copyedit	VERB
fnp-4675	1	96	by	by	ADP
fnp-4675	1	97	:	:	PUNCT
fnp-4675	1	98	monica	monica	PROPN
fnp-4675	1	99	miranda	miranda	PROPN
fnp-4675	1	100	published	publish	VERB
fnp-4675	1	101	:	:	PUNCT
fnp-4675	1	102	09	09	NUM
fnp-4675	1	103	march	march	NOUN
fnp-4675	1	104	2023	2023	NUM
fnp-4675	1	105	https://doi.org/10.17879/freeneuropathology-2023-4675	https://doi.org/10.17879/freeneuropathology-2023-4675	PROPN
fnp-4675	1	106	keywords	keyword	NOUN
fnp-4675	1	107	:	:	PUNCT
fnp-4675	1	108	multiple	multiple	ADJ
fnp-4675	1	109	sclerosis	sclerosis	NOUN
fnp-4675	1	110	,	,	PUNCT
fnp-4675	1	111	ebv	ebv	NOUN
fnp-4675	1	112	,	,	PUNCT
fnp-4675	1	113	remyelination	remyelination	NOUN
fnp-4675	1	114	,	,	PUNCT
fnp-4675	1	115	slowly	slowly	ADV
fnp-4675	1	116	expanding	expand	VERB
fnp-4675	1	117	lesions	lesion	NOUN
fnp-4675	1	118	,	,	PUNCT
fnp-4675	1	119	spatial	spatial	ADJ
fnp-4675	1	120	transcriptomics	transcriptomic	NOUN
fnp-4675	1	121	abstract	abstract	ADJ
fnp-4675	1	122	multiple	multiple	ADJ
fnp-4675	1	123	sclerosis	sclerosis	NOUN
fnp-4675	1	124	(	(	PUNCT
fnp-4675	1	125	ms	ms	NOUN
fnp-4675	1	126	)	)	PUNCT
fnp-4675	1	127	is	be	AUX
fnp-4675	1	128	the	the	DET
fnp-4675	1	129	most	most	ADV
fnp-4675	1	130	frequent	frequent	ADJ
fnp-4675	1	131	inflammatory	inflammatory	ADJ
fnp-4675	1	132	and	and	CCONJ
fnp-4675	1	133	demyelinating	demyelinate	VERB
fnp-4675	1	134	disease	disease	NOUN
fnp-4675	1	135	of	of	ADP
fnp-4675	1	136	the	the	DET
fnp-4675	1	137	central	central	ADJ
fnp-4675	1	138	nervous	nervous	ADJ
fnp-4675	1	139	system	system	NOUN
fnp-4675	1	140	(	(	PUNCT
fnp-4675	1	141	cns	cns	NOUN
fnp-4675	1	142	)	)	PUNCT
fnp-4675	1	143	.	.	PUNCT
fnp-4675	2	1	significant	significant	ADJ
fnp-4675	2	2	progress	progress	NOUN
fnp-4675	2	3	has	have	AUX
fnp-4675	2	4	been	be	AUX
fnp-4675	2	5	made	make	VERB
fnp-4675	2	6	during	during	ADP
fnp-4675	2	7	recent	recent	ADJ
fnp-4675	2	8	years	year	NOUN
fnp-4675	2	9	in	in	ADP
fnp-4675	2	10	preventing	prevent	VERB
fnp-4675	2	11	relapses	relapse	NOUN
fnp-4675	2	12	by	by	ADP
fnp-4675	2	13	using	use	VERB
fnp-4675	2	14	systemic	systemic	ADJ
fnp-4675	2	15	immunomodulatory	immunomodulatory	ADJ
fnp-4675	2	16	or	or	CCONJ
fnp-4675	2	17	immunosuppressive	immunosuppressive	ADJ
fnp-4675	2	18	therapies	therapy	NOUN
fnp-4675	2	19	.	.	PUNCT
fnp-4675	3	1	however	however	ADV
fnp-4675	3	2	,	,	PUNCT
fnp-4675	3	3	the	the	DET
fnp-4675	3	4	limited	limited	ADJ
fnp-4675	3	5	effectiveness	effectiveness	NOUN
fnp-4675	3	6	of	of	ADP
fnp-4675	3	7	such	such	ADJ
fnp-4675	3	8	therapies	therapy	NOUN
fnp-4675	3	9	for	for	ADP
fnp-4675	3	10	controlling	control	VERB
fnp-4675	3	11	the	the	DET
fnp-4675	3	12	progressive	progressive	ADJ
fnp-4675	3	13	disease	disease	NOUN
fnp-4675	3	14	course	course	NOUN
fnp-4675	3	15	indicates	indicate	VERB
fnp-4675	3	16	there	there	PRON
fnp-4675	3	17	is	be	VERB
fnp-4675	3	18	a	a	DET
fnp-4675	3	19	continuous	continuous	ADJ
fnp-4675	3	20	disease	disease	NOUN
fnp-4675	3	21	progression	progression	NOUN
fnp-4675	3	22	independent	independent	ADJ
fnp-4675	3	23	of	of	ADP
fnp-4675	3	24	relapse	relapse	NOUN
fnp-4675	3	25	activity	activity	NOUN
fnp-4675	3	26	which	which	PRON
fnp-4675	3	27	may	may	AUX
fnp-4675	3	28	start	start	VERB
fnp-4675	3	29	very	very	ADV
fnp-4675	3	30	early	early	ADV
fnp-4675	3	31	during	during	ADP
fnp-4675	3	32	the	the	DET
fnp-4675	3	33	disease	disease	NOUN
fnp-4675	3	34	course	course	NOUN
fnp-4675	3	35	.	.	PUNCT
fnp-4675	4	1	dissecting	dissect	VERB
fnp-4675	4	2	the	the	DET
fnp-4675	4	3	underlying	underlie	VERB
fnp-4675	4	4	mechanisms	mechanism	NOUN
fnp-4675	4	5	and	and	CCONJ
fnp-4675	4	6	developing	develop	VERB
fnp-4675	4	7	therapies	therapy	NOUN
fnp-4675	4	8	for	for	ADP
fnp-4675	4	9	preventing	prevent	VERB
fnp-4675	4	10	or	or	CCONJ
fnp-4675	4	11	stopping	stop	VERB
fnp-4675	4	12	this	this	DET
fnp-4675	4	13	disease	disease	NOUN
fnp-4675	4	14	progression	progression	NOUN
fnp-4675	4	15	represent	represent	VERB
fnp-4675	4	16	,	,	PUNCT
fnp-4675	4	17	currently	currently	ADV
fnp-4675	4	18	,	,	PUNCT
fnp-4675	4	19	the	the	DET
fnp-4675	4	20	biggest	big	ADJ
fnp-4675	4	21	challenges	challenge	NOUN
fnp-4675	4	22	in	in	ADP
fnp-4675	4	23	the	the	DET
fnp-4675	4	24	field	field	NOUN
fnp-4675	4	25	of	of	ADP
fnp-4675	4	26	ms	ms	PROPN
fnp-4675	4	27	.	.	PROPN
fnp-4675	4	28	here	here	ADV
fnp-4675	4	29	,	,	PUNCT
fnp-4675	4	30	we	we	PRON
fnp-4675	4	31	summarize	summarize	VERB
fnp-4675	4	32	publications	publication	NOUN
fnp-4675	4	33	of	of	ADP
fnp-4675	4	34	2022	2022	NUM
fnp-4675	4	35	which	which	PRON
fnp-4675	4	36	provide	provide	VERB
fnp-4675	4	37	insight	insight	NOUN
fnp-4675	4	38	into	into	ADP
fnp-4675	4	39	susceptibility	susceptibility	NOUN
fnp-4675	4	40	to	to	ADP
fnp-4675	4	41	ms	ms	PROPN
fnp-4675	4	42	,	,	PUNCT
fnp-4675	4	43	the	the	DET
fnp-4675	4	44	basis	basis	NOUN
fnp-4675	4	45	of	of	ADP
fnp-4675	4	46	disease	disease	NOUN
fnp-4675	4	47	progression	progression	NOUN
fnp-4675	4	48	and	and	CCONJ
fnp-4675	4	49	features	feature	NOUN
fnp-4675	4	50	of	of	ADP
fnp-4675	4	51	relatively	relatively	ADV
fnp-4675	4	52	recently	recently	ADV
fnp-4675	4	53	recognized	recognize	VERB
fnp-4675	4	54	distinct	distinct	ADJ
fnp-4675	4	55	forms	form	NOUN
fnp-4675	4	56	of	of	ADP
fnp-4675	4	57	inflammatory	inflammatory	ADJ
fnp-4675	4	58	/	/	SYM
fnp-4675	4	59	demyelinating	demyelinate	VERB
fnp-4675	4	60	disorders	disorder	NOUN
fnp-4675	4	61	of	of	ADP
fnp-4675	4	62	the	the	DET
fnp-4675	4	63	cns	cns	NOUN
fnp-4675	4	64	,	,	PUNCT
fnp-4675	4	65	such	such	ADJ
fnp-4675	4	66	as	as	ADP
fnp-4675	4	67	myelin	myelin	ADJ
fnp-4675	4	68	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	4	69	glycoprotein	glycoprotein	NOUN
fnp-4675	4	70	antibody	antibody	NOUN
fnp-4675	4	71	-	-	PUNCT
fnp-4675	4	72	associated	associate	VERB
fnp-4675	4	73	disease	disease	NOUN
fnp-4675	4	74	(	(	PUNCT
fnp-4675	4	75	mogad	mogad	PROPN
fnp-4675	4	76	)	)	PUNCT
fnp-4675	4	77	.	.	PUNCT
fnp-4675	5	1	introduction	introduction	NOUN
fnp-4675	5	2	multiple	multiple	ADJ
fnp-4675	5	3	sclerosis	sclerosis	NOUN
fnp-4675	5	4	(	(	PUNCT
fnp-4675	5	5	ms	ms	NOUN
fnp-4675	5	6	)	)	PUNCT
fnp-4675	5	7	is	be	AUX
fnp-4675	5	8	the	the	DET
fnp-4675	5	9	most	most	ADV
fnp-4675	5	10	frequent	frequent	ADJ
fnp-4675	5	11	inflammatory	inflammatory	ADJ
fnp-4675	5	12	demyelinating	demyelinate	VERB
fnp-4675	5	13	disease	disease	NOUN
fnp-4675	5	14	of	of	ADP
fnp-4675	5	15	the	the	DET
fnp-4675	5	16	central	central	ADJ
fnp-4675	5	17	nervous	nervous	ADJ
fnp-4675	5	18	system	system	NOUN
fnp-4675	5	19	(	(	PUNCT
fnp-4675	5	20	cns	cns	NOUN
fnp-4675	5	21	)	)	PUNCT
fnp-4675	5	22	and	and	CCONJ
fnp-4675	5	23	a	a	DET
fnp-4675	5	24	leading	lead	VERB
fnp-4675	5	25	cause	cause	NOUN
fnp-4675	5	26	for	for	ADP
fnp-4675	5	27	permanent	permanent	ADJ
fnp-4675	5	28	neurological	neurological	ADJ
fnp-4675	5	29	disability	disability	NOUN
fnp-4675	5	30	in	in	ADP
fnp-4675	5	31	young	young	ADJ
fnp-4675	5	32	adults	adult	NOUN
fnp-4675	5	33	.	.	PUNCT
fnp-4675	6	1	the	the	DET
fnp-4675	6	2	variability	variability	NOUN
fnp-4675	6	3	in	in	ADP
fnp-4675	6	4	disease	disease	NOUN
fnp-4675	6	5	course	course	NOUN
fnp-4675	6	6	amongst	amongst	ADP
fnp-4675	6	7	cases	case	NOUN
fnp-4675	6	8	is	be	AUX
fnp-4675	6	9	well	well	ADV
fnp-4675	6	10	known	know	VERB
fnp-4675	6	11	.	.	PUNCT
fnp-4675	7	1	significant	significant	ADJ
fnp-4675	7	2	progress	progress	NOUN
fnp-4675	7	3	has	have	AUX
fnp-4675	7	4	been	be	AUX
fnp-4675	7	5	made	make	VERB
fnp-4675	7	6	during	during	ADP
fnp-4675	7	7	recent	recent	ADJ
fnp-4675	7	8	years	year	NOUN
fnp-4675	7	9	in	in	ADP
fnp-4675	7	10	using	use	VERB
fnp-4675	7	11	systemic	systemic	ADJ
fnp-4675	7	12	immune	immune	NOUN
fnp-4675	7	13	-	-	PUNCT
fnp-4675	7	14	system	system	NOUN
fnp-4675	7	15	directed	direct	VERB
fnp-4675	7	16	therapies	therapy	NOUN
fnp-4675	7	17	to	to	PART
fnp-4675	7	18	prevent	prevent	VERB
fnp-4675	7	19	relapses	relapse	NOUN
fnp-4675	7	20	that	that	PRON
fnp-4675	7	21	characterize	characterize	VERB
fnp-4675	7	22	the	the	DET
fnp-4675	7	23	initial	initial	ADJ
fnp-4675	7	24	disease	disease	NOUN
fnp-4675	7	25	course	course	NOUN
fnp-4675	7	26	.	.	PUNCT
fnp-4675	8	1	however	however	ADV
fnp-4675	8	2	,	,	PUNCT
fnp-4675	8	3	the	the	DET
fnp-4675	8	4	limited	limited	ADJ
fnp-4675	8	5	effectiveness	effectiveness	NOUN
fnp-4675	8	6	of	of	ADP
fnp-4675	8	7	such	such	ADJ
fnp-4675	8	8	therapies	therapy	NOUN
fnp-4675	8	9	for	for	ADP
fnp-4675	8	10	the	the	DET
fnp-4675	8	11	later	later	ADV
fnp-4675	8	12	-	-	PUNCT
fnp-4675	8	13	recognized	recognize	VERB
fnp-4675	8	14	progressive	progressive	ADJ
fnp-4675	8	15	disease	disease	NOUN
fnp-4675	8	16	course	course	NOUN
fnp-4675	8	17	indicates	indicate	VERB
fnp-4675	8	18	there	there	PRON
fnp-4675	8	19	is	be	VERB
fnp-4675	8	20	a	a	DET
fnp-4675	8	21	continuous	continuous	ADJ
fnp-4675	8	22	disease	disease	NOUN
fnp-4675	8	23	progression	progression	NOUN
fnp-4675	8	24	independent	independent	ADJ
fnp-4675	8	25	of	of	ADP
fnp-4675	8	26	relapse	relapse	NOUN
fnp-4675	8	27	activity	activity	NOUN
fnp-4675	8	28	which	which	PRON
fnp-4675	8	29	may	may	AUX
fnp-4675	8	30	start	start	VERB
fnp-4675	8	31	very	very	ADV
fnp-4675	8	32	early	early	ADV
fnp-4675	8	33	during	during	ADP
fnp-4675	8	34	this	this	DET
fnp-4675	8	35	condition	condition	NOUN
fnp-4675	8	36	 	 	SPACE
fnp-4675	8	37	1,2	1,2	NUM
fnp-4675	8	38	.	.	PUNCT
fnp-4675	9	1	we	we	PRON
fnp-4675	9	2	select	select	VERB
fnp-4675	9	3	articles	article	NOUN
fnp-4675	9	4	published	publish	VERB
fnp-4675	9	5	in	in	ADP
fnp-4675	9	6	2022	2022	NUM
fnp-4675	9	7	that	that	PRON
fnp-4675	9	8	provide	provide	VERB
fnp-4675	9	9	insight	insight	NOUN
fnp-4675	9	10	into	into	ADP
fnp-4675	9	11	susceptibility	susceptibility	NOUN
fnp-4675	9	12	to	to	ADP
fnp-4675	9	13	ms	ms	PROPN
fnp-4675	9	14	,	,	PUNCT
fnp-4675	9	15	the	the	DET
fnp-4675	9	16	basis	basis	NOUN
fnp-4675	9	17	of	of	ADP
fnp-4675	9	18	disease	disease	NOUN
fnp-4675	9	19	progression	progression	NOUN
fnp-4675	9	20	,	,	PUNCT
fnp-4675	9	21	and	and	CCONJ
fnp-4675	9	22	features	feature	NOUN
fnp-4675	9	23	of	of	ADP
fnp-4675	9	24	relatively	relatively	ADV
fnp-4675	9	25	recently	recently	ADV
fnp-4675	9	26	recognized	recognize	VERB
fnp-4675	9	27	distinct	distinct	ADJ
fnp-4675	9	28	forms	form	NOUN
fnp-4675	9	29	of	of	ADP
fnp-4675	9	30	inflammatory	inflammatory	ADJ
fnp-4675	9	31	/	/	SYM
fnp-4675	9	32	demyelinating	demyelinate	VERB
fnp-4675	9	33	disorders	disorder	NOUN
fnp-4675	9	34	of	of	ADP
fnp-4675	9	35	the	the	DET
fnp-4675	9	36	cns	cns	NOUN
fnp-4675	9	37	(	(	PUNCT
fnp-4675	9	38	figure	figure	NOUN
fnp-4675	9	39	1	1	NUM
fnp-4675	9	40	)	)	PUNCT
fnp-4675	9	41	.	.	PUNCT
fnp-4675	10	1	ms	ms	PROPN
fnp-4675	10	2	has	have	VERB
fnp-4675	10	3	a	a	DET
fnp-4675	10	4	strong	strong	ADJ
fnp-4675	10	5	hereditary	hereditary	ADJ
fnp-4675	10	6	component	component	NOUN
fnp-4675	10	7	,	,	PUNCT
fnp-4675	10	8	but	but	CCONJ
fnp-4675	10	9	also	also	ADV
fnp-4675	10	10	environmental	environmental	ADJ
fnp-4675	10	11	factors	factor	NOUN
fnp-4675	10	12	play	play	VERB
fnp-4675	10	13	an	an	DET
fnp-4675	10	14	important	important	ADJ
fnp-4675	10	15	role	role	NOUN
fnp-4675	10	16	,	,	PUNCT
fnp-4675	10	17	as	as	SCONJ
fnp-4675	10	18	shown	show	VERB
fnp-4675	10	19	in	in	ADP
fnp-4675	10	20	studies	study	NOUN
fnp-4675	10	21	of	of	ADP
fnp-4675	10	22	monozygotic	monozygotic	ADJ
fnp-4675	10	23	twins	twin	NOUN
fnp-4675	10	24	discordant	discordant	ADJ
fnp-4675	10	25	for	for	ADP
fnp-4675	10	26	the	the	DET
fnp-4675	10	27	disease	disease	NOUN
fnp-4675	10	28	.	.	PUNCT
fnp-4675	11	1	several	several	ADJ
fnp-4675	11	2	articles	article	NOUN
fnp-4675	11	3	published	publish	VERB
fnp-4675	11	4	in	in	ADP
fnp-4675	11	5	2022	2022	NUM
fnp-4675	11	6	support	support	NOUN
fnp-4675	11	7	that	that	PRON
fnp-4675	11	8	epstein	epstein	PROPN
fnp-4675	11	9	-	-	PUNCT
fnp-4675	11	10	barr	barr	PROPN
fnp-4675	11	11	virus	virus	PROPN
fnp-4675	11	12	(	(	PUNCT
fnp-4675	11	13	ebv	ebv	NOUN
fnp-4675	11	14	)	)	PUNCT
fnp-4675	11	15	,	,	PUNCT
fnp-4675	11	16	which	which	PRON
fnp-4675	11	17	has	have	AUX
fnp-4675	11	18	long	long	ADV
fnp-4675	11	19	been	be	AUX
fnp-4675	11	20	implicated	implicate	VERB
fnp-4675	11	21	in	in	ADP
fnp-4675	11	22	ms	ms	PROPN
fnp-4675	11	23	,	,	PUNCT
fnp-4675	11	24	plays	play	VERB
fnp-4675	11	25	an	an	DET
fnp-4675	11	26	important	important	ADJ
fnp-4675	11	27	role	role	NOUN
fnp-4675	11	28	in	in	ADP
fnp-4675	11	29	the	the	DET
fnp-4675	11	30	development	development	NOUN
fnp-4675	11	31	of	of	ADP
fnp-4675	11	32	ms	ms	PROPN
fnp-4675	11	33	.	.	PROPN
fnp-4675	12	1	this	this	PRON
fnp-4675	12	2	raises	raise	VERB
fnp-4675	12	3	the	the	DET
fnp-4675	12	4	tantalizing	tantalizing	ADJ
fnp-4675	12	5	possibility	possibility	NOUN
fnp-4675	12	6	that	that	SCONJ
fnp-4675	12	7	vaccination	vaccination	NOUN
fnp-4675	12	8	against	against	ADP
fnp-4675	12	9	ebv	ebv	NOUN
fnp-4675	12	10	may	may	AUX
fnp-4675	12	11	eliminate	eliminate	VERB
fnp-4675	12	12	ms	ms	PROPN
fnp-4675	12	13	.	.	PROPN
fnp-4675	12	14	another	another	DET
fnp-4675	12	15	topic	topic	NOUN
fnp-4675	12	16	,	,	PUNCT
fnp-4675	12	17	which	which	PRON
fnp-4675	12	18	continues	continue	VERB
fnp-4675	12	19	to	to	PART
fnp-4675	12	20	be	be	AUX
fnp-4675	12	21	heavily	heavily	ADV
fnp-4675	12	22	discussed	discuss	VERB
fnp-4675	12	23	in	in	ADP
fnp-4675	12	24	the	the	DET
fnp-4675	12	25	ms	ms	PROPN
fnp-4675	12	26	field	field	NOUN
fnp-4675	12	27	,	,	PUNCT
fnp-4675	12	28	is	be	AUX
fnp-4675	12	29	the	the	DET
fnp-4675	12	30	impact	impact	NOUN
fnp-4675	12	31	of	of	ADP
fnp-4675	12	32	the	the	DET
fnp-4675	12	33	microbiome	microbiome	NOUN
fnp-4675	12	34	,	,	PUNCT
fnp-4675	12	35	not	not	PART
fnp-4675	12	36	only	only	ADV
fnp-4675	12	37	in	in	ADP
fnp-4675	12	38	the	the	DET
fnp-4675	12	39	gut	gut	NOUN
fnp-4675	12	40	but	but	CCONJ
fnp-4675	12	41	also	also	ADV
fnp-4675	12	42	in	in	ADP
fnp-4675	12	43	the	the	DET
fnp-4675	12	44	lung	lung	NOUN
fnp-4675	12	45	,	,	PUNCT
fnp-4675	12	46	on	on	ADP
fnp-4675	12	47	ms	ms	PROPN
fnp-4675	12	48	disease	disease	NOUN
fnp-4675	12	49	course	course	NOUN
fnp-4675	12	50	.	.	PUNCT
fnp-4675	13	1	potential	potential	ADJ
fnp-4675	13	2	mechanisms	mechanism	NOUN
fnp-4675	13	3	driving	drive	VERB
fnp-4675	13	4	disease	disease	NOUN
fnp-4675	13	5	progression	progression	NOUN
fnp-4675	13	6	include	include	VERB
fnp-4675	13	7	persistent	persistent	ADJ
fnp-4675	13	8	focal	focal	ADJ
fnp-4675	13	9	inflammation	inflammation	NOUN
fnp-4675	13	10	resulting	result	VERB
fnp-4675	13	11	in	in	ADP
fnp-4675	13	12	slowly	slowly	ADV
fnp-4675	13	13	expanding	expand	VERB
fnp-4675	13	14	lesions	lesion	NOUN
fnp-4675	13	15	,	,	PUNCT
fnp-4675	13	16	meningeal	meningeal	ADJ
fnp-4675	13	17	inflammation	inflammation	NOUN
fnp-4675	13	18	causing	cause	VERB
fnp-4675	13	19	cortical	cortical	ADJ
fnp-4675	13	20	demyelination	demyelination	NOUN
fnp-4675	13	21	and	and	CCONJ
fnp-4675	13	22	neuronal	neuronal	ADJ
fnp-4675	13	23	injury	injury	NOUN
fnp-4675	13	24	,	,	PUNCT
fnp-4675	13	25	and	and	CCONJ
fnp-4675	13	26	inflammation	inflammation	NOUN
fnp-4675	13	27	induced	induce	VERB
fnp-4675	13	28	diffuse	diffuse	NOUN
fnp-4675	13	29	changes	change	NOUN
fnp-4675	13	30	in	in	ADP
fnp-4675	13	31	white	white	ADJ
fnp-4675	13	32	matter	matter	NOUN
fnp-4675	13	33	(	(	PUNCT
fnp-4675	13	34	wm	wm	PROPN
fnp-4675	13	35	)	)	PUNCT
fnp-4675	13	36	as	as	ADV
fnp-4675	13	37	well	well	ADV
fnp-4675	13	38	as	as	ADP
fnp-4675	13	39	loss	loss	NOUN
fnp-4675	13	40	of	of	ADP
fnp-4675	13	41	compensatory	compensatory	ADJ
fnp-4675	13	42	mechanism	mechanism	NOUN
fnp-4675	13	43	,	,	PUNCT
fnp-4675	13	44	such	such	ADJ
fnp-4675	13	45	as	as	ADP
fnp-4675	13	46	remyelination	remyelination	NOUN
fnp-4675	13	47	and	and	CCONJ
fnp-4675	13	48	brain	brain	NOUN
fnp-4675	13	49	plasticity	plasticity	NOUN
fnp-4675	13	50	 	 	SPACE
fnp-4675	13	51	3	3	NUM
fnp-4675	13	52	.	.	PUNCT
fnp-4675	14	1	we	we	PRON
fnp-4675	14	2	summarize	summarize	VERB
fnp-4675	14	3	several	several	ADJ
fnp-4675	14	4	pathological	pathological	ADJ
fnp-4675	14	5	and	and	CCONJ
fnp-4675	14	6	imaging	imaging	NOUN
fnp-4675	14	7	studies	study	NOUN
fnp-4675	14	8	,	,	PUNCT
fnp-4675	14	9	which	which	PRON
fnp-4675	14	10	aim	aim	VERB
fnp-4675	14	11	to	to	PART
fnp-4675	14	12	dissect	dissect	VERB
fnp-4675	14	13	the	the	DET
fnp-4675	14	14	underlying	underlie	VERB
fnp-4675	14	15	mechanisms	mechanism	NOUN
fnp-4675	14	16	driving	drive	VERB
fnp-4675	14	17	disease	disease	NOUN
fnp-4675	14	18	progression	progression	NOUN
fnp-4675	14	19	.	.	PUNCT
fnp-4675	15	1	however	however	ADV
fnp-4675	15	2	,	,	PUNCT
fnp-4675	15	3	these	these	DET
fnp-4675	15	4	mechanisms	mechanism	NOUN
fnp-4675	15	5	most	most	ADV
fnp-4675	15	6	likely	likely	ADV
fnp-4675	15	7	vary	vary	VERB
fnp-4675	15	8	over	over	ADP
fnp-4675	15	9	time	time	NOUN
fnp-4675	15	10	,	,	PUNCT
fnp-4675	15	11	adding	add	VERB
fnp-4675	15	12	another	another	DET
fnp-4675	15	13	layer	layer	NOUN
fnp-4675	15	14	of	of	ADP
fnp-4675	15	15	complexity	complexity	NOUN
fnp-4675	15	16	for	for	ADP
fnp-4675	15	17	the	the	DET
fnp-4675	15	18	successful	successful	ADJ
fnp-4675	15	19	development	development	NOUN
fnp-4675	15	20	of	of	ADP
fnp-4675	15	21	new	new	ADJ
fnp-4675	15	22	treatment	treatment	NOUN
fnp-4675	15	23	strategies	strategy	NOUN
fnp-4675	15	24	to	to	PART
fnp-4675	15	25	prevent	prevent	VERB
fnp-4675	15	26	or	or	CCONJ
fnp-4675	15	27	stop	stop	VERB
fnp-4675	15	28	disease	disease	NOUN
fnp-4675	15	29	progression	progression	NOUN
fnp-4675	15	30	.	.	PUNCT
fnp-4675	16	1	furthermore	furthermore	ADV
fnp-4675	16	2	,	,	PUNCT
fnp-4675	16	3	individual	individual	ADJ
fnp-4675	16	4	patient	patient	ADJ
fnp-4675	16	5	specific	specific	ADJ
fnp-4675	16	6	factors	factor	NOUN
fnp-4675	16	7	may	may	AUX
fnp-4675	16	8	modulate	modulate	VERB
fnp-4675	16	9	ms	ms	ADJ
fnp-4675	16	10	pathology	pathology	NOUN
fnp-4675	16	11	significantly	significantly	ADV
fnp-4675	16	12	.	.	PUNCT
fnp-4675	17	1	this	this	PRON
fnp-4675	17	2	is	be	AUX
fnp-4675	17	3	supported	support	VERB
fnp-4675	17	4	by	by	ADP
fnp-4675	17	5	results	result	NOUN
fnp-4675	17	6	from	from	ADP
fnp-4675	17	7	a	a	DET
fnp-4675	17	8	single	single	ADJ
fnp-4675	17	9	nuclei	nucleus	NOUN
fnp-4675	17	10	rna	rna	NOUN
fnp-4675	17	11	sequencing	sequence	VERB
fnp-4675	17	12	(	(	PUNCT
fnp-4675	17	13	snrnaseq	snrnaseq	NOUN
fnp-4675	17	14	)	)	PUNCT
fnp-4675	17	15	study	study	NOUN
fnp-4675	17	16	of	of	ADP
fnp-4675	17	17	human	human	ADJ
fnp-4675	17	18	ms	ms	NOUN
fnp-4675	17	19	tissue	tissue	NOUN
fnp-4675	17	20	samples	sample	NOUN
fnp-4675	17	21	which	which	PRON
fnp-4675	17	22	reveals	reveal	VERB
fnp-4675	17	23	that	that	SCONJ
fnp-4675	17	24	the	the	DET
fnp-4675	17	25	variability	variability	NOUN
fnp-4675	17	26	in	in	ADP
fnp-4675	17	27	gene	gene	NOUN
fnp-4675	17	28	expression	expression	NOUN
fnp-4675	17	29	between	between	ADP
fnp-4675	17	30	patients	patient	NOUN
fnp-4675	17	31	is	be	AUX
fnp-4675	17	32	higher	high	ADJ
fnp-4675	17	33	than	than	ADP
fnp-4675	17	34	between	between	ADP
fnp-4675	17	35	lesions	lesion	NOUN
fnp-4675	17	36	 	 	SPACE
fnp-4675	17	37	4	4	NUM
fnp-4675	17	38	.	.	PUNCT
fnp-4675	17	39	based	base	VERB
fnp-4675	17	40	on	on	ADP
fnp-4675	17	41	findings	finding	NOUN
fnp-4675	17	42	from	from	ADP
fnp-4675	17	43	animal	animal	NOUN
fnp-4675	17	44	studies	study	NOUN
fnp-4675	17	45	,	,	PUNCT
fnp-4675	17	46	it	it	PRON
fnp-4675	17	47	is	be	AUX
fnp-4675	17	48	assumed	assume	VERB
fnp-4675	17	49	that	that	SCONJ
fnp-4675	17	50	promotion	promotion	NOUN
fnp-4675	17	51	of	of	ADP
fnp-4675	17	52	remyelination	remyelination	NOUN
fnp-4675	17	53	can	can	AUX
fnp-4675	17	54	prevent	prevent	VERB
fnp-4675	17	55	disease	disease	NOUN
fnp-4675	17	56	progression	progression	NOUN
fnp-4675	17	57	.	.	PUNCT
fnp-4675	18	1	however	however	ADV
fnp-4675	18	2	,	,	PUNCT
fnp-4675	18	3	the	the	DET
fnp-4675	18	4	evidence	evidence	NOUN
fnp-4675	18	5	that	that	PRON
fnp-4675	18	6	remyelination	remyelination	NOUN
fnp-4675	18	7	in	in	ADP
fnp-4675	18	8	ms	ms	PROPN
fnp-4675	18	9	is	be	AUX
fnp-4675	18	10	neuroprotective	neuroprotective	ADJ
fnp-4675	18	11	is	be	AUX
fnp-4675	18	12	relatively	relatively	ADV
fnp-4675	18	13	sparse	sparse	ADJ
fnp-4675	18	14	.	.	PUNCT
fnp-4675	19	1	in	in	ADP
fnp-4675	19	2	2022	2022	NUM
fnp-4675	19	3	,	,	PUNCT
fnp-4675	19	4	an	an	DET
fnp-4675	19	5	imaging	imaging	NOUN
fnp-4675	19	6	study	study	NOUN
fnp-4675	19	7	provides	provide	VERB
fnp-4675	19	8	first	first	ADJ
fnp-4675	19	9	evidence	evidence	NOUN
fnp-4675	19	10	that	that	SCONJ
fnp-4675	19	11	lack	lack	NOUN
fnp-4675	19	12	of	of	ADP
fnp-4675	19	13	remyelination	remyelination	NOUN
fnp-4675	19	14	in	in	ADP
fnp-4675	19	15	ms	ms	PROPN
fnp-4675	19	16	is	be	AUX
fnp-4675	19	17	associated	associate	VERB
fnp-4675	19	18	with	with	ADP
fnp-4675	19	19	increased	increase	VERB
fnp-4675	19	20	brain	brain	NOUN
fnp-4675	19	21	atrophy	atrophy	NOUN
fnp-4675	19	22	,	,	PUNCT
fnp-4675	19	23	a	a	DET
fnp-4675	19	24	maker	maker	NOUN
fnp-4675	19	25	of	of	ADP
fnp-4675	19	26	neurodegeneration	neurodegeneration	NOUN
fnp-4675	19	27	 	 	SPACE
fnp-4675	19	28	5	5	NUM
fnp-4675	19	29	.	.	PUNCT
fnp-4675	19	30	figure	figure	NOUN
fnp-4675	19	31	1	1	NUM
fnp-4675	19	32	:	:	PUNCT
fnp-4675	19	33	insights	insight	NOUN
fnp-4675	19	34	into	into	ADP
fnp-4675	19	35	disease	disease	NOUN
fnp-4675	19	36	course	course	NOUN
fnp-4675	19	37	of	of	ADP
fnp-4675	19	38	ms	ms	PROPN
fnp-4675	19	39	.	.	PROPN
fnp-4675	20	1	we	we	PRON
fnp-4675	20	2	selected	select	VERB
fnp-4675	20	3	articles	article	NOUN
fnp-4675	20	4	published	publish	VERB
fnp-4675	20	5	in	in	ADP
fnp-4675	20	6	2022	2022	NUM
fnp-4675	20	7	providing	provide	VERB
fnp-4675	20	8	insights	insight	NOUN
fnp-4675	20	9	into	into	ADP
fnp-4675	20	10	the	the	DET
fnp-4675	20	11	susceptibility	susceptibility	NOUN
fnp-4675	20	12	to	to	ADP
fnp-4675	20	13	ms	ms	PROPN
fnp-4675	20	14	,	,	PUNCT
fnp-4675	20	15	potential	potential	ADJ
fnp-4675	20	16	modulators	modulator	NOUN
fnp-4675	20	17	of	of	ADP
fnp-4675	20	18	the	the	DET
fnp-4675	20	19	disease	disease	NOUN
fnp-4675	20	20	course	course	NOUN
fnp-4675	20	21	and	and	CCONJ
fnp-4675	20	22	new	new	ADJ
fnp-4675	20	23	technologies	technology	NOUN
fnp-4675	20	24	to	to	PART
fnp-4675	20	25	monitor	monitor	VERB
fnp-4675	20	26	the	the	DET
fnp-4675	20	27	disease	disease	NOUN
fnp-4675	20	28	or	or	CCONJ
fnp-4675	20	29	to	to	PART
fnp-4675	20	30	dissect	dissect	VERB
fnp-4675	20	31	underlying	underlying	ADJ
fnp-4675	20	32	pathways	pathway	NOUN
fnp-4675	20	33	.	.	PUNCT
fnp-4675	21	1	finally	finally	ADV
fnp-4675	21	2	,	,	PUNCT
fnp-4675	21	3	we	we	PRON
fnp-4675	21	4	discuss	discuss	VERB
fnp-4675	21	5	the	the	DET
fnp-4675	21	6	most	most	ADV
fnp-4675	21	7	recent	recent	ADJ
fnp-4675	21	8	findings	finding	NOUN
fnp-4675	21	9	in	in	ADP
fnp-4675	21	10	myelin	myelin	ADJ
fnp-4675	21	11	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	21	12	glycoprotein	glycoprotein	NOUN
fnp-4675	21	13	antibody	antibody	NOUN
fnp-4675	21	14	-	-	PUNCT
fnp-4675	21	15	associated	associate	VERB
fnp-4675	21	16	disease	disease	NOUN
fnp-4675	21	17	(	(	PUNCT
fnp-4675	21	18	mogad	mogad	PROPN
fnp-4675	21	19	)	)	PUNCT
fnp-4675	21	20	,	,	PUNCT
fnp-4675	21	21	a	a	DET
fnp-4675	21	22	relatively	relatively	ADV
fnp-4675	21	23	recently	recently	ADV
fnp-4675	21	24	newly	newly	ADV
fnp-4675	21	25	defined	define	VERB
fnp-4675	21	26	inflammatory	inflammatory	ADJ
fnp-4675	21	27	and	and	CCONJ
fnp-4675	21	28	demyelinating	demyelinate	VERB
fnp-4675	21	29	disease	disease	NOUN
fnp-4675	21	30	recognized	recognize	VERB
fnp-4675	21	31	by	by	ADP
fnp-4675	21	32	the	the	DET
fnp-4675	21	33	presence	presence	NOUN
fnp-4675	21	34	of	of	ADP
fnp-4675	21	35	anti	anti	ADJ
fnp-4675	21	36	-	-	ADJ
fnp-4675	21	37	myelin	myelin	ADJ
fnp-4675	21	38	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	21	39	glycoprotein	glycoprotein	NOUN
fnp-4675	21	40	(	(	PUNCT
fnp-4675	21	41	mog	mog	NOUN
fnp-4675	21	42	)	)	PUNCT
fnp-4675	21	43	antibodies	antibodie	VERB
fnp-4675	21	44	in	in	ADP
fnp-4675	21	45	the	the	DET
fnp-4675	21	46	serum	serum	NOUN
fnp-4675	21	47	.	.	PUNCT
fnp-4675	22	1	(	(	PUNCT
fnp-4675	22	2	i	i	NOUN
fnp-4675	22	3	)	)	PUNCT
fnp-4675	22	4	ms	ms	NOUN
fnp-4675	22	5	susceptibility	susceptibility	NOUN
fnp-4675	22	6	and	and	CCONJ
fnp-4675	22	7	disease	disease	NOUN
fnp-4675	22	8	course	course	NOUN
fnp-4675	22	9	–	–	PUNCT
fnp-4675	22	10	population	population	NOUN
fnp-4675	22	11	based	base	VERB
fnp-4675	22	12	studies	study	NOUN
fnp-4675	22	13	role	role	NOUN
fnp-4675	22	14	of	of	ADP
fnp-4675	22	15	ebv	ebv	NOUN
fnp-4675	22	16	in	in	ADP
fnp-4675	22	17	susceptibility	susceptibility	NOUN
fnp-4675	22	18	to	to	ADP
fnp-4675	22	19	ms	ms	PROPN
fnp-4675	22	20	epidemiologic	epidemiologic	ADJ
fnp-4675	22	21	based	base	VERB
fnp-4675	22	22	studies	study	NOUN
fnp-4675	22	23	in	in	ADP
fnp-4675	22	24	2022	2022	NUM
fnp-4675	22	25	bolstered	bolster	VERB
fnp-4675	22	26	the	the	DET
fnp-4675	22	27	evidence	evidence	NOUN
fnp-4675	22	28	for	for	ADP
fnp-4675	22	29	ebv	ebv	NOUN
fnp-4675	22	30	infection	infection	NOUN
fnp-4675	22	31	being	be	AUX
fnp-4675	22	32	a	a	DET
fnp-4675	22	33	necessary	necessary	ADJ
fnp-4675	22	34	albeit	albeit	SCONJ
fnp-4675	22	35	,	,	PUNCT
fnp-4675	22	36	not	not	PART
fnp-4675	22	37	sufficient	sufficient	ADJ
fnp-4675	22	38	trigger	trigger	NOUN
fnp-4675	22	39	,	,	PUNCT
fnp-4675	22	40	for	for	ADP
fnp-4675	22	41	development	development	NOUN
fnp-4675	22	42	of	of	ADP
fnp-4675	22	43	ms	ms	PROPN
fnp-4675	22	44	.	.	PROPN
fnp-4675	22	45	bjornevik	bjornevik	PROPN
fnp-4675	22	46	et	et	PROPN
fnp-4675	22	47	al	al	PROPN
fnp-4675	22	48	.	.	PROPN
fnp-4675	22	49	examined	examine	VERB
fnp-4675	22	50	the	the	DET
fnp-4675	22	51	records	record	NOUN
fnp-4675	22	52	of	of	ADP
fnp-4675	22	53	a	a	DET
fnp-4675	22	54	cohort	cohort	NOUN
fnp-4675	22	55	of	of	ADP
fnp-4675	22	56	more	more	ADJ
fnp-4675	22	57	than	than	ADP
fnp-4675	22	58	10	10	NUM
fnp-4675	22	59	million	million	NUM
fnp-4675	22	60	active	active	ADJ
fnp-4675	22	61	us	us	PROPN
fnp-4675	22	62	military	military	ADJ
fnp-4675	22	63	personnel	personnel	NOUN
fnp-4675	22	64	in	in	ADP
fnp-4675	22	65	which	which	PRON
fnp-4675	22	66	801	801	NUM
fnp-4675	22	67	of	of	ADP
fnp-4675	22	68	955	955	NUM
fnp-4675	22	69	cases	case	NOUN
fnp-4675	22	70	that	that	PRON
fnp-4675	22	71	developed	develop	VERB
fnp-4675	22	72	ms	ms	NOUN
fnp-4675	22	73	could	could	AUX
fnp-4675	22	74	be	be	AUX
fnp-4675	22	75	evaluated	evaluate	VERB
fnp-4675	22	76	with	with	ADP
fnp-4675	22	77	regard	regard	NOUN
fnp-4675	22	78	to	to	ADP
fnp-4675	22	79	ebv	ebv	NOUN
fnp-4675	22	80	serology	serology	NOUN
fnp-4675	22	81	 	 	SPACE
fnp-4675	22	82	6	6	NUM
fnp-4675	22	83	.	.	PUNCT
fnp-4675	23	1	all	all	PRON
fnp-4675	23	2	but	but	SCONJ
fnp-4675	23	3	one	one	NUM
fnp-4675	23	4	were	be	AUX
fnp-4675	23	5	serologically	serologically	ADV
fnp-4675	23	6	positive	positive	ADJ
fnp-4675	23	7	at	at	ADP
fnp-4675	23	8	the	the	DET
fnp-4675	23	9	time	time	NOUN
fnp-4675	23	10	of	of	ADP
fnp-4675	23	11	diagnosis	diagnosis	NOUN
fnp-4675	23	12	.	.	PUNCT
fnp-4675	24	1	although	although	SCONJ
fnp-4675	24	2	35	35	NUM
fnp-4675	24	3	had	have	AUX
fnp-4675	24	4	initially	initially	ADV
fnp-4675	24	5	been	be	AUX
fnp-4675	24	6	serologically	serologically	ADV
fnp-4675	24	7	negative	negative	ADJ
fnp-4675	24	8	,	,	PUNCT
fnp-4675	24	9	34	34	NUM
fnp-4675	24	10	converted	convert	VERB
fnp-4675	24	11	prior	prior	ADV
fnp-4675	24	12	to	to	ADP
fnp-4675	24	13	diagnosis	diagnosis	NOUN
fnp-4675	24	14	.	.	PUNCT
fnp-4675	25	1	seroconversion	seroconversion	NOUN
fnp-4675	25	2	rate	rate	NOUN
fnp-4675	25	3	was	be	AUX
fnp-4675	25	4	57	57	NUM
fnp-4675	25	5	%	%	NOUN
fnp-4675	25	6	in	in	ADP
fnp-4675	25	7	the	the	DET
fnp-4675	25	8	non	non	ADJ
fnp-4675	25	9	-	-	ADJ
fnp-4675	25	10	ms	ms	ADJ
fnp-4675	25	11	cohort	cohort	NOUN
fnp-4675	25	12	.	.	PUNCT
fnp-4675	26	1	no	no	DET
fnp-4675	26	2	enhanced	enhanced	ADJ
fnp-4675	26	3	conversion	conversion	NOUN
fnp-4675	26	4	rate	rate	NOUN
fnp-4675	26	5	was	be	AUX
fnp-4675	26	6	found	find	VERB
fnp-4675	26	7	for	for	ADP
fnp-4675	26	8	other	other	ADJ
fnp-4675	26	9	viruses	virus	NOUN
fnp-4675	26	10	;	;	PUNCT
fnp-4675	26	11	cytomegalovirus	cytomegalovirus	NOUN
fnp-4675	26	12	(	(	PUNCT
fnp-4675	26	13	cmv	cmv	NOUN
fnp-4675	26	14	)	)	PUNCT
fnp-4675	26	15	conversion	conversion	NOUN
fnp-4675	26	16	may	may	AUX
fnp-4675	26	17	have	have	AUX
fnp-4675	26	18	been	be	AUX
fnp-4675	26	19	protective	protective	ADJ
fnp-4675	26	20	.	.	PUNCT
fnp-4675	27	1	in	in	ADP
fnp-4675	27	2	a	a	DET
fnp-4675	27	3	retrospective	retrospective	ADJ
fnp-4675	27	4	cohort	cohort	NOUN
fnp-4675	27	5	study	study	NOUN
fnp-4675	27	6	of	of	ADP
fnp-4675	27	7	2,576,011	2,576,011	NUM
fnp-4675	27	8	individuals	individual	NOUN
fnp-4675	27	9	born	bear	VERB
fnp-4675	27	10	in	in	ADP
fnp-4675	27	11	denmark	denmark	NOUN
fnp-4675	27	12	between	between	ADP
fnp-4675	27	13	1971	1971	NUM
fnp-4675	27	14	and	and	CCONJ
fnp-4675	27	15	2018	2018	NUM
fnp-4675	27	16	,	,	PUNCT
fnp-4675	27	17	rostgaard	rostgaard	NOUN
fnp-4675	27	18	et	et	PROPN
fnp-4675	27	19	al	al	PROPN
fnp-4675	27	20	.	.	PROPN
fnp-4675	27	21	found	find	VERB
fnp-4675	27	22	that	that	SCONJ
fnp-4675	27	23	having	have	VERB
fnp-4675	27	24	a	a	DET
fnp-4675	27	25	sibling	sible	VERB
fnp-4675	27	26	0–2	0–2	NUM
fnp-4675	27	27	years	year	NOUN
fnp-4675	27	28	younger	young	ADJ
fnp-4675	27	29	reduces	reduce	VERB
fnp-4675	27	30	the	the	DET
fnp-4675	27	31	probability	probability	NOUN
fnp-4675	27	32	of	of	ADP
fnp-4675	27	33	ms	ms	NOUN
fnp-4675	27	34	by	by	ADP
fnp-4675	27	35	25	25	NUM
fnp-4675	27	36	%	%	NOUN
fnp-4675	27	37	compared	compare	VERB
fnp-4675	27	38	to	to	ADP
fnp-4675	27	39	having	have	VERB
fnp-4675	27	40	no	no	DET
fnp-4675	27	41	siblings	sibling	NOUN
fnp-4675	27	42	.	.	PUNCT
fnp-4675	28	1	furthermore	furthermore	ADV
fnp-4675	28	2	,	,	PUNCT
fnp-4675	28	3	having	have	VERB
fnp-4675	28	4	a	a	DET
fnp-4675	28	5	second	second	ADJ
fnp-4675	28	6	sibling	sible	VERB
fnp-4675	28	7	6–8	6–8	NUM
fnp-4675	28	8	years	year	NOUN
fnp-4675	28	9	younger	young	ADJ
fnp-4675	28	10	reduces	reduce	VERB
fnp-4675	28	11	this	this	DET
fnp-4675	28	12	probability	probability	NOUN
fnp-4675	28	13	by	by	ADP
fnp-4675	28	14	30	30	NUM
fnp-4675	28	15	%	%	NOUN
fnp-4675	28	16	 	 	SPACE
fnp-4675	28	17	7	7	NUM
fnp-4675	28	18	.	.	PUNCT
fnp-4675	29	1	they	they	PRON
fnp-4675	29	2	concluded	conclude	VERB
fnp-4675	29	3	that	that	SCONJ
fnp-4675	29	4	having	have	VERB
fnp-4675	29	5	younger	young	ADJ
fnp-4675	29	6	siblings	sibling	NOUN
fnp-4675	29	7	reduces	reduce	VERB
fnp-4675	29	8	the	the	DET
fnp-4675	29	9	risk	risk	NOUN
fnp-4675	29	10	of	of	ADP
fnp-4675	29	11	infectious	infectious	ADJ
fnp-4675	29	12	mononucleosis	mononucleosis	NOUN
fnp-4675	29	13	and	and	CCONJ
fnp-4675	29	14	the	the	DET
fnp-4675	29	15	risk	risk	NOUN
fnp-4675	29	16	of	of	ADP
fnp-4675	29	17	ms	ms	NOUN
fnp-4675	29	18	in	in	ADP
fnp-4675	29	19	a	a	DET
fnp-4675	29	20	mirror	mirror	NOUN
fnp-4675	29	21	-	-	PUNCT
fnp-4675	29	22	like	like	ADJ
fnp-4675	29	23	manner	manner	NOUN
fnp-4675	29	24	,	,	PUNCT
fnp-4675	29	25	suggesting	suggest	VERB
fnp-4675	29	26	that	that	SCONJ
fnp-4675	29	27	the	the	DET
fnp-4675	29	28	reduction	reduction	NOUN
fnp-4675	29	29	in	in	ADP
fnp-4675	29	30	ms	ms	ADJ
fnp-4675	29	31	risk	risk	NOUN
fnp-4675	29	32	results	result	NOUN
fnp-4675	29	33	from	from	ADP
fnp-4675	29	34	earlier	early	ADJ
fnp-4675	29	35	primary	primary	ADJ
fnp-4675	29	36	ebv	ebv	NOUN
fnp-4675	29	37	infection	infection	NOUN
fnp-4675	29	38	.	.	PUNCT
fnp-4675	30	1	the	the	DET
fnp-4675	30	2	basis	basis	NOUN
fnp-4675	30	3	whereby	whereby	SCONJ
fnp-4675	30	4	ebv	ebv	NOUN
fnp-4675	30	5	infection	infection	NOUN
fnp-4675	30	6	links	link	NOUN
fnp-4675	30	7	to	to	PART
fnp-4675	30	8	disease	disease	NOUN
fnp-4675	30	9	susceptibility	susceptibility	NOUN
fnp-4675	30	10	and/or	and/or	CCONJ
fnp-4675	30	11	disease	disease	NOUN
fnp-4675	30	12	course	course	NOUN
fnp-4675	30	13	remains	remain	VERB
fnp-4675	30	14	under	under	ADP
fnp-4675	30	15	investigation	investigation	NOUN
fnp-4675	30	16	.	.	PUNCT
fnp-4675	31	1	ebv	ebv	NOUN
fnp-4675	31	2	is	be	AUX
fnp-4675	31	3	known	know	VERB
fnp-4675	31	4	to	to	PART
fnp-4675	31	5	infect	infect	VERB
fnp-4675	31	6	b	b	PROPN
fnp-4675	31	7	cells	cell	NOUN
fnp-4675	31	8	and	and	CCONJ
fnp-4675	31	9	these	these	DET
fnp-4675	31	10	cells	cell	NOUN
fnp-4675	31	11	have	have	AUX
fnp-4675	31	12	been	be	AUX
fnp-4675	31	13	detected	detect	VERB
fnp-4675	31	14	in	in	ADP
fnp-4675	31	15	ms	ms	ADJ
fnp-4675	31	16	lesions	lesion	NOUN
fnp-4675	31	17	in	in	ADP
fnp-4675	31	18	some	some	DET
fnp-4675	31	19	studies	study	NOUN
fnp-4675	31	20	,	,	PUNCT
fnp-4675	31	21	but	but	CCONJ
fnp-4675	31	22	still	still	ADV
fnp-4675	31	23	require	require	VERB
fnp-4675	31	24	unequivocal	unequivocal	ADJ
fnp-4675	31	25	confirmation	confirmation	NOUN
fnp-4675	31	26	.	.	PUNCT
fnp-4675	32	1	b	b	NOUN
fnp-4675	32	2	cells	cell	NOUN
fnp-4675	32	3	are	be	AUX
fnp-4675	32	4	implicated	implicate	VERB
fnp-4675	32	5	in	in	ADP
fnp-4675	32	6	producing	produce	VERB
fnp-4675	32	7	factors	factor	NOUN
fnp-4675	32	8	that	that	PRON
fnp-4675	32	9	contribute	contribute	VERB
fnp-4675	32	10	to	to	ADP
fnp-4675	32	11	underlying	underlie	VERB
fnp-4675	32	12	tissue	tissue	NOUN
fnp-4675	32	13	injury	injury	NOUN
fnp-4675	32	14	.	.	PUNCT
fnp-4675	33	1	support	support	NOUN
fnp-4675	33	2	for	for	ADP
fnp-4675	33	3	the	the	DET
fnp-4675	33	4	postulate	postulate	NOUN
fnp-4675	33	5	that	that	PRON
fnp-4675	33	6	ebv	ebv	VERB
fnp-4675	33	7	specific	specific	ADJ
fnp-4675	33	8	humoral	humoral	ADJ
fnp-4675	33	9	and/or	and/or	CCONJ
fnp-4675	33	10	cellular	cellular	ADJ
fnp-4675	33	11	immune	immune	ADJ
fnp-4675	33	12	mediators	mediator	NOUN
fnp-4675	33	13	contribute	contribute	VERB
fnp-4675	33	14	to	to	ADP
fnp-4675	33	15	the	the	DET
fnp-4675	33	16	disease	disease	NOUN
fnp-4675	33	17	pathology	pathology	NOUN
fnp-4675	33	18	is	be	AUX
fnp-4675	33	19	supported	support	VERB
fnp-4675	33	20	by	by	ADP
fnp-4675	33	21	the	the	DET
fnp-4675	33	22	findings	finding	NOUN
fnp-4675	33	23	by	by	ADP
fnp-4675	33	24	lanz	lanz	PROPN
fnp-4675	33	25	et	et	PROPN
fnp-4675	33	26	al	al	PROPN
fnp-4675	33	27	.	.	PROPN
fnp-4675	33	28	,	,	PUNCT
fnp-4675	33	29	regarding	regard	VERB
fnp-4675	33	30	cross	cross	NOUN
fnp-4675	33	31	-	-	NOUN
fnp-4675	33	32	reactivity	reactivity	NOUN
fnp-4675	33	33	between	between	ADP
fnp-4675	33	34	ebv	ebv	NOUN
fnp-4675	33	35	and	and	CCONJ
fnp-4675	33	36	neural	neural	ADJ
fnp-4675	33	37	tissue	tissue	NOUN
fnp-4675	33	38	components	component	NOUN
fnp-4675	33	39	 	 	SPACE
fnp-4675	33	40	8	8	NUM
fnp-4675	33	41	.	.	PUNCT
fnp-4675	34	1	they	they	PRON
fnp-4675	34	2	demonstrated	demonstrate	VERB
fnp-4675	34	3	high	high	ADJ
fnp-4675	34	4	affinity	affinity	NOUN
fnp-4675	34	5	molecular	molecular	ADJ
fnp-4675	34	6	mimicry	mimicry	NOUN
fnp-4675	34	7	between	between	ADP
fnp-4675	34	8	the	the	DET
fnp-4675	34	9	ebv	ebv	NOUN
fnp-4675	34	10	transcription	transcription	NOUN
fnp-4675	34	11	factor	factor	NOUN
fnp-4675	34	12	epstein	epstein	PROPN
fnp-4675	34	13	–	–	PUNCT
fnp-4675	34	14	barr	barr	PROPN
fnp-4675	34	15	nuclear	nuclear	ADJ
fnp-4675	34	16	antigen	antigen	PROPN
fnp-4675	34	17	1	1	NUM
fnp-4675	34	18	(	(	PUNCT
fnp-4675	34	19	ebna1	ebna1	X
fnp-4675	34	20	)	)	PUNCT
fnp-4675	34	21	and	and	CCONJ
fnp-4675	34	22	the	the	DET
fnp-4675	34	23	cns	cns	PROPN
fnp-4675	34	24	protein	protein	NOUN
fnp-4675	34	25	glialcam	glialcam	NOUN
fnp-4675	34	26	,	,	PUNCT
fnp-4675	34	27	as	as	ADV
fnp-4675	34	28	well	well	ADV
fnp-4675	34	29	as	as	ADP
fnp-4675	34	30	presence	presence	NOUN
fnp-4675	34	31	of	of	ADP
fnp-4675	34	32	cross	cross	PROPN
fnp-4675	34	33	reactive	reactive	ADJ
fnp-4675	34	34	antibodies	antibody	NOUN
fnp-4675	34	35	in	in	ADP
fnp-4675	34	36	the	the	DET
fnp-4675	34	37	cerebrospinal	cerebrospinal	ADJ
fnp-4675	34	38	fluid	fluid	NOUN
fnp-4675	34	39	(	(	PUNCT
fnp-4675	34	40	csf	csf	NOUN
fnp-4675	34	41	)	)	PUNCT
fnp-4675	34	42	of	of	ADP
fnp-4675	34	43	ms	ms	NOUN
fnp-4675	34	44	patients	patient	NOUN
fnp-4675	34	45	.	.	PUNCT
fnp-4675	35	1	interestingly	interestingly	ADV
fnp-4675	35	2	,	,	PUNCT
fnp-4675	35	3	these	these	DET
fnp-4675	35	4	cross	cross	ADJ
fnp-4675	35	5	-	-	ADJ
fnp-4675	35	6	reactive	reactive	ADJ
fnp-4675	35	7	antibodies	antibody	NOUN
fnp-4675	35	8	bound	bind	VERB
fnp-4675	35	9	to	to	PART
fnp-4675	35	10	rodent	rodent	VERB
fnp-4675	35	11	oligodendrocytes	oligodendrocyte	NOUN
fnp-4675	35	12	and	and	CCONJ
fnp-4675	35	13	astrocytes	astrocyte	NOUN
fnp-4675	35	14	,	,	PUNCT
fnp-4675	35	15	glia	glia	NOUN
fnp-4675	35	16	limitans	limitan	NOUN
fnp-4675	35	17	and	and	CCONJ
fnp-4675	35	18	,	,	PUNCT
fnp-4675	35	19	likely	likely	ADJ
fnp-4675	35	20	,	,	PUNCT
fnp-4675	35	21	perivascular	perivascular	ADJ
fnp-4675	35	22	glial	glial	ADJ
fnp-4675	35	23	cells	cell	NOUN
fnp-4675	35	24	in	in	ADP
fnp-4675	35	25	the	the	DET
fnp-4675	35	26	hippocampus	hippocampus	NOUN
fnp-4675	35	27	and	and	CCONJ
fnp-4675	35	28	brainstem	brainstem	NOUN
fnp-4675	35	29	,	,	PUNCT
fnp-4675	35	30	a	a	DET
fnp-4675	35	31	pattern	pattern	NOUN
fnp-4675	35	32	reminiscent	reminiscent	ADJ
fnp-4675	35	33	of	of	ADP
fnp-4675	35	34	the	the	DET
fnp-4675	35	35	expression	expression	NOUN
fnp-4675	35	36	pattern	pattern	NOUN
fnp-4675	35	37	of	of	ADP
fnp-4675	35	38	aquaporin-4	aquaporin-4	PROPN
fnp-4675	35	39	(	(	PUNCT
fnp-4675	35	40	aqp4	aqp4	PROPN
fnp-4675	35	41	)	)	PUNCT
fnp-4675	35	42	.	.	PUNCT
fnp-4675	36	1	anti	anti	ADJ
fnp-4675	36	2	-	-	ADJ
fnp-4675	36	3	aqp4	aqp4	ADJ
fnp-4675	36	4	antibodies	antibody	NOUN
fnp-4675	36	5	are	be	AUX
fnp-4675	36	6	the	the	DET
fnp-4675	36	7	hallmark	hallmark	NOUN
fnp-4675	36	8	of	of	ADP
fnp-4675	36	9	neuromyelitis	neuromyelitis	PROPN
fnp-4675	36	10	optica	optica	PROPN
fnp-4675	36	11	(	(	PUNCT
fnp-4675	36	12	nmo	nmo	PROPN
fnp-4675	36	13	)	)	PUNCT
fnp-4675	36	14	,	,	PUNCT
fnp-4675	36	15	another	another	DET
fnp-4675	36	16	inflammatory	inflammatory	ADJ
fnp-4675	36	17	demyelinating	demyelinate	VERB
fnp-4675	36	18	disease	disease	NOUN
fnp-4675	36	19	with	with	ADP
fnp-4675	36	20	pathological	pathological	ADJ
fnp-4675	36	21	features	feature	NOUN
fnp-4675	36	22	distinct	distinct	ADJ
fnp-4675	36	23	from	from	ADP
fnp-4675	36	24	ms	ms	PROPN
fnp-4675	36	25	 	 	SPACE
fnp-4675	36	26	9,10	9,10	NOUN
fnp-4675	36	27	.	.	PUNCT
fnp-4675	37	1	further	further	ADJ
fnp-4675	37	2	support	support	NOUN
fnp-4675	37	3	for	for	ADP
fnp-4675	37	4	the	the	DET
fnp-4675	37	5	potential	potential	ADJ
fnp-4675	37	6	relevance	relevance	NOUN
fnp-4675	37	7	of	of	ADP
fnp-4675	37	8	ebv	ebv	NOUN
fnp-4675	37	9	specific	specific	ADJ
fnp-4675	37	10	humoral	humoral	ADJ
fnp-4675	37	11	and/or	and/or	CCONJ
fnp-4675	37	12	cellular	cellular	ADJ
fnp-4675	37	13	immune	immune	ADJ
fnp-4675	37	14	mediators	mediator	NOUN
fnp-4675	37	15	in	in	ADP
fnp-4675	37	16	ms	ms	PROPN
fnp-4675	37	17	pathogenesis	pathogenesis	NOUN
fnp-4675	37	18	is	be	AUX
fnp-4675	37	19	the	the	DET
fnp-4675	37	20	study	study	NOUN
fnp-4675	37	21	by	by	ADP
fnp-4675	37	22	schneider	schneider	PROPN
fnp-4675	37	23	-	-	PUNCT
fnp-4675	37	24	hohendorf	hohendorf	PROPN
fnp-4675	37	25	et	et	PROPN
fnp-4675	37	26	al	al	PROPN
fnp-4675	37	27	.	.	PROPN
fnp-4675	37	28	conducted	conduct	VERB
fnp-4675	37	29	on	on	ADP
fnp-4675	37	30	ms	ms	ADJ
fnp-4675	37	31	disease	disease	NOUN
fnp-4675	37	32	discordant	discordant	ADJ
fnp-4675	37	33	monozygotic	monozygotic	ADJ
fnp-4675	37	34	twins	twin	NOUN
fnp-4675	37	35	,	,	PUNCT
fnp-4675	37	36	showing	show	VERB
fnp-4675	37	37	a	a	DET
fnp-4675	37	38	broader	broad	ADJ
fnp-4675	37	39	ebv	ebv	NOUN
fnp-4675	37	40	-	-	PUNCT
fnp-4675	37	41	specific	specific	ADJ
fnp-4675	37	42	t	t	NOUN
fnp-4675	37	43	cell	cell	NOUN
fnp-4675	37	44	receptor	receptor	NOUN
fnp-4675	37	45	(	(	PUNCT
fnp-4675	37	46	tcr	tcr	PROPN
fnp-4675	37	47	)	)	PUNCT
fnp-4675	37	48	repertoire	repertoire	NOUN
fnp-4675	37	49	in	in	ADP
fnp-4675	37	50	the	the	DET
fnp-4675	37	51	affected	affected	ADJ
fnp-4675	37	52	one	one	NUM
fnp-4675	37	53	of	of	ADP
fnp-4675	37	54	the	the	DET
fnp-4675	37	55	pair	pair	NOUN
fnp-4675	37	56	 	 	SPACE
fnp-4675	37	57	11	11	NUM
fnp-4675	37	58	.	.	PUNCT
fnp-4675	38	1	these	these	DET
fnp-4675	38	2	combined	combined	ADJ
fnp-4675	38	3	population	population	NOUN
fnp-4675	38	4	and	and	CCONJ
fnp-4675	38	5	laboratory	laboratory	NOUN
fnp-4675	38	6	based	base	VERB
fnp-4675	38	7	studies	study	NOUN
fnp-4675	38	8	raise	raise	VERB
fnp-4675	38	9	the	the	DET
fnp-4675	38	10	issue	issue	NOUN
fnp-4675	38	11	of	of	ADP
fnp-4675	38	12	potential	potential	ADJ
fnp-4675	38	13	benefit	benefit	NOUN
fnp-4675	38	14	of	of	ADP
fnp-4675	38	15	ebv	ebv	NOUN
fnp-4675	38	16	directed	direct	VERB
fnp-4675	38	17	vaccines	vaccine	NOUN
fnp-4675	38	18	in	in	ADP
fnp-4675	38	19	the	the	DET
fnp-4675	38	20	very	very	ADV
fnp-4675	38	21	young	young	ADJ
fnp-4675	38	22	population	population	NOUN
fnp-4675	38	23	.	.	PUNCT
fnp-4675	39	1	however	however	ADV
fnp-4675	39	2	,	,	PUNCT
fnp-4675	39	3	one	one	PRON
fnp-4675	39	4	need	need	AUX
fnp-4675	39	5	consider	consider	VERB
fnp-4675	39	6	the	the	DET
fnp-4675	39	7	potential	potential	ADJ
fnp-4675	39	8	risk	risk	NOUN
fnp-4675	39	9	of	of	ADP
fnp-4675	39	10	such	such	ADJ
fnp-4675	39	11	vaccination	vaccination	NOUN
fnp-4675	39	12	,	,	PUNCT
fnp-4675	39	13	including	include	VERB
fnp-4675	39	14	inducing	induce	VERB
fnp-4675	39	15	a	a	DET
fnp-4675	39	16	neural	neural	ADJ
fnp-4675	39	17	-	-	PUNCT
fnp-4675	39	18	target	target	NOUN
fnp-4675	39	19	directed	direct	VERB
fnp-4675	39	20	cross	cross	NOUN
fnp-4675	39	21	reactive	reactive	ADJ
fnp-4675	39	22	immune	immune	ADJ
fnp-4675	39	23	response	response	NOUN
fnp-4675	39	24	and	and	CCONJ
fnp-4675	39	25	persistent	persistent	ADJ
fnp-4675	39	26	modulation	modulation	NOUN
fnp-4675	39	27	of	of	ADP
fnp-4675	39	28	overall	overall	ADJ
fnp-4675	39	29	immune	immune	ADJ
fnp-4675	39	30	-	-	PUNCT
fnp-4675	39	31	regulatory	regulatory	ADJ
fnp-4675	39	32	mechanisms	mechanism	NOUN
fnp-4675	39	33	which	which	PRON
fnp-4675	39	34	may	may	AUX
fnp-4675	39	35	have	have	VERB
fnp-4675	39	36	protective	protective	ADJ
fnp-4675	39	37	purposes	purpose	NOUN
fnp-4675	39	38	.	.	PUNCT
fnp-4675	40	1	microbiome	microbiome	ADJ
fnp-4675	40	2	impacts	impact	NOUN
fnp-4675	40	3	on	on	ADP
fnp-4675	40	4	disease	disease	NOUN
fnp-4675	40	5	susceptibility	susceptibility	NOUN
fnp-4675	40	6	and	and	CCONJ
fnp-4675	40	7	course	course	NOUN
fnp-4675	40	8	in	in	ADP
fnp-4675	40	9	ms	ms	PROPN
fnp-4675	40	10	having	having	AUX
fnp-4675	40	11	identified	identify	VERB
fnp-4675	40	12	that	that	SCONJ
fnp-4675	40	13	an	an	DET
fnp-4675	40	14	array	array	NOUN
fnp-4675	40	15	of	of	ADP
fnp-4675	40	16	environmental	environmental	ADJ
fnp-4675	40	17	factors	factor	NOUN
fnp-4675	40	18	contribute	contribute	VERB
fnp-4675	40	19	to	to	ADP
fnp-4675	40	20	the	the	DET
fnp-4675	40	21	susceptibility	susceptibility	NOUN
fnp-4675	40	22	and	and	CCONJ
fnp-4675	40	23	course	course	NOUN
fnp-4675	40	24	of	of	ADP
fnp-4675	40	25	ms	ms	PROPN
fnp-4675	40	26	,	,	PUNCT
fnp-4675	40	27	the	the	DET
fnp-4675	40	28	challenge	challenge	NOUN
fnp-4675	40	29	remains	remain	VERB
fnp-4675	40	30	to	to	PART
fnp-4675	40	31	understand	understand	VERB
fnp-4675	40	32	the	the	DET
fnp-4675	40	33	underlying	underlying	ADJ
fnp-4675	40	34	mechanisms	mechanism	NOUN
fnp-4675	40	35	for	for	ADP
fnp-4675	40	36	such	such	ADJ
fnp-4675	40	37	effects	effect	NOUN
fnp-4675	40	38	.	.	PUNCT
fnp-4675	41	1	further	further	ADJ
fnp-4675	41	2	research	research	NOUN
fnp-4675	41	3	is	be	AUX
fnp-4675	41	4	needed	need	VERB
fnp-4675	41	5	to	to	PART
fnp-4675	41	6	find	find	VERB
fnp-4675	41	7	out	out	ADP
fnp-4675	41	8	how	how	SCONJ
fnp-4675	41	9	these	these	DET
fnp-4675	41	10	factors	factor	NOUN
fnp-4675	41	11	can	can	AUX
fnp-4675	41	12	act	act	VERB
fnp-4675	41	13	via	via	ADP
fnp-4675	41	14	modulating	modulate	VERB
fnp-4675	41	15	the	the	DET
fnp-4675	41	16	systemic	systemic	ADJ
fnp-4675	41	17	immune	immune	ADJ
fnp-4675	41	18	system	system	NOUN
fnp-4675	41	19	to	to	PART
fnp-4675	41	20	acquire	acquire	VERB
fnp-4675	41	21	pro	pro	ADJ
fnp-4675	41	22	-	-	ADJ
fnp-4675	41	23	inflammatory	inflammatory	ADJ
fnp-4675	41	24	properties	property	NOUN
fnp-4675	41	25	.	.	PUNCT
fnp-4675	42	1	to	to	PART
fnp-4675	42	2	dissect	dissect	VERB
fnp-4675	42	3	the	the	DET
fnp-4675	42	4	influence	influence	NOUN
fnp-4675	42	5	of	of	ADP
fnp-4675	42	6	genetic	genetic	ADJ
fnp-4675	42	7	predisposition	predisposition	NOUN
fnp-4675	42	8	versus	versus	ADP
fnp-4675	42	9	environmental	environmental	ADJ
fnp-4675	42	10	factors	factor	NOUN
fnp-4675	42	11	on	on	ADP
fnp-4675	42	12	shaping	shape	VERB
fnp-4675	42	13	the	the	DET
fnp-4675	42	14	immune	immune	ADJ
fnp-4675	42	15	system	system	NOUN
fnp-4675	42	16	,	,	PUNCT
fnp-4675	42	17	ingelfinger	ingelfinger	PROPN
fnp-4675	42	18	et	et	PROPN
fnp-4675	42	19	al	al	PROPN
fnp-4675	42	20	.	.	PROPN
fnp-4675	42	21	applied	apply	VERB
fnp-4675	42	22	a	a	DET
fnp-4675	42	23	combination	combination	NOUN
fnp-4675	42	24	of	of	ADP
fnp-4675	42	25	antibody	antibody	NOUN
fnp-4675	42	26	-	-	PUNCT
fnp-4675	42	27	based	base	VERB
fnp-4675	42	28	and	and	CCONJ
fnp-4675	42	29	single	single	ADJ
fnp-4675	42	30	-	-	PUNCT
fnp-4675	42	31	cell	cell	NOUN
fnp-4675	42	32	technologies	technology	NOUN
fnp-4675	42	33	to	to	PART
fnp-4675	42	34	define	define	VERB
fnp-4675	42	35	the	the	DET
fnp-4675	42	36	peripheral	peripheral	ADJ
fnp-4675	42	37	immune	immune	ADJ
fnp-4675	42	38	signatures	signature	NOUN
fnp-4675	42	39	of	of	ADP
fnp-4675	42	40	61	61	NUM
fnp-4675	42	41	monozygotic	monozygotic	ADJ
fnp-4675	42	42	(	(	PUNCT
fnp-4675	42	43	mz	mz	PROPN
fnp-4675	42	44	)	)	PUNCT
fnp-4675	42	45	twin	twin	ADJ
fnp-4675	42	46	pairs	pair	NOUN
fnp-4675	42	47	discordant	discordant	ADJ
fnp-4675	42	48	for	for	ADP
fnp-4675	42	49	ms	ms	PROPN
fnp-4675	42	50	(	(	PUNCT
fnp-4675	42	51	+	+	NUM
fnp-4675	42	52	healthy	healthy	ADJ
fnp-4675	42	53	mz	mz	PROPN
fnp-4675	42	54	twin	twin	NOUN
fnp-4675	42	55	and	and	CCONJ
fnp-4675	42	56	dizygotic	dizygotic	ADJ
fnp-4675	42	57	twin	twin	ADJ
fnp-4675	42	58	pairs	pair	NOUN
fnp-4675	42	59	)	)	PUNCT
fnp-4675	42	60	 	 	SPACE
fnp-4675	42	61	12	12	NUM
fnp-4675	42	62	.	.	PUNCT
fnp-4675	43	1	they	they	PRON
fnp-4675	43	2	could	could	AUX
fnp-4675	43	3	discern	discern	VERB
fnp-4675	43	4	both	both	PRON
fnp-4675	43	5	genetically	genetically	ADV
fnp-4675	43	6	(	(	PUNCT
fnp-4675	43	7	cd25	cd25	PROPN
fnp-4675	43	8	expression	expression	NOUN
fnp-4675	43	9	by	by	ADP
fnp-4675	43	10	naïve	naïve	ADJ
fnp-4675	43	11	helper	helper	NOUN
fnp-4675	43	12	t	t	PROPN
fnp-4675	43	13	cells	cell	NOUN
fnp-4675	43	14	)	)	PUNCT
fnp-4675	43	15	and	and	CCONJ
fnp-4675	43	16	environmentally	environmentally	ADV
fnp-4675	43	17	(	(	PUNCT
fnp-4675	43	18	helper	helper	NOUN
fnp-4675	43	19	t	t	NOUN
fnp-4675	43	20	cells	cell	NOUN
fnp-4675	43	21	with	with	ADP
fnp-4675	43	22	a	a	DET
fnp-4675	43	23	dysregulated	dysregulated	ADJ
fnp-4675	43	24	cd25	cd25	PROPN
fnp-4675	43	25	-	-	PUNCT
fnp-4675	43	26	il-2	il-2	VERB
fnp-4675	43	27	axis	axis	NOUN
fnp-4675	43	28	)	)	PUNCT
fnp-4675	43	29	determined	determine	VERB
fnp-4675	43	30	features	feature	NOUN
fnp-4675	43	31	of	of	ADP
fnp-4675	43	32	an	an	DET
fnp-4675	43	33	ms	ms	ADJ
fnp-4675	43	34	-	-	PUNCT
fnp-4675	43	35	associated	associated	ADJ
fnp-4675	43	36	immune	immune	ADJ
fnp-4675	43	37	signature	signature	NOUN
fnp-4675	43	38	.	.	PUNCT
fnp-4675	44	1	the	the	DET
fnp-4675	44	2	microbiome	microbiome	NOUN
fnp-4675	44	3	serves	serve	VERB
fnp-4675	44	4	as	as	ADP
fnp-4675	44	5	a	a	DET
fnp-4675	44	6	major	major	ADJ
fnp-4675	44	7	interaction	interaction	NOUN
fnp-4675	44	8	of	of	ADP
fnp-4675	44	9	a	a	DET
fnp-4675	44	10	host	host	NOUN
fnp-4675	44	11	with	with	ADP
fnp-4675	44	12	the	the	DET
fnp-4675	44	13	environment	environment	NOUN
fnp-4675	44	14	.	.	PUNCT
fnp-4675	45	1	the	the	DET
fnp-4675	45	2	gut	gut	NOUN
fnp-4675	45	3	is	be	AUX
fnp-4675	45	4	long	long	ADV
fnp-4675	45	5	recognized	recognize	VERB
fnp-4675	45	6	as	as	ADP
fnp-4675	45	7	a	a	DET
fnp-4675	45	8	major	major	ADJ
fnp-4675	45	9	resident	resident	ADJ
fnp-4675	45	10	niche	niche	NOUN
fnp-4675	45	11	for	for	ADP
fnp-4675	45	12	the	the	DET
fnp-4675	45	13	immune	immune	ADJ
fnp-4675	45	14	system	system	NOUN
fnp-4675	45	15	,	,	PUNCT
fnp-4675	45	16	being	be	AUX
fnp-4675	45	17	a	a	DET
fnp-4675	45	18	major	major	ADJ
fnp-4675	45	19	site	site	NOUN
fnp-4675	45	20	of	of	ADP
fnp-4675	45	21	host	host	NOUN
fnp-4675	45	22	immune	immune	ADJ
fnp-4675	45	23	interaction	interaction	NOUN
fnp-4675	45	24	with	with	ADP
fnp-4675	45	25	the	the	DET
fnp-4675	45	26	enormous	enormous	ADJ
fnp-4675	45	27	population	population	NOUN
fnp-4675	45	28	of	of	ADP
fnp-4675	45	29	resident	resident	ADJ
fnp-4675	45	30	microbes	microbe	NOUN
fnp-4675	45	31	.	.	PUNCT
fnp-4675	46	1	the	the	DET
fnp-4675	46	2	results	result	NOUN
fnp-4675	46	3	of	of	ADP
fnp-4675	46	4	the	the	DET
fnp-4675	46	5	international	international	ADJ
fnp-4675	46	6	multiple	multiple	ADJ
fnp-4675	46	7	sclerosis	sclerosis	NOUN
fnp-4675	46	8	microbiome	microbiome	NOUN
fnp-4675	46	9	study	study	NOUN
fnp-4675	46	10	(	(	PUNCT
fnp-4675	46	11	imsms	imsm	NOUN
fnp-4675	46	12	)	)	PUNCT
fnp-4675	46	13	,	,	PUNCT
fnp-4675	46	14	derived	derive	VERB
fnp-4675	46	15	from	from	ADP
fnp-4675	46	16	an	an	DET
fnp-4675	46	17	analysis	analysis	NOUN
fnp-4675	46	18	of	of	ADP
fnp-4675	46	19	the	the	DET
fnp-4675	46	20	gut	gut	NOUN
fnp-4675	46	21	microbiome	microbiome	NOUN
fnp-4675	46	22	of	of	ADP
fnp-4675	46	23	576	576	NUM
fnp-4675	46	24	ms	ms	NOUN
fnp-4675	46	25	patients	patient	NOUN
fnp-4675	46	26	(	(	PUNCT
fnp-4675	46	27	36	36	NUM
fnp-4675	46	28	%	%	NOUN
fnp-4675	46	29	untreated	untreated	ADJ
fnp-4675	46	30	)	)	PUNCT
fnp-4675	46	31	and	and	CCONJ
fnp-4675	46	32	genetically	genetically	ADV
fnp-4675	46	33	unrelated	unrelated	ADJ
fnp-4675	46	34	household	household	NOUN
fnp-4675	46	35	healthy	healthy	ADJ
fnp-4675	46	36	controls	control	NOUN
fnp-4675	46	37	(	(	PUNCT
fnp-4675	46	38	1,152	1,152	NUM
fnp-4675	46	39	total	total	ADJ
fnp-4675	46	40	subjects	subject	NOUN
fnp-4675	46	41	)	)	PUNCT
fnp-4675	46	42	,	,	PUNCT
fnp-4675	46	43	indicated	indicate	VERB
fnp-4675	46	44	that	that	SCONJ
fnp-4675	46	45	the	the	DET
fnp-4675	46	46	phytate	phytate	NOUN
fnp-4675	46	47	degradation	degradation	NOUN
fnp-4675	46	48	pathway	pathway	NOUN
fnp-4675	46	49	was	be	AUX
fnp-4675	46	50	over	over	ADV
fnp-4675	46	51	-	-	PUNCT
fnp-4675	46	52	represented	represent	VERB
fnp-4675	46	53	in	in	ADP
fnp-4675	46	54	untreated	untreated	ADJ
fnp-4675	46	55	ms	ms	PROPN
fnp-4675	46	56	,	,	PUNCT
fnp-4675	46	57	while	while	SCONJ
fnp-4675	46	58	pyruvate	pyruvate	NOUN
fnp-4675	46	59	-	-	PUNCT
fnp-4675	46	60	producing	produce	VERB
fnp-4675	46	61	carbohydrate	carbohydrate	NOUN
fnp-4675	46	62	metabolism	metabolism	NOUN
fnp-4675	46	63	pathways	pathway	NOUN
fnp-4675	46	64	were	be	AUX
fnp-4675	46	65	significantly	significantly	ADV
fnp-4675	46	66	reduced	reduce	VERB
fnp-4675	46	67	 	 	SPACE
fnp-4675	46	68	13	13	NUM
fnp-4675	46	69	.	.	PUNCT
fnp-4675	46	70	microbiome	microbiome	ADJ
fnp-4675	46	71	composition	composition	NOUN
fnp-4675	46	72	,	,	PUNCT
fnp-4675	46	73	function	function	NOUN
fnp-4675	46	74	,	,	PUNCT
fnp-4675	46	75	and	and	CCONJ
fnp-4675	46	76	derived	derived	ADJ
fnp-4675	46	77	metabolites	metabolite	NOUN
fnp-4675	46	78	were	be	AUX
fnp-4675	46	79	all	all	PRON
fnp-4675	46	80	modified	modify	VERB
fnp-4675	46	81	in	in	ADP
fnp-4675	46	82	response	response	NOUN
fnp-4675	46	83	to	to	ADP
fnp-4675	46	84	disease	disease	NOUN
fnp-4675	46	85	-	-	PUNCT
fnp-4675	46	86	modifying	modify	VERB
fnp-4675	46	87	treatments	treatment	NOUN
fnp-4675	46	88	.	.	PUNCT
fnp-4675	47	1	as	as	SCONJ
fnp-4675	47	2	pointed	point	VERB
fnp-4675	47	3	out	out	ADP
fnp-4675	47	4	by	by	ADP
fnp-4675	47	5	hosang	hosang	PROPN
fnp-4675	47	6	et	et	PROPN
fnp-4675	47	7	al	al	PROPN
fnp-4675	47	8	.	.	PROPN
fnp-4675	47	9	,	,	PUNCT
fnp-4675	47	10	the	the	DET
fnp-4675	47	11	lung	lung	NOUN
fnp-4675	47	12	(	(	PUNCT
fnp-4675	47	13	airway	airway	NOUN
fnp-4675	47	14	)	)	PUNCT
fnp-4675	47	15	also	also	ADV
fnp-4675	47	16	serves	serve	VERB
fnp-4675	47	17	as	as	ADP
fnp-4675	47	18	a	a	DET
fnp-4675	47	19	niche	niche	NOUN
fnp-4675	47	20	for	for	ADP
fnp-4675	47	21	immune	immune	ADJ
fnp-4675	47	22	cells	cell	NOUN
fnp-4675	47	23	supporting	support	VERB
fnp-4675	47	24	their	their	PRON
fnp-4675	47	25	long	long	ADJ
fnp-4675	47	26	-	-	PUNCT
fnp-4675	47	27	term	term	NOUN
fnp-4675	47	28	survival	survival	NOUN
fnp-4675	47	29	and	and	CCONJ
fnp-4675	47	30	maturation	maturation	NOUN
fnp-4675	47	31	into	into	ADP
fnp-4675	47	32	migration	migration	NOUN
fnp-4675	47	33	-	-	PUNCT
fnp-4675	47	34	competent	competent	ADJ
fnp-4675	47	35	effector	effector	NOUN
fnp-4675	47	36	t	t	NOUN
fnp-4675	47	37	cells	cell	NOUN
fnp-4675	47	38	 	 	SPACE
fnp-4675	47	39	14	14	NUM
fnp-4675	47	40	.	.	PUNCT
fnp-4675	48	1	smoking	smoking	NOUN
fnp-4675	48	2	is	be	AUX
fnp-4675	48	3	a	a	DET
fnp-4675	48	4	recognized	recognize	VERB
fnp-4675	48	5	risk	risk	NOUN
fnp-4675	48	6	factor	factor	NOUN
fnp-4675	48	7	for	for	ADP
fnp-4675	48	8	the	the	DET
fnp-4675	48	9	development	development	NOUN
fnp-4675	48	10	of	of	ADP
fnp-4675	48	11	ms	ms	PROPN
fnp-4675	48	12	.	.	PROPN
fnp-4675	48	13	hosang	hosang	PROPN
fnp-4675	48	14	et	et	PROPN
fnp-4675	48	15	al	al	PROPN
fnp-4675	48	16	.	.	PROPN
fnp-4675	48	17	demonstrated	demonstrate	VERB
fnp-4675	48	18	the	the	DET
fnp-4675	48	19	potential	potential	NOUN
fnp-4675	48	20	for	for	ADP
fnp-4675	48	21	the	the	DET
fnp-4675	48	22	interaction	interaction	NOUN
fnp-4675	48	23	of	of	ADP
fnp-4675	48	24	this	this	DET
fnp-4675	48	25	niche	niche	NOUN
fnp-4675	48	26	with	with	ADP
fnp-4675	48	27	the	the	DET
fnp-4675	48	28	environment	environment	NOUN
fnp-4675	48	29	to	to	PART
fnp-4675	48	30	influence	influence	VERB
fnp-4675	48	31	the	the	DET
fnp-4675	48	32	susceptibility	susceptibility	NOUN
fnp-4675	48	33	to	to	ADP
fnp-4675	48	34	autoimmune	autoimmune	ADJ
fnp-4675	48	35	neurologic	neurologic	ADJ
fnp-4675	48	36	disease	disease	NOUN
fnp-4675	48	37	,	,	PUNCT
fnp-4675	48	38	using	use	VERB
fnp-4675	48	39	the	the	DET
fnp-4675	48	40	experimental	experimental	ADJ
fnp-4675	48	41	autoimmune	autoimmune	ADJ
fnp-4675	48	42	encephalomyelitis	encephalomyelitis	NOUN
fnp-4675	48	43	(	(	PUNCT
fnp-4675	48	44	eae	eae	PROPN
fnp-4675	48	45	)	)	PUNCT
fnp-4675	48	46	model	model	NOUN
fnp-4675	48	47	.	.	PUNCT
fnp-4675	49	1	treating	treat	VERB
fnp-4675	49	2	animals	animal	NOUN
fnp-4675	49	3	with	with	ADP
fnp-4675	49	4	antibiotics	antibiotic	NOUN
fnp-4675	49	5	(	(	PUNCT
fnp-4675	49	6	neomycin	neomycin	PROPN
fnp-4675	49	7	)	)	PUNCT
fnp-4675	49	8	shifted	shift	VERB
fnp-4675	49	9	the	the	DET
fnp-4675	49	10	microbiota	microbiota	NOUN
fnp-4675	49	11	towards	towards	ADP
fnp-4675	49	12	lipopolysaccharide	lipopolysaccharide	NOUN
fnp-4675	49	13	(	(	PUNCT
fnp-4675	49	14	lps)-enriched	lps)-enriche	VERB
fnp-4675	49	15	phyla	phylum	NOUN
fnp-4675	49	16	without	without	ADP
fnp-4675	49	17	an	an	DET
fnp-4675	49	18	effect	effect	NOUN
fnp-4675	49	19	on	on	ADP
fnp-4675	49	20	the	the	DET
fnp-4675	49	21	gut	gut	NOUN
fnp-4675	49	22	microbiome	microbiome	NOUN
fnp-4675	49	23	.	.	PUNCT
fnp-4675	50	1	the	the	DET
fnp-4675	50	2	underlying	underlying	ADJ
fnp-4675	50	3	mechanism	mechanism	NOUN
fnp-4675	50	4	of	of	ADP
fnp-4675	50	5	effect	effect	NOUN
fnp-4675	50	6	implicated	implicate	VERB
fnp-4675	50	7	was	be	AUX
fnp-4675	50	8	that	that	SCONJ
fnp-4675	50	9	lps	lps	PROPN
fnp-4675	50	10	would	would	AUX
fnp-4675	50	11	usually	usually	ADV
fnp-4675	50	12	induce	induce	VERB
fnp-4675	50	13	a	a	DET
fnp-4675	50	14	type	type	NOUN
fnp-4675	50	15	1	1	NUM
fnp-4675	50	16	interferon	interferon	ADJ
fnp-4675	50	17	response	response	NOUN
fnp-4675	50	18	in	in	ADP
fnp-4675	50	19	microglia	microglia	NOUN
fnp-4675	50	20	and	and	CCONJ
fnp-4675	50	21	reduce	reduce	VERB
fnp-4675	50	22	immune	immune	ADJ
fnp-4675	50	23	activation	activation	NOUN
fnp-4675	50	24	within	within	ADP
fnp-4675	50	25	the	the	DET
fnp-4675	50	26	cns	cns	NOUN
fnp-4675	50	27	.	.	PUNCT
fnp-4675	51	1	however	however	ADV
fnp-4675	51	2	,	,	PUNCT
fnp-4675	51	3	lps	lps	PROPN
fnp-4675	51	4	is	be	AUX
fnp-4675	51	5	also	also	ADV
fnp-4675	51	6	used	use	VERB
fnp-4675	51	7	to	to	PART
fnp-4675	51	8	induce	induce	VERB
fnp-4675	51	9	a	a	DET
fnp-4675	51	10	pro	pro	ADJ
fnp-4675	51	11	-	-	ADJ
fnp-4675	51	12	inflammatory	inflammatory	ADJ
fnp-4675	51	13	response	response	NOUN
fnp-4675	51	14	in	in	ADP
fnp-4675	51	15	human	human	ADJ
fnp-4675	51	16	microglia	microglia	NOUN
fnp-4675	51	17	 	 	SPACE
fnp-4675	51	18	15	15	NUM
fnp-4675	51	19	.	.	PUNCT
fnp-4675	52	1	the	the	DET
fnp-4675	52	2	above	above	ADJ
fnp-4675	52	3	studies	study	NOUN
fnp-4675	52	4	indicate	indicate	VERB
fnp-4675	52	5	the	the	DET
fnp-4675	52	6	potential	potential	NOUN
fnp-4675	52	7	for	for	SCONJ
fnp-4675	52	8	the	the	DET
fnp-4675	52	9	microbiome	microbiome	NOUN
fnp-4675	52	10	in	in	ADP
fnp-4675	52	11	multiple	multiple	ADJ
fnp-4675	52	12	niches	niche	NOUN
fnp-4675	52	13	to	to	PART
fnp-4675	52	14	impact	impact	VERB
fnp-4675	52	15	on	on	ADP
fnp-4675	52	16	ms	ms	NOUN
fnp-4675	52	17	throughout	throughout	ADP
fnp-4675	52	18	its	its	PRON
fnp-4675	52	19	disease	disease	NOUN
fnp-4675	52	20	course	course	NOUN
fnp-4675	52	21	.	.	PUNCT
fnp-4675	53	1	microbiome	microbiome	ADJ
fnp-4675	53	2	influences	influence	NOUN
fnp-4675	53	3	on	on	ADP
fnp-4675	53	4	adaptive	adaptive	ADJ
fnp-4675	53	5	immune	immune	ADJ
fnp-4675	53	6	cells	cell	NOUN
fnp-4675	53	7	would	would	AUX
fnp-4675	53	8	impact	impact	VERB
fnp-4675	53	9	on	on	ADP
fnp-4675	53	10	their	their	PRON
fnp-4675	53	11	initial	initial	ADJ
fnp-4675	53	12	activation	activation	NOUN
fnp-4675	53	13	and	and	CCONJ
fnp-4675	53	14	migration	migration	NOUN
fnp-4675	53	15	into	into	ADP
fnp-4675	53	16	the	the	DET
fnp-4675	53	17	cns	cns	NOUN
fnp-4675	53	18	as	as	ADP
fnp-4675	53	19	part	part	NOUN
fnp-4675	53	20	of	of	ADP
fnp-4675	53	21	new	new	ADJ
fnp-4675	53	22	lesion	lesion	NOUN
fnp-4675	53	23	formation	formation	NOUN
fnp-4675	53	24	.	.	PUNCT
fnp-4675	54	1	modulation	modulation	NOUN
fnp-4675	54	2	of	of	ADP
fnp-4675	54	3	the	the	DET
fnp-4675	54	4	endogenous	endogenous	ADJ
fnp-4675	54	5	glia	glia	NOUN
fnp-4675	54	6	cells	cell	NOUN
fnp-4675	54	7	populations	population	NOUN
fnp-4675	54	8	(	(	PUNCT
fnp-4675	54	9	astrocytes	astrocyte	NOUN
fnp-4675	54	10	,	,	PUNCT
fnp-4675	54	11	microglia	microglia	NOUN
fnp-4675	54	12	)	)	PUNCT
fnp-4675	54	13	by	by	ADP
fnp-4675	54	14	products	product	NOUN
fnp-4675	54	15	derived	derive	VERB
fnp-4675	54	16	from	from	ADP
fnp-4675	54	17	the	the	DET
fnp-4675	54	18	microbiome	microbiome	NOUN
fnp-4675	54	19	would	would	AUX
fnp-4675	54	20	impact	impact	VERB
fnp-4675	54	21	on	on	ADP
fnp-4675	54	22	the	the	DET
fnp-4675	54	23	extent	extent	NOUN
fnp-4675	54	24	to	to	PART
fnp-4675	54	25	which	which	PRON
fnp-4675	54	26	these	these	DET
fnp-4675	54	27	glial	glial	ADJ
fnp-4675	54	28	cells	cell	NOUN
fnp-4675	54	29	participate	participate	VERB
fnp-4675	54	30	in	in	ADP
fnp-4675	54	31	tissue	tissue	NOUN
fnp-4675	54	32	injury	injury	NOUN
fnp-4675	54	33	and	and	CCONJ
fnp-4675	54	34	repair	repair	NOUN
fnp-4675	54	35	processes	process	NOUN
fnp-4675	54	36	throughout	throughout	ADP
fnp-4675	54	37	the	the	DET
fnp-4675	54	38	ms	ms	PROPN
fnp-4675	54	39	disease	disease	NOUN
fnp-4675	54	40	course	course	NOUN
fnp-4675	54	41	.	.	PUNCT
fnp-4675	55	1	progression	progression	NOUN
fnp-4675	55	2	independent	independent	ADJ
fnp-4675	55	3	of	of	ADP
fnp-4675	55	4	relapse	relapse	NOUN
fnp-4675	55	5	activity	activity	NOUN
fnp-4675	55	6	the	the	DET
fnp-4675	55	7	natural	natural	ADJ
fnp-4675	55	8	history	history	NOUN
fnp-4675	55	9	of	of	ADP
fnp-4675	55	10	multiple	multiple	ADJ
fnp-4675	55	11	sclerosis	sclerosis	NOUN
fnp-4675	55	12	has	have	AUX
fnp-4675	55	13	been	be	AUX
fnp-4675	55	14	considered	consider	VERB
fnp-4675	55	15	in	in	ADP
fnp-4675	55	16	terms	term	NOUN
fnp-4675	55	17	of	of	ADP
fnp-4675	55	18	relapsing	relapse	VERB
fnp-4675	55	19	and	and	CCONJ
fnp-4675	55	20	progressive	progressive	ADJ
fnp-4675	55	21	categories	category	NOUN
fnp-4675	55	22	;	;	PUNCT
fnp-4675	55	23	the	the	DET
fnp-4675	55	24	latter	latter	ADJ
fnp-4675	55	25	could	could	AUX
fnp-4675	55	26	occur	occur	VERB
fnp-4675	55	27	in	in	ADP
fnp-4675	55	28	those	those	PRON
fnp-4675	55	29	with	with	ADP
fnp-4675	55	30	previous	previous	ADJ
fnp-4675	55	31	clinical	clinical	ADJ
fnp-4675	55	32	relapses	relapse	NOUN
fnp-4675	55	33	(	(	PUNCT
fnp-4675	55	34	secondary	secondary	ADJ
fnp-4675	55	35	progressive	progressive	ADJ
fnp-4675	55	36	(	(	PUNCT
fnp-4675	55	37	sp	sp	NOUN
fnp-4675	55	38	)	)	PUNCT
fnp-4675	55	39	)	)	PUNCT
fnp-4675	55	40	or	or	CCONJ
fnp-4675	55	41	not	not	PART
fnp-4675	55	42	(	(	PUNCT
fnp-4675	55	43	primary	primary	ADJ
fnp-4675	55	44	progressive	progressive	NOUN
fnp-4675	55	45	(	(	PUNCT
fnp-4675	55	46	pp	pp	ADJ
fnp-4675	55	47	)	)	PUNCT
fnp-4675	55	48	)	)	PUNCT
fnp-4675	55	49	.	.	PUNCT
fnp-4675	56	1	specific	specific	ADJ
fnp-4675	56	2	criteria	criterion	NOUN
fnp-4675	56	3	have	have	AUX
fnp-4675	56	4	been	be	AUX
fnp-4675	56	5	defined	define	VERB
fnp-4675	56	6	for	for	ADP
fnp-4675	56	7	diagnosis	diagnosis	NOUN
fnp-4675	56	8	of	of	ADP
fnp-4675	56	9	either	either	CCONJ
fnp-4675	56	10	relapsing	relapse	VERB
fnp-4675	56	11	or	or	CCONJ
fnp-4675	56	12	pp	pp	ADP
fnp-4675	56	13	forms	form	NOUN
fnp-4675	56	14	of	of	ADP
fnp-4675	56	15	the	the	DET
fnp-4675	56	16	disease	disease	NOUN
fnp-4675	56	17	that	that	PRON
fnp-4675	56	18	now	now	ADV
fnp-4675	56	19	include	include	VERB
fnp-4675	56	20	paraclinical	paraclinical	ADJ
fnp-4675	56	21	measures	measure	NOUN
fnp-4675	56	22	(	(	PUNCT
fnp-4675	56	23	csf	csf	NOUN
fnp-4675	56	24	,	,	PUNCT
fnp-4675	56	25	imaging	imaging	NOUN
fnp-4675	56	26	)	)	PUNCT
fnp-4675	56	27	as	as	ADV
fnp-4675	56	28	well	well	ADV
fnp-4675	56	29	as	as	ADP
fnp-4675	56	30	clinical	clinical	ADJ
fnp-4675	56	31	features	feature	NOUN
fnp-4675	56	32	 	 	SPACE
fnp-4675	56	33	16	16	NUM
fnp-4675	56	34	.	.	PUNCT
fnp-4675	57	1	progression	progression	NOUN
fnp-4675	57	2	needs	need	VERB
fnp-4675	57	3	not	not	PART
fnp-4675	57	4	be	be	AUX
fnp-4675	57	5	sustained	sustain	VERB
fnp-4675	57	6	in	in	ADP
fnp-4675	57	7	either	either	PRON
fnp-4675	57	8	sp	sp	ADP
fnp-4675	57	9	or	or	CCONJ
fnp-4675	57	10	pp	pp	ADP
fnp-4675	57	11	forms	form	NOUN
fnp-4675	57	12	resulting	result	VERB
fnp-4675	57	13	in	in	ADP
fnp-4675	57	14	use	use	NOUN
fnp-4675	57	15	of	of	ADP
fnp-4675	57	16	the	the	DET
fnp-4675	57	17	term	term	NOUN
fnp-4675	57	18	“	"	PUNCT
fnp-4675	57	19	confirmed	confirm	VERB
fnp-4675	57	20	progression	progression	NOUN
fnp-4675	57	21	”	"	PUNCT
fnp-4675	57	22	(	(	PUNCT
fnp-4675	57	23	over	over	ADP
fnp-4675	57	24	3	3	NUM
fnp-4675	57	25	-	-	SYM
fnp-4675	57	26	6	6	NUM
fnp-4675	57	27	months	month	NOUN
fnp-4675	57	28	)	)	PUNCT
fnp-4675	57	29	in	in	ADP
fnp-4675	57	30	clinical	clinical	ADJ
fnp-4675	57	31	trials	trial	NOUN
fnp-4675	57	32	.	.	PUNCT
fnp-4675	58	1	more	more	ADJ
fnp-4675	58	2	recent	recent	ADJ
fnp-4675	58	3	focus	focus	NOUN
fnp-4675	58	4	is	be	AUX
fnp-4675	58	5	whether	whether	SCONJ
fnp-4675	58	6	progressive	progressive	ADJ
fnp-4675	58	7	forms	form	NOUN
fnp-4675	58	8	are	be	AUX
fnp-4675	58	9	associated	associate	VERB
fnp-4675	58	10	with	with	ADP
fnp-4675	58	11	ongoing	ongoing	ADJ
fnp-4675	58	12	disease	disease	NOUN
fnp-4675	58	13	activity	activity	NOUN
fnp-4675	58	14	,	,	PUNCT
fnp-4675	58	15	as	as	SCONJ
fnp-4675	58	16	defined	define	VERB
fnp-4675	58	17	by	by	ADP
fnp-4675	58	18	imaging	imaging	NOUN
fnp-4675	58	19	or	or	CCONJ
fnp-4675	58	20	clinical	clinical	ADJ
fnp-4675	58	21	activity	activity	NOUN
fnp-4675	58	22	,	,	PUNCT
fnp-4675	58	23	introducing	introduce	VERB
fnp-4675	58	24	the	the	DET
fnp-4675	58	25	term	term	NOUN
fnp-4675	58	26	progression	progression	NOUN
fnp-4675	58	27	independent	independent	ADJ
fnp-4675	58	28	of	of	ADP
fnp-4675	58	29	relapse	relapse	NOUN
fnp-4675	58	30	activity	activity	NOUN
fnp-4675	58	31	(	(	PUNCT
fnp-4675	58	32	pira	pira	NOUN
fnp-4675	58	33	)	)	PUNCT
fnp-4675	58	34	 	 	SPACE
fnp-4675	58	35	1,2,17	1,2,17	NUM
fnp-4675	58	36	.	.	PUNCT
fnp-4675	59	1	this	this	DET
fnp-4675	59	2	designation	designation	NOUN
fnp-4675	59	3	has	have	AUX
fnp-4675	59	4	acquired	acquire	VERB
fnp-4675	59	5	increased	increase	VERB
fnp-4675	59	6	significance	significance	NOUN
fnp-4675	59	7	in	in	ADP
fnp-4675	59	8	that	that	DET
fnp-4675	59	9	regulatory	regulatory	ADJ
fnp-4675	59	10	approval	approval	NOUN
fnp-4675	59	11	for	for	ADP
fnp-4675	59	12	agents	agent	NOUN
fnp-4675	59	13	in	in	ADP
fnp-4675	59	14	sp	sp	ADP
fnp-4675	59	15	ms	ms	PROPN
fnp-4675	59	16	has	have	AUX
fnp-4675	59	17	been	be	AUX
fnp-4675	59	18	denied	deny	VERB
fnp-4675	59	19	for	for	ADP
fnp-4675	59	20	cases	case	NOUN
fnp-4675	59	21	lacking	lack	VERB
fnp-4675	59	22	of	of	ADP
fnp-4675	59	23	documented	document	VERB
fnp-4675	59	24	activity	activity	NOUN
fnp-4675	59	25	.	.	PUNCT
fnp-4675	60	1	lublin	lublin	PROPN
fnp-4675	60	2	et	et	PROPN
fnp-4675	60	3	al	al	PROPN
fnp-4675	60	4	.	.	PROPN
fnp-4675	60	5	used	use	VERB
fnp-4675	60	6	the	the	DET
fnp-4675	60	7	novartis	novartis	NOUN
fnp-4675	60	8	-	-	PUNCT
fnp-4675	60	9	oxford	oxford	PROPN
fnp-4675	60	10	multiple	multiple	ADJ
fnp-4675	60	11	sclerosis	sclerosis	NOUN
fnp-4675	60	12	(	(	PUNCT
fnp-4675	60	13	no.ms	no.ms	ADJ
fnp-4675	60	14	)	)	PUNCT
fnp-4675	60	15	data	datum	NOUN
fnp-4675	60	16	pool	pool	NOUN
fnp-4675	60	17	,	,	PUNCT
fnp-4675	60	18	spanning	span	VERB
fnp-4675	60	19	all	all	DET
fnp-4675	60	20	multiple	multiple	ADJ
fnp-4675	60	21	sclerosis	sclerosis	NOUN
fnp-4675	60	22	phenotypes	phenotype	NOUN
fnp-4675	60	23	and	and	CCONJ
fnp-4675	60	24	paediatric	paediatric	ADJ
fnp-4675	60	25	multiple	multiple	ADJ
fnp-4675	60	26	sclerosis	sclerosis	NOUN
fnp-4675	60	27	,	,	PUNCT
fnp-4675	60	28	to	to	PART
fnp-4675	60	29	evaluate	evaluate	VERB
fnp-4675	60	30	∼200,000	∼200,000	PROPN
fnp-4675	60	31	expanded	expand	VERB
fnp-4675	60	32	disability	disability	NOUN
fnp-4675	60	33	status	status	NOUN
fnp-4675	60	34	scale	scale	NOUN
fnp-4675	60	35	(	(	PUNCT
fnp-4675	60	36	edss	edss	ADJ
fnp-4675	60	37	)	)	PUNCT
fnp-4675	60	38	transitions	transition	NOUN
fnp-4675	60	39	from	from	ADP
fnp-4675	60	40	>	>	PUNCT
fnp-4675	60	41	27,000	27,000	NUM
fnp-4675	60	42	patients	patient	NOUN
fnp-4675	60	43	with	with	ADP
fnp-4675	60	44	≤15	≤15	NOUN
fnp-4675	60	45	years	year	NOUN
fnp-4675	60	46	follow	follow	VERB
fnp-4675	60	47	-	-	PUNCT
fnp-4675	60	48	up	up	NOUN
fnp-4675	60	49	 	 	SPACE
fnp-4675	60	50	18	18	NUM
fnp-4675	60	51	.	.	PUNCT
fnp-4675	61	1	their	their	PRON
fnp-4675	61	2	conclusions	conclusion	NOUN
fnp-4675	61	3	were	be	AUX
fnp-4675	61	4	that	that	SCONJ
fnp-4675	61	5	although	although	SCONJ
fnp-4675	61	6	relapses	relapse	NOUN
fnp-4675	61	7	contribute	contribute	VERB
fnp-4675	61	8	to	to	ADP
fnp-4675	61	9	the	the	DET
fnp-4675	61	10	accumulation	accumulation	NOUN
fnp-4675	61	11	of	of	ADP
fnp-4675	61	12	disability	disability	NOUN
fnp-4675	61	13	,	,	PUNCT
fnp-4675	61	14	primarily	primarily	ADV
fnp-4675	61	15	early	early	ADV
fnp-4675	61	16	in	in	ADP
fnp-4675	61	17	multiple	multiple	ADJ
fnp-4675	61	18	sclerosis	sclerosis	NOUN
fnp-4675	61	19	,	,	PUNCT
fnp-4675	61	20	pira	pira	PROPN
fnp-4675	61	21	started	start	VERB
fnp-4675	61	22	early	early	ADV
fnp-4675	61	23	in	in	ADP
fnp-4675	61	24	the	the	DET
fnp-4675	61	25	disease	disease	NOUN
fnp-4675	61	26	process	process	NOUN
fnp-4675	61	27	,	,	PUNCT
fnp-4675	61	28	occurred	occur	VERB
fnp-4675	61	29	in	in	ADP
fnp-4675	61	30	all	all	DET
fnp-4675	61	31	phenotypes	phenotype	NOUN
fnp-4675	61	32	and	and	CCONJ
fnp-4675	61	33	became	become	VERB
fnp-4675	61	34	the	the	DET
fnp-4675	61	35	principal	principal	ADJ
fnp-4675	61	36	driver	driver	NOUN
fnp-4675	61	37	of	of	ADP
fnp-4675	61	38	disability	disability	NOUN
fnp-4675	61	39	accumulation	accumulation	NOUN
fnp-4675	61	40	in	in	ADP
fnp-4675	61	41	the	the	DET
fnp-4675	61	42	progressive	progressive	ADJ
fnp-4675	61	43	phase	phase	NOUN
fnp-4675	61	44	of	of	ADP
fnp-4675	61	45	the	the	DET
fnp-4675	61	46	disease	disease	NOUN
fnp-4675	61	47	.	.	PUNCT
fnp-4675	62	1	tur	tur	INTJ
fnp-4675	62	2	et	et	PROPN
fnp-4675	62	3	al	al	PROPN
fnp-4675	62	4	.	.	PROPN
fnp-4675	62	5	could	could	AUX
fnp-4675	62	6	show	show	VERB
fnp-4675	62	7	that	that	SCONJ
fnp-4675	62	8	pira	pira	NOUN
fnp-4675	62	9	,	,	PUNCT
fnp-4675	62	10	after	after	ADP
fnp-4675	62	11	a	a	DET
fnp-4675	62	12	first	first	ADJ
fnp-4675	62	13	demyelinating	demyelinate	VERB
fnp-4675	62	14	event	event	NOUN
fnp-4675	62	15	,	,	PUNCT
fnp-4675	62	16	was	be	AUX
fnp-4675	62	17	not	not	PART
fnp-4675	62	18	uncommon	uncommon	ADJ
fnp-4675	62	19	and	and	CCONJ
fnp-4675	62	20	suggested	suggest	VERB
fnp-4675	62	21	an	an	DET
fnp-4675	62	22	unfavorable	unfavorable	ADJ
fnp-4675	62	23	long	long	ADJ
fnp-4675	62	24	-	-	PUNCT
fnp-4675	62	25	term	term	NOUN
fnp-4675	62	26	prognosis	prognosis	NOUN
fnp-4675	62	27	,	,	PUNCT
fnp-4675	62	28	especially	especially	ADV
fnp-4675	62	29	if	if	SCONJ
fnp-4675	62	30	it	it	PRON
fnp-4675	62	31	occurs	occur	VERB
fnp-4675	62	32	early	early	ADV
fnp-4675	62	33	in	in	ADP
fnp-4675	62	34	the	the	DET
fnp-4675	62	35	disease	disease	NOUN
fnp-4675	62	36	course	course	NOUN
fnp-4675	62	37	 	 	SPACE
fnp-4675	62	38	19	19	NUM
fnp-4675	62	39	.	.	PUNCT
fnp-4675	62	40	focal	focal	ADJ
fnp-4675	62	41	inflammation	inflammation	NOUN
fnp-4675	62	42	as	as	SCONJ
fnp-4675	62	43	driver	driver	NOUN
fnp-4675	62	44	of	of	ADP
fnp-4675	62	45	disease	disease	NOUN
fnp-4675	62	46	progression	progression	NOUN
fnp-4675	62	47	the	the	DET
fnp-4675	62	48	observation	observation	NOUN
fnp-4675	62	49	that	that	SCONJ
fnp-4675	62	50	disease	disease	NOUN
fnp-4675	62	51	progression	progression	NOUN
fnp-4675	62	52	is	be	AUX
fnp-4675	62	53	driven	drive	VERB
fnp-4675	62	54	by	by	ADP
fnp-4675	62	55	mechanisms	mechanism	NOUN
fnp-4675	62	56	other	other	ADJ
fnp-4675	62	57	than	than	ADP
fnp-4675	62	58	peripherally	peripherally	ADV
fnp-4675	62	59	-	-	PUNCT
fnp-4675	62	60	driven	drive	VERB
fnp-4675	62	61	acute	acute	ADJ
fnp-4675	62	62	focal	focal	ADJ
fnp-4675	62	63	inflammatory	inflammatory	ADJ
fnp-4675	62	64	lesions	lesion	NOUN
fnp-4675	62	65	,	,	PUNCT
fnp-4675	62	66	raise	raise	VERB
fnp-4675	62	67	the	the	DET
fnp-4675	62	68	issue	issue	NOUN
fnp-4675	62	69	of	of	ADP
fnp-4675	62	70	the	the	DET
fnp-4675	62	71	pathogenic	pathogenic	ADJ
fnp-4675	62	72	mechanisms	mechanism	NOUN
fnp-4675	62	73	responsible	responsible	ADJ
fnp-4675	62	74	for	for	ADP
fnp-4675	62	75	progression	progression	NOUN
fnp-4675	62	76	.	.	PUNCT
fnp-4675	63	1	this	this	PRON
fnp-4675	63	2	has	have	AUX
fnp-4675	63	3	become	become	VERB
fnp-4675	63	4	a	a	DET
fnp-4675	63	5	hot	hot	ADJ
fnp-4675	63	6	topic	topic	NOUN
fnp-4675	63	7	for	for	ADP
fnp-4675	63	8	both	both	CCONJ
fnp-4675	63	9	histopathologic	histopathologic	NOUN
fnp-4675	63	10	and	and	CCONJ
fnp-4675	63	11	serial	serial	ADJ
fnp-4675	63	12	neuroimaging	neuroimaging	ADJ
fnp-4675	63	13	studies	study	NOUN
fnp-4675	63	14	,	,	PUNCT
fnp-4675	63	15	with	with	ADP
fnp-4675	63	16	a	a	DET
fnp-4675	63	17	challenge	challenge	NOUN
fnp-4675	63	18	of	of	ADP
fnp-4675	63	19	how	how	SCONJ
fnp-4675	63	20	to	to	PART
fnp-4675	63	21	reconcile	reconcile	VERB
fnp-4675	63	22	these	these	DET
fnp-4675	63	23	two	two	NUM
fnp-4675	63	24	approaches	approach	NOUN
fnp-4675	63	25	.	.	PUNCT
fnp-4675	64	1	both	both	PRON
fnp-4675	64	2	have	have	AUX
fnp-4675	64	3	implicated	implicate	VERB
fnp-4675	64	4	pathogenic	pathogenic	ADJ
fnp-4675	64	5	processes	process	NOUN
fnp-4675	64	6	in	in	ADP
fnp-4675	64	7	the	the	DET
fnp-4675	64	8	white	white	ADJ
fnp-4675	64	9	matter	matter	NOUN
fnp-4675	64	10	,	,	PUNCT
fnp-4675	64	11	cortical	cortical	ADJ
fnp-4675	64	12	grey	grey	NOUN
fnp-4675	64	13	,	,	PUNCT
fnp-4675	64	14	periventricular	periventricular	ADJ
fnp-4675	64	15	,	,	PUNCT
fnp-4675	64	16	and	and	CCONJ
fnp-4675	64	17	spinal	spinal	ADJ
fnp-4675	64	18	cord	cord	NOUN
fnp-4675	64	19	regions	region	NOUN
fnp-4675	64	20	of	of	ADP
fnp-4675	64	21	the	the	DET
fnp-4675	64	22	cns	cns	NOUN
fnp-4675	64	23	.	.	PUNCT
fnp-4675	65	1	as	as	SCONJ
fnp-4675	65	2	regards	regard	VERB
fnp-4675	65	3	focal	focal	ADJ
fnp-4675	65	4	white	white	ADJ
fnp-4675	65	5	matter	matter	NOUN
fnp-4675	65	6	lesions	lesion	NOUN
fnp-4675	65	7	,	,	PUNCT
fnp-4675	65	8	beynon	beynon	PROPN
fnp-4675	65	9	et	et	PROPN
fnp-4675	65	10	al	al	PROPN
fnp-4675	65	11	.	.	PROPN
fnp-4675	65	12	examined	examine	VERB
fnp-4675	65	13	chronic	chronic	ADJ
fnp-4675	65	14	lesion	lesion	NOUN
fnp-4675	65	15	activity	activity	NOUN
fnp-4675	65	16	(	(	PUNCT
fnp-4675	65	17	cla	cla	NOUN
fnp-4675	65	18	)	)	PUNCT
fnp-4675	65	19	(	(	PUNCT
fnp-4675	65	20	assessed	assess	VERB
fnp-4675	65	21	by	by	ADP
fnp-4675	65	22	t1	t1	NOUN
fnp-4675	65	23	-	-	PUNCT
fnp-4675	65	24	hypointense	hypointense	NOUN
fnp-4675	65	25	lesion	lesion	NOUN
fnp-4675	65	26	volume	volume	NOUN
fnp-4675	65	27	increase	increase	NOUN
fnp-4675	65	28	within	within	ADP
fnp-4675	65	29	baseline	baseline	ADJ
fnp-4675	65	30	t2	t2	NOUN
fnp-4675	65	31	-	-	PUNCT
fnp-4675	65	32	non	non	NOUN
fnp-4675	65	33	-	-	ADJ
fnp-4675	65	34	enhancing	enhancing	ADJ
fnp-4675	65	35	lesions	lesion	NOUN
fnp-4675	65	36	identified	identify	VERB
fnp-4675	65	37	as	as	ADP
fnp-4675	65	38	either	either	CCONJ
fnp-4675	65	39	slowly	slowly	ADV
fnp-4675	65	40	expanding	expand	VERB
fnp-4675	65	41	(	(	PUNCT
fnp-4675	65	42	sels	sel	NOUN
fnp-4675	65	43	)	)	PUNCT
fnp-4675	65	44	or	or	CCONJ
fnp-4675	65	45	not	not	PART
fnp-4675	65	46	slowly	slowly	ADV
fnp-4675	65	47	expanding	expand	VERB
fnp-4675	65	48	(	(	PUNCT
fnp-4675	65	49	non	non	ADJ
fnp-4675	65	50	-	-	ADJ
fnp-4675	65	51	sels	sel	NOUN
fnp-4675	65	52	)	)	PUNCT
fnp-4675	65	53	)	)	PUNCT
fnp-4675	65	54	in	in	ADP
fnp-4675	65	55	a	a	DET
fnp-4675	65	56	108	108	NUM
fnp-4675	65	57	week	week	NOUN
fnp-4675	65	58	phase	phase	NOUN
fnp-4675	65	59	3	3	NUM
fnp-4675	65	60	clinical	clinical	ADJ
fnp-4675	65	61	trial	trial	NOUN
fnp-4675	65	62	of	of	ADP
fnp-4675	65	63	natalizumab	natalizumab	NOUN
fnp-4675	65	64	(	(	PUNCT
fnp-4675	65	65	ascend	ascend	NOUN
fnp-4675	65	66	)	)	PUNCT
fnp-4675	65	67	in	in	ADP
fnp-4675	65	68	sp	sp	ADP
fnp-4675	65	69	ms	ms	NOUN
fnp-4675	65	70	patients	patient	NOUN
fnp-4675	65	71	 	 	SPACE
fnp-4675	65	72	20	20	NUM
fnp-4675	65	73	.	.	PUNCT
fnp-4675	66	1	they	they	PRON
fnp-4675	66	2	found	find	VERB
fnp-4675	66	3	that	that	SCONJ
fnp-4675	66	4	cla	cla	NOUN
fnp-4675	66	5	in	in	ADP
fnp-4675	66	6	both	both	DET
fnp-4675	66	7	sels	sel	NOUN
fnp-4675	66	8	and	and	CCONJ
fnp-4675	66	9	non	non	NOUN
fnp-4675	66	10	-	-	NOUN
fnp-4675	66	11	sels	sel	NOUN
fnp-4675	66	12	was	be	AUX
fnp-4675	66	13	greater	great	ADJ
fnp-4675	66	14	in	in	ADP
fnp-4675	66	15	patients	patient	NOUN
fnp-4675	66	16	with	with	ADP
fnp-4675	66	17	spms	spm	NOUN
fnp-4675	66	18	and	and	CCONJ
fnp-4675	66	19	confirmed	confirm	VERB
fnp-4675	66	20	disability	disability	NOUN
fnp-4675	66	21	progression	progression	NOUN
fnp-4675	66	22	than	than	ADP
fnp-4675	66	23	in	in	ADP
fnp-4675	66	24	those	those	PRON
fnp-4675	66	25	with	with	ADP
fnp-4675	66	26	no	no	DET
fnp-4675	66	27	progression	progression	NOUN
fnp-4675	66	28	.	.	PUNCT
fnp-4675	67	1	sel	sel	ADJ
fnp-4675	67	2	prevalence	prevalence	NOUN
fnp-4675	67	3	was	be	AUX
fnp-4675	67	4	lower	low	ADJ
fnp-4675	67	5	in	in	ADP
fnp-4675	67	6	the	the	DET
fnp-4675	67	7	absence	absence	NOUN
fnp-4675	67	8	of	of	ADP
fnp-4675	67	9	acute	acute	ADJ
fnp-4675	67	10	lesion	lesion	NOUN
fnp-4675	67	11	activity	activity	NOUN
fnp-4675	67	12	(	(	PUNCT
fnp-4675	67	13	ala	ala	PROPN
fnp-4675	67	14	)	)	PUNCT
fnp-4675	67	15	(	(	PUNCT
fnp-4675	67	16	5	5	NUM
fnp-4675	67	17	%	%	NOUN
fnp-4675	67	18	vs.	vs.	ADP
fnp-4675	67	19	19	19	NUM
fnp-4675	67	20	%	%	NOUN
fnp-4675	67	21	in	in	ADP
fnp-4675	67	22	subjects	subject	NOUN
fnp-4675	67	23	with	with	ADP
fnp-4675	67	24	ala	ala	PROPN
fnp-4675	67	25	)	)	PUNCT
fnp-4675	67	26	,	,	PUNCT
fnp-4675	67	27	while	while	SCONJ
fnp-4675	67	28	cla	cla	PROPN
fnp-4675	67	29	remained	remain	VERB
fnp-4675	67	30	associated	associate	VERB
fnp-4675	67	31	with	with	ADP
fnp-4675	67	32	disability	disability	NOUN
fnp-4675	67	33	progression	progression	NOUN
fnp-4675	67	34	.	.	PUNCT
fnp-4675	68	1	in	in	ADP
fnp-4675	68	2	view	view	NOUN
fnp-4675	68	3	of	of	ADP
fnp-4675	68	4	the	the	DET
fnp-4675	68	5	association	association	NOUN
fnp-4675	68	6	of	of	ADP
fnp-4675	68	7	ala	ala	PROPN
fnp-4675	68	8	with	with	ADP
fnp-4675	68	9	sel	sel	PROPN
fnp-4675	68	10	prevalence	prevalence	NOUN
fnp-4675	68	11	,	,	PUNCT
fnp-4675	68	12	the	the	DET
fnp-4675	68	13	authors	author	NOUN
fnp-4675	68	14	suggest	suggest	VERB
fnp-4675	68	15	that	that	SCONJ
fnp-4675	68	16	the	the	DET
fnp-4675	68	17	effect	effect	NOUN
fnp-4675	68	18	of	of	ADP
fnp-4675	68	19	natalizumab	natalizumab	NOUN
fnp-4675	68	20	on	on	ADP
fnp-4675	68	21	cla	cla	PROPN
fnp-4675	68	22	may	may	AUX
fnp-4675	68	23	be	be	AUX
fnp-4675	68	24	related	relate	VERB
fnp-4675	68	25	to	to	ADP
fnp-4675	68	26	its	its	PRON
fnp-4675	68	27	effect	effect	NOUN
fnp-4675	68	28	on	on	ADP
fnp-4675	68	29	ala	ala	PROPN
fnp-4675	68	30	and	and	CCONJ
fnp-4675	68	31	the	the	DET
fnp-4675	68	32	suppression	suppression	NOUN
fnp-4675	68	33	of	of	ADP
fnp-4675	68	34	ala	ala	PROPN
fnp-4675	68	35	in	in	ADP
fnp-4675	68	36	mixed	mixed	ADJ
fnp-4675	68	37	active	active	ADJ
fnp-4675	68	38	/	/	SYM
fnp-4675	68	39	inactive	inactive	ADJ
fnp-4675	68	40	lesions	lesion	NOUN
fnp-4675	68	41	.	.	PUNCT
fnp-4675	69	1	further	further	ADJ
fnp-4675	69	2	studies	study	NOUN
fnp-4675	69	3	are	be	AUX
fnp-4675	69	4	required	require	VERB
fnp-4675	69	5	to	to	PART
fnp-4675	69	6	understand	understand	VERB
fnp-4675	69	7	whether	whether	SCONJ
fnp-4675	69	8	and	and	CCONJ
fnp-4675	69	9	to	to	PART
fnp-4675	69	10	which	which	DET
fnp-4675	69	11	extent	extent	NOUN
fnp-4675	69	12	the	the	DET
fnp-4675	69	13	established	establish	VERB
fnp-4675	69	14	immunosuppressive	immunosuppressive	ADJ
fnp-4675	69	15	and	and	CCONJ
fnp-4675	69	16	immunomodulatory	immunomodulatory	ADJ
fnp-4675	69	17	ms	ms	PROPN
fnp-4675	69	18	treatments	treatments	PROPN
fnp-4675	69	19	target	target	VERB
fnp-4675	69	20	sel	sel	NOUN
fnp-4675	69	21	(	(	PUNCT
fnp-4675	69	22	with	with	ADP
fnp-4675	69	23	or	or	CCONJ
fnp-4675	69	24	without	without	ADP
fnp-4675	69	25	paramagnetic	paramagnetic	ADJ
fnp-4675	69	26	rims	rim	NOUN
fnp-4675	69	27	)	)	PUNCT
fnp-4675	69	28	.	.	PUNCT
fnp-4675	70	1	(	(	PUNCT
fnp-4675	70	2	ii	ii	NOUN
fnp-4675	70	3	)	)	PUNCT
fnp-4675	70	4	ms	ms	NOUN
fnp-4675	70	5	susceptibility	susceptibility	NOUN
fnp-4675	70	6	and	and	CCONJ
fnp-4675	70	7	disease	disease	NOUN
fnp-4675	70	8	course	course	NOUN
fnp-4675	70	9	–	–	PUNCT
fnp-4675	70	10	tissue	tissue	NOUN
fnp-4675	70	11	based	base	VERB
fnp-4675	70	12	studies	study	NOUN
fnp-4675	70	13	meningeal	meningeal	ADJ
fnp-4675	70	14	inflammation	inflammation	NOUN
fnp-4675	70	15	correlates	correlate	VERB
fnp-4675	70	16	with	with	ADP
fnp-4675	70	17	lesion	lesion	NOUN
fnp-4675	70	18	activity	activity	NOUN
fnp-4675	70	19	the	the	DET
fnp-4675	70	20	meninges	meninge	NOUN
fnp-4675	70	21	consists	consist	VERB
fnp-4675	70	22	of	of	ADP
fnp-4675	70	23	the	the	DET
fnp-4675	70	24	dura	dura	NOUN
fnp-4675	70	25	mater	mater	NOUN
fnp-4675	70	26	and	and	CCONJ
fnp-4675	70	27	the	the	DET
fnp-4675	70	28	leptomeninges	leptomeninge	NOUN
fnp-4675	70	29	comprising	comprise	VERB
fnp-4675	70	30	pia	pia	NOUN
fnp-4675	70	31	mater	mater	NOUN
fnp-4675	70	32	and	and	CCONJ
fnp-4675	70	33	arachnoid	arachnoid	PROPN
fnp-4675	70	34	.	.	PUNCT
fnp-4675	71	1	during	during	ADP
fnp-4675	71	2	recent	recent	ADJ
fnp-4675	71	3	years	year	NOUN
fnp-4675	71	4	,	,	PUNCT
fnp-4675	71	5	a	a	DET
fnp-4675	71	6	number	number	NOUN
fnp-4675	71	7	of	of	ADP
fnp-4675	71	8	papers	paper	NOUN
fnp-4675	71	9	have	have	AUX
fnp-4675	71	10	elucidated	elucidate	VERB
fnp-4675	71	11	the	the	DET
fnp-4675	71	12	relationship	relationship	NOUN
fnp-4675	71	13	between	between	ADP
fnp-4675	71	14	leptomeningeal	leptomeningeal	ADJ
fnp-4675	71	15	inflammation	inflammation	NOUN
fnp-4675	71	16	and	and	CCONJ
fnp-4675	71	17	subpial	subpial	ADJ
fnp-4675	71	18	cortical	cortical	ADJ
fnp-4675	71	19	lesions	lesion	NOUN
fnp-4675	71	20	 	 	SPACE
fnp-4675	71	21	21	21	NUM
fnp-4675	71	22	-	-	SYM
fnp-4675	71	23	23	23	NUM
fnp-4675	71	24	.	.	PUNCT
fnp-4675	72	1	subpial	subpial	ADJ
fnp-4675	72	2	lesions	lesion	NOUN
fnp-4675	72	3	are	be	AUX
fnp-4675	72	4	more	more	ADV
fnp-4675	72	5	frequently	frequently	ADV
fnp-4675	72	6	found	find	VERB
fnp-4675	72	7	in	in	ADP
fnp-4675	72	8	close	close	ADJ
fnp-4675	72	9	proximity	proximity	NOUN
fnp-4675	72	10	to	to	ADP
fnp-4675	72	11	meningeal	meningeal	ADJ
fnp-4675	72	12	infiltrates	infiltrate	NOUN
fnp-4675	72	13	and	and	CCONJ
fnp-4675	72	14	,	,	PUNCT
fnp-4675	72	15	subpial	subpial	ADJ
fnp-4675	72	16	demyelination	demyelination	NOUN
fnp-4675	72	17	is	be	AUX
fnp-4675	72	18	associated	associate	VERB
fnp-4675	72	19	with	with	ADP
fnp-4675	72	20	neuronal	neuronal	ADJ
fnp-4675	72	21	,	,	PUNCT
fnp-4675	72	22	oligodendroglial	oligodendroglial	ADJ
fnp-4675	72	23	and	and	CCONJ
fnp-4675	72	24	astrocytic	astrocytic	ADJ
fnp-4675	72	25	injury	injury	NOUN
fnp-4675	72	26	and	and	CCONJ
fnp-4675	72	27	loss	loss	NOUN
fnp-4675	72	28	;	;	PUNCT
fnp-4675	72	29	cortical	cortical	ADJ
fnp-4675	72	30	pathology	pathology	NOUN
fnp-4675	72	31	is	be	AUX
fnp-4675	72	32	now	now	ADV
fnp-4675	72	33	considered	consider	VERB
fnp-4675	72	34	as	as	ADP
fnp-4675	72	35	a	a	DET
fnp-4675	72	36	driver	driver	NOUN
fnp-4675	72	37	of	of	ADP
fnp-4675	72	38	disease	disease	NOUN
fnp-4675	72	39	progression	progression	NOUN
fnp-4675	72	40	 	 	SPACE
fnp-4675	72	41	22	22	NUM
fnp-4675	72	42	.	.	PUNCT
fnp-4675	73	1	subpial	subpial	ADJ
fnp-4675	73	2	lesions	lesion	NOUN
fnp-4675	73	3	are	be	AUX
fnp-4675	73	4	characterized	characterize	VERB
fnp-4675	73	5	by	by	ADP
fnp-4675	73	6	reduced	reduced	ADJ
fnp-4675	73	7	extent	extent	NOUN
fnp-4675	73	8	of	of	ADP
fnp-4675	73	9	grey	grey	ADJ
fnp-4675	73	10	matter	matter	NOUN
fnp-4675	73	11	(	(	PUNCT
fnp-4675	73	12	gm	gm	NOUN
fnp-4675	73	13	)	)	PUNCT
fnp-4675	73	14	inflammation	inflammation	NOUN
fnp-4675	73	15	compared	compare	VERB
fnp-4675	73	16	to	to	ADP
fnp-4675	73	17	white	white	ADJ
fnp-4675	73	18	matter	matter	NOUN
fnp-4675	73	19	lesions	lesion	NOUN
fnp-4675	73	20	;	;	PUNCT
fnp-4675	73	21	therefore	therefore	ADV
fnp-4675	73	22	,	,	PUNCT
fnp-4675	73	23	the	the	DET
fnp-4675	73	24	question	question	NOUN
fnp-4675	73	25	occurs	occur	VERB
fnp-4675	73	26	whether	whether	SCONJ
fnp-4675	73	27	additional	additional	ADJ
fnp-4675	73	28	mechanisms	mechanism	NOUN
fnp-4675	73	29	may	may	AUX
fnp-4675	73	30	contribute	contribute	VERB
fnp-4675	73	31	to	to	ADP
fnp-4675	73	32	the	the	DET
fnp-4675	73	33	development	development	NOUN
fnp-4675	73	34	of	of	ADP
fnp-4675	73	35	these	these	DET
fnp-4675	73	36	lesions	lesion	NOUN
fnp-4675	73	37	.	.	PUNCT
fnp-4675	74	1	an	an	DET
fnp-4675	74	2	obvious	obvious	ADJ
fnp-4675	74	3	possibility	possibility	NOUN
fnp-4675	74	4	would	would	AUX
fnp-4675	74	5	be	be	AUX
fnp-4675	74	6	that	that	SCONJ
fnp-4675	74	7	soluble	soluble	ADJ
fnp-4675	74	8	factors	factor	NOUN
fnp-4675	74	9	secreted	secrete	VERB
fnp-4675	74	10	by	by	ADP
fnp-4675	74	11	the	the	DET
fnp-4675	74	12	inflammatory	inflammatory	ADJ
fnp-4675	74	13	cells	cell	NOUN
fnp-4675	74	14	contribute	contribute	VERB
fnp-4675	74	15	to	to	ADP
fnp-4675	74	16	subpial	subpial	ADJ
fnp-4675	74	17	demyelination	demyelination	NOUN
fnp-4675	74	18	and	and	CCONJ
fnp-4675	74	19	cellular	cellular	ADJ
fnp-4675	74	20	injury	injury	NOUN
fnp-4675	74	21	.	.	PUNCT
fnp-4675	75	1	earlier	early	ADJ
fnp-4675	75	2	pathological	pathological	ADJ
fnp-4675	75	3	studies	study	NOUN
fnp-4675	75	4	could	could	AUX
fnp-4675	75	5	not	not	PART
fnp-4675	75	6	identify	identify	VERB
fnp-4675	75	7	a	a	DET
fnp-4675	75	8	correlation	correlation	NOUN
fnp-4675	75	9	between	between	ADP
fnp-4675	75	10	meningeal	meningeal	ADJ
fnp-4675	75	11	inflammation	inflammation	NOUN
fnp-4675	75	12	and	and	CCONJ
fnp-4675	75	13	number	number	NOUN
fnp-4675	75	14	of	of	ADP
fnp-4675	75	15	wm	wm	PROPN
fnp-4675	75	16	lesions	lesion	NOUN
fnp-4675	75	17	 	 	SPACE
fnp-4675	75	18	23,24	23,24	NUM
fnp-4675	75	19	.	.	PUNCT
fnp-4675	76	1	ahmed	ahmed	PROPN
fnp-4675	76	2	et	et	PROPN
fnp-4675	76	3	al	al	PROPN
fnp-4675	76	4	.	.	PROPN
fnp-4675	76	5	addressed	address	VERB
fnp-4675	76	6	the	the	DET
fnp-4675	76	7	question	question	NOUN
fnp-4675	76	8	whether	whether	SCONJ
fnp-4675	76	9	meningeal	meningeal	ADJ
fnp-4675	76	10	infiltrates	infiltrate	NOUN
fnp-4675	76	11	correlate	correlate	VERB
fnp-4675	76	12	with	with	ADP
fnp-4675	76	13	wm	wm	PROPN
fnp-4675	76	14	lesion	lesion	NOUN
fnp-4675	76	15	activity	activity	NOUN
fnp-4675	76	16	 	 	SPACE
fnp-4675	76	17	25	25	NUM
fnp-4675	76	18	.	.	PUNCT
fnp-4675	77	1	they	they	PRON
fnp-4675	77	2	analyzed	analyze	VERB
fnp-4675	77	3	the	the	DET
fnp-4675	77	4	density	density	NOUN
fnp-4675	77	5	of	of	ADP
fnp-4675	77	6	meningeal	meningeal	ADJ
fnp-4675	77	7	lymphocytes	lymphocyte	NOUN
fnp-4675	77	8	and	and	CCONJ
fnp-4675	77	9	their	their	PRON
fnp-4675	77	10	topographical	topographical	ADJ
fnp-4675	77	11	association	association	NOUN
fnp-4675	77	12	with	with	ADP
fnp-4675	77	13	grey	grey	PROPN
fnp-4675	77	14	(	(	PUNCT
fnp-4675	77	15	cortical	cortical	ADJ
fnp-4675	77	16	)	)	PUNCT
fnp-4675	77	17	and	and	CCONJ
fnp-4675	77	18	white	white	ADJ
fnp-4675	77	19	matter	matter	NOUN
fnp-4675	77	20	lesions	lesion	NOUN
fnp-4675	77	21	in	in	ADP
fnp-4675	77	22	27	27	NUM
fnp-4675	77	23	patients	patient	NOUN
fnp-4675	77	24	with	with	ADP
fnp-4675	77	25	progressive	progressive	ADJ
fnp-4675	77	26	ms	ms	NOUN
fnp-4675	77	27	and	and	CCONJ
fnp-4675	77	28	nine	nine	NUM
fnp-4675	77	29	controls	control	NOUN
fnp-4675	77	30	.	.	PUNCT
fnp-4675	78	1	numbers	number	NOUN
fnp-4675	78	2	of	of	ADP
fnp-4675	78	3	t	t	PROPN
fnp-4675	78	4	and	and	CCONJ
fnp-4675	78	5	b	b	PROPN
fnp-4675	78	6	cells	cell	NOUN
fnp-4675	78	7	per	per	ADP
fnp-4675	78	8	unit	unit	NOUN
fnp-4675	78	9	length	length	NOUN
fnp-4675	78	10	of	of	ADP
fnp-4675	78	11	meninges	meninge	NOUN
fnp-4675	78	12	were	be	AUX
fnp-4675	78	13	significantly	significantly	ADV
fnp-4675	78	14	increased	increase	VERB
fnp-4675	78	15	in	in	ADP
fnp-4675	78	16	ms	ms	NOUN
fnp-4675	78	17	compared	compare	VERB
fnp-4675	78	18	to	to	ADP
fnp-4675	78	19	controls	control	NOUN
fnp-4675	78	20	and	and	CCONJ
fnp-4675	78	21	number	number	NOUN
fnp-4675	78	22	of	of	ADP
fnp-4675	78	23	meningeal	meningeal	ADJ
fnp-4675	78	24	lymphocytes	lymphocyte	NOUN
fnp-4675	78	25	correlated	correlate	VERB
fnp-4675	78	26	with	with	ADP
fnp-4675	78	27	extent	extent	NOUN
fnp-4675	78	28	of	of	ADP
fnp-4675	78	29	subpial	subpial	ADJ
fnp-4675	78	30	demyelination	demyelination	NOUN
fnp-4675	78	31	,	,	PUNCT
fnp-4675	78	32	confirming	confirm	VERB
fnp-4675	78	33	earlier	early	ADJ
fnp-4675	78	34	studies	study	NOUN
fnp-4675	78	35	 	 	SPACE
fnp-4675	78	36	22,23,24,26	22,23,24,26	NUM
fnp-4675	78	37	.	.	PUNCT
fnp-4675	79	1	patients	patient	NOUN
fnp-4675	79	2	with	with	ADP
fnp-4675	79	3	high	high	ADJ
fnp-4675	79	4	meningeal	meningeal	ADJ
fnp-4675	79	5	lymphocytic	lymphocytic	ADJ
fnp-4675	79	6	counts	count	NOUN
fnp-4675	79	7	had	have	VERB
fnp-4675	79	8	more	more	ADV
fnp-4675	79	9	cortical	cortical	ADJ
fnp-4675	79	10	lesions	lesion	NOUN
fnp-4675	79	11	compared	compare	VERB
fnp-4675	79	12	to	to	ADP
fnp-4675	79	13	patients	patient	NOUN
fnp-4675	79	14	with	with	ADP
fnp-4675	79	15	low	low	ADJ
fnp-4675	79	16	lymphocytic	lymphocytic	ADJ
fnp-4675	79	17	counts	count	NOUN
fnp-4675	79	18	,	,	PUNCT
fnp-4675	79	19	but	but	CCONJ
fnp-4675	79	20	no	no	DET
fnp-4675	79	21	difference	difference	NOUN
fnp-4675	79	22	in	in	ADP
fnp-4675	79	23	the	the	DET
fnp-4675	79	24	percentage	percentage	NOUN
fnp-4675	79	25	of	of	ADP
fnp-4675	79	26	subpial	subpial	ADJ
fnp-4675	79	27	,	,	PUNCT
fnp-4675	79	28	leukocortical	leukocortical	ADJ
fnp-4675	79	29	or	or	CCONJ
fnp-4675	79	30	intracortical	intracortical	ADJ
fnp-4675	79	31	lesions	lesion	NOUN
fnp-4675	79	32	.	.	PUNCT
fnp-4675	80	1	importantly	importantly	ADV
fnp-4675	80	2	,	,	PUNCT
fnp-4675	80	3	patients	patient	NOUN
fnp-4675	80	4	with	with	ADP
fnp-4675	80	5	a	a	DET
fnp-4675	80	6	high	high	ADJ
fnp-4675	80	7	density	density	NOUN
fnp-4675	80	8	of	of	ADP
fnp-4675	80	9	meningeal	meningeal	ADJ
fnp-4675	80	10	lymphocytic	lymphocytic	ADJ
fnp-4675	80	11	infiltrates	infiltrate	NOUN
fnp-4675	80	12	had	have	VERB
fnp-4675	80	13	a	a	DET
fnp-4675	80	14	higher	high	ADJ
fnp-4675	80	15	proportion	proportion	NOUN
fnp-4675	80	16	of	of	ADP
fnp-4675	80	17	active	active	ADJ
fnp-4675	80	18	and	and	CCONJ
fnp-4675	80	19	mixed	mixed	ADJ
fnp-4675	80	20	lesions	lesion	NOUN
fnp-4675	80	21	and	and	CCONJ
fnp-4675	80	22	a	a	DET
fnp-4675	80	23	lower	low	ADJ
fnp-4675	80	24	percentage	percentage	NOUN
fnp-4675	80	25	of	of	ADP
fnp-4675	80	26	inactive	inactive	ADJ
fnp-4675	80	27	or	or	CCONJ
fnp-4675	80	28	remyelinated	remyelinate	VERB
fnp-4675	80	29	lesions	lesion	NOUN
fnp-4675	80	30	than	than	ADP
fnp-4675	80	31	patients	patient	NOUN
fnp-4675	80	32	with	with	ADP
fnp-4675	80	33	a	a	DET
fnp-4675	80	34	low	low	ADJ
fnp-4675	80	35	density	density	NOUN
fnp-4675	80	36	of	of	ADP
fnp-4675	80	37	meningeal	meningeal	ADJ
fnp-4675	80	38	infiltrates	infiltrate	NOUN
fnp-4675	80	39	.	.	PUNCT
fnp-4675	81	1	interestingly	interestingly	ADV
fnp-4675	81	2	,	,	PUNCT
fnp-4675	81	3	no	no	DET
fnp-4675	81	4	correlation	correlation	NOUN
fnp-4675	81	5	between	between	ADP
fnp-4675	81	6	meningeal	meningeal	ADJ
fnp-4675	81	7	myeloid	myeloid	NOUN
fnp-4675	81	8	infiltrates	infiltrate	NOUN
fnp-4675	81	9	and	and	CCONJ
fnp-4675	81	10	subpial	subpial	ADJ
fnp-4675	81	11	demyelination	demyelination	NOUN
fnp-4675	81	12	or	or	CCONJ
fnp-4675	81	13	wm	wm	PROPN
fnp-4675	81	14	lesion	lesion	NOUN
fnp-4675	81	15	activity	activity	NOUN
fnp-4675	81	16	was	be	AUX
fnp-4675	81	17	detected	detect	VERB
fnp-4675	81	18	.	.	PUNCT
fnp-4675	82	1	the	the	DET
fnp-4675	82	2	authors	author	NOUN
fnp-4675	82	3	speculated	speculate	VERB
fnp-4675	82	4	that	that	SCONJ
fnp-4675	82	5	the	the	DET
fnp-4675	82	6	correlation	correlation	NOUN
fnp-4675	82	7	of	of	ADP
fnp-4675	82	8	the	the	DET
fnp-4675	82	9	extent	extent	NOUN
fnp-4675	82	10	of	of	ADP
fnp-4675	82	11	meningeal	meningeal	ADJ
fnp-4675	82	12	inflammation	inflammation	NOUN
fnp-4675	82	13	and	and	CCONJ
fnp-4675	82	14	the	the	DET
fnp-4675	82	15	presence	presence	NOUN
fnp-4675	82	16	of	of	ADP
fnp-4675	82	17	higher	high	ADJ
fnp-4675	82	18	proportions	proportion	NOUN
fnp-4675	82	19	of	of	ADP
fnp-4675	82	20	active	active	ADJ
fnp-4675	82	21	and	and	CCONJ
fnp-4675	82	22	mixed	mixed	ADJ
fnp-4675	82	23	lesions	lesion	NOUN
fnp-4675	82	24	may	may	AUX
fnp-4675	82	25	represent	represent	VERB
fnp-4675	82	26	two	two	NUM
fnp-4675	82	27	independent	independent	ADJ
fnp-4675	82	28	pathogenic	pathogenic	ADJ
fnp-4675	82	29	mechanisms	mechanism	NOUN
fnp-4675	82	30	which	which	PRON
fnp-4675	82	31	reflect	reflect	VERB
fnp-4675	82	32	an	an	DET
fnp-4675	82	33	overall	overall	ADJ
fnp-4675	82	34	higher	high	ADJ
fnp-4675	82	35	disease	disease	NOUN
fnp-4675	82	36	activity	activity	NOUN
fnp-4675	82	37	.	.	PUNCT
fnp-4675	83	1	in	in	ADP
fnp-4675	83	2	line	line	NOUN
fnp-4675	83	3	with	with	ADP
fnp-4675	83	4	this	this	DET
fnp-4675	83	5	observation	observation	NOUN
fnp-4675	83	6	are	be	AUX
fnp-4675	83	7	studies	study	NOUN
fnp-4675	83	8	which	which	PRON
fnp-4675	83	9	demonstrated	demonstrate	VERB
fnp-4675	83	10	a	a	DET
fnp-4675	83	11	correlation	correlation	NOUN
fnp-4675	83	12	between	between	ADP
fnp-4675	83	13	numbers	number	NOUN
fnp-4675	83	14	of	of	ADP
fnp-4675	83	15	leptomeningeal	leptomeningeal	ADJ
fnp-4675	83	16	b	b	PROPN
fnp-4675	83	17	cells	cell	NOUN
fnp-4675	83	18	and	and	CCONJ
fnp-4675	83	19	perivascular	perivascular	ADJ
fnp-4675	83	20	t	t	PROPN
fnp-4675	83	21	and	and	CCONJ
fnp-4675	83	22	b	b	PROPN
fnp-4675	83	23	cells	cell	NOUN
fnp-4675	83	24	in	in	ADP
fnp-4675	83	25	wm	wm	PROPN
fnp-4675	83	26	or	or	CCONJ
fnp-4675	83	27	brain	brain	NOUN
fnp-4675	83	28	stem	stem	NOUN
fnp-4675	83	29	lesions	lesion	NOUN
fnp-4675	83	30	 	 	SPACE
fnp-4675	83	31	27,28	27,28	NUM
fnp-4675	83	32	.	.	PUNCT
fnp-4675	84	1	cellular	cellular	ADJ
fnp-4675	84	2	trafficking	trafficking	NOUN
fnp-4675	84	3	to	to	ADP
fnp-4675	84	4	and	and	CCONJ
fnp-4675	84	5	from	from	ADP
fnp-4675	84	6	the	the	DET
fnp-4675	84	7	meninges	meninge	NOUN
fnp-4675	84	8	the	the	DET
fnp-4675	84	9	bi	bi	ADJ
fnp-4675	84	10	-	-	ADJ
fnp-4675	84	11	directional	directional	ADJ
fnp-4675	84	12	communication	communication	NOUN
fnp-4675	84	13	between	between	ADP
fnp-4675	84	14	the	the	DET
fnp-4675	84	15	systemic	systemic	ADJ
fnp-4675	84	16	and	and	CCONJ
fnp-4675	84	17	cns	cns	PROPN
fnp-4675	84	18	compartments	compartment	NOUN
fnp-4675	84	19	is	be	AUX
fnp-4675	84	20	a	a	DET
fnp-4675	84	21	central	central	ADJ
fnp-4675	84	22	process	process	NOUN
fnp-4675	84	23	contributing	contribute	VERB
fnp-4675	84	24	to	to	ADP
fnp-4675	84	25	the	the	DET
fnp-4675	84	26	disease	disease	NOUN
fnp-4675	84	27	course	course	NOUN
fnp-4675	84	28	of	of	ADP
fnp-4675	84	29	multiple	multiple	ADJ
fnp-4675	84	30	sclerosis	sclerosis	NOUN
fnp-4675	84	31	.	.	PUNCT
fnp-4675	85	1	to	to	PART
fnp-4675	85	2	be	be	AUX
fnp-4675	85	3	considered	consider	VERB
fnp-4675	85	4	are	be	AUX
fnp-4675	85	5	the	the	DET
fnp-4675	85	6	connections	connection	NOUN
fnp-4675	85	7	whereby	whereby	SCONJ
fnp-4675	85	8	systemic	systemic	ADJ
fnp-4675	85	9	immune	immune	ADJ
fnp-4675	85	10	constituents	constituent	NOUN
fnp-4675	85	11	can	can	AUX
fnp-4675	85	12	access	access	VERB
fnp-4675	85	13	the	the	DET
fnp-4675	85	14	cns	cns	NOUN
fnp-4675	85	15	and	and	CCONJ
fnp-4675	85	16	how	how	SCONJ
fnp-4675	85	17	materials	material	NOUN
fnp-4675	85	18	released	release	VERB
fnp-4675	85	19	within	within	ADP
fnp-4675	85	20	the	the	DET
fnp-4675	85	21	cns	cns	NOUN
fnp-4675	85	22	are	be	AUX
fnp-4675	85	23	cleared	clear	VERB
fnp-4675	85	24	from	from	ADP
fnp-4675	85	25	this	this	DET
fnp-4675	85	26	compartment	compartment	NOUN
fnp-4675	85	27	and	and	CCONJ
fnp-4675	85	28	transferred	transfer	VERB
fnp-4675	85	29	back	back	ADV
fnp-4675	85	30	to	to	ADP
fnp-4675	85	31	the	the	DET
fnp-4675	85	32	systemic	systemic	ADJ
fnp-4675	85	33	compartment	compartment	NOUN
fnp-4675	85	34	.	.	PUNCT
fnp-4675	86	1	in	in	ADP
fnp-4675	86	2	context	context	NOUN
fnp-4675	86	3	of	of	ADP
fnp-4675	86	4	immune	immune	NOUN
fnp-4675	86	5	-	-	PUNCT
fnp-4675	86	6	brain	brain	NOUN
fnp-4675	86	7	interactions	interaction	NOUN
fnp-4675	86	8	,	,	PUNCT
fnp-4675	86	9	entry	entry	NOUN
fnp-4675	86	10	via	via	ADP
fnp-4675	86	11	the	the	DET
fnp-4675	86	12	blood	blood	NOUN
fnp-4675	86	13	-	-	PUNCT
fnp-4675	86	14	brain	brain	NOUN
fnp-4675	86	15	barrier	barrier	NOUN
fnp-4675	86	16	(	(	PUNCT
fnp-4675	86	17	bbb	bbb	NOUN
fnp-4675	86	18	)	)	PUNCT
fnp-4675	86	19	has	have	AUX
fnp-4675	86	20	been	be	AUX
fnp-4675	86	21	the	the	DET
fnp-4675	86	22	classic	classic	ADJ
fnp-4675	86	23	pathway	pathway	NOUN
fnp-4675	86	24	.	.	PUNCT
fnp-4675	87	1	blocking	block	VERB
fnp-4675	87	2	immune	immune	ADJ
fnp-4675	87	3	cell	cell	NOUN
fnp-4675	87	4	passage	passage	NOUN
fnp-4675	87	5	with	with	ADP
fnp-4675	87	6	adhesion	adhesion	NOUN
fnp-4675	87	7	molecule	molecule	NOUN
fnp-4675	87	8	directed	direct	VERB
fnp-4675	87	9	inhibitors	inhibitor	NOUN
fnp-4675	87	10	or	or	CCONJ
fnp-4675	87	11	antibodies	antibody	NOUN
fnp-4675	87	12	is	be	AUX
fnp-4675	87	13	an	an	DET
fnp-4675	87	14	effective	effective	ADJ
fnp-4675	87	15	therapy	therapy	NOUN
fnp-4675	87	16	in	in	ADP
fnp-4675	87	17	the	the	DET
fnp-4675	87	18	eae	eae	NOUN
fnp-4675	87	19	model	model	NOUN
fnp-4675	87	20	and	and	CCONJ
fnp-4675	87	21	translates	translate	VERB
fnp-4675	87	22	into	into	ADP
fnp-4675	87	23	clinical	clinical	ADJ
fnp-4675	87	24	therapy	therapy	NOUN
fnp-4675	87	25	(	(	PUNCT
fnp-4675	87	26	natalizumab	natalizumab	NOUN
fnp-4675	87	27	is	be	AUX
fnp-4675	87	28	an	an	DET
fnp-4675	87	29	approved	approve	VERB
fnp-4675	87	30	therapy	therapy	NOUN
fnp-4675	87	31	for	for	ADP
fnp-4675	87	32	relapsing	relapse	VERB
fnp-4675	87	33	ms	ms	NOUN
fnp-4675	87	34	)	)	PUNCT
fnp-4675	87	35	.	.	PUNCT
fnp-4675	88	1	a	a	DET
fnp-4675	88	2	further	further	ADJ
fnp-4675	88	3	pathway	pathway	NOUN
fnp-4675	88	4	involves	involve	VERB
fnp-4675	88	5	blood	blood	NOUN
fnp-4675	88	6	-	-	PUNCT
fnp-4675	88	7	csf	csf	NOUN
fnp-4675	88	8	trafficking	trafficking	NOUN
fnp-4675	88	9	that	that	PRON
fnp-4675	88	10	underlies	underlie	VERB
fnp-4675	88	11	immune	immune	ADJ
fnp-4675	88	12	seeding	seeding	NOUN
fnp-4675	88	13	within	within	ADP
fnp-4675	88	14	the	the	DET
fnp-4675	88	15	meninges	meninge	NOUN
fnp-4675	88	16	.	.	PUNCT
fnp-4675	89	1	the	the	DET
fnp-4675	89	2	observed	observe	VERB
fnp-4675	89	3	pathologic	pathologic	ADJ
fnp-4675	89	4	changes	change	NOUN
fnp-4675	89	5	in	in	ADP
fnp-4675	89	6	ms	ms	NOUN
fnp-4675	89	7	in	in	ADP
fnp-4675	89	8	the	the	DET
fnp-4675	89	9	subpial	subpial	ADJ
fnp-4675	89	10	grey	grey	NOUN
fnp-4675	89	11	matter	matter	NOUN
fnp-4675	89	12	and	and	CCONJ
fnp-4675	89	13	periventricular	periventricular	ADJ
fnp-4675	89	14	regions	region	NOUN
fnp-4675	89	15	support	support	VERB
fnp-4675	89	16	the	the	DET
fnp-4675	89	17	impact	impact	NOUN
fnp-4675	89	18	of	of	ADP
fnp-4675	89	19	immune	immune	ADJ
fnp-4675	89	20	constituents	constituent	NOUN
fnp-4675	89	21	from	from	ADP
fnp-4675	89	22	the	the	DET
fnp-4675	89	23	csf	csf	NOUN
fnp-4675	89	24	-	-	PUNCT
fnp-4675	89	25	meninges	meninge	NOUN
fnp-4675	89	26	acting	act	VERB
fnp-4675	89	27	on	on	ADP
fnp-4675	89	28	the	the	DET
fnp-4675	89	29	brain	brain	NOUN
fnp-4675	89	30	parenchyma	parenchyma	NOUN
fnp-4675	89	31	.	.	PUNCT
fnp-4675	90	1	drieu	drieu	NOUN
fnp-4675	90	2	et	et	PROPN
fnp-4675	90	3	al	al	PROPN
fnp-4675	90	4	.	.	PROPN
fnp-4675	90	5	,	,	PUNCT
fnp-4675	90	6	taking	take	VERB
fnp-4675	90	7	advantage	advantage	NOUN
fnp-4675	90	8	of	of	ADP
fnp-4675	90	9	the	the	DET
fnp-4675	90	10	capacity	capacity	NOUN
fnp-4675	90	11	to	to	PART
fnp-4675	90	12	pharmacologically	pharmacologically	ADV
fnp-4675	90	13	or	or	CCONJ
fnp-4675	90	14	genetically	genetically	ADV
fnp-4675	90	15	delete	delete	ADJ
fnp-4675	90	16	selective	selective	ADJ
fnp-4675	90	17	cell	cell	NOUN
fnp-4675	90	18	populations	population	NOUN
fnp-4675	90	19	in	in	ADP
fnp-4675	90	20	mice	mouse	NOUN
fnp-4675	90	21	,	,	PUNCT
fnp-4675	90	22	showed	show	VERB
fnp-4675	90	23	that	that	SCONJ
fnp-4675	90	24	populations	population	NOUN
fnp-4675	90	25	of	of	ADP
fnp-4675	90	26	perivascular	perivascular	ADJ
fnp-4675	90	27	and	and	CCONJ
fnp-4675	90	28	leptomeningeal	leptomeningeal	ADJ
fnp-4675	90	29	macrophages	macrophage	NOUN
fnp-4675	90	30	,	,	PUNCT
fnp-4675	90	31	referred	refer	VERB
fnp-4675	90	32	to	to	ADP
fnp-4675	90	33	as	as	ADP
fnp-4675	90	34	parenchymal	parenchymal	ADJ
fnp-4675	90	35	border	border	NOUN
fnp-4675	90	36	macrophages	macrophage	NOUN
fnp-4675	90	37	(	(	PUNCT
fnp-4675	90	38	pbms	pbms	ADJ
fnp-4675	90	39	)	)	PUNCT
fnp-4675	90	40	,	,	PUNCT
fnp-4675	90	41	regulate	regulate	VERB
fnp-4675	90	42	arterial	arterial	ADJ
fnp-4675	90	43	motion	motion	NOUN
fnp-4675	90	44	that	that	PRON
fnp-4675	90	45	drives	drive	VERB
fnp-4675	90	46	csf	csf	ADJ
fnp-4675	90	47	flow	flow	NOUN
fnp-4675	90	48	 	 	SPACE
fnp-4675	90	49	29	29	NUM
fnp-4675	90	50	.	.	PUNCT
fnp-4675	91	1	the	the	DET
fnp-4675	91	2	cns	cns	PROPN
fnp-4675	91	3	'	'	PUNCT
fnp-4675	91	4	waste	waste	NOUN
fnp-4675	91	5	clearance	clearance	NOUN
fnp-4675	91	6	'	'	PUNCT
fnp-4675	91	7	system	system	NOUN
fnp-4675	91	8	is	be	AUX
fnp-4675	91	9	defined	define	VERB
fnp-4675	91	10	as	as	ADP
fnp-4675	91	11	the	the	DET
fnp-4675	91	12	glymphatic	glymphatic	ADJ
fnp-4675	91	13	system	system	NOUN
fnp-4675	91	14	.	.	PUNCT
fnp-4675	92	1	carotenuto	carotenuto	PROPN
fnp-4675	92	2	et	et	PROPN
fnp-4675	92	3	al	al	PROPN
fnp-4675	92	4	.	.	PROPN
fnp-4675	92	5	used	use	VERB
fnp-4675	92	6	an	an	DET
fnp-4675	92	7	array	array	NOUN
fnp-4675	92	8	of	of	ADP
fnp-4675	92	9	different	different	ADJ
fnp-4675	92	10	magnetic	magnetic	ADJ
fnp-4675	92	11	resonance	resonance	NOUN
fnp-4675	92	12	imaging	imaging	NOUN
fnp-4675	92	13	(	(	PUNCT
fnp-4675	92	14	mri	mri	NOUN
fnp-4675	92	15	)	)	PUNCT
fnp-4675	92	16	techniques	technique	NOUN
fnp-4675	92	17	to	to	PART
fnp-4675	92	18	identify	identify	VERB
fnp-4675	92	19	dysfunction	dysfunction	NOUN
fnp-4675	92	20	of	of	ADP
fnp-4675	92	21	the	the	DET
fnp-4675	92	22	glymphatic	glymphatic	ADJ
fnp-4675	92	23	system	system	NOUN
fnp-4675	92	24	function	function	NOUN
fnp-4675	92	25	in	in	ADP
fnp-4675	92	26	multiple	multiple	ADJ
fnp-4675	92	27	sclerosis	sclerosis	NOUN
fnp-4675	92	28	and	and	CCONJ
fnp-4675	92	29	found	find	VERB
fnp-4675	92	30	an	an	DET
fnp-4675	92	31	association	association	NOUN
fnp-4675	92	32	with	with	ADP
fnp-4675	92	33	clinical	clinical	ADJ
fnp-4675	92	34	disability	disability	NOUN
fnp-4675	92	35	,	,	PUNCT
fnp-4675	92	36	disease	disease	NOUN
fnp-4675	92	37	course	course	NOUN
fnp-4675	92	38	,	,	PUNCT
fnp-4675	92	39	demyelination	demyelination	NOUN
fnp-4675	92	40	and	and	CCONJ
fnp-4675	92	41	neurodegeneration	neurodegeneration	NOUN
fnp-4675	92	42	 	 	SPACE
fnp-4675	92	43	30	30	NUM
fnp-4675	92	44	.	.	PUNCT
fnp-4675	93	1	transport	transport	NOUN
fnp-4675	93	2	of	of	ADP
fnp-4675	93	3	neural	neural	ADJ
fnp-4675	93	4	tissue	tissue	NOUN
fnp-4675	93	5	breakdown	breakdown	NOUN
fnp-4675	93	6	products	product	NOUN
fnp-4675	93	7	,	,	PUNCT
fnp-4675	93	8	specifically	specifically	ADV
fnp-4675	93	9	myelin	myelin	ADJ
fnp-4675	93	10	constituents	constituent	NOUN
fnp-4675	93	11	,	,	PUNCT
fnp-4675	93	12	back	back	ADV
fnp-4675	93	13	to	to	ADP
fnp-4675	93	14	regional	regional	ADJ
fnp-4675	93	15	lymph	lymph	NOUN
fnp-4675	93	16	nodes	node	NOUN
fnp-4675	93	17	has	have	AUX
fnp-4675	93	18	previously	previously	ADV
fnp-4675	93	19	been	be	AUX
fnp-4675	93	20	documented	document	VERB
fnp-4675	93	21	by	by	ADP
fnp-4675	93	22	showing	show	VERB
fnp-4675	93	23	their	their	PRON
fnp-4675	93	24	presence	presence	NOUN
fnp-4675	93	25	in	in	ADP
fnp-4675	93	26	cervical	cervical	ADJ
fnp-4675	93	27	lymph	lymph	NOUN
fnp-4675	93	28	nodes	node	NOUN
fnp-4675	93	29	of	of	ADP
fnp-4675	93	30	ms	ms	NOUN
fnp-4675	93	31	cases	case	NOUN
fnp-4675	93	32	 	 	SPACE
fnp-4675	93	33	31.the	31.the	DET
fnp-4675	93	34	detection	detection	NOUN
fnp-4675	93	35	of	of	ADP
fnp-4675	93	36	lymphatic	lymphatic	ADJ
fnp-4675	93	37	dural	dural	ADJ
fnp-4675	93	38	vessels	vessel	NOUN
fnp-4675	93	39	,	,	PUNCT
fnp-4675	93	40	which	which	PRON
fnp-4675	93	41	connect	connect	VERB
fnp-4675	93	42	csf	csf	ADJ
fnp-4675	93	43	and	and	CCONJ
fnp-4675	93	44	draining	drain	VERB
fnp-4675	93	45	cervical	cervical	ADJ
fnp-4675	93	46	lymph	lymph	NOUN
fnp-4675	93	47	nodes	node	NOUN
fnp-4675	93	48	,	,	PUNCT
fnp-4675	93	49	raises	raise	VERB
fnp-4675	93	50	the	the	DET
fnp-4675	93	51	question	question	NOUN
fnp-4675	93	52	of	of	ADP
fnp-4675	93	53	the	the	DET
fnp-4675	93	54	relevance	relevance	NOUN
fnp-4675	93	55	of	of	ADP
fnp-4675	93	56	these	these	DET
fnp-4675	93	57	vessels	vessel	NOUN
fnp-4675	93	58	and	and	CCONJ
fnp-4675	93	59	dural	dural	ADJ
fnp-4675	93	60	inflammation	inflammation	NOUN
fnp-4675	93	61	for	for	ADP
fnp-4675	93	62	autoimmune	autoimmune	ADJ
fnp-4675	93	63	disease	disease	NOUN
fnp-4675	93	64	such	such	ADJ
fnp-4675	93	65	as	as	ADP
fnp-4675	93	66	multiple	multiple	ADJ
fnp-4675	93	67	sclerosis	sclerosis	NOUN
fnp-4675	93	68	 	 	SPACE
fnp-4675	93	69	32	32	NUM
fnp-4675	93	70	.	.	PUNCT
fnp-4675	94	1	merlini	merlini	PROPN
fnp-4675	94	2	et	et	PROPN
fnp-4675	94	3	al	al	PROPN
fnp-4675	94	4	.	.	PROPN
fnp-4675	94	5	have	have	AUX
fnp-4675	94	6	studied	study	VERB
fnp-4675	94	7	the	the	DET
fnp-4675	94	8	functional	functional	ADJ
fnp-4675	94	9	role	role	NOUN
fnp-4675	94	10	of	of	ADP
fnp-4675	94	11	dural	dural	ADJ
fnp-4675	94	12	and	and	CCONJ
fnp-4675	94	13	leptomeningeal	leptomeningeal	ADJ
fnp-4675	94	14	inflammation	inflammation	NOUN
fnp-4675	94	15	in	in	ADP
fnp-4675	94	16	eae	eae	PROPN
fnp-4675	94	17	using	use	VERB
fnp-4675	94	18	intravital	intravital	ADJ
fnp-4675	94	19	microscopy	microscopy	NOUN
fnp-4675	94	20	to	to	PART
fnp-4675	94	21	address	address	VERB
fnp-4675	94	22	this	this	DET
fnp-4675	94	23	question	question	NOUN
fnp-4675	94	24	 	 	SPACE
fnp-4675	94	25	32	32	NUM
fnp-4675	94	26	.	.	PUNCT
fnp-4675	95	1	they	they	PRON
fnp-4675	95	2	could	could	AUX
fnp-4675	95	3	show	show	VERB
fnp-4675	95	4	that	that	SCONJ
fnp-4675	95	5	the	the	DET
fnp-4675	95	6	leptomeninges	leptomeninge	NOUN
fnp-4675	95	7	were	be	AUX
fnp-4675	95	8	highly	highly	ADV
fnp-4675	95	9	inflamed	inflame	VERB
fnp-4675	95	10	in	in	ADP
fnp-4675	95	11	acute	acute	ADJ
fnp-4675	95	12	and	and	CCONJ
fnp-4675	95	13	chronic	chronic	ADJ
fnp-4675	95	14	eae	eae	PROPN
fnp-4675	95	15	,	,	PUNCT
fnp-4675	95	16	whereas	whereas	SCONJ
fnp-4675	95	17	the	the	DET
fnp-4675	95	18	dura	dura	NOUN
fnp-4675	95	19	was	be	AUX
fnp-4675	95	20	only	only	ADV
fnp-4675	95	21	minimal	minimal	ADJ
fnp-4675	95	22	affected	affect	VERB
fnp-4675	95	23	.	.	PUNCT
fnp-4675	96	1	t	t	PROPN
fnp-4675	96	2	cells	cell	NOUN
fnp-4675	96	3	adhered	adhere	VERB
fnp-4675	96	4	more	more	ADV
fnp-4675	96	5	weakly	weakly	ADJ
fnp-4675	96	6	,	,	PUNCT
fnp-4675	96	7	antigen	antigen	ADJ
fnp-4675	96	8	presentation	presentation	NOUN
fnp-4675	96	9	was	be	AUX
fnp-4675	96	10	less	less	ADV
fnp-4675	96	11	efficient	efficient	ADJ
fnp-4675	96	12	and	and	CCONJ
fnp-4675	96	13	activation	activation	NOUN
fnp-4675	96	14	of	of	ADP
fnp-4675	96	15	autoreactive	autoreactive	ADJ
fnp-4675	96	16	t	t	PROPN
fnp-4675	96	17	cells	cell	NOUN
fnp-4675	96	18	was	be	AUX
fnp-4675	96	19	lower	low	ADJ
fnp-4675	96	20	in	in	ADP
fnp-4675	96	21	the	the	DET
fnp-4675	96	22	dura	dura	NOUN
fnp-4675	96	23	compared	compare	VERB
fnp-4675	96	24	to	to	ADP
fnp-4675	96	25	the	the	DET
fnp-4675	96	26	leptomeninges	leptomeninge	NOUN
fnp-4675	96	27	suggesting	suggest	VERB
fnp-4675	96	28	that	that	SCONJ
fnp-4675	96	29	the	the	DET
fnp-4675	96	30	dura	dura	NOUN
fnp-4675	96	31	plays	play	VERB
fnp-4675	96	32	only	only	ADV
fnp-4675	96	33	a	a	DET
fnp-4675	96	34	minor	minor	ADJ
fnp-4675	96	35	role	role	NOUN
fnp-4675	96	36	in	in	ADP
fnp-4675	96	37	autoimmune	autoimmune	ADJ
fnp-4675	96	38	inflammation	inflammation	NOUN
fnp-4675	96	39	.	.	PUNCT
fnp-4675	97	1	these	these	DET
fnp-4675	97	2	observations	observation	NOUN
fnp-4675	97	3	were	be	AUX
fnp-4675	97	4	matched	match	VERB
fnp-4675	97	5	by	by	ADP
fnp-4675	97	6	findings	finding	NOUN
fnp-4675	97	7	in	in	ADP
fnp-4675	97	8	ms	ms	ADJ
fnp-4675	97	9	brains	brain	NOUN
fnp-4675	97	10	.	.	PUNCT
fnp-4675	98	1	histological	histological	ADJ
fnp-4675	98	2	studies	study	NOUN
fnp-4675	98	3	analyzing	analyze	VERB
fnp-4675	98	4	the	the	DET
fnp-4675	98	5	extent	extent	NOUN
fnp-4675	98	6	of	of	ADP
fnp-4675	98	7	inflammation	inflammation	NOUN
fnp-4675	98	8	in	in	ADP
fnp-4675	98	9	leptomeninges	leptomeninge	NOUN
fnp-4675	98	10	compared	compare	VERB
fnp-4675	98	11	to	to	ADP
fnp-4675	98	12	the	the	DET
fnp-4675	98	13	dura	dura	NOUN
fnp-4675	98	14	observed	observe	VERB
fnp-4675	98	15	significant	significant	ADJ
fnp-4675	98	16	t	t	NOUN
fnp-4675	98	17	cell	cell	NOUN
fnp-4675	98	18	infiltrates	infiltrate	VERB
fnp-4675	98	19	only	only	ADV
fnp-4675	98	20	in	in	ADP
fnp-4675	98	21	the	the	DET
fnp-4675	98	22	leptomeninges	leptomeninge	NOUN
fnp-4675	98	23	,	,	PUNCT
fnp-4675	98	24	but	but	CCONJ
fnp-4675	98	25	not	not	PART
fnp-4675	98	26	in	in	ADP
fnp-4675	98	27	the	the	DET
fnp-4675	98	28	dura	dura	NOUN
fnp-4675	98	29	.	.	PUNCT
fnp-4675	99	1	diffuse	diffuse	VERB
fnp-4675	99	2	white	white	ADJ
fnp-4675	99	3	mater	mater	NOUN
fnp-4675	99	4	inflammation	inflammation	NOUN
fnp-4675	99	5	and	and	CCONJ
fnp-4675	99	6	it	it	PRON
fnp-4675	99	7	consequences	consequence	VERB
fnp-4675	99	8	for	for	ADP
fnp-4675	99	9	the	the	DET
fnp-4675	99	10	myelin	myelin	NOUN
fnp-4675	99	11	-	-	PUNCT
fnp-4675	99	12	axon	axon	NOUN
fnp-4675	99	13	unit	unit	NOUN
fnp-4675	99	14	the	the	DET
fnp-4675	99	15	pathogenic	pathogenic	ADJ
fnp-4675	99	16	mechanisms	mechanism	NOUN
fnp-4675	99	17	driving	drive	VERB
fnp-4675	99	18	disease	disease	NOUN
fnp-4675	99	19	progression	progression	NOUN
fnp-4675	99	20	independent	independent	ADJ
fnp-4675	99	21	of	of	ADP
fnp-4675	99	22	new	new	ADJ
fnp-4675	99	23	lesions	lesion	NOUN
fnp-4675	99	24	are	be	AUX
fnp-4675	99	25	,	,	PUNCT
fnp-4675	99	26	so	so	ADV
fnp-4675	99	27	far	far	ADV
fnp-4675	99	28	,	,	PUNCT
fnp-4675	99	29	only	only	ADV
fnp-4675	99	30	incompletely	incompletely	ADV
fnp-4675	99	31	understood	understand	VERB
fnp-4675	99	32	.	.	PUNCT
fnp-4675	100	1	potential	potential	ADJ
fnp-4675	100	2	mechanisms	mechanism	NOUN
fnp-4675	100	3	include	include	VERB
fnp-4675	100	4	the	the	DET
fnp-4675	100	5	expansion	expansion	NOUN
fnp-4675	100	6	of	of	ADP
fnp-4675	100	7	focal	focal	ADJ
fnp-4675	100	8	lesions	lesion	NOUN
fnp-4675	100	9	,	,	PUNCT
fnp-4675	100	10	as	as	SCONJ
fnp-4675	100	11	described	describe	VERB
fnp-4675	100	12	above	above	ADV
fnp-4675	100	13	,	,	PUNCT
fnp-4675	100	14	but	but	CCONJ
fnp-4675	100	15	also	also	ADV
fnp-4675	100	16	diffuse	diffuse	VERB
fnp-4675	100	17	changes	change	NOUN
fnp-4675	100	18	in	in	ADP
fnp-4675	100	19	normal	normal	ADJ
fnp-4675	100	20	appearing	appear	VERB
fnp-4675	100	21	white	white	ADJ
fnp-4675	100	22	matter	matter	NOUN
fnp-4675	100	23	in	in	ADP
fnp-4675	100	24	ms	ms	PROPN
fnp-4675	100	25	.	.	PROPN
fnp-4675	100	26	in	in	ADP
fnp-4675	100	27	their	their	PRON
fnp-4675	100	28	study	study	NOUN
fnp-4675	100	29	,	,	PUNCT
fnp-4675	100	30	van	van	PROPN
fnp-4675	100	31	den	den	PROPN
fnp-4675	100	32	bosch	bosch	PROPN
fnp-4675	100	33	et	et	PROPN
fnp-4675	100	34	al	al	PROPN
fnp-4675	100	35	.	.	PROPN
fnp-4675	101	1	elucidate	elucidate	VERB
fnp-4675	101	2	the	the	DET
fnp-4675	101	3	consequences	consequence	NOUN
fnp-4675	101	4	of	of	ADP
fnp-4675	101	5	diffuse	diffuse	ADJ
fnp-4675	101	6	microglia	microglia	ADJ
fnp-4675	101	7	activation	activation	NOUN
fnp-4675	101	8	and	and	CCONJ
fnp-4675	101	9	low	low	ADJ
fnp-4675	101	10	-	-	PUNCT
fnp-4675	101	11	level	level	NOUN
fnp-4675	101	12	t	t	NOUN
fnp-4675	101	13	cell	cell	NOUN
fnp-4675	101	14	infiltration	infiltration	NOUN
fnp-4675	101	15	for	for	ADP
fnp-4675	101	16	axon	axon	NOUN
fnp-4675	101	17	-	-	PUNCT
fnp-4675	101	18	myelin	myelin	NOUN
fnp-4675	101	19	units	unit	NOUN
fnp-4675	101	20	in	in	ADP
fnp-4675	101	21	the	the	DET
fnp-4675	101	22	normal	normal	ADJ
fnp-4675	101	23	appearing	appearing	ADJ
fnp-4675	101	24	white	white	ADJ
fnp-4675	101	25	matter	matter	NOUN
fnp-4675	101	26	(	(	PUNCT
fnp-4675	101	27	nawm	nawm	PROPN
fnp-4675	101	28	)	)	PUNCT
fnp-4675	101	29	,	,	PUNCT
fnp-4675	101	30	using	use	VERB
fnp-4675	101	31	high	high	ADJ
fnp-4675	101	32	-	-	PUNCT
fnp-4675	101	33	resolution	resolution	NOUN
fnp-4675	101	34	immunohistochemistry	immunohistochemistry	NOUN
fnp-4675	101	35	(	(	PUNCT
fnp-4675	101	36	ihc	ihc	PROPN
fnp-4675	101	37	)	)	PUNCT
fnp-4675	101	38	and	and	CCONJ
fnp-4675	101	39	transmission	transmission	NOUN
fnp-4675	101	40	electron	electron	NOUN
fnp-4675	101	41	microscopy	microscopy	NOUN
fnp-4675	101	42	(	(	PUNCT
fnp-4675	101	43	tem	tem	PROPN
fnp-4675	101	44	)	)	PUNCT
fnp-4675	101	45	 	 	SPACE
fnp-4675	101	46	33	33	NUM
fnp-4675	101	47	.	.	PUNCT
fnp-4675	102	1	they	they	PRON
fnp-4675	102	2	compared	compare	VERB
fnp-4675	102	3	the	the	DET
fnp-4675	102	4	ultrastructural	ultrastructural	ADJ
fnp-4675	102	5	characteristics	characteristic	NOUN
fnp-4675	102	6	of	of	ADP
fnp-4675	102	7	the	the	DET
fnp-4675	102	8	axon	axon	NOUN
fnp-4675	102	9	-	-	PUNCT
fnp-4675	102	10	myelin	myelin	NOUN
fnp-4675	102	11	unit	unit	NOUN
fnp-4675	102	12	in	in	ADP
fnp-4675	102	13	non	non	ADJ
fnp-4675	102	14	-	-	ADJ
fnp-4675	102	15	lesional	lesional	ADJ
fnp-4675	102	16	optic	optic	ADJ
fnp-4675	102	17	nerves	nerve	NOUN
fnp-4675	102	18	from	from	ADP
fnp-4675	102	19	8	8	NUM
fnp-4675	102	20	people	people	NOUN
fnp-4675	102	21	with	with	ADP
fnp-4675	102	22	ms	ms	PROPN
fnp-4675	102	23	and	and	CCONJ
fnp-4675	102	24	8	8	NUM
fnp-4675	102	25	controls	control	NOUN
fnp-4675	102	26	.	.	PUNCT
fnp-4675	103	1	in	in	ADP
fnp-4675	103	2	the	the	DET
fnp-4675	103	3	optic	optic	ADJ
fnp-4675	103	4	nerves	nerve	NOUN
fnp-4675	103	5	of	of	ADP
fnp-4675	103	6	ms	ms	NOUN
fnp-4675	103	7	patients	patient	NOUN
fnp-4675	103	8	,	,	PUNCT
fnp-4675	103	9	they	they	PRON
fnp-4675	103	10	observed	observe	VERB
fnp-4675	103	11	,	,	PUNCT
fnp-4675	103	12	as	as	SCONJ
fnp-4675	103	13	expected	expect	VERB
fnp-4675	103	14	,	,	PUNCT
fnp-4675	103	15	more	more	ADV
fnp-4675	103	16	activated	activated	ADJ
fnp-4675	103	17	and	and	CCONJ
fnp-4675	103	18	phagocytic	phagocytic	ADJ
fnp-4675	103	19	microglia	microglia	NOUN
fnp-4675	103	20	and	and	CCONJ
fnp-4675	103	21	more	more	ADJ
fnp-4675	103	22	t	t	NOUN
fnp-4675	103	23	cells	cell	NOUN
fnp-4675	103	24	than	than	ADP
fnp-4675	103	25	in	in	ADP
fnp-4675	103	26	controls	control	NOUN
fnp-4675	103	27	.	.	PUNCT
fnp-4675	104	1	they	they	PRON
fnp-4675	104	2	analyzed	analyze	VERB
fnp-4675	104	3	the	the	DET
fnp-4675	104	4	structure	structure	NOUN
fnp-4675	104	5	of	of	ADP
fnp-4675	104	6	the	the	DET
fnp-4675	104	7	nodes	node	NOUN
fnp-4675	104	8	of	of	ADP
fnp-4675	104	9	ranvier	ranvier	NOUN
fnp-4675	104	10	and	and	CCONJ
fnp-4675	104	11	found	find	VERB
fnp-4675	104	12	an	an	DET
fnp-4675	104	13	elongation	elongation	NOUN
fnp-4675	104	14	of	of	ADP
fnp-4675	104	15	paranodes	paranode	NOUN
fnp-4675	104	16	and	and	CCONJ
fnp-4675	104	17	juxtaparanodes	juxtaparanode	NOUN
fnp-4675	104	18	,	,	PUNCT
fnp-4675	104	19	as	as	ADV
fnp-4675	104	20	well	well	ADV
fnp-4675	104	21	as	as	ADP
fnp-4675	104	22	an	an	DET
fnp-4675	104	23	increased	increase	VERB
fnp-4675	104	24	overlap	overlap	NOUN
fnp-4675	104	25	between	between	ADP
fnp-4675	104	26	paranodal	paranodal	ADJ
fnp-4675	104	27	and	and	CCONJ
fnp-4675	104	28	juxtaparanodal	juxtaparanodal	ADJ
fnp-4675	104	29	regions	region	NOUN
fnp-4675	104	30	,	,	PUNCT
fnp-4675	104	31	confirming	confirm	VERB
fnp-4675	104	32	the	the	DET
fnp-4675	104	33	results	result	NOUN
fnp-4675	104	34	of	of	ADP
fnp-4675	104	35	earlier	early	ADJ
fnp-4675	104	36	studies	study	NOUN
fnp-4675	104	37	 	 	SPACE
fnp-4675	104	38	34,35	34,35	NOUN
fnp-4675	104	39	.	.	PUNCT
fnp-4675	105	1	when	when	SCONJ
fnp-4675	105	2	analyzing	analyze	VERB
fnp-4675	105	3	the	the	DET
fnp-4675	105	4	structure	structure	NOUN
fnp-4675	105	5	of	of	ADP
fnp-4675	105	6	the	the	DET
fnp-4675	105	7	myelin	myelin	ADJ
fnp-4675	105	8	sheath	sheath	NOUN
fnp-4675	105	9	,	,	PUNCT
fnp-4675	105	10	they	they	PRON
fnp-4675	105	11	found	find	VERB
fnp-4675	105	12	a	a	DET
fnp-4675	105	13	decrease	decrease	NOUN
fnp-4675	105	14	in	in	ADP
fnp-4675	105	15	the	the	DET
fnp-4675	105	16	g	g	NOUN
fnp-4675	105	17	-	-	PUNCT
fnp-4675	105	18	ratio	ratio	NOUN
fnp-4675	105	19	compared	compare	VERB
fnp-4675	105	20	to	to	ADP
fnp-4675	105	21	controls	control	NOUN
fnp-4675	105	22	,	,	PUNCT
fnp-4675	105	23	suggesting	suggest	VERB
fnp-4675	105	24	a	a	DET
fnp-4675	105	25	thicker	thick	ADJ
fnp-4675	105	26	myelin	myelin	NOUN
fnp-4675	105	27	sheath	sheath	NOUN
fnp-4675	105	28	in	in	ADP
fnp-4675	105	29	ms	ms	ADJ
fnp-4675	105	30	optic	optic	ADJ
fnp-4675	105	31	nerves	nerve	NOUN
fnp-4675	105	32	.	.	PUNCT
fnp-4675	106	1	however	however	ADV
fnp-4675	106	2	,	,	PUNCT
fnp-4675	106	3	more	more	ADV
fnp-4675	106	4	detailed	detailed	ADJ
fnp-4675	106	5	analyses	analysis	NOUN
fnp-4675	106	6	demonstrated	demonstrate	VERB
fnp-4675	106	7	a	a	DET
fnp-4675	106	8	loss	loss	NOUN
fnp-4675	106	9	of	of	ADP
fnp-4675	106	10	myelin	myelin	ADJ
fnp-4675	106	11	compaction	compaction	NOUN
fnp-4675	106	12	as	as	ADP
fnp-4675	106	13	the	the	DET
fnp-4675	106	14	underlying	underlying	ADJ
fnp-4675	106	15	cause	cause	NOUN
fnp-4675	106	16	for	for	ADP
fnp-4675	106	17	the	the	DET
fnp-4675	106	18	decreased	decrease	VERB
fnp-4675	106	19	g	g	NOUN
fnp-4675	106	20	-	-	PUNCT
fnp-4675	106	21	ratio	ratio	NOUN
fnp-4675	106	22	.	.	PUNCT
fnp-4675	107	1	tem	tem	PROPN
fnp-4675	107	2	analyses	analysis	NOUN
fnp-4675	107	3	revealed	reveal	VERB
fnp-4675	107	4	a	a	DET
fnp-4675	107	5	higher	high	ADJ
fnp-4675	107	6	percentage	percentage	NOUN
fnp-4675	107	7	of	of	ADP
fnp-4675	107	8	axons	axon	NOUN
fnp-4675	107	9	containing	contain	VERB
fnp-4675	107	10	mitochondria	mitochondria	NOUN
fnp-4675	107	11	in	in	ADP
fnp-4675	107	12	patients	patient	NOUN
fnp-4675	107	13	with	with	ADP
fnp-4675	107	14	ms	ms	PROPN
fnp-4675	107	15	,	,	PUNCT
fnp-4675	107	16	which	which	PRON
fnp-4675	107	17	was	be	AUX
fnp-4675	107	18	confirmed	confirm	VERB
fnp-4675	107	19	by	by	ADP
fnp-4675	107	20	high	high	ADJ
fnp-4675	107	21	-	-	PUNCT
fnp-4675	107	22	resolution	resolution	NOUN
fnp-4675	107	23	ihc	ihc	NOUN
fnp-4675	107	24	.	.	PUNCT
fnp-4675	108	1	the	the	DET
fnp-4675	108	2	overlap	overlap	NOUN
fnp-4675	108	3	of	of	ADP
fnp-4675	108	4	paranodes	paranode	NOUN
fnp-4675	108	5	and	and	CCONJ
fnp-4675	108	6	juxtaparanodes	juxtaparanode	NOUN
fnp-4675	108	7	,	,	PUNCT
fnp-4675	108	8	less	less	ADV
fnp-4675	108	9	compacted	compact	VERB
fnp-4675	108	10	myelin	myelin	NOUN
fnp-4675	108	11	and	and	CCONJ
fnp-4675	108	12	mitochondrial	mitochondrial	ADJ
fnp-4675	108	13	frequency	frequency	NOUN
fnp-4675	108	14	in	in	ADP
fnp-4675	108	15	axons	axon	NOUN
fnp-4675	108	16	correlated	correlate	VERB
fnp-4675	108	17	with	with	ADP
fnp-4675	108	18	the	the	DET
fnp-4675	108	19	number	number	NOUN
fnp-4675	108	20	of	of	ADP
fnp-4675	108	21	activated	activated	ADJ
fnp-4675	108	22	microglia	microglia	NOUN
fnp-4675	108	23	.	.	PUNCT
fnp-4675	109	1	these	these	DET
fnp-4675	109	2	findings	finding	NOUN
fnp-4675	109	3	suggest	suggest	VERB
fnp-4675	109	4	that	that	SCONJ
fnp-4675	109	5	activated	activate	VERB
fnp-4675	109	6	microglia	microglia	NOUN
fnp-4675	109	7	contribute	contribute	NOUN
fnp-4675	109	8	to	to	ADP
fnp-4675	109	9	nodal	nodal	NOUN
fnp-4675	109	10	and	and	CCONJ
fnp-4675	109	11	myelin	myelin	ADJ
fnp-4675	109	12	disorganization	disorganization	NOUN
fnp-4675	109	13	in	in	ADP
fnp-4675	109	14	nawm	nawm	NOUN
fnp-4675	109	15	in	in	ADP
fnp-4675	109	16	ms	ms	ADJ
fnp-4675	109	17	patients	patient	NOUN
fnp-4675	109	18	,	,	PUNCT
fnp-4675	109	19	which	which	PRON
fnp-4675	109	20	may	may	AUX
fnp-4675	109	21	result	result	VERB
fnp-4675	109	22	in	in	ADP
fnp-4675	109	23	a	a	DET
fnp-4675	109	24	higher	high	ADJ
fnp-4675	109	25	axonal	axonal	ADJ
fnp-4675	109	26	energy	energy	NOUN
fnp-4675	109	27	demand	demand	NOUN
fnp-4675	109	28	and	and	CCONJ
fnp-4675	109	29	increased	increase	VERB
fnp-4675	109	30	mitochondrial	mitochondrial	ADJ
fnp-4675	109	31	numbers	number	NOUN
fnp-4675	109	32	to	to	PART
fnp-4675	109	33	compensate	compensate	VERB
fnp-4675	109	34	it	it	PRON
fnp-4675	109	35	.	.	PUNCT
fnp-4675	110	1	further	further	ADJ
fnp-4675	110	2	studies	study	NOUN
fnp-4675	110	3	are	be	AUX
fnp-4675	110	4	required	require	VERB
fnp-4675	110	5	to	to	PART
fnp-4675	110	6	determine	determine	VERB
fnp-4675	110	7	whether	whether	SCONJ
fnp-4675	110	8	the	the	DET
fnp-4675	110	9	same	same	ADJ
fnp-4675	110	10	changes	change	NOUN
fnp-4675	110	11	occur	occur	VERB
fnp-4675	110	12	throughout	throughout	ADP
fnp-4675	110	13	the	the	DET
fnp-4675	110	14	cns	cns	NOUN
fnp-4675	110	15	in	in	ADP
fnp-4675	110	16	patients	patient	NOUN
fnp-4675	110	17	with	with	ADP
fnp-4675	110	18	ms	ms	PROPN
fnp-4675	110	19	,	,	PUNCT
fnp-4675	110	20	when	when	SCONJ
fnp-4675	110	21	these	these	DET
fnp-4675	110	22	changes	change	NOUN
fnp-4675	110	23	start	start	VERB
fnp-4675	110	24	and	and	CCONJ
fnp-4675	110	25	whether	whether	SCONJ
fnp-4675	110	26	these	these	DET
fnp-4675	110	27	pathological	pathological	ADJ
fnp-4675	110	28	changes	change	NOUN
fnp-4675	110	29	correlate	correlate	VERB
fnp-4675	110	30	with	with	ADP
fnp-4675	110	31	pira	pira	NOUN
fnp-4675	110	32	.	.	PUNCT
fnp-4675	111	1	(	(	PUNCT
fnp-4675	111	2	iii	iii	X
fnp-4675	111	3	)	)	PUNCT
fnp-4675	111	4	ms	ms	NOUN
fnp-4675	111	5	susceptibility	susceptibility	NOUN
fnp-4675	111	6	and	and	CCONJ
fnp-4675	111	7	disease	disease	NOUN
fnp-4675	111	8	course	course	VERB
fnp-4675	111	9	new	new	ADJ
fnp-4675	111	10	technologies	technology	NOUN
fnp-4675	111	11	in	in	ADP
fnp-4675	111	12	vivo	vivo	ADJ
fnp-4675	111	13	imaging	imaging	NOUN
fnp-4675	111	14	to	to	PART
fnp-4675	111	15	assess	assess	VERB
fnp-4675	111	16	consequences	consequence	NOUN
fnp-4675	111	17	of	of	ADP
fnp-4675	111	18	demyelination	demyelination	NOUN
fnp-4675	111	19	and	and	CCONJ
fnp-4675	111	20	presence	presence	NOUN
fnp-4675	111	21	of	of	ADP
fnp-4675	111	22	re	re	NOUN
fnp-4675	111	23	-	-	NOUN
fnp-4675	111	24	myelination	myelination	NOUN
fnp-4675	111	25	in	in	ADP
fnp-4675	111	26	ms	ms	ADJ
fnp-4675	111	27	emerging	emerge	VERB
fnp-4675	111	28	concepts	concept	NOUN
fnp-4675	111	29	suggest	suggest	VERB
fnp-4675	111	30	that	that	SCONJ
fnp-4675	111	31	a	a	DET
fnp-4675	111	32	combination	combination	NOUN
fnp-4675	111	33	of	of	ADP
fnp-4675	111	34	persisting	persist	VERB
fnp-4675	111	35	focal	focal	ADJ
fnp-4675	111	36	and	and	CCONJ
fnp-4675	111	37	diffuse	diffuse	VERB
fnp-4675	111	38	inflammation	inflammation	NOUN
fnp-4675	111	39	within	within	ADP
fnp-4675	111	40	the	the	DET
fnp-4675	111	41	cns	cns	NOUN
fnp-4675	111	42	and	and	CCONJ
fnp-4675	111	43	a	a	DET
fnp-4675	111	44	gradual	gradual	ADJ
fnp-4675	111	45	failure	failure	NOUN
fnp-4675	111	46	of	of	ADP
fnp-4675	111	47	compensatory	compensatory	ADJ
fnp-4675	111	48	mechanisms	mechanism	NOUN
fnp-4675	111	49	,	,	PUNCT
fnp-4675	111	50	including	include	VERB
fnp-4675	111	51	remyelination	remyelination	NOUN
fnp-4675	111	52	and	and	CCONJ
fnp-4675	111	53	brain	brain	NOUN
fnp-4675	111	54	plasticity	plasticity	NOUN
fnp-4675	111	55	,	,	PUNCT
fnp-4675	111	56	result	result	VERB
fnp-4675	111	57	in	in	ADP
fnp-4675	111	58	disease	disease	NOUN
fnp-4675	111	59	progression	progression	NOUN
fnp-4675	111	60	.	.	PUNCT
fnp-4675	112	1	in	in	ADP
fnp-4675	112	2	demyelinating	demyelinate	VERB
fnp-4675	112	3	animal	animal	NOUN
fnp-4675	112	4	models	model	NOUN
fnp-4675	112	5	,	,	PUNCT
fnp-4675	112	6	remyelination	remyelination	NOUN
fnp-4675	112	7	reduces	reduce	VERB
fnp-4675	112	8	axonal	axonal	ADJ
fnp-4675	112	9	as	as	ADV
fnp-4675	112	10	well	well	ADV
fnp-4675	112	11	as	as	ADP
fnp-4675	112	12	neuronal	neuronal	ADJ
fnp-4675	112	13	damage	damage	NOUN
fnp-4675	112	14	and	and	CCONJ
fnp-4675	112	15	is	be	AUX
fnp-4675	112	16	associated	associate	VERB
fnp-4675	112	17	with	with	ADP
fnp-4675	112	18	clinical	clinical	ADJ
fnp-4675	112	19	recovery	recovery	NOUN
fnp-4675	112	20	 	 	SPACE
fnp-4675	112	21	36	36	NUM
fnp-4675	112	22	-	-	SYM
fnp-4675	112	23	38	38	NUM
fnp-4675	112	24	.	.	PUNCT
fnp-4675	113	1	therefore	therefore	ADV
fnp-4675	113	2	,	,	PUNCT
fnp-4675	113	3	promotion	promotion	NOUN
fnp-4675	113	4	of	of	ADP
fnp-4675	113	5	remyelination	remyelination	NOUN
fnp-4675	113	6	appears	appear	VERB
fnp-4675	113	7	to	to	PART
fnp-4675	113	8	be	be	AUX
fnp-4675	113	9	a	a	DET
fnp-4675	113	10	promising	promising	ADJ
fnp-4675	113	11	new	new	ADJ
fnp-4675	113	12	treatment	treatment	NOUN
fnp-4675	113	13	approach	approach	NOUN
fnp-4675	113	14	in	in	ADP
fnp-4675	113	15	ms	ms	PROPN
fnp-4675	113	16	to	to	PART
fnp-4675	113	17	prevent	prevent	VERB
fnp-4675	113	18	disease	disease	NOUN
fnp-4675	113	19	progression	progression	NOUN
fnp-4675	113	20	.	.	PUNCT
fnp-4675	114	1	however	however	ADV
fnp-4675	114	2	,	,	PUNCT
fnp-4675	114	3	despite	despite	SCONJ
fnp-4675	114	4	increasing	increase	VERB
fnp-4675	114	5	knowledge	knowledge	NOUN
fnp-4675	114	6	regarding	regard	VERB
fnp-4675	114	7	the	the	DET
fnp-4675	114	8	molecular	molecular	ADJ
fnp-4675	114	9	mechanisms	mechanism	NOUN
fnp-4675	114	10	regulating	regulate	VERB
fnp-4675	114	11	deand	deand	NOUN
fnp-4675	114	12	remyelination	remyelination	NOUN
fnp-4675	114	13	in	in	ADP
fnp-4675	114	14	animal	animal	NOUN
fnp-4675	114	15	models	model	NOUN
fnp-4675	114	16	,	,	PUNCT
fnp-4675	114	17	the	the	DET
fnp-4675	114	18	development	development	NOUN
fnp-4675	114	19	of	of	ADP
fnp-4675	114	20	new	new	ADJ
fnp-4675	114	21	remyelination	remyelination	NOUN
fnp-4675	114	22	promoting	promote	VERB
fnp-4675	114	23	drugs	drug	NOUN
fnp-4675	114	24	is	be	AUX
fnp-4675	114	25	still	still	ADV
fnp-4675	114	26	a	a	DET
fnp-4675	114	27	challenge	challenge	NOUN
fnp-4675	114	28	.	.	PUNCT
fnp-4675	115	1	to	to	ADP
fnp-4675	115	2	date	date	NOUN
fnp-4675	115	3	,	,	PUNCT
fnp-4675	115	4	clinical	clinical	ADJ
fnp-4675	115	5	trials	trial	NOUN
fnp-4675	115	6	testing	test	VERB
fnp-4675	115	7	experimentally	experimentally	ADV
fnp-4675	115	8	identified	identify	VERB
fnp-4675	115	9	drugs	drug	NOUN
fnp-4675	115	10	have	have	AUX
fnp-4675	115	11	had	have	VERB
fnp-4675	115	12	limited	limited	ADJ
fnp-4675	115	13	success	success	NOUN
fnp-4675	115	14	.	.	PUNCT
fnp-4675	116	1	the	the	DET
fnp-4675	116	2	failure	failure	NOUN
fnp-4675	116	3	of	of	ADP
fnp-4675	116	4	these	these	DET
fnp-4675	116	5	clinical	clinical	ADJ
fnp-4675	116	6	trials	trial	NOUN
fnp-4675	116	7	might	might	AUX
fnp-4675	116	8	be	be	AUX
fnp-4675	116	9	at	at	ADV
fnp-4675	116	10	least	least	ADJ
fnp-4675	116	11	partly	partly	ADV
fnp-4675	116	12	explained	explain	VERB
fnp-4675	116	13	by	by	ADP
fnp-4675	116	14	our	our	PRON
fnp-4675	116	15	still	still	ADV
fnp-4675	116	16	limited	limited	ADJ
fnp-4675	116	17	knowledge	knowledge	NOUN
fnp-4675	116	18	about	about	ADP
fnp-4675	116	19	the	the	DET
fnp-4675	116	20	natural	natural	ADJ
fnp-4675	116	21	course	course	NOUN
fnp-4675	116	22	and	and	CCONJ
fnp-4675	116	23	clinical	clinical	ADJ
fnp-4675	116	24	effects	effect	NOUN
fnp-4675	116	25	of	of	ADP
fnp-4675	116	26	remyelination	remyelination	NOUN
fnp-4675	116	27	in	in	ADP
fnp-4675	116	28	ms	ms	ADJ
fnp-4675	116	29	patients	patient	NOUN
fnp-4675	116	30	.	.	PUNCT
fnp-4675	117	1	tonietto	tonietto	NOUN
fnp-4675	117	2	et	et	PROPN
fnp-4675	117	3	al	al	PROPN
fnp-4675	117	4	.	.	PROPN
fnp-4675	118	1	combined	combined	PROPN
fnp-4675	118	2	voxel	voxel	PROPN
fnp-4675	118	3	based	base	VERB
fnp-4675	118	4	positron	positron	NOUN
fnp-4675	118	5	emission	emission	NOUN
fnp-4675	118	6	tomography	tomography	NOUN
fnp-4675	118	7	(	(	PUNCT
fnp-4675	118	8	pet	pet	NOUN
fnp-4675	118	9	)	)	PUNCT
fnp-4675	118	10	and	and	CCONJ
fnp-4675	118	11	magnetization	magnetization	NOUN
fnp-4675	118	12	transfer	transfer	NOUN
fnp-4675	118	13	mri	mri	NOUN
fnp-4675	118	14	(	(	PUNCT
fnp-4675	118	15	mtr	mtr	NOUN
fnp-4675	118	16	)	)	PUNCT
fnp-4675	118	17	approaches	approach	NOUN
fnp-4675	118	18	to	to	PART
fnp-4675	118	19	study	study	VERB
fnp-4675	118	20	the	the	DET
fnp-4675	118	21	influence	influence	NOUN
fnp-4675	118	22	of	of	ADP
fnp-4675	118	23	lesion	lesion	NOUN
fnp-4675	118	24	location	location	NOUN
fnp-4675	118	25	on	on	ADP
fnp-4675	118	26	myelin	myelin	ADJ
fnp-4675	118	27	repair	repair	NOUN
fnp-4675	118	28	and	and	CCONJ
fnp-4675	118	29	the	the	DET
fnp-4675	118	30	correlation	correlation	NOUN
fnp-4675	118	31	between	between	ADP
fnp-4675	118	32	remyelination	remyelination	NOUN
fnp-4675	118	33	and	and	CCONJ
fnp-4675	118	34	grey	grey	ADJ
fnp-4675	118	35	matter	matter	NOUN
fnp-4675	118	36	atrophy	atrophy	NOUN
fnp-4675	118	37	 	 	SPACE
fnp-4675	118	38	5	5	NUM
fnp-4675	118	39	.	.	PUNCT
fnp-4675	119	1	at	at	ADP
fnp-4675	119	2	baseline	baseline	NOUN
fnp-4675	119	3	,	,	PUNCT
fnp-4675	119	4	the	the	DET
fnp-4675	119	5	probability	probability	NOUN
fnp-4675	119	6	of	of	ADP
fnp-4675	119	7	demyelinated	demyelinated	ADJ
fnp-4675	119	8	voxels	voxel	NOUN
fnp-4675	119	9	was	be	AUX
fnp-4675	119	10	highest	high	ADJ
fnp-4675	119	11	close	close	ADJ
fnp-4675	119	12	to	to	ADP
fnp-4675	119	13	the	the	DET
fnp-4675	119	14	ventricle	ventricle	NOUN
fnp-4675	119	15	and	and	CCONJ
fnp-4675	119	16	,	,	PUNCT
fnp-4675	119	17	increasing	increase	VERB
fnp-4675	119	18	distance	distance	NOUN
fnp-4675	119	19	from	from	ADP
fnp-4675	119	20	the	the	DET
fnp-4675	119	21	ventricle	ventricle	NOUN
fnp-4675	119	22	was	be	AUX
fnp-4675	119	23	associated	associate	VERB
fnp-4675	119	24	with	with	ADP
fnp-4675	119	25	an	an	DET
fnp-4675	119	26	increased	increase	VERB
fnp-4675	119	27	myelin	myelin	NOUN
fnp-4675	119	28	content	content	NOUN
fnp-4675	119	29	in	in	ADP
fnp-4675	119	30	lesions	lesion	NOUN
fnp-4675	119	31	.	.	PUNCT
fnp-4675	120	1	they	they	PRON
fnp-4675	120	2	also	also	ADV
fnp-4675	120	3	reported	report	VERB
fnp-4675	120	4	that	that	SCONJ
fnp-4675	120	5	the	the	DET
fnp-4675	120	6	probability	probability	NOUN
fnp-4675	120	7	of	of	ADP
fnp-4675	120	8	a	a	DET
fnp-4675	120	9	demyelinated	demyelinated	ADJ
fnp-4675	120	10	voxel	voxel	PROPN
fnp-4675	120	11	to	to	PART
fnp-4675	120	12	remyelinate	remyelinate	VERB
fnp-4675	120	13	in	in	ADP
fnp-4675	120	14	the	the	DET
fnp-4675	120	15	follow	follow	NOUN
fnp-4675	120	16	-	-	PUNCT
fnp-4675	120	17	up	up	NOUN
fnp-4675	120	18	period	period	NOUN
fnp-4675	120	19	correlated	correlate	VERB
fnp-4675	120	20	with	with	ADP
fnp-4675	120	21	the	the	DET
fnp-4675	120	22	distance	distance	NOUN
fnp-4675	120	23	from	from	ADP
fnp-4675	120	24	the	the	DET
fnp-4675	120	25	ventricle	ventricle	NOUN
fnp-4675	120	26	.	.	PUNCT
fnp-4675	121	1	these	these	DET
fnp-4675	121	2	findings	finding	NOUN
fnp-4675	121	3	are	be	AUX
fnp-4675	121	4	in	in	ADP
fnp-4675	121	5	line	line	NOUN
fnp-4675	121	6	with	with	ADP
fnp-4675	121	7	histopathological	histopathological	ADJ
fnp-4675	121	8	studies	study	NOUN
fnp-4675	121	9	,	,	PUNCT
fnp-4675	121	10	observing	observe	VERB
fnp-4675	121	11	a	a	DET
fnp-4675	121	12	lower	low	ADJ
fnp-4675	121	13	extent	extent	NOUN
fnp-4675	121	14	of	of	ADP
fnp-4675	121	15	remyelination	remyelination	NOUN
fnp-4675	121	16	in	in	ADP
fnp-4675	121	17	periventricular	periventricular	NOUN
fnp-4675	121	18	compared	compare	VERB
fnp-4675	121	19	to	to	ADP
fnp-4675	121	20	subcortical	subcortical	ADJ
fnp-4675	121	21	lesions	lesion	NOUN
fnp-4675	121	22	 	 	SPACE
fnp-4675	121	23	39,40	39,40	VERB
fnp-4675	121	24	.	.	PUNCT
fnp-4675	122	1	interestingly	interestingly	ADV
fnp-4675	122	2	,	,	PUNCT
fnp-4675	122	3	tonietto	tonietto	PROPN
fnp-4675	122	4	et	et	PROPN
fnp-4675	122	5	al	al	PROPN
fnp-4675	122	6	.	.	PROPN
fnp-4675	122	7	also	also	ADV
fnp-4675	122	8	observed	observe	VERB
fnp-4675	122	9	that	that	PRON
fnp-4675	122	10	failure	failure	NOUN
fnp-4675	122	11	of	of	ADP
fnp-4675	122	12	remyelination	remyelination	NOUN
fnp-4675	122	13	was	be	AUX
fnp-4675	122	14	associated	associate	VERB
fnp-4675	122	15	with	with	ADP
fnp-4675	122	16	lower	low	ADJ
fnp-4675	122	17	thalamic	thalamic	ADJ
fnp-4675	122	18	volume	volume	NOUN
fnp-4675	122	19	,	,	PUNCT
fnp-4675	122	20	an	an	DET
fnp-4675	122	21	imaging	imaging	NOUN
fnp-4675	122	22	marker	marker	NOUN
fnp-4675	122	23	of	of	ADP
fnp-4675	122	24	neurodegeneration	neurodegeneration	NOUN
fnp-4675	122	25	 	 	SPACE
fnp-4675	122	26	5	5	NUM
fnp-4675	122	27	.	.	PUNCT
fnp-4675	122	28	additionally	additionally	ADV
fnp-4675	122	29	,	,	PUNCT
fnp-4675	122	30	they	they	PRON
fnp-4675	122	31	found	find	VERB
fnp-4675	122	32	a	a	DET
fnp-4675	122	33	weak	weak	ADJ
fnp-4675	122	34	association	association	NOUN
fnp-4675	122	35	between	between	ADP
fnp-4675	122	36	periventricular	periventricular	ADJ
fnp-4675	122	37	remyelination	remyelination	NOUN
fnp-4675	122	38	failure	failure	NOUN
fnp-4675	122	39	and	and	CCONJ
fnp-4675	122	40	regional	regional	ADJ
fnp-4675	122	41	cortical	cortical	ADJ
fnp-4675	122	42	atrophy	atrophy	NOUN
fnp-4675	122	43	depending	depend	VERB
fnp-4675	122	44	on	on	ADP
fnp-4675	122	45	the	the	DET
fnp-4675	122	46	number	number	NOUN
fnp-4675	122	47	of	of	ADP
fnp-4675	122	48	cortex	cortex	NOUN
fnp-4675	122	49	-	-	PUNCT
fnp-4675	122	50	derived	derive	VERB
fnp-4675	122	51	tracks	track	NOUN
fnp-4675	122	52	passing	pass	VERB
fnp-4675	122	53	through	through	ADP
fnp-4675	122	54	periventricular	periventricular	ADJ
fnp-4675	122	55	white	white	ADJ
fnp-4675	122	56	matter	matter	NOUN
fnp-4675	122	57	.	.	PUNCT
fnp-4675	123	1	these	these	DET
fnp-4675	123	2	finding	finding	NOUN
fnp-4675	123	3	suggest	suggest	VERB
fnp-4675	123	4	that	that	SCONJ
fnp-4675	123	5	lack	lack	NOUN
fnp-4675	123	6	of	of	ADP
fnp-4675	123	7	periventricular	periventricular	ADJ
fnp-4675	123	8	remyelination	remyelination	NOUN
fnp-4675	123	9	contributes	contribute	VERB
fnp-4675	123	10	to	to	ADP
fnp-4675	123	11	cortical	cortical	ADJ
fnp-4675	123	12	damage	damage	NOUN
fnp-4675	123	13	in	in	ADP
fnp-4675	123	14	ms	ms	PROPN
fnp-4675	123	15	.	.	PROPN
fnp-4675	123	16	however	however	ADV
fnp-4675	123	17	,	,	PUNCT
fnp-4675	123	18	the	the	DET
fnp-4675	123	19	small	small	ADJ
fnp-4675	123	20	sample	sample	NOUN
fnp-4675	123	21	size	size	NOUN
fnp-4675	123	22	and	and	CCONJ
fnp-4675	123	23	the	the	DET
fnp-4675	123	24	relatively	relatively	ADV
fnp-4675	123	25	short	short	ADJ
fnp-4675	123	26	follow	follow	NOUN
fnp-4675	123	27	-	-	PUNCT
fnp-4675	123	28	up	up	NOUN
fnp-4675	123	29	are	be	AUX
fnp-4675	123	30	limitations	limitation	NOUN
fnp-4675	123	31	of	of	ADP
fnp-4675	123	32	these	these	DET
fnp-4675	123	33	findings	finding	NOUN
fnp-4675	123	34	.	.	PUNCT
fnp-4675	124	1	further	further	ADJ
fnp-4675	124	2	studies	study	NOUN
fnp-4675	124	3	are	be	AUX
fnp-4675	124	4	required	require	VERB
fnp-4675	124	5	to	to	PART
fnp-4675	124	6	determine	determine	VERB
fnp-4675	124	7	the	the	DET
fnp-4675	124	8	relationship	relationship	NOUN
fnp-4675	124	9	between	between	ADP
fnp-4675	124	10	remyelination	remyelination	NOUN
fnp-4675	124	11	(	(	PUNCT
fnp-4675	124	12	failure	failure	NOUN
fnp-4675	124	13	)	)	PUNCT
fnp-4675	124	14	and	and	CCONJ
fnp-4675	124	15	brain	brain	NOUN
fnp-4675	124	16	atrophy	atrophy	NOUN
fnp-4675	124	17	.	.	PUNCT
fnp-4675	125	1	arnold	arnold	PROPN
fnp-4675	125	2	et	et	PROPN
fnp-4675	125	3	al	al	PROPN
fnp-4675	125	4	.	.	PROPN
fnp-4675	125	5	reported	report	VERB
fnp-4675	125	6	that	that	SCONJ
fnp-4675	125	7	siponimod	siponimod	PROPN
fnp-4675	125	8	therapy	therapy	NOUN
fnp-4675	125	9	(	(	PUNCT
fnp-4675	125	10	expnd	expnd	NOUN
fnp-4675	125	11	trial	trial	NOUN
fnp-4675	125	12	)	)	PUNCT
fnp-4675	125	13	improved	improve	VERB
fnp-4675	125	14	magnetic	magnetic	ADJ
fnp-4675	125	15	transfer	transfer	NOUN
fnp-4675	125	16	ratios	ratio	NOUN
fnp-4675	125	17	(	(	PUNCT
fnp-4675	125	18	mtr	mtr	NOUN
fnp-4675	125	19	)	)	PUNCT
fnp-4675	125	20	,	,	PUNCT
fnp-4675	125	21	a	a	DET
fnp-4675	125	22	measure	measure	NOUN
fnp-4675	125	23	of	of	ADP
fnp-4675	125	24	myelination	myelination	NOUN
fnp-4675	125	25	within	within	ADP
fnp-4675	125	26	new	new	ADJ
fnp-4675	125	27	lesions	lesion	NOUN
fnp-4675	125	28	and	and	CCONJ
fnp-4675	125	29	across	across	ADP
fnp-4675	125	30	grey	grey	ADJ
fnp-4675	125	31	and	and	CCONJ
fnp-4675	125	32	white	white	ADJ
fnp-4675	125	33	matter	matter	NOUN
fnp-4675	125	34	 	 	SPACE
fnp-4675	125	35	41	41	NUM
fnp-4675	125	36	.	.	PUNCT
fnp-4675	126	1	this	this	PRON
fnp-4675	126	2	was	be	AUX
fnp-4675	126	3	associated	associate	VERB
fnp-4675	126	4	with	with	ADP
fnp-4675	126	5	reduced	reduced	ADJ
fnp-4675	126	6	loss	loss	NOUN
fnp-4675	126	7	of	of	ADP
fnp-4675	126	8	cortical	cortical	ADJ
fnp-4675	126	9	grey	grey	NOUN
fnp-4675	126	10	matter	matter	NOUN
fnp-4675	126	11	,	,	PUNCT
fnp-4675	126	12	thalamic	thalamic	ADJ
fnp-4675	126	13	,	,	PUNCT
fnp-4675	126	14	and	and	CCONJ
fnp-4675	126	15	total	total	ADJ
fnp-4675	126	16	brain	brain	NOUN
fnp-4675	126	17	volume	volume	NOUN
fnp-4675	126	18	,	,	PUNCT
fnp-4675	126	19	again	again	ADV
fnp-4675	126	20	suggesting	suggest	VERB
fnp-4675	126	21	a	a	DET
fnp-4675	126	22	beneficial	beneficial	ADJ
fnp-4675	126	23	effect	effect	NOUN
fnp-4675	126	24	of	of	ADP
fnp-4675	126	25	remyelination	remyelination	NOUN
fnp-4675	126	26	for	for	ADP
fnp-4675	126	27	brain	brain	NOUN
fnp-4675	126	28	atrophy	atrophy	NOUN
fnp-4675	126	29	.	.	PUNCT
fnp-4675	127	1	as	as	SCONJ
fnp-4675	127	2	mentioned	mention	VERB
fnp-4675	127	3	,	,	PUNCT
fnp-4675	127	4	the	the	DET
fnp-4675	127	5	challenge	challenge	NOUN
fnp-4675	127	6	remains	remain	VERB
fnp-4675	127	7	to	to	PART
fnp-4675	127	8	distinguish	distinguish	VERB
fnp-4675	127	9	therapeutic	therapeutic	ADJ
fnp-4675	127	10	effects	effect	NOUN
fnp-4675	127	11	acting	act	VERB
fnp-4675	127	12	via	via	ADP
fnp-4675	127	13	impact	impact	NOUN
fnp-4675	127	14	on	on	ADP
fnp-4675	127	15	inflammation	inflammation	NOUN
fnp-4675	127	16	from	from	ADP
fnp-4675	127	17	neuroprotective	neuroprotective	ADJ
fnp-4675	127	18	and	and	CCONJ
fnp-4675	127	19	repair	repair	NOUN
fnp-4675	127	20	promoting	promote	VERB
fnp-4675	127	21	effects	effect	NOUN
fnp-4675	127	22	.	.	PUNCT
fnp-4675	128	1	to	to	ADP
fnp-4675	128	2	date	date	NOUN
fnp-4675	128	3	,	,	PUNCT
fnp-4675	128	4	no	no	DET
fnp-4675	128	5	therapy	therapy	NOUN
fnp-4675	128	6	has	have	AUX
fnp-4675	128	7	received	receive	VERB
fnp-4675	128	8	regulatory	regulatory	ADJ
fnp-4675	128	9	approval	approval	NOUN
fnp-4675	128	10	based	base	VERB
fnp-4675	128	11	entirely	entirely	ADV
fnp-4675	128	12	on	on	ADP
fnp-4675	128	13	the	the	DET
fnp-4675	128	14	latter	latter	ADJ
fnp-4675	128	15	.	.	PUNCT
fnp-4675	129	1	a	a	DET
fnp-4675	129	2	challenge	challenge	NOUN
fnp-4675	129	3	remains	remain	VERB
fnp-4675	129	4	how	how	SCONJ
fnp-4675	129	5	to	to	PART
fnp-4675	129	6	use	use	VERB
fnp-4675	129	7	advances	advance	NOUN
fnp-4675	129	8	in	in	ADP
fnp-4675	129	9	imaging	imaging	NOUN
fnp-4675	129	10	(	(	PUNCT
fnp-4675	129	11	and	and	CCONJ
fnp-4675	129	12	other	other	ADJ
fnp-4675	129	13	para	para	ADJ
fnp-4675	129	14	-	-	PUNCT
fnp-4675	129	15	clinical	clinical	ADJ
fnp-4675	129	16	measures	measure	NOUN
fnp-4675	129	17	(	(	PUNCT
fnp-4675	129	18	electrophysiology	electrophysiology	NOUN
fnp-4675	129	19	,	,	PUNCT
fnp-4675	129	20	biomarkers	biomarker	NOUN
fnp-4675	129	21	)	)	PUNCT
fnp-4675	129	22	)	)	PUNCT
fnp-4675	129	23	to	to	PART
fnp-4675	129	24	rapidly	rapidly	ADV
fnp-4675	129	25	predict	predict	VERB
fnp-4675	129	26	meaningful	meaningful	ADJ
fnp-4675	129	27	efficacy	efficacy	NOUN
fnp-4675	129	28	of	of	ADP
fnp-4675	129	29	therapies	therapy	NOUN
fnp-4675	129	30	aimed	aim	VERB
fnp-4675	129	31	at	at	ADP
fnp-4675	129	32	the	the	DET
fnp-4675	129	33	latter	latter	ADJ
fnp-4675	129	34	,	,	PUNCT
fnp-4675	129	35	as	as	SCONJ
fnp-4675	129	36	so	so	ADV
fnp-4675	129	37	successfully	successfully	ADV
fnp-4675	129	38	done	do	VERB
fnp-4675	129	39	for	for	ADP
fnp-4675	129	40	immune	immune	NOUN
fnp-4675	129	41	-	-	PUNCT
fnp-4675	129	42	therapies	therapy	NOUN
fnp-4675	129	43	for	for	ADP
fnp-4675	129	44	relapsing	relapse	VERB
fnp-4675	129	45	ms	ms	PROPN
fnp-4675	129	46	.	.	PROPN
fnp-4675	129	47	new	new	ADJ
fnp-4675	129	48	imaging	imaging	NOUN
fnp-4675	129	49	techniques	technique	NOUN
fnp-4675	129	50	may	may	AUX
fnp-4675	129	51	help	help	VERB
fnp-4675	129	52	to	to	PART
fnp-4675	129	53	differentiate	differentiate	VERB
fnp-4675	129	54	repair	repair	NOUN
fnp-4675	129	55	and	and	CCONJ
fnp-4675	129	56	injury	injury	NOUN
fnp-4675	129	57	mechanisms	mechanism	NOUN
fnp-4675	129	58	.	.	PUNCT
fnp-4675	130	1	rahmandazeh	rahmandazeh	PROPN
fnp-4675	130	2	et	et	PROPN
fnp-4675	130	3	al	al	PROPN
fnp-4675	130	4	.	.	PROPN
fnp-4675	130	5	combined	combine	VERB
fnp-4675	130	6	cross	cross	ADJ
fnp-4675	130	7	-	-	ADJ
fnp-4675	130	8	sectional	sectional	ADJ
fnp-4675	130	9	,	,	PUNCT
fnp-4675	130	10	longitudinal	longitudinal	ADJ
fnp-4675	130	11	and	and	CCONJ
fnp-4675	130	12	post	post	ADJ
fnp-4675	130	13	-	-	ADJ
fnp-4675	130	14	mortem	mortem	ADJ
fnp-4675	130	15	histopathology	histopathology	NOUN
fnp-4675	130	16	-	-	PUNCT
fnp-4675	130	17	imaging	image	VERB
fnp-4675	130	18	validation	validation	NOUN
fnp-4675	130	19	studies	study	NOUN
fnp-4675	130	20	to	to	PART
fnp-4675	130	21	evaluate	evaluate	VERB
fnp-4675	130	22	,	,	PUNCT
fnp-4675	130	23	for	for	ADP
fnp-4675	130	24	the	the	DET
fnp-4675	130	25	first	first	ADJ
fnp-4675	130	26	time	time	NOUN
fnp-4675	130	27	,	,	PUNCT
fnp-4675	130	28	the	the	DET
fnp-4675	130	29	usefulness	usefulness	NOUN
fnp-4675	130	30	of	of	ADP
fnp-4675	130	31	quantitative	quantitative	ADJ
fnp-4675	130	32	susceptibility	susceptibility	NOUN
fnp-4675	130	33	mapping	mapping	NOUN
fnp-4675	130	34	(	(	PUNCT
fnp-4675	130	35	qsm	qsm	PROPN
fnp-4675	130	36	)	)	PUNCT
fnp-4675	130	37	for	for	ADP
fnp-4675	130	38	the	the	DET
fnp-4675	130	39	identification	identification	NOUN
fnp-4675	130	40	of	of	ADP
fnp-4675	130	41	different	different	ADJ
fnp-4675	130	42	ms	ms	NOUN
fnp-4675	130	43	lesion	lesion	NOUN
fnp-4675	130	44	types	type	NOUN
fnp-4675	130	45	,	,	PUNCT
fnp-4675	130	46	including	include	VERB
fnp-4675	130	47	remyelinated	remyelinate	VERB
fnp-4675	130	48	lesions	lesion	NOUN
fnp-4675	130	49	 	 	SPACE
fnp-4675	130	50	42	42	NUM
fnp-4675	130	51	.	.	PUNCT
fnp-4675	131	1	qsm	qsm	PROPN
fnp-4675	131	2	quantifies	quantifie	NOUN
fnp-4675	131	3	the	the	DET
fnp-4675	131	4	distribution	distribution	NOUN
fnp-4675	131	5	of	of	ADP
fnp-4675	131	6	magnetic	magnetic	ADJ
fnp-4675	131	7	susceptibility	susceptibility	NOUN
fnp-4675	131	8	in	in	ADP
fnp-4675	131	9	tissues	tissue	NOUN
fnp-4675	131	10	and	and	CCONJ
fnp-4675	131	11	is	be	AUX
fnp-4675	131	12	sensitive	sensitive	ADJ
fnp-4675	131	13	to	to	ADP
fnp-4675	131	14	myelin	myelin	NOUN
fnp-4675	131	15	content	content	NOUN
fnp-4675	131	16	and	and	CCONJ
fnp-4675	131	17	iron	iron	NOUN
fnp-4675	131	18	accumulation	accumulation	NOUN
fnp-4675	131	19	in	in	ADP
fnp-4675	131	20	the	the	DET
fnp-4675	131	21	brain	brain	NOUN
fnp-4675	131	22	 	 	SPACE
fnp-4675	131	23	43,44	43,44	PROPN
fnp-4675	131	24	.	.	PUNCT
fnp-4675	132	1	due	due	ADP
fnp-4675	132	2	to	to	ADP
fnp-4675	132	3	its	its	PRON
fnp-4675	132	4	ability	ability	NOUN
fnp-4675	132	5	to	to	PART
fnp-4675	132	6	detect	detect	VERB
fnp-4675	132	7	iron	iron	NOUN
fnp-4675	132	8	,	,	PUNCT
fnp-4675	132	9	it	it	PRON
fnp-4675	132	10	has	have	AUX
fnp-4675	132	11	been	be	AUX
fnp-4675	132	12	used	use	VERB
fnp-4675	132	13	in	in	ADP
fnp-4675	132	14	the	the	DET
fnp-4675	132	15	past	past	NOUN
fnp-4675	132	16	for	for	ADP
fnp-4675	132	17	the	the	DET
fnp-4675	132	18	detection	detection	NOUN
fnp-4675	132	19	of	of	ADP
fnp-4675	132	20	paramagnetic	paramagnetic	ADJ
fnp-4675	132	21	rim	rim	NOUN
fnp-4675	132	22	lesions	lesion	NOUN
fnp-4675	132	23	(	(	PUNCT
fnp-4675	132	24	prls	prl	NOUN
fnp-4675	132	25	)	)	PUNCT
fnp-4675	132	26	,	,	PUNCT
fnp-4675	132	27	which	which	PRON
fnp-4675	132	28	histopathologically	histopathologically	ADV
fnp-4675	132	29	,	,	PUNCT
fnp-4675	132	30	at	at	ADP
fnp-4675	132	31	least	least	ADJ
fnp-4675	132	32	partly	partly	ADV
fnp-4675	132	33	,	,	PUNCT
fnp-4675	132	34	correspond	correspond	VERB
fnp-4675	132	35	to	to	ADP
fnp-4675	132	36	mixed	mixed	ADJ
fnp-4675	132	37	active	active	ADJ
fnp-4675	132	38	/	/	SYM
fnp-4675	132	39	inactive	inactive	ADJ
fnp-4675	132	40	lesions	lesion	NOUN
fnp-4675	132	41	(=	(=	SYM
fnp-4675	132	42	chronic	chronic	VERB
fnp-4675	132	43	active	active	ADJ
fnp-4675	132	44	lesions	lesion	NOUN
fnp-4675	132	45	)	)	PUNCT
fnp-4675	132	46	.	.	PUNCT
fnp-4675	133	1	in	in	ADP
fnp-4675	133	2	this	this	DET
fnp-4675	133	3	cross	cross	ADJ
fnp-4675	133	4	-	-	ADJ
fnp-4675	133	5	sectional	sectional	ADJ
fnp-4675	133	6	study	study	NOUN
fnp-4675	133	7	,	,	PUNCT
fnp-4675	133	8	the	the	DET
fnp-4675	133	9	authors	author	NOUN
fnp-4675	133	10	analyzed	analyze	VERB
fnp-4675	133	11	1,621	1,621	NUM
fnp-4675	133	12	lesions	lesion	NOUN
fnp-4675	133	13	and	and	CCONJ
fnp-4675	133	14	classified	classify	VERB
fnp-4675	133	15	them	they	PRON
fnp-4675	133	16	in	in	ADP
fnp-4675	133	17	the	the	DET
fnp-4675	133	18	qsm	qsm	PROPN
fnp-4675	133	19	maps	map	NOUN
fnp-4675	133	20	as	as	ADP
fnp-4675	133	21	either	either	CCONJ
fnp-4675	133	22	isointense	isointense	NOUN
fnp-4675	133	23	(	(	PUNCT
fnp-4675	133	24	29	29	NUM
fnp-4675	133	25	%	%	NOUN
fnp-4675	133	26	)	)	PUNCT
fnp-4675	133	27	,	,	PUNCT
fnp-4675	133	28	hypointense	hypointense	NOUN
fnp-4675	133	29	(	(	PUNCT
fnp-4675	133	30	4	4	NUM
fnp-4675	133	31	%	%	NOUN
fnp-4675	133	32	)	)	PUNCT
fnp-4675	133	33	,	,	PUNCT
fnp-4675	133	34	hyperintense	hyperintense	NOUN
fnp-4675	133	35	(	(	PUNCT
fnp-4675	133	36	52	52	NUM
fnp-4675	133	37	%	%	NOUN
fnp-4675	133	38	)	)	PUNCT
fnp-4675	133	39	,	,	PUNCT
fnp-4675	133	40	lesions	lesion	NOUN
fnp-4675	133	41	with	with	ADP
fnp-4675	133	42	a	a	DET
fnp-4675	133	43	hypointense	hypointense	ADJ
fnp-4675	133	44	rim	rim	NOUN
fnp-4675	133	45	(	(	PUNCT
fnp-4675	133	46	1	1	NUM
fnp-4675	133	47	%	%	NOUN
fnp-4675	133	48	)	)	PUNCT
fnp-4675	133	49	and	and	CCONJ
fnp-4675	133	50	prls	prl	NOUN
fnp-4675	133	51	(	(	PUNCT
fnp-4675	133	52	13	13	NUM
fnp-4675	133	53	%	%	NOUN
fnp-4675	133	54	)	)	PUNCT
fnp-4675	133	55	.	.	PUNCT
fnp-4675	134	1	the	the	DET
fnp-4675	134	2	qsm	qsm	PROPN
fnp-4675	134	3	histopathological	histopathological	ADJ
fnp-4675	134	4	correlation	correlation	NOUN
fnp-4675	134	5	study	study	NOUN
fnp-4675	134	6	revealed	reveal	VERB
fnp-4675	134	7	that	that	SCONJ
fnp-4675	134	8	iso	iso	NOUN
fnp-4675	134	9	/	/	SYM
fnp-4675	134	10	hypointense	hypointense	NOUN
fnp-4675	134	11	lesions	lesion	NOUN
fnp-4675	134	12	mostly	mostly	ADV
fnp-4675	134	13	corresponded	correspond	VERB
fnp-4675	134	14	to	to	ADP
fnp-4675	134	15	remyelinated	remyelinate	VERB
fnp-4675	134	16	lesions	lesion	NOUN
fnp-4675	134	17	,	,	PUNCT
fnp-4675	134	18	hyperintense	hyperintense	NOUN
fnp-4675	134	19	lesions	lesion	NOUN
fnp-4675	134	20	to	to	ADP
fnp-4675	134	21	inactive	inactive	ADJ
fnp-4675	134	22	lesions	lesion	NOUN
fnp-4675	134	23	and	and	CCONJ
fnp-4675	134	24	prls	prl	NOUN
fnp-4675	134	25	mostly	mostly	ADV
fnp-4675	134	26	to	to	PART
fnp-4675	134	27	mixed	mixed	ADJ
fnp-4675	134	28	active	active	ADJ
fnp-4675	134	29	/	/	SYM
fnp-4675	134	30	inactive	inactive	ADJ
fnp-4675	134	31	lesions	lesion	NOUN
fnp-4675	134	32	.	.	PUNCT
fnp-4675	135	1	however	however	ADV
fnp-4675	135	2	,	,	PUNCT
fnp-4675	135	3	one	one	NUM
fnp-4675	135	4	caveat	caveat	NOUN
fnp-4675	135	5	is	be	AUX
fnp-4675	135	6	that	that	SCONJ
fnp-4675	135	7	hypo	hypo	ADJ
fnp-4675	135	8	-	-	PUNCT
fnp-4675	135	9	intensity	intensity	NOUN
fnp-4675	135	10	in	in	ADP
fnp-4675	135	11	qsm	qsm	PROPN
fnp-4675	135	12	indicates	indicate	VERB
fnp-4675	135	13	complete	complete	ADJ
fnp-4675	135	14	remyelination	remyelination	NOUN
fnp-4675	135	15	in	in	ADP
fnp-4675	135	16	the	the	DET
fnp-4675	135	17	absence	absence	NOUN
fnp-4675	135	18	of	of	ADP
fnp-4675	135	19	ongoing	ongoing	ADJ
fnp-4675	135	20	inflammation	inflammation	NOUN
fnp-4675	135	21	;	;	PUNCT
fnp-4675	135	22	therefore	therefore	ADV
fnp-4675	135	23	,	,	PUNCT
fnp-4675	135	24	it	it	PRON
fnp-4675	135	25	appears	appear	VERB
fnp-4675	135	26	less	less	ADV
fnp-4675	135	27	suitable	suitable	ADJ
fnp-4675	135	28	for	for	ADP
fnp-4675	135	29	the	the	DET
fnp-4675	135	30	detection	detection	NOUN
fnp-4675	135	31	of	of	ADP
fnp-4675	135	32	ongoing	ongoing	ADJ
fnp-4675	135	33	remyelination	remyelination	NOUN
fnp-4675	135	34	during	during	ADP
fnp-4675	135	35	the	the	DET
fnp-4675	135	36	first	first	ADJ
fnp-4675	135	37	five	five	NUM
fnp-4675	135	38	to	to	PART
fnp-4675	135	39	six	six	NUM
fnp-4675	135	40	months	month	NOUN
fnp-4675	135	41	after	after	ADP
fnp-4675	135	42	lesion	lesion	NOUN
fnp-4675	135	43	formation	formation	NOUN
fnp-4675	135	44	 	 	SPACE
fnp-4675	135	45	45	45	NUM
fnp-4675	135	46	.	.	PUNCT
fnp-4675	136	1	further	further	ADJ
fnp-4675	136	2	studies	study	NOUN
fnp-4675	136	3	comparing	compare	VERB
fnp-4675	136	4	different	different	ADJ
fnp-4675	136	5	imaging	imaging	NOUN
fnp-4675	136	6	technologies	technology	NOUN
fnp-4675	136	7	with	with	ADP
fnp-4675	136	8	histopathological	histopathological	ADJ
fnp-4675	136	9	findings	finding	NOUN
fnp-4675	136	10	are	be	AUX
fnp-4675	136	11	required	require	VERB
fnp-4675	136	12	to	to	PART
fnp-4675	136	13	evaluate	evaluate	VERB
fnp-4675	136	14	the	the	DET
fnp-4675	136	15	advantages	advantage	NOUN
fnp-4675	136	16	and	and	CCONJ
fnp-4675	136	17	limitations	limitation	NOUN
fnp-4675	136	18	of	of	ADP
fnp-4675	136	19	these	these	DET
fnp-4675	136	20	approaches	approach	NOUN
fnp-4675	136	21	in	in	ADP
fnp-4675	136	22	the	the	DET
fnp-4675	136	23	follow	follow	NOUN
fnp-4675	136	24	-	-	PUNCT
fnp-4675	136	25	up	up	NOUN
fnp-4675	136	26	of	of	ADP
fnp-4675	136	27	remyelination	remyelination	NOUN
fnp-4675	136	28	in	in	ADP
fnp-4675	136	29	people	people	NOUN
fnp-4675	136	30	with	with	ADP
fnp-4675	136	31	ms	ms	PROPN
fnp-4675	136	32	.	.	PROPN
fnp-4675	136	33	novel	novel	PROPN
fnp-4675	136	34	molecular	molecular	ADJ
fnp-4675	136	35	technologies	technology	NOUN
fnp-4675	136	36	to	to	PART
fnp-4675	136	37	dissect	dissect	VERB
fnp-4675	136	38	ms	ms	NOUN
fnp-4675	136	39	pathogenesis	pathogenesis	NOUN
fnp-4675	136	40	in	in	ADP
fnp-4675	136	41	human	human	ADJ
fnp-4675	136	42	tissue	tissue	NOUN
fnp-4675	136	43	sections	section	NOUN
fnp-4675	136	44	a	a	DET
fnp-4675	136	45	number	number	NOUN
fnp-4675	136	46	of	of	ADP
fnp-4675	136	47	studies	study	NOUN
fnp-4675	136	48	so	so	ADV
fnp-4675	136	49	far	far	ADV
fnp-4675	136	50	have	have	AUX
fnp-4675	136	51	analyzed	analyze	VERB
fnp-4675	136	52	human	human	ADJ
fnp-4675	136	53	ms	ms	NOUN
fnp-4675	136	54	tissue	tissue	NOUN
fnp-4675	136	55	samples	sample	NOUN
fnp-4675	136	56	by	by	ADP
fnp-4675	136	57	snrnaseq	snrnaseq	NOUN
fnp-4675	136	58	 	 	SPACE
fnp-4675	136	59	46	46	NUM
fnp-4675	136	60	-	-	SYM
fnp-4675	136	61	48	48	NUM
fnp-4675	136	62	.	.	PUNCT
fnp-4675	137	1	however	however	ADV
fnp-4675	137	2	,	,	PUNCT
fnp-4675	137	3	these	these	DET
fnp-4675	137	4	studies	study	NOUN
fnp-4675	137	5	included	include	VERB
fnp-4675	137	6	only	only	ADV
fnp-4675	137	7	a	a	DET
fnp-4675	137	8	relatively	relatively	ADV
fnp-4675	137	9	small	small	ADJ
fnp-4675	137	10	number	number	NOUN
fnp-4675	137	11	of	of	ADP
fnp-4675	137	12	tissue	tissue	NOUN
fnp-4675	137	13	samples	sample	NOUN
fnp-4675	137	14	from	from	ADP
fnp-4675	137	15	few	few	ADJ
fnp-4675	137	16	patients	patient	NOUN
fnp-4675	137	17	.	.	PUNCT
fnp-4675	138	1	macnair	macnair	NOUN
fnp-4675	138	2	et	et	PROPN
fnp-4675	138	3	al	al	PROPN
fnp-4675	138	4	.	.	PROPN
fnp-4675	138	5	analyzed	analyze	VERB
fnp-4675	138	6	in	in	ADP
fnp-4675	138	7	their	their	PRON
fnp-4675	138	8	not	not	PART
fnp-4675	138	9	yet	yet	ADV
fnp-4675	138	10	peer	peer	NOUN
fnp-4675	138	11	-	-	PUNCT
fnp-4675	138	12	reviewed	review	VERB
fnp-4675	138	13	study	study	NOUN
fnp-4675	138	14	the	the	DET
fnp-4675	138	15	largest	large	ADJ
fnp-4675	138	16	cohort	cohort	NOUN
fnp-4675	138	17	of	of	ADP
fnp-4675	138	18	ms	ms	NOUN
fnp-4675	138	19	and	and	CCONJ
fnp-4675	138	20	control	control	NOUN
fnp-4675	138	21	tissue	tissue	NOUN
fnp-4675	138	22	samples	sample	NOUN
fnp-4675	138	23	by	by	ADP
fnp-4675	138	24	snrnaseq	snrnaseq	NOUN
fnp-4675	138	25	 	 	SPACE
fnp-4675	138	26	4	4	NUM
fnp-4675	138	27	.	.	PUNCT
fnp-4675	139	1	they	they	PRON
fnp-4675	139	2	analysed	analyse	VERB
fnp-4675	139	3	740,000	740,000	NUM
fnp-4675	139	4	snrnaseq	snrnaseq	NOUN
fnp-4675	139	5	profiles	profile	NOUN
fnp-4675	139	6	from	from	ADP
fnp-4675	139	7	165	165	NUM
fnp-4675	139	8	samples	sample	NOUN
fnp-4675	139	9	including	include	VERB
fnp-4675	139	10	wm	wm	PROPN
fnp-4675	139	11	lesions	lesion	NOUN
fnp-4675	139	12	(	(	PUNCT
fnp-4675	139	13	n	n	NOUN
fnp-4675	139	14	=	=	SYM
fnp-4675	139	15	62	62	NUM
fnp-4675	139	16	)	)	PUNCT
fnp-4675	139	17	,	,	PUNCT
fnp-4675	139	18	normal	normal	ADJ
fnp-4675	139	19	appearing	appear	VERB
fnp-4675	139	20	wm	wm	PROPN
fnp-4675	139	21	(	(	PUNCT
fnp-4675	139	22	n	n	NOUN
fnp-4675	139	23	=	=	NUM
fnp-4675	139	24	17	17	NUM
fnp-4675	139	25	)	)	PUNCT
fnp-4675	139	26	,	,	PUNCT
fnp-4675	139	27	gm	gm	PROPN
fnp-4675	139	28	lesions	lesion	NOUN
fnp-4675	139	29	(	(	PUNCT
fnp-4675	139	30	n	n	NOUN
fnp-4675	139	31	=	=	SYM
fnp-4675	139	32	39	39	NUM
fnp-4675	139	33	)	)	PUNCT
fnp-4675	139	34	and	and	CCONJ
fnp-4675	139	35	normal	normal	ADJ
fnp-4675	139	36	appearing	appear	VERB
fnp-4675	139	37	gm	gm	PROPN
fnp-4675	139	38	(	(	PUNCT
fnp-4675	139	39	n	n	NOUN
fnp-4675	139	40	=	=	SYM
fnp-4675	139	41	16	16	NUM
fnp-4675	139	42	)	)	PUNCT
fnp-4675	139	43	from	from	ADP
fnp-4675	139	44	55	55	NUM
fnp-4675	139	45	ms	ms	ADJ
fnp-4675	139	46	patients	patient	NOUN
fnp-4675	139	47	,	,	PUNCT
fnp-4675	139	48	as	as	ADV
fnp-4675	139	49	well	well	ADV
fnp-4675	139	50	as	as	ADP
fnp-4675	139	51	,	,	PUNCT
fnp-4675	139	52	15	15	NUM
fnp-4675	139	53	wm	wm	NOUN
fnp-4675	139	54	and	and	CCONJ
fnp-4675	139	55	16	16	NUM
fnp-4675	139	56	gm	gm	PROPN
fnp-4675	139	57	tissue	tissue	NOUN
fnp-4675	139	58	samples	sample	NOUN
fnp-4675	139	59	from	from	ADP
fnp-4675	139	60	28	28	NUM
fnp-4675	139	61	controls	control	NOUN
fnp-4675	139	62	.	.	PUNCT
fnp-4675	140	1	they	they	PRON
fnp-4675	140	2	reached	reach	VERB
fnp-4675	140	3	a	a	DET
fnp-4675	140	4	median	median	ADJ
fnp-4675	140	5	sequencing	sequence	VERB
fnp-4675	140	6	depth	depth	NOUN
fnp-4675	140	7	of	of	ADP
fnp-4675	140	8	4,194	4,194	NUM
fnp-4675	140	9	nuclei	nucleus	NOUN
fnp-4675	140	10	/	/	SYM
fnp-4675	140	11	sample	sample	NOUN
fnp-4675	140	12	,	,	PUNCT
fnp-4675	140	13	3,154	3,154	NUM
fnp-4675	140	14	reads	read	NOUN
fnp-4675	140	15	/	/	SYM
fnp-4675	140	16	nucleus	nucleus	NOUN
fnp-4675	140	17	and	and	CCONJ
fnp-4675	140	18	1,702	1,702	NUM
fnp-4675	140	19	genes	gene	NOUN
fnp-4675	140	20	per	per	ADP
fnp-4675	140	21	nucleus	nucleus	NOUN
fnp-4675	140	22	.	.	PUNCT
fnp-4675	141	1	unsurprisingly	unsurprisingly	ADV
fnp-4675	141	2	,	,	PUNCT
fnp-4675	141	3	the	the	DET
fnp-4675	141	4	authors	author	NOUN
fnp-4675	141	5	observed	observe	VERB
fnp-4675	141	6	highly	highly	ADV
fnp-4675	141	7	cell	cell	NOUN
fnp-4675	141	8	-	-	PUNCT
fnp-4675	141	9	type	type	NOUN
fnp-4675	141	10	specific	specific	ADJ
fnp-4675	141	11	changes	change	NOUN
fnp-4675	141	12	in	in	ADP
fnp-4675	141	13	gene	gene	NOUN
fnp-4675	141	14	expression	expression	NOUN
fnp-4675	141	15	in	in	ADP
fnp-4675	141	16	wm	wm	PROPN
fnp-4675	141	17	and	and	CCONJ
fnp-4675	141	18	gm	gm	PROPN
fnp-4675	141	19	lesions	lesion	NOUN
fnp-4675	141	20	in	in	ADP
fnp-4675	141	21	ms	ms	PROPN
fnp-4675	141	22	.	.	PROPN
fnp-4675	141	23	interestingly	interestingly	ADV
fnp-4675	141	24	,	,	PUNCT
fnp-4675	141	25	cell	cell	NOUN
fnp-4675	141	26	-	-	PUNCT
fnp-4675	141	27	type	type	NOUN
fnp-4675	141	28	specific	specific	ADJ
fnp-4675	141	29	changes	change	NOUN
fnp-4675	141	30	were	be	AUX
fnp-4675	141	31	largely	largely	ADV
fnp-4675	141	32	shared	share	VERB
fnp-4675	141	33	across	across	ADP
fnp-4675	141	34	lesions	lesion	NOUN
fnp-4675	141	35	,	,	PUNCT
fnp-4675	141	36	and	and	CCONJ
fnp-4675	141	37	patient	patient	ADJ
fnp-4675	141	38	identity	identity	NOUN
fnp-4675	141	39	was	be	AUX
fnp-4675	141	40	a	a	DET
fnp-4675	141	41	much	much	ADV
fnp-4675	141	42	stronger	strong	ADJ
fnp-4675	141	43	driver	driver	NOUN
fnp-4675	141	44	of	of	ADP
fnp-4675	141	45	variability	variability	NOUN
fnp-4675	141	46	in	in	ADP
fnp-4675	141	47	cell	cell	NOUN
fnp-4675	141	48	type	type	NOUN
fnp-4675	141	49	-	-	PUNCT
fnp-4675	141	50	specific	specific	ADJ
fnp-4675	141	51	expression	expression	NOUN
fnp-4675	141	52	for	for	ADP
fnp-4675	141	53	many	many	ADJ
fnp-4675	141	54	genes	gene	NOUN
fnp-4675	141	55	than	than	ADP
fnp-4675	141	56	lesion	lesion	NOUN
fnp-4675	141	57	type	type	NOUN
fnp-4675	141	58	.	.	PUNCT
fnp-4675	142	1	nevertheless	nevertheless	ADV
fnp-4675	142	2	,	,	PUNCT
fnp-4675	142	3	since	since	SCONJ
fnp-4675	142	4	the	the	DET
fnp-4675	142	5	composition	composition	NOUN
fnp-4675	142	6	of	of	ADP
fnp-4675	142	7	ms	ms	ADJ
fnp-4675	142	8	lesions	lesion	NOUN
fnp-4675	142	9	is	be	AUX
fnp-4675	142	10	heterogeneous	heterogeneous	ADJ
fnp-4675	142	11	and	and	CCONJ
fnp-4675	142	12	the	the	DET
fnp-4675	142	13	authors	author	NOUN
fnp-4675	142	14	did	do	AUX
fnp-4675	142	15	not	not	PART
fnp-4675	142	16	dissect	dissect	VERB
fnp-4675	142	17	specific	specific	ADJ
fnp-4675	142	18	lesion	lesion	NOUN
fnp-4675	142	19	areas	area	NOUN
fnp-4675	142	20	,	,	PUNCT
fnp-4675	142	21	for	for	ADP
fnp-4675	142	22	example	example	NOUN
fnp-4675	142	23	the	the	DET
fnp-4675	142	24	rim	rim	NOUN
fnp-4675	142	25	of	of	ADP
fnp-4675	142	26	mixed	mixed	ADJ
fnp-4675	142	27	lesions	lesion	NOUN
fnp-4675	142	28	,	,	PUNCT
fnp-4675	142	29	more	more	ADV
fnp-4675	142	30	specific	specific	ADJ
fnp-4675	142	31	signatures	signature	NOUN
fnp-4675	142	32	may	may	AUX
fnp-4675	142	33	have	have	AUX
fnp-4675	142	34	been	be	AUX
fnp-4675	142	35	overlooked	overlook	VERB
fnp-4675	142	36	.	.	PUNCT
fnp-4675	143	1	the	the	DET
fnp-4675	143	2	authors	author	NOUN
fnp-4675	143	3	observed	observe	VERB
fnp-4675	143	4	an	an	DET
fnp-4675	143	5	enrichment	enrichment	NOUN
fnp-4675	143	6	of	of	ADP
fnp-4675	143	7	ms	ms	NOUN
fnp-4675	143	8	risk	risk	NOUN
fnp-4675	143	9	genes	gene	NOUN
fnp-4675	143	10	differentially	differentially	ADV
fnp-4675	143	11	expressed	express	VERB
fnp-4675	143	12	in	in	ADP
fnp-4675	143	13	immune	immune	ADJ
fnp-4675	143	14	cells	cell	NOUN
fnp-4675	143	15	,	,	PUNCT
fnp-4675	143	16	but	but	CCONJ
fnp-4675	143	17	also	also	ADV
fnp-4675	143	18	in	in	ADP
fnp-4675	143	19	neurons	neuron	NOUN
fnp-4675	143	20	,	,	PUNCT
fnp-4675	143	21	astrocytes	astrocyte	NOUN
fnp-4675	143	22	and	and	CCONJ
fnp-4675	143	23	oligodendrocytes	oligodendrocyte	NOUN
fnp-4675	143	24	,	,	PUNCT
fnp-4675	143	25	supporting	support	VERB
fnp-4675	143	26	the	the	DET
fnp-4675	143	27	notion	notion	NOUN
fnp-4675	143	28	that	that	SCONJ
fnp-4675	143	29	not	not	PART
fnp-4675	143	30	only	only	ADV
fnp-4675	143	31	immune	immune	ADJ
fnp-4675	143	32	cells	cell	NOUN
fnp-4675	143	33	but	but	CCONJ
fnp-4675	143	34	also	also	ADV
fnp-4675	143	35	neural	neural	ADJ
fnp-4675	143	36	cells	cell	NOUN
fnp-4675	143	37	play	play	VERB
fnp-4675	143	38	a	a	DET
fnp-4675	143	39	role	role	NOUN
fnp-4675	143	40	for	for	ADP
fnp-4675	143	41	ms	ms	PROPN
fnp-4675	143	42	disease	disease	NOUN
fnp-4675	143	43	risk	risk	NOUN
fnp-4675	143	44	and	and	CCONJ
fnp-4675	143	45	progression	progression	NOUN
fnp-4675	143	46	.	.	PUNCT
fnp-4675	144	1	they	they	PRON
fnp-4675	144	2	also	also	ADV
fnp-4675	144	3	found	find	VERB
fnp-4675	144	4	an	an	DET
fnp-4675	144	5	enrichment	enrichment	NOUN
fnp-4675	144	6	of	of	ADP
fnp-4675	144	7	different	different	ADJ
fnp-4675	144	8	oligodendroglial	oligodendroglial	ADJ
fnp-4675	144	9	subpopulations	subpopulation	NOUN
fnp-4675	144	10	in	in	ADP
fnp-4675	144	11	lesions	lesion	NOUN
fnp-4675	144	12	and	and	CCONJ
fnp-4675	144	13	nawm	nawm	NOUN
fnp-4675	144	14	in	in	ADP
fnp-4675	144	15	ms	ms	NOUN
fnp-4675	144	16	compared	compare	VERB
fnp-4675	144	17	to	to	PART
fnp-4675	144	18	control	control	VERB
fnp-4675	144	19	wm	wm	PROPN
fnp-4675	144	20	;	;	PUNCT
fnp-4675	144	21	however	however	ADV
fnp-4675	144	22	,	,	PUNCT
fnp-4675	144	23	again	again	ADV
fnp-4675	144	24	donor	donor	NOUN
fnp-4675	144	25	i	i	PRON
fnp-4675	144	26	d	d	PROPN
fnp-4675	144	27	was	be	AUX
fnp-4675	144	28	a	a	DET
fnp-4675	144	29	stronger	strong	ADJ
fnp-4675	144	30	driver	driver	NOUN
fnp-4675	144	31	of	of	ADP
fnp-4675	144	32	variability	variability	NOUN
fnp-4675	144	33	than	than	ADP
fnp-4675	144	34	lesion	lesion	NOUN
fnp-4675	144	35	type	type	NOUN
fnp-4675	144	36	.	.	PUNCT
fnp-4675	145	1	they	they	PRON
fnp-4675	145	2	identified	identify	VERB
fnp-4675	145	3	three	three	NUM
fnp-4675	145	4	different	different	ADJ
fnp-4675	145	5	oligodendroglial	oligodendroglial	ADJ
fnp-4675	145	6	patterns	pattern	NOUN
fnp-4675	145	7	.	.	PUNCT
fnp-4675	146	1	the	the	DET
fnp-4675	146	2	first	first	ADJ
fnp-4675	146	3	pattern	pattern	NOUN
fnp-4675	146	4	was	be	AUX
fnp-4675	146	5	similar	similar	ADJ
fnp-4675	146	6	to	to	ADP
fnp-4675	146	7	controls	control	NOUN
fnp-4675	146	8	,	,	PUNCT
fnp-4675	146	9	the	the	DET
fnp-4675	146	10	second	second	ADJ
fnp-4675	146	11	was	be	AUX
fnp-4675	146	12	characterized	characterize	VERB
fnp-4675	146	13	by	by	ADP
fnp-4675	146	14	a	a	DET
fnp-4675	146	15	high	high	ADJ
fnp-4675	146	16	proportion	proportion	NOUN
fnp-4675	146	17	of	of	ADP
fnp-4675	146	18	an	an	DET
fnp-4675	146	19	oligodendroglial	oligodendroglial	ADJ
fnp-4675	146	20	subtype	subtype	NOUN
fnp-4675	146	21	upregulating	upregulating	ADJ
fnp-4675	146	22	cellular	cellular	ADJ
fnp-4675	146	23	stress	stress	NOUN
fnp-4675	146	24	genes	gene	NOUN
fnp-4675	146	25	and	and	CCONJ
fnp-4675	146	26	,	,	PUNCT
fnp-4675	146	27	the	the	DET
fnp-4675	146	28	third	third	ADJ
fnp-4675	146	29	pattern	pattern	NOUN
fnp-4675	146	30	showed	show	VERB
fnp-4675	146	31	high	high	ADJ
fnp-4675	146	32	proportions	proportion	NOUN
fnp-4675	146	33	of	of	ADP
fnp-4675	146	34	early	early	ADJ
fnp-4675	146	35	oligodendrocytes	oligodendrocyte	NOUN
fnp-4675	146	36	and	and	CCONJ
fnp-4675	146	37	reduced	reduced	ADJ
fnp-4675	146	38	levels	level	NOUN
fnp-4675	146	39	of	of	ADP
fnp-4675	146	40	more	more	ADV
fnp-4675	146	41	mature	mature	ADJ
fnp-4675	146	42	oligodendrocytes	oligodendrocyte	NOUN
fnp-4675	146	43	,	,	PUNCT
fnp-4675	146	44	suggestive	suggestive	ADJ
fnp-4675	146	45	of	of	ADP
fnp-4675	146	46	an	an	DET
fnp-4675	146	47	arrest	arrest	NOUN
fnp-4675	146	48	of	of	ADP
fnp-4675	146	49	oligodendroglial	oligodendroglial	ADJ
fnp-4675	146	50	maturation	maturation	NOUN
fnp-4675	146	51	or	or	CCONJ
fnp-4675	146	52	differentiation	differentiation	NOUN
fnp-4675	146	53	.	.	PUNCT
fnp-4675	147	1	these	these	DET
fnp-4675	147	2	data	datum	NOUN
fnp-4675	147	3	suggest	suggest	VERB
fnp-4675	147	4	that	that	SCONJ
fnp-4675	147	5	patients	patient	NOUN
fnp-4675	147	6	may	may	AUX
fnp-4675	147	7	respond	respond	VERB
fnp-4675	147	8	differently	differently	ADV
fnp-4675	147	9	to	to	ADP
fnp-4675	147	10	potential	potential	ADJ
fnp-4675	147	11	remyelination	remyelination	NOUN
fnp-4675	147	12	promoting	promote	VERB
fnp-4675	147	13	drugs	drug	NOUN
fnp-4675	147	14	.	.	PUNCT
fnp-4675	148	1	the	the	DET
fnp-4675	148	2	challenge	challenge	NOUN
fnp-4675	148	3	for	for	ADP
fnp-4675	148	4	the	the	DET
fnp-4675	148	5	future	future	NOUN
fnp-4675	148	6	will	will	AUX
fnp-4675	148	7	be	be	AUX
fnp-4675	148	8	to	to	PART
fnp-4675	148	9	develop	develop	VERB
fnp-4675	148	10	measure	measure	NOUN
fnp-4675	148	11	to	to	PART
fnp-4675	148	12	identify	identify	VERB
fnp-4675	148	13	patients	patient	NOUN
fnp-4675	148	14	who	who	PRON
fnp-4675	148	15	will	will	AUX
fnp-4675	148	16	especially	especially	ADV
fnp-4675	148	17	benefit	benefit	VERB
fnp-4675	148	18	from	from	ADP
fnp-4675	148	19	remyelination	remyelination	NOUN
fnp-4675	148	20	promoting	promote	VERB
fnp-4675	148	21	drugs	drug	NOUN
fnp-4675	148	22	.	.	PUNCT
fnp-4675	149	1	one	one	NUM
fnp-4675	149	2	limitation	limitation	NOUN
fnp-4675	149	3	of	of	ADP
fnp-4675	149	4	snrnaseq	snrnaseq	NOUN
fnp-4675	149	5	is	be	AUX
fnp-4675	149	6	the	the	DET
fnp-4675	149	7	lack	lack	NOUN
fnp-4675	149	8	of	of	ADP
fnp-4675	149	9	spatial	spatial	ADJ
fnp-4675	149	10	resolution	resolution	NOUN
fnp-4675	149	11	.	.	PUNCT
fnp-4675	150	1	this	this	PRON
fnp-4675	150	2	is	be	AUX
fnp-4675	150	3	of	of	ADP
fnp-4675	150	4	special	special	ADJ
fnp-4675	150	5	interest	interest	NOUN
fnp-4675	150	6	for	for	ADP
fnp-4675	150	7	ms	ms	ADJ
fnp-4675	150	8	lesions	lesion	NOUN
fnp-4675	150	9	,	,	PUNCT
fnp-4675	150	10	which	which	PRON
fnp-4675	150	11	may	may	AUX
fnp-4675	150	12	be	be	AUX
fnp-4675	150	13	spatially	spatially	ADV
fnp-4675	150	14	heterogeneous	heterogeneous	ADJ
fnp-4675	150	15	with	with	ADP
fnp-4675	150	16	respect	respect	NOUN
fnp-4675	150	17	to	to	ADP
fnp-4675	150	18	extent	extent	NOUN
fnp-4675	150	19	and	and	CCONJ
fnp-4675	150	20	composition	composition	NOUN
fnp-4675	150	21	of	of	ADP
fnp-4675	150	22	inflammation	inflammation	NOUN
fnp-4675	150	23	(	(	PUNCT
fnp-4675	150	24	such	such	ADJ
fnp-4675	150	25	as	as	ADP
fnp-4675	150	26	mixed	mixed	ADJ
fnp-4675	150	27	lesions	lesion	NOUN
fnp-4675	150	28	)	)	PUNCT
fnp-4675	150	29	or	or	CCONJ
fnp-4675	150	30	remyelination	remyelination	NOUN
fnp-4675	150	31	(	(	PUNCT
fnp-4675	150	32	for	for	ADP
fnp-4675	150	33	example	example	NOUN
fnp-4675	150	34	,	,	PUNCT
fnp-4675	150	35	partially	partially	ADV
fnp-4675	150	36	remyelinated	remyelinate	VERB
fnp-4675	150	37	lesions	lesion	NOUN
fnp-4675	150	38	)	)	PUNCT
fnp-4675	150	39	.	.	PUNCT
fnp-4675	151	1	spatial	spatial	ADJ
fnp-4675	151	2	transcriptomics	transcriptomic	NOUN
fnp-4675	151	3	allows	allow	VERB
fnp-4675	151	4	transcriptomic	transcriptomic	ADJ
fnp-4675	151	5	analyses	analysis	NOUN
fnp-4675	151	6	in	in	ADP
fnp-4675	151	7	a	a	DET
fnp-4675	151	8	spatially	spatially	ADV
fnp-4675	151	9	highly	highly	ADV
fnp-4675	151	10	defined	define	VERB
fnp-4675	151	11	manner	manner	NOUN
fnp-4675	151	12	.	.	PUNCT
fnp-4675	152	1	kaufmann	kaufmann	PROPN
fnp-4675	152	2	et	et	PROPN
fnp-4675	152	3	al	al	PROPN
fnp-4675	152	4	.	.	PROPN
fnp-4675	152	5	combined	combine	VERB
fnp-4675	152	6	this	this	DET
fnp-4675	152	7	technology	technology	NOUN
fnp-4675	152	8	with	with	ADP
fnp-4675	152	9	high	high	ADJ
fnp-4675	152	10	sensitivity	sensitivity	NOUN
fnp-4675	152	11	proteomics	proteomic	NOUN
fnp-4675	152	12	,	,	PUNCT
fnp-4675	152	13	published	publish	VERB
fnp-4675	152	14	single	single	ADJ
fnp-4675	152	15	cell	cell	NOUN
fnp-4675	152	16	-	-	PUNCT
fnp-4675	152	17	rna	rna	NOUN
fnp-4675	152	18	sequencing	sequencing	NOUN
fnp-4675	152	19	data	datum	NOUN
fnp-4675	152	20	and	and	CCONJ
fnp-4675	152	21	in	in	ADP
fnp-4675	152	22	vivo	vivo	ADJ
fnp-4675	152	23	perturbation	perturbation	NOUN
fnp-4675	152	24	model	model	NOUN
fnp-4675	152	25	data	datum	NOUN
fnp-4675	152	26	to	to	PART
fnp-4675	152	27	dissect	dissect	VERB
fnp-4675	152	28	underlying	underlying	ADJ
fnp-4675	152	29	disease	disease	NOUN
fnp-4675	152	30	mechanisms	mechanism	NOUN
fnp-4675	152	31	of	of	ADP
fnp-4675	152	32	progressive	progressive	ADJ
fnp-4675	152	33	ms	ms	NOUN
fnp-4675	152	34	and	and	CCONJ
fnp-4675	152	35	to	to	PART
fnp-4675	152	36	identify	identify	VERB
fnp-4675	152	37	new	new	ADJ
fnp-4675	152	38	drug	drug	NOUN
fnp-4675	152	39	targets	target	NOUN
fnp-4675	152	40	 	 	SPACE
fnp-4675	152	41	49	49	NUM
fnp-4675	152	42	.	.	PUNCT
fnp-4675	153	1	they	they	PRON
fnp-4675	153	2	focussed	focusse	VERB
fnp-4675	153	3	their	their	PRON
fnp-4675	153	4	analysis	analysis	NOUN
fnp-4675	153	5	on	on	ADP
fnp-4675	153	6	cortical	cortical	ADJ
fnp-4675	153	7	grey	grey	NOUN
fnp-4675	153	8	matter	matter	NOUN
fnp-4675	153	9	from	from	ADP
fnp-4675	153	10	13	13	NUM
fnp-4675	153	11	progressive	progressive	ADJ
fnp-4675	153	12	ms	ms	ADJ
fnp-4675	153	13	patients	patient	NOUN
fnp-4675	153	14	.	.	PUNCT
fnp-4675	154	1	there	there	PRON
fnp-4675	154	2	was	be	VERB
fnp-4675	154	3	a	a	DET
fnp-4675	154	4	heterogenous	heterogenous	ADJ
fnp-4675	154	5	distribution	distribution	NOUN
fnp-4675	154	6	of	of	ADP
fnp-4675	154	7	neurodegeneration	neurodegeneration	NOUN
fnp-4675	154	8	within	within	ADP
fnp-4675	154	9	the	the	DET
fnp-4675	154	10	tissue	tissue	NOUN
fnp-4675	154	11	and	and	CCONJ
fnp-4675	154	12	across	across	ADP
fnp-4675	154	13	patients	patient	NOUN
fnp-4675	154	14	,	,	PUNCT
fnp-4675	154	15	and	and	CCONJ
fnp-4675	154	16	pseudotemporal	pseudotemporal	ADJ
fnp-4675	154	17	analyses	analysis	NOUN
fnp-4675	154	18	allowed	allow	VERB
fnp-4675	154	19	the	the	DET
fnp-4675	154	20	identification	identification	NOUN
fnp-4675	154	21	of	of	ADP
fnp-4675	154	22	early	early	ADJ
fnp-4675	154	23	neurodegenerative	neurodegenerative	ADJ
fnp-4675	154	24	pathways	pathway	NOUN
fnp-4675	154	25	in	in	ADP
fnp-4675	154	26	cortical	cortical	ADJ
fnp-4675	154	27	ms	ms	ADJ
fnp-4675	154	28	tissue	tissue	NOUN
fnp-4675	154	29	.	.	PUNCT
fnp-4675	155	1	interestingly	interestingly	ADV
fnp-4675	155	2	,	,	PUNCT
fnp-4675	155	3	these	these	DET
fnp-4675	155	4	pathways	pathway	NOUN
fnp-4675	155	5	were	be	AUX
fnp-4675	155	6	cell	cell	NOUN
fnp-4675	155	7	-	-	PUNCT
fnp-4675	155	8	type	type	NOUN
fnp-4675	155	9	specific	specific	ADJ
fnp-4675	155	10	;	;	PUNCT
fnp-4675	155	11	however	however	ADV
fnp-4675	155	12	their	their	PRON
fnp-4675	155	13	regulation	regulation	NOUN
fnp-4675	155	14	was	be	AUX
fnp-4675	155	15	highly	highly	ADV
fnp-4675	155	16	connected	connect	VERB
fnp-4675	155	17	between	between	ADP
fnp-4675	155	18	cell	cell	NOUN
fnp-4675	155	19	types	type	NOUN
fnp-4675	155	20	suggesting	suggest	VERB
fnp-4675	155	21	multicellular	multicellular	ADJ
fnp-4675	155	22	pathological	pathological	ADJ
fnp-4675	155	23	networks	network	NOUN
fnp-4675	155	24	driving	drive	VERB
fnp-4675	155	25	neurodegeneration	neurodegeneration	NOUN
fnp-4675	155	26	.	.	PUNCT
fnp-4675	156	1	kaufmann	kaufmann	PROPN
fnp-4675	156	2	et	et	PROPN
fnp-4675	156	3	al	al	PROPN
fnp-4675	156	4	.	.	PROPN
fnp-4675	156	5	confirmed	confirm	VERB
fnp-4675	156	6	earlier	early	ADJ
fnp-4675	156	7	studies	study	NOUN
fnp-4675	156	8	describing	describe	VERB
fnp-4675	156	9	significant	significant	ADJ
fnp-4675	156	10	synaptic	synaptic	ADJ
fnp-4675	156	11	loss	loss	NOUN
fnp-4675	156	12	in	in	ADP
fnp-4675	156	13	cortical	cortical	ADJ
fnp-4675	156	14	ms	ms	ADJ
fnp-4675	156	15	lesions	lesion	NOUN
fnp-4675	156	16	and	and	CCONJ
fnp-4675	156	17	normal	normal	ADJ
fnp-4675	156	18	appearing	appear	VERB
fnp-4675	156	19	grey	grey	NOUN
fnp-4675	156	20	matter	matter	NOUN
fnp-4675	156	21	(	(	PUNCT
fnp-4675	156	22	nagm	nagm	PROPN
fnp-4675	156	23	)	)	PUNCT
fnp-4675	156	24	 	 	SPACE
fnp-4675	156	25	50	50	NUM
fnp-4675	156	26	.	.	PUNCT
fnp-4675	157	1	they	they	PRON
fnp-4675	157	2	also	also	ADV
fnp-4675	157	3	found	find	VERB
fnp-4675	157	4	an	an	DET
fnp-4675	157	5	inverse	inverse	NOUN
fnp-4675	157	6	correlation	correlation	NOUN
fnp-4675	157	7	between	between	ADP
fnp-4675	157	8	genes	gene	NOUN
fnp-4675	157	9	regulating	regulate	VERB
fnp-4675	157	10	synaptic	synaptic	ADJ
fnp-4675	157	11	plasticity	plasticity	NOUN
fnp-4675	157	12	and	and	CCONJ
fnp-4675	157	13	maintenance	maintenance	NOUN
fnp-4675	157	14	and	and	CCONJ
fnp-4675	157	15	genes	gene	NOUN
fnp-4675	157	16	regulating	regulate	VERB
fnp-4675	157	17	inflammation	inflammation	NOUN
fnp-4675	157	18	and	and	CCONJ
fnp-4675	157	19	tissues	tissue	NOUN
fnp-4675	157	20	remodelling	remodelling	NOUN
fnp-4675	157	21	expressed	express	VERB
fnp-4675	157	22	by	by	ADP
fnp-4675	157	23	astrocytes	astrocyte	NOUN
fnp-4675	157	24	and	and	CCONJ
fnp-4675	157	25	innate	innate	ADJ
fnp-4675	157	26	immune	immune	ADJ
fnp-4675	157	27	cells	cell	NOUN
fnp-4675	157	28	.	.	PUNCT
fnp-4675	158	1	interestingly	interestingly	ADV
fnp-4675	158	2	,	,	PUNCT
fnp-4675	158	3	their	their	PRON
fnp-4675	158	4	data	datum	NOUN
fnp-4675	158	5	suggested	suggest	VERB
fnp-4675	158	6	that	that	SCONJ
fnp-4675	158	7	chronic	chronic	ADJ
fnp-4675	158	8	inflammation	inflammation	NOUN
fnp-4675	158	9	only	only	ADV
fnp-4675	158	10	in	in	ADP
fnp-4675	158	11	combination	combination	NOUN
fnp-4675	158	12	with	with	ADP
fnp-4675	158	13	local	local	ADJ
fnp-4675	158	14	failure	failure	NOUN
fnp-4675	158	15	of	of	ADP
fnp-4675	158	16	neurotrophic	neurotrophic	ADJ
fnp-4675	158	17	support	support	NOUN
fnp-4675	158	18	result	result	NOUN
fnp-4675	158	19	in	in	ADP
fnp-4675	158	20	full	full	ADJ
fnp-4675	158	21	extent	extent	NOUN
fnp-4675	158	22	of	of	ADP
fnp-4675	158	23	multicomponent	multicomponent	ADJ
fnp-4675	158	24	neurodegeneration	neurodegeneration	NOUN
fnp-4675	158	25	.	.	PUNCT
fnp-4675	159	1	one	one	NUM
fnp-4675	159	2	caveat	caveat	NOUN
fnp-4675	159	3	might	might	AUX
fnp-4675	159	4	be	be	AUX
fnp-4675	159	5	that	that	SCONJ
fnp-4675	159	6	the	the	DET
fnp-4675	159	7	authors	author	NOUN
fnp-4675	159	8	used	use	VERB
fnp-4675	159	9	pseudotemporal	pseudotemporal	ADJ
fnp-4675	159	10	biostatistical	biostatistical	ADJ
fnp-4675	159	11	approaches	approach	NOUN
fnp-4675	159	12	to	to	PART
fnp-4675	159	13	identify	identify	VERB
fnp-4675	159	14	early	early	ADJ
fnp-4675	159	15	neurodegenerative	neurodegenerative	ADJ
fnp-4675	159	16	events	event	NOUN
fnp-4675	159	17	.	.	PUNCT
fnp-4675	160	1	it	it	PRON
fnp-4675	160	2	would	would	AUX
fnp-4675	160	3	be	be	AUX
fnp-4675	160	4	desirable	desirable	ADJ
fnp-4675	160	5	to	to	PART
fnp-4675	160	6	validate	validate	VERB
fnp-4675	160	7	these	these	DET
fnp-4675	160	8	results	result	NOUN
fnp-4675	160	9	in	in	ADP
fnp-4675	160	10	tissue	tissue	NOUN
fnp-4675	160	11	samples	sample	NOUN
fnp-4675	160	12	from	from	ADP
fnp-4675	160	13	ms	ms	ADJ
fnp-4675	160	14	patients	patient	NOUN
fnp-4675	160	15	with	with	ADP
fnp-4675	160	16	ongoing	ongoing	ADJ
fnp-4675	160	17	cortical	cortical	ADJ
fnp-4675	160	18	demyelination	demyelination	NOUN
fnp-4675	160	19	;	;	PUNCT
fnp-4675	160	20	but	but	CCONJ
fnp-4675	160	21	these	these	DET
fnp-4675	160	22	lesions	lesion	NOUN
fnp-4675	160	23	are	be	AUX
fnp-4675	160	24	rarely	rarely	ADV
fnp-4675	160	25	available	available	ADJ
fnp-4675	160	26	in	in	ADP
fnp-4675	160	27	post	post	ADJ
fnp-4675	160	28	-	-	ADJ
fnp-4675	160	29	mortem	mortem	ADJ
fnp-4675	160	30	tissue	tissue	NOUN
fnp-4675	160	31	collections	collection	NOUN
fnp-4675	160	32	.	.	PUNCT
fnp-4675	161	1	using	use	VERB
fnp-4675	161	2	complex	complex	ADJ
fnp-4675	161	3	and	and	CCONJ
fnp-4675	161	4	elegant	elegant	ADJ
fnp-4675	161	5	biostatistical	biostatistical	ADJ
fnp-4675	161	6	analyses	analysis	NOUN
fnp-4675	161	7	including	include	VERB
fnp-4675	161	8	in	in	ADP
fnp-4675	161	9	vivo	vivo	ADJ
fnp-4675	161	10	cns	cns	NOUN
fnp-4675	161	11	disease	disease	NOUN
fnp-4675	161	12	model	model	NOUN
fnp-4675	161	13	data	datum	NOUN
fnp-4675	161	14	and	and	CCONJ
fnp-4675	161	15	their	their	PRON
fnp-4675	161	16	own	own	ADJ
fnp-4675	161	17	spatial	spatial	ADJ
fnp-4675	161	18	transcriptomic	transcriptomic	ADJ
fnp-4675	161	19	and	and	CCONJ
fnp-4675	161	20	proteomic	proteomic	ADJ
fnp-4675	161	21	results	result	NOUN
fnp-4675	161	22	they	they	PRON
fnp-4675	161	23	identified	identify	VERB
fnp-4675	161	24	and	and	CCONJ
fnp-4675	161	25	prioritized	prioritize	VERB
fnp-4675	161	26	cns	cns	NOUN
fnp-4675	161	27	enriched	enrich	VERB
fnp-4675	161	28	receptors	receptor	NOUN
fnp-4675	161	29	as	as	ADV
fnp-4675	161	30	well	well	ADV
fnp-4675	161	31	as	as	ADP
fnp-4675	161	32	new	new	ADJ
fnp-4675	161	33	pharmacological	pharmacological	ADJ
fnp-4675	161	34	drug	drug	NOUN
fnp-4675	161	35	targets	target	NOUN
fnp-4675	161	36	.	.	PUNCT
fnp-4675	162	1	(	(	PUNCT
fnp-4675	162	2	iv	iv	X
fnp-4675	162	3	)	)	PUNCT
fnp-4675	162	4	other	other	ADJ
fnp-4675	162	5	demyelinating	demyelinate	VERB
fnp-4675	162	6	diseases	disease	NOUN
fnp-4675	162	7	multiple	multiple	ADJ
fnp-4675	162	8	sclerosis	sclerosis	NOUN
fnp-4675	162	9	remains	remain	VERB
fnp-4675	162	10	a	a	DET
fnp-4675	162	11	diagnosis	diagnosis	NOUN
fnp-4675	162	12	based	base	VERB
fnp-4675	162	13	on	on	ADP
fnp-4675	162	14	carefully	carefully	ADV
fnp-4675	162	15	considered	consider	VERB
fnp-4675	162	16	clinical	clinical	ADJ
fnp-4675	162	17	and	and	CCONJ
fnp-4675	162	18	mri	mri	NOUN
fnp-4675	162	19	based	base	VERB
fnp-4675	162	20	criteria	criterion	NOUN
fnp-4675	162	21	plus	plus	CCONJ
fnp-4675	162	22	csf	csf	ADJ
fnp-4675	162	23	findings	finding	NOUN
fnp-4675	162	24	of	of	ADP
fnp-4675	162	25	immunoglobulin	immunoglobulin	NOUN
fnp-4675	162	26	(	(	PUNCT
fnp-4675	162	27	ig	ig	NOUN
fnp-4675	162	28	)	)	PUNCT
fnp-4675	162	29	synthesis	synthesis	NOUN
fnp-4675	162	30	and	and	CCONJ
fnp-4675	162	31	oligoclonal	oligoclonal	ADJ
fnp-4675	162	32	bands	band	NOUN
fnp-4675	162	33	.	.	PUNCT
fnp-4675	163	1	although	although	SCONJ
fnp-4675	163	2	considered	consider	VERB
fnp-4675	163	3	as	as	ADP
fnp-4675	163	4	an	an	DET
fnp-4675	163	5	autoimmune	autoimmune	ADJ
fnp-4675	163	6	disorder	disorder	NOUN
fnp-4675	163	7	,	,	PUNCT
fnp-4675	163	8	no	no	DET
fnp-4675	163	9	specific	specific	ADJ
fnp-4675	163	10	antigen	antigen	ADV
fnp-4675	163	11	-	-	PUNCT
fnp-4675	163	12	directed	direct	VERB
fnp-4675	163	13	immune	immune	ADJ
fnp-4675	163	14	response	response	NOUN
fnp-4675	163	15	is	be	AUX
fnp-4675	163	16	yet	yet	ADV
fnp-4675	163	17	incorporated	incorporate	VERB
fnp-4675	163	18	into	into	ADP
fnp-4675	163	19	the	the	DET
fnp-4675	163	20	diagnostic	diagnostic	ADJ
fnp-4675	163	21	criteria	criterion	NOUN
fnp-4675	163	22	.	.	PUNCT
fnp-4675	164	1	however	however	ADV
fnp-4675	164	2	,	,	PUNCT
fnp-4675	164	3	over	over	ADP
fnp-4675	164	4	the	the	DET
fnp-4675	164	5	last	last	ADJ
fnp-4675	164	6	years	year	NOUN
fnp-4675	164	7	,	,	PUNCT
fnp-4675	164	8	antigen	antigen	ADJ
fnp-4675	164	9	specific	specific	ADJ
fnp-4675	164	10	immune	immune	ADJ
fnp-4675	164	11	responses	response	NOUN
fnp-4675	164	12	have	have	AUX
fnp-4675	164	13	been	be	AUX
fnp-4675	164	14	identified	identify	VERB
fnp-4675	164	15	in	in	ADP
fnp-4675	164	16	patients	patient	NOUN
fnp-4675	164	17	who	who	PRON
fnp-4675	164	18	would	would	AUX
fnp-4675	164	19	previously	previously	ADV
fnp-4675	164	20	have	have	AUX
fnp-4675	164	21	been	be	AUX
fnp-4675	164	22	included	include	VERB
fnp-4675	164	23	within	within	ADP
fnp-4675	164	24	the	the	DET
fnp-4675	164	25	ms	ms	ADJ
fnp-4675	164	26	umbrella	umbrella	NOUN
fnp-4675	164	27	.	.	PUNCT
fnp-4675	165	1	the	the	DET
fnp-4675	165	2	first	first	ADJ
fnp-4675	165	3	of	of	ADP
fnp-4675	165	4	these	these	PRON
fnp-4675	165	5	was	be	AUX
fnp-4675	165	6	nmo	nmo	NOUN
fnp-4675	165	7	featuring	feature	VERB
fnp-4675	165	8	aqp4directed	aqp4directed	PROPN
fnp-4675	165	9	antibodies	antibodie	VERB
fnp-4675	165	10	.	.	PUNCT
fnp-4675	166	1	consensus	consensus	NOUN
fnp-4675	166	2	clinical	clinical	ADJ
fnp-4675	166	3	syndromes	syndrome	NOUN
fnp-4675	166	4	and	and	CCONJ
fnp-4675	166	5	mri	mri	NOUN
fnp-4675	166	6	findings	finding	NOUN
fnp-4675	166	7	related	relate	VERB
fnp-4675	166	8	to	to	ADP
fnp-4675	166	9	optic	optic	ADJ
fnp-4675	166	10	nerve	nerve	NOUN
fnp-4675	166	11	,	,	PUNCT
fnp-4675	166	12	spinal	spinal	ADJ
fnp-4675	166	13	cord	cord	NOUN
fnp-4675	166	14	,	,	PUNCT
fnp-4675	166	15	area	area	NOUN
fnp-4675	166	16	postrema	postrema	NOUN
fnp-4675	166	17	,	,	PUNCT
fnp-4675	166	18	other	other	ADJ
fnp-4675	166	19	brainstem	brainstem	NOUN
fnp-4675	166	20	,	,	PUNCT
fnp-4675	166	21	diencephalic	diencephalic	ADJ
fnp-4675	166	22	,	,	PUNCT
fnp-4675	166	23	or	or	CCONJ
fnp-4675	166	24	cerebral	cerebral	ADJ
fnp-4675	166	25	presentations	presentation	NOUN
fnp-4675	166	26	are	be	AUX
fnp-4675	166	27	now	now	ADV
fnp-4675	166	28	recognized	recognize	VERB
fnp-4675	166	29	 	 	SPACE
fnp-4675	166	30	51	51	NUM
fnp-4675	166	31	.	.	PUNCT
fnp-4675	167	1	more	more	ADJ
fnp-4675	167	2	recent	recent	ADJ
fnp-4675	167	3	has	have	AUX
fnp-4675	167	4	been	be	AUX
fnp-4675	167	5	recognition	recognition	NOUN
fnp-4675	167	6	of	of	ADP
fnp-4675	167	7	monophasic	monophasic	ADJ
fnp-4675	167	8	or	or	CCONJ
fnp-4675	167	9	recurrent	recurrent	ADJ
fnp-4675	167	10	syndromes	syndrome	NOUN
fnp-4675	167	11	linked	link	VERB
fnp-4675	167	12	to	to	ADP
fnp-4675	167	13	presence	presence	NOUN
fnp-4675	167	14	of	of	ADP
fnp-4675	167	15	anti	anti	ADJ
fnp-4675	167	16	-	-	ADJ
fnp-4675	167	17	mog	mog	ADJ
fnp-4675	167	18	antibody	antibody	NOUN
fnp-4675	167	19	.	.	PUNCT
fnp-4675	168	1	these	these	PRON
fnp-4675	168	2	expanding	expand	VERB
fnp-4675	168	3	syndromes	syndrome	NOUN
fnp-4675	168	4	now	now	ADV
fnp-4675	168	5	include	include	VERB
fnp-4675	168	6	optic	optic	ADJ
fnp-4675	168	7	neuritis	neuritis	NOUN
fnp-4675	168	8	(	(	PUNCT
fnp-4675	168	9	on	on	ADP
fnp-4675	168	10	)	)	PUNCT
fnp-4675	168	11	,	,	PUNCT
fnp-4675	168	12	transverse	transverse	NOUN
fnp-4675	168	13	myelitis	myelitis	NOUN
fnp-4675	168	14	(	(	PUNCT
fnp-4675	168	15	tm	tm	NOUN
fnp-4675	168	16	)	)	PUNCT
fnp-4675	168	17	,	,	PUNCT
fnp-4675	168	18	encephalitis	encephalitis	NOUN
fnp-4675	168	19	,	,	PUNCT
fnp-4675	168	20	and	and	CCONJ
fnp-4675	168	21	seizures	seizure	NOUN
fnp-4675	168	22	,	,	PUNCT
fnp-4675	168	23	as	as	ADV
fnp-4675	168	24	well	well	ADV
fnp-4675	168	25	as	as	ADP
fnp-4675	168	26	aseptic	aseptic	ADJ
fnp-4675	168	27	meningitis	meningitis	NOUN
fnp-4675	168	28	and	and	CCONJ
fnp-4675	168	29	peripheral	peripheral	ADJ
fnp-4675	168	30	nervous	nervous	ADJ
fnp-4675	168	31	system	system	NOUN
fnp-4675	168	32	demyelination	demyelination	NOUN
fnp-4675	168	33	(	(	PUNCT
fnp-4675	168	34	reviewed	review	VERB
fnp-4675	168	35	in	in	ADP
fnp-4675	168	36	 	 	SPACE
fnp-4675	168	37	52	52	NUM
fnp-4675	168	38	)	)	PUNCT
fnp-4675	168	39	.	.	PUNCT
fnp-4675	169	1	mogad	mogad	PROPN
fnp-4675	169	2	can	can	AUX
fnp-4675	169	3	be	be	AUX
fnp-4675	169	4	presented	present	VERB
fnp-4675	169	5	across	across	ADP
fnp-4675	169	6	the	the	DET
fnp-4675	169	7	age	age	NOUN
fnp-4675	169	8	spectrum	spectrum	NOUN
fnp-4675	169	9	.	.	PUNCT
fnp-4675	170	1	a	a	DET
fnp-4675	170	2	specific	specific	ADJ
fnp-4675	170	3	question	question	NOUN
fnp-4675	170	4	of	of	ADP
fnp-4675	170	5	interest	interest	NOUN
fnp-4675	170	6	addressed	address	VERB
fnp-4675	170	7	by	by	ADP
fnp-4675	170	8	gaudioso	gaudioso	PROPN
fnp-4675	170	9	et	et	PROPN
fnp-4675	170	10	al	al	PROPN
fnp-4675	170	11	.	.	PROPN
fnp-4675	170	12	is	be	AUX
fnp-4675	170	13	the	the	DET
fnp-4675	170	14	frequency	frequency	NOUN
fnp-4675	170	15	of	of	ADP
fnp-4675	170	16	mog	mog	PROPN
fnp-4675	170	17	-	-	PUNCT
fnp-4675	170	18	igg	igg	PROPN
fnp-4675	170	19	and	and	CCONJ
fnp-4675	170	20	aqp4	aqp4	PROPN
fnp-4675	170	21	-	-	PUNCT
fnp-4675	170	22	igg	igg	PROPN
fnp-4675	170	23	among	among	ADP
fnp-4675	170	24	patients	patient	NOUN
fnp-4675	170	25	with	with	ADP
fnp-4675	170	26	pediatric	pediatric	ADJ
fnp-4675	170	27	-	-	PUNCT
fnp-4675	170	28	onset	onset	NOUN
fnp-4675	170	29	multiple	multiple	ADJ
fnp-4675	170	30	sclerosis	sclerosis	NOUN
fnp-4675	170	31	(	(	PUNCT
fnp-4675	170	32	poms	pom	NOUN
fnp-4675	170	33	)	)	PUNCT
fnp-4675	170	34	 	 	SPACE
fnp-4675	170	35	53	53	NUM
fnp-4675	170	36	.	.	PUNCT
fnp-4675	171	1	in	in	ADP
fnp-4675	171	2	their	their	PRON
fnp-4675	171	3	review	review	NOUN
fnp-4675	171	4	of	of	ADP
fnp-4675	171	5	493	493	NUM
fnp-4675	171	6	cases	case	NOUN
fnp-4675	171	7	,	,	PUNCT
fnp-4675	171	8	mog	mog	NOUN
fnp-4675	171	9	-	-	PUNCT
fnp-4675	171	10	igg	igg	PROPN
fnp-4675	171	11	was	be	AUX
fnp-4675	171	12	positive	positive	ADJ
fnp-4675	171	13	in	in	ADP
fnp-4675	171	14	30	30	NUM
fnp-4675	171	15	cases	case	NOUN
fnp-4675	171	16	(	(	PUNCT
fnp-4675	171	17	6	6	NUM
fnp-4675	171	18	%	%	NOUN
fnp-4675	171	19	)	)	PUNCT
fnp-4675	171	20	and	and	CCONJ
fnp-4675	171	21	zero	zero	NUM
fnp-4675	171	22	controls	control	NOUN
fnp-4675	171	23	;	;	PUNCT
fnp-4675	171	24	none	none	NOUN
fnp-4675	171	25	were	be	AUX
fnp-4675	171	26	nmo	nmo	NOUN
fnp-4675	171	27	-	-	PUNCT
fnp-4675	171	28	antibody	antibody	NOUN
fnp-4675	171	29	positive	positive	ADJ
fnp-4675	171	30	.	.	PUNCT
fnp-4675	172	1	twenty	twenty	NUM
fnp-4675	172	2	-	-	PUNCT
fnp-4675	172	3	five	five	NUM
fnp-4675	172	4	of	of	ADP
fnp-4675	172	5	the	the	DET
fnp-4675	172	6	30	30	NUM
fnp-4675	172	7	positive	positive	ADJ
fnp-4675	172	8	patients	patient	NOUN
fnp-4675	172	9	were	be	AUX
fnp-4675	172	10	judged	judge	VERB
fnp-4675	172	11	to	to	PART
fnp-4675	172	12	have	have	AUX
fnp-4675	172	13	mogad	mogad	VERB
fnp-4675	172	14	clinical	clinical	ADJ
fnp-4675	172	15	criteria	criterion	NOUN
fnp-4675	172	16	,	,	PUNCT
fnp-4675	172	17	5	5	NUM
fnp-4675	172	18	maintained	maintain	VERB
fnp-4675	172	19	a	a	DET
fnp-4675	172	20	diagnosis	diagnosis	NOUN
fnp-4675	172	21	of	of	ADP
fnp-4675	172	22	multiple	multiple	ADJ
fnp-4675	172	23	sclerosis	sclerosis	NOUN
fnp-4675	172	24	(	(	PUNCT
fnp-4675	172	25	ms	ms	NOUN
fnp-4675	172	26	)	)	PUNCT
fnp-4675	172	27	.	.	PUNCT
fnp-4675	173	1	only	only	ADV
fnp-4675	173	2	44	44	NUM
fnp-4675	173	3	%	%	NOUN
fnp-4675	173	4	had	have	VERB
fnp-4675	173	5	serum	serum	PROPN
fnp-4675	173	6	epstein	epstein	PROPN
fnp-4675	173	7	-	-	PUNCT
fnp-4675	173	8	barr	barr	PROPN
fnp-4675	173	9	virus	virus	PROPN
fnp-4675	173	10	(	(	PUNCT
fnp-4675	173	11	ebv	ebv	NOUN
fnp-4675	173	12	)	)	PUNCT
fnp-4675	173	13	positivity	positivity	NOUN
fnp-4675	173	14	and	and	CCONJ
fnp-4675	173	15	only	only	ADV
fnp-4675	173	16	20	20	NUM
fnp-4675	173	17	%	%	NOUN
fnp-4675	173	18	had	have	VERB
fnp-4675	173	19	cerebrospinal	cerebrospinal	ADJ
fnp-4675	173	20	fluid	fluid	ADJ
fnp-4675	173	21	oligoclonal	oligoclonal	ADJ
fnp-4675	173	22	bands	band	NOUN
fnp-4675	173	23	.	.	PUNCT
fnp-4675	174	1	these	these	DET
fnp-4675	174	2	distinct	distinct	ADJ
fnp-4675	174	3	“	"	PUNCT
fnp-4675	174	4	ms	ms	ADJ
fnp-4675	174	5	-	-	PUNCT
fnp-4675	174	6	related	relate	VERB
fnp-4675	174	7	”	"	PUNCT
fnp-4675	174	8	disorders	disorder	NOUN
fnp-4675	174	9	are	be	AUX
fnp-4675	174	10	receiving	receive	VERB
fnp-4675	174	11	increasing	increase	VERB
fnp-4675	174	12	attention	attention	NOUN
fnp-4675	174	13	with	with	ADP
fnp-4675	174	14	regard	regard	NOUN
fnp-4675	174	15	to	to	ADP
fnp-4675	174	16	optimal	optimal	ADJ
fnp-4675	174	17	treatment	treatment	NOUN
fnp-4675	174	18	paradigms	paradigm	NOUN
fnp-4675	174	19	,	,	PUNCT
fnp-4675	174	20	both	both	PRON
fnp-4675	174	21	for	for	ADP
fnp-4675	174	22	acute	acute	ADJ
fnp-4675	174	23	episodes	episode	NOUN
fnp-4675	174	24	and	and	CCONJ
fnp-4675	174	25	for	for	ADP
fnp-4675	174	26	prevention	prevention	NOUN
fnp-4675	174	27	of	of	ADP
fnp-4675	174	28	recurrences	recurrence	NOUN
fnp-4675	174	29	.	.	PUNCT
fnp-4675	175	1	cerebral	cerebral	ADJ
fnp-4675	175	2	cortical	cortical	ADJ
fnp-4675	175	3	encephalitis	encephalitis	NOUN
fnp-4675	175	4	(	(	PUNCT
fnp-4675	175	5	cce	cce	PROPN
fnp-4675	175	6	)	)	PUNCT
fnp-4675	175	7	is	be	AUX
fnp-4675	175	8	a	a	DET
fnp-4675	175	9	recently	recently	ADV
fnp-4675	175	10	recognized	recognize	VERB
fnp-4675	175	11	phenotype	phenotype	NOUN
fnp-4675	175	12	of	of	ADP
fnp-4675	175	13	mogad	mogad	PROPN
fnp-4675	175	14	.	.	PUNCT
fnp-4675	176	1	it	it	PRON
fnp-4675	176	2	is	be	AUX
fnp-4675	176	3	characterized	characterize	VERB
fnp-4675	176	4	by	by	ADP
fnp-4675	176	5	cortical	cortical	ADJ
fnp-4675	176	6	t2	t2	NOUN
fnp-4675	176	7	-	-	PUNCT
fnp-4675	176	8	fluid	fluid	NOUN
fnp-4675	176	9	-	-	PUNCT
fnp-4675	176	10	attenuated	attenuate	VERB
fnp-4675	176	11	inversion	inversion	NOUN
fnp-4675	176	12	recovery	recovery	NOUN
fnp-4675	176	13	hyperintensity	hyperintensity	NOUN
fnp-4675	176	14	on	on	ADP
fnp-4675	176	15	mri	mri	PROPN
fnp-4675	176	16	 	 	SPACE
fnp-4675	176	17	54	54	NUM
fnp-4675	176	18	.	.	PUNCT
fnp-4675	177	1	valencia	valencia	PROPN
fnp-4675	177	2	-	-	PUNCT
fnp-4675	177	3	sanchez	sanchez	PROPN
fnp-4675	177	4	et	et	PROPN
fnp-4675	177	5	al	al	PROPN
fnp-4675	177	6	.	.	PROPN
fnp-4675	177	7	presented	present	VERB
fnp-4675	177	8	the	the	DET
fnp-4675	177	9	clinical	clinical	ADJ
fnp-4675	177	10	,	,	PUNCT
fnp-4675	177	11	imaging	imaging	NOUN
fnp-4675	177	12	and	and	CCONJ
fnp-4675	177	13	pathological	pathological	ADJ
fnp-4675	177	14	features	feature	NOUN
fnp-4675	177	15	of	of	ADP
fnp-4675	177	16	19	19	NUM
fnp-4675	177	17	cce	cce	NOUN
fnp-4675	177	18	patients	patient	NOUN
fnp-4675	177	19	,	,	PUNCT
fnp-4675	177	20	identified	identify	VERB
fnp-4675	177	21	by	by	ADP
fnp-4675	177	22	screening	screen	VERB
fnp-4675	177	23	their	their	PRON
fnp-4675	177	24	cohort	cohort	NOUN
fnp-4675	177	25	of	of	ADP
fnp-4675	177	26	285	285	NUM
fnp-4675	177	27	mogad	mogad	NOUN
fnp-4675	177	28	patients	patient	NOUN
fnp-4675	177	29	 	 	SPACE
fnp-4675	177	30	55	55	NUM
fnp-4675	177	31	.	.	PUNCT
fnp-4675	178	1	the	the	DET
fnp-4675	178	2	majority	majority	NOUN
fnp-4675	178	3	of	of	ADP
fnp-4675	178	4	cce	cce	PROPN
fnp-4675	178	5	occurred	occur	VERB
fnp-4675	178	6	in	in	ADP
fnp-4675	178	7	patients	patient	NOUN
fnp-4675	178	8	with	with	ADP
fnp-4675	178	9	childhood	childhood	NOUN
fnp-4675	178	10	onset	onset	NOUN
fnp-4675	178	11	of	of	ADP
fnp-4675	178	12	mogad	mogad	NOUN
fnp-4675	178	13	and	and	CCONJ
fnp-4675	178	14	many	many	ADJ
fnp-4675	178	15	patients	patient	NOUN
fnp-4675	178	16	presented	present	VERB
fnp-4675	178	17	with	with	ADP
fnp-4675	178	18	epilepsy	epilepsy	PROPN
fnp-4675	178	19	.	.	PUNCT
fnp-4675	179	1	pathology	pathology	NOUN
fnp-4675	179	2	details	detail	NOUN
fnp-4675	179	3	were	be	AUX
fnp-4675	179	4	available	available	ADJ
fnp-4675	179	5	in	in	ADP
fnp-4675	179	6	two	two	NUM
fnp-4675	179	7	patients	patient	NOUN
fnp-4675	179	8	.	.	PUNCT
fnp-4675	180	1	in	in	ADP
fnp-4675	180	2	one	one	NUM
fnp-4675	180	3	patient	patient	NOUN
fnp-4675	180	4	inactive	inactive	ADJ
fnp-4675	180	5	perivascular	perivascular	ADJ
fnp-4675	180	6	demyelinated	demyelinate	VERB
fnp-4675	180	7	lesions	lesion	NOUN
fnp-4675	180	8	in	in	ADP
fnp-4675	180	9	cortex	cortex	NOUN
fnp-4675	180	10	and	and	CCONJ
fnp-4675	180	11	subcortical	subcortical	ADJ
fnp-4675	180	12	white	white	ADJ
fnp-4675	180	13	matter	matter	NOUN
fnp-4675	180	14	were	be	AUX
fnp-4675	180	15	observed	observe	VERB
fnp-4675	180	16	.	.	PUNCT
fnp-4675	181	1	the	the	DET
fnp-4675	181	2	second	second	ADJ
fnp-4675	181	3	biopsy	biopsy	NOUN
fnp-4675	181	4	was	be	AUX
fnp-4675	181	5	characterized	characterize	VERB
fnp-4675	181	6	by	by	ADP
fnp-4675	181	7	marked	mark	VERB
fnp-4675	181	8	meningeal	meningeal	ADJ
fnp-4675	181	9	inflammation	inflammation	NOUN
fnp-4675	181	10	,	,	PUNCT
fnp-4675	181	11	extensive	extensive	ADJ
fnp-4675	181	12	macrophage	macrophage	ADJ
fnp-4675	181	13	and	and	CCONJ
fnp-4675	181	14	microglia	microglia	ADJ
fnp-4675	181	15	activation	activation	NOUN
fnp-4675	181	16	in	in	ADP
fnp-4675	181	17	the	the	DET
fnp-4675	181	18	meninges	meninge	NOUN
fnp-4675	181	19	as	as	ADV
fnp-4675	181	20	well	well	ADV
fnp-4675	181	21	as	as	ADP
fnp-4675	181	22	cortex	cortex	NOUN
fnp-4675	181	23	and	and	CCONJ
fnp-4675	181	24	extensive	extensive	ADJ
fnp-4675	181	25	subpial	subpial	ADJ
fnp-4675	181	26	demyelination	demyelination	NOUN
fnp-4675	181	27	.	.	PUNCT
fnp-4675	182	1	the	the	DET
fnp-4675	182	2	cd4	cd4	PROPN
fnp-4675	182	3	/	/	SYM
fnp-4675	182	4	cd8	cd8	PROPN
fnp-4675	182	5	ratio	ratio	NOUN
fnp-4675	182	6	was	be	AUX
fnp-4675	182	7	variable	variable	ADJ
fnp-4675	182	8	in	in	ADP
fnp-4675	182	9	these	these	DET
fnp-4675	182	10	two	two	NUM
fnp-4675	182	11	cases	case	NOUN
fnp-4675	182	12	and	and	CCONJ
fnp-4675	182	13	varied	varied	ADJ
fnp-4675	182	14	between	between	ADP
fnp-4675	182	15	2.4	2.4	NUM
fnp-4675	182	16	and	and	CCONJ
fnp-4675	182	17	0.7	0.7	NUM
fnp-4675	182	18	.	.	PUNCT
fnp-4675	183	1	few	few	ADJ
fnp-4675	183	2	b	b	PROPN
fnp-4675	183	3	cells	cell	NOUN
fnp-4675	183	4	aggregates	aggregate	NOUN
fnp-4675	183	5	were	be	AUX
fnp-4675	183	6	found	find	VERB
fnp-4675	183	7	in	in	ADP
fnp-4675	183	8	the	the	DET
fnp-4675	183	9	meninges	meninge	NOUN
fnp-4675	183	10	of	of	ADP
fnp-4675	183	11	one	one	NUM
fnp-4675	183	12	patient	patient	NOUN
fnp-4675	183	13	;	;	PUNCT
fnp-4675	183	14	terminal	terminal	ADJ
fnp-4675	183	15	complement	complement	NOUN
fnp-4675	183	16	activation	activation	NOUN
fnp-4675	183	17	products	product	NOUN
fnp-4675	183	18	were	be	AUX
fnp-4675	183	19	absent	absent	ADJ
fnp-4675	183	20	.	.	PUNCT
fnp-4675	184	1	extensive	extensive	ADJ
fnp-4675	184	2	subpial	subpial	ADJ
fnp-4675	184	3	demyelination	demyelination	NOUN
fnp-4675	184	4	has	have	AUX
fnp-4675	184	5	been	be	AUX
fnp-4675	184	6	described	describe	VERB
fnp-4675	184	7	to	to	PART
fnp-4675	184	8	be	be	AUX
fnp-4675	184	9	specific	specific	ADJ
fnp-4675	184	10	for	for	ADP
fnp-4675	184	11	multiple	multiple	ADJ
fnp-4675	184	12	sclerosis	sclerosis	NOUN
fnp-4675	184	13	 	 	SPACE
fnp-4675	184	14	56	56	NUM
fnp-4675	184	15	.	.	PUNCT
fnp-4675	185	1	this	this	DET
fnp-4675	185	2	recent	recent	ADJ
fnp-4675	185	3	report	report	NOUN
fnp-4675	185	4	,	,	PUNCT
fnp-4675	185	5	together	together	ADV
fnp-4675	185	6	with	with	ADP
fnp-4675	185	7	earlier	early	ADJ
fnp-4675	185	8	mogad	mogad	PROPN
fnp-4675	185	9	case	case	NOUN
fnp-4675	185	10	reports	report	NOUN
fnp-4675	185	11	demonstrate	demonstrate	VERB
fnp-4675	185	12	that	that	SCONJ
fnp-4675	185	13	subpial	subpial	ADJ
fnp-4675	185	14	demyelination	demyelination	NOUN
fnp-4675	185	15	can	can	AUX
fnp-4675	185	16	also	also	ADV
fnp-4675	185	17	be	be	AUX
fnp-4675	185	18	found	find	VERB
fnp-4675	185	19	in	in	ADP
fnp-4675	185	20	other	other	ADJ
fnp-4675	185	21	inflammatory	inflammatory	ADJ
fnp-4675	185	22	demyelinating	demyelinate	VERB
fnp-4675	185	23	diseases	disease	NOUN
fnp-4675	185	24	and	and	CCONJ
fnp-4675	185	25	raises	raise	VERB
fnp-4675	185	26	speculation	speculation	NOUN
fnp-4675	185	27	regarding	regard	VERB
fnp-4675	185	28	the	the	DET
fnp-4675	185	29	role	role	NOUN
fnp-4675	185	30	of	of	ADP
fnp-4675	185	31	humoral	humoral	ADJ
fnp-4675	185	32	immune	immune	ADJ
fnp-4675	185	33	constituents	constituent	NOUN
fnp-4675	185	34	and	and	CCONJ
fnp-4675	185	35	soluble	soluble	ADJ
fnp-4675	185	36	inflammatory	inflammatory	ADJ
fnp-4675	185	37	mediators	mediator	NOUN
fnp-4675	185	38	as	as	ADP
fnp-4675	185	39	contributors	contributor	NOUN
fnp-4675	185	40	 	 	SPACE
fnp-4675	185	41	57,58	57,58	NOUN
fnp-4675	185	42	.	.	PUNCT
fnp-4675	186	1	a	a	DET
fnp-4675	186	2	further	far	ADV
fnp-4675	186	3	recently	recently	ADV
fnp-4675	186	4	addressed	address	VERB
fnp-4675	186	5	issue	issue	NOUN
fnp-4675	186	6	is	be	AUX
fnp-4675	186	7	whether	whether	SCONJ
fnp-4675	186	8	sars	sar	NOUN
fnp-4675	186	9	-	-	PUNCT
fnp-4675	186	10	cov-2	cov-2	PART
fnp-4675	186	11	vaccination	vaccination	NOUN
fnp-4675	186	12	programs	program	NOUN
fnp-4675	186	13	could	could	AUX
fnp-4675	186	14	result	result	VERB
fnp-4675	186	15	in	in	ADP
fnp-4675	186	16	increased	increase	VERB
fnp-4675	186	17	rates	rate	NOUN
fnp-4675	186	18	of	of	ADP
fnp-4675	186	19	mogad	mogad	PROPN
fnp-4675	186	20	.	.	PUNCT
fnp-4675	187	1	francis	francis	PROPN
fnp-4675	187	2	et	et	PROPN
fnp-4675	187	3	al	al	PROPN
fnp-4675	187	4	reported	report	VERB
fnp-4675	187	5	a	a	DET
fnp-4675	187	6	total	total	NOUN
fnp-4675	187	7	of	of	ADP
fnp-4675	187	8	25	25	NUM
fnp-4675	187	9	cases	case	NOUN
fnp-4675	187	10	referred	refer	VERB
fnp-4675	187	11	to	to	ADP
fnp-4675	187	12	specialized	specialized	PROPN
fnp-4675	187	13	mogad	mogad	PROPN
fnp-4675	187	14	centers	center	NOUN
fnp-4675	187	15	in	in	ADP
fnp-4675	187	16	the	the	DET
fnp-4675	187	17	uk	uk	PROPN
fnp-4675	187	18	after	after	ADP
fnp-4675	187	19	the	the	DET
fnp-4675	187	20	introduction	introduction	NOUN
fnp-4675	187	21	of	of	ADP
fnp-4675	187	22	the	the	DET
fnp-4675	187	23	covid	covid	PROPN
fnp-4675	187	24	vaccination	vaccination	NOUN
fnp-4675	187	25	program	program	NOUN
fnp-4675	187	26	;	;	PUNCT
fnp-4675	187	27	their	their	PRON
fnp-4675	187	28	conclusion	conclusion	NOUN
fnp-4675	187	29	was	be	AUX
fnp-4675	187	30	“	"	PUNCT
fnp-4675	187	31	these	these	DET
fnp-4675	187	32	observations	observation	NOUN
fnp-4675	187	33	might	might	AUX
fnp-4675	187	34	support	support	VERB
fnp-4675	187	35	a	a	DET
fnp-4675	187	36	causative	causative	ADJ
fnp-4675	187	37	role	role	NOUN
fnp-4675	187	38	of	of	ADP
fnp-4675	187	39	the	the	DET
fnp-4675	187	40	chadox1s	chadox1s	NOUN
fnp-4675	187	41	vaccine	vaccine	NOUN
fnp-4675	187	42	in	in	ADP
fnp-4675	187	43	inflammatory	inflammatory	ADJ
fnp-4675	187	44	cns	cns	NOUN
fnp-4675	187	45	disease	disease	NOUN
fnp-4675	187	46	and	and	CCONJ
fnp-4675	187	47	particularly	particularly	ADV
fnp-4675	187	48	mogad	mogad	VERB
fnp-4675	187	49	”	"	PUNCT
fnp-4675	187	50	 	 	SPACE
fnp-4675	187	51	59	59	NUM
fnp-4675	187	52	.	.	PUNCT
fnp-4675	188	1	summary	summary	VERB
fnp-4675	188	2	the	the	DET
fnp-4675	188	3	development	development	NOUN
fnp-4675	188	4	of	of	ADP
fnp-4675	188	5	successful	successful	ADJ
fnp-4675	188	6	systemic	systemic	ADJ
fnp-4675	188	7	immunomodulatory	immunomodulatory	NOUN
fnp-4675	188	8	or	or	CCONJ
fnp-4675	188	9	anti	anti	ADJ
fnp-4675	188	10	-	-	ADJ
fnp-4675	188	11	inflammatory	inflammatory	ADJ
fnp-4675	188	12	treatment	treatment	NOUN
fnp-4675	188	13	options	option	NOUN
fnp-4675	188	14	for	for	ADP
fnp-4675	188	15	ms	ms	NOUN
fnp-4675	188	16	within	within	ADP
fnp-4675	188	17	the	the	DET
fnp-4675	188	18	last	last	ADJ
fnp-4675	188	19	two	two	NUM
fnp-4675	188	20	decades	decade	NOUN
fnp-4675	188	21	resulted	result	VERB
fnp-4675	188	22	in	in	ADP
fnp-4675	188	23	the	the	DET
fnp-4675	188	24	discovery	discovery	NOUN
fnp-4675	188	25	of	of	ADP
fnp-4675	188	26	progression	progression	NOUN
fnp-4675	188	27	independent	independent	ADJ
fnp-4675	188	28	of	of	ADP
fnp-4675	188	29	relapse	relapse	NOUN
fnp-4675	188	30	activity	activity	NOUN
fnp-4675	188	31	.	.	PUNCT
fnp-4675	189	1	to	to	PART
fnp-4675	189	2	dissect	dissect	VERB
fnp-4675	189	3	the	the	DET
fnp-4675	189	4	underlying	underlying	ADJ
fnp-4675	189	5	mechanisms	mechanism	NOUN
fnp-4675	189	6	driving	drive	VERB
fnp-4675	189	7	this	this	DET
fnp-4675	189	8	progression	progression	NOUN
fnp-4675	189	9	represents	represent	VERB
fnp-4675	189	10	currently	currently	ADV
fnp-4675	189	11	the	the	DET
fnp-4675	189	12	biggest	big	ADJ
fnp-4675	189	13	challenge	challenge	NOUN
fnp-4675	189	14	in	in	ADP
fnp-4675	189	15	the	the	DET
fnp-4675	189	16	field	field	NOUN
fnp-4675	189	17	of	of	ADP
fnp-4675	189	18	ms	ms	PROPN
fnp-4675	189	19	.	.	PROPN
fnp-4675	189	20	no	no	DET
fnp-4675	189	21	animal	animal	NOUN
fnp-4675	189	22	model	model	NOUN
fnp-4675	189	23	for	for	ADP
fnp-4675	189	24	the	the	DET
fnp-4675	189	25	progressive	progressive	ADJ
fnp-4675	189	26	disease	disease	NOUN
fnp-4675	189	27	phase	phase	NOUN
fnp-4675	189	28	of	of	ADP
fnp-4675	189	29	ms	ms	PROPN
fnp-4675	189	30	exists	exist	NOUN
fnp-4675	189	31	.	.	PUNCT
fnp-4675	190	1	therefore	therefore	ADV
fnp-4675	190	2	,	,	PUNCT
fnp-4675	190	3	clinically	clinically	ADV
fnp-4675	190	4	well	well	INTJ
fnp-4675	190	5	characterized	characterize	VERB
fnp-4675	190	6	human	human	ADJ
fnp-4675	190	7	tissue	tissue	NOUN
fnp-4675	190	8	collections	collection	NOUN
fnp-4675	190	9	and	and	CCONJ
fnp-4675	190	10	modern	modern	ADJ
fnp-4675	190	11	technologies	technology	NOUN
fnp-4675	190	12	,	,	PUNCT
fnp-4675	190	13	such	such	ADJ
fnp-4675	190	14	as	as	ADP
fnp-4675	190	15	sc	sc	PROPN
fnp-4675	190	16	/	/	SYM
fnp-4675	190	17	snrna	snrna	ADJ
fnp-4675	190	18	sequencing	sequencing	NOUN
fnp-4675	190	19	and	and	CCONJ
fnp-4675	190	20	spatial	spatial	ADJ
fnp-4675	190	21	transcriptomics	transcriptomic	NOUN
fnp-4675	190	22	will	will	AUX
fnp-4675	190	23	be	be	AUX
fnp-4675	190	24	essential	essential	ADJ
fnp-4675	190	25	to	to	PART
fnp-4675	190	26	dissect	dissect	VERB
fnp-4675	190	27	the	the	DET
fnp-4675	190	28	cellular	cellular	ADJ
fnp-4675	190	29	and	and	CCONJ
fnp-4675	190	30	molecular	molecular	ADJ
fnp-4675	190	31	mechanisms	mechanism	NOUN
fnp-4675	190	32	driving	drive	VERB
fnp-4675	190	33	disease	disease	NOUN
fnp-4675	190	34	progression	progression	NOUN
fnp-4675	190	35	and	and	CCONJ
fnp-4675	190	36	to	to	PART
fnp-4675	190	37	detect	detect	VERB
fnp-4675	190	38	potential	potential	ADJ
fnp-4675	190	39	biomarkers	biomarker	NOUN
fnp-4675	190	40	.	.	PUNCT
fnp-4675	191	1	clinical	clinical	ADJ
fnp-4675	191	2	,	,	PUNCT
fnp-4675	191	3	imaging	imaging	NOUN
fnp-4675	191	4	and	and	CCONJ
fnp-4675	191	5	other	other	ADJ
fnp-4675	191	6	para	para	ADJ
fnp-4675	191	7	-	-	PUNCT
fnp-4675	191	8	clinical	clinical	ADJ
fnp-4675	191	9	studies	study	NOUN
fnp-4675	191	10	are	be	AUX
fnp-4675	191	11	required	require	VERB
fnp-4675	191	12	to	to	PART
fnp-4675	191	13	further	far	ADV
fnp-4675	191	14	validate	validate	VERB
fnp-4675	191	15	candidate	candidate	NOUN
fnp-4675	191	16	pathways	pathway	NOUN
fnp-4675	191	17	and	and	CCONJ
fnp-4675	191	18	potential	potential	ADJ
fnp-4675	191	19	biomarkers	biomarker	NOUN
fnp-4675	191	20	.	.	PUNCT
fnp-4675	192	1	here	here	ADV
fnp-4675	192	2	,	,	PUNCT
fnp-4675	192	3	we	we	PRON
fnp-4675	192	4	summarized	summarize	VERB
fnp-4675	192	5	some	some	DET
fnp-4675	192	6	studies	study	NOUN
fnp-4675	192	7	which	which	PRON
fnp-4675	192	8	started	start	VERB
fnp-4675	192	9	to	to	PART
fnp-4675	192	10	disentangle	disentangle	VERB
fnp-4675	192	11	the	the	DET
fnp-4675	192	12	underlying	underlie	VERB
fnp-4675	192	13	pathways	pathway	NOUN
fnp-4675	192	14	for	for	ADP
fnp-4675	192	15	disease	disease	NOUN
fnp-4675	192	16	progression	progression	NOUN
fnp-4675	192	17	and	and	CCONJ
fnp-4675	192	18	may	may	AUX
fnp-4675	192	19	serve	serve	VERB
fnp-4675	192	20	as	as	ADP
fnp-4675	192	21	blueprint	blueprint	NOUN
fnp-4675	192	22	for	for	ADP
fnp-4675	192	23	future	future	ADJ
fnp-4675	192	24	studies	study	NOUN
fnp-4675	192	25	.	.	PUNCT
fnp-4675	193	1	references	reference	NOUN
fnp-4675	193	2	1	1	NUM
fnp-4675	193	3	.	.	PUNCT
fnp-4675	194	1	kappos	kappos	PROPN
fnp-4675	194	2	,	,	PUNCT
fnp-4675	194	3	l.	l.	PROPN
fnp-4675	194	4	et	et	PROPN
fnp-4675	194	5	al	al	PROPN
fnp-4675	194	6	.	.	PROPN
fnp-4675	194	7	contribution	contribution	NOUN
fnp-4675	194	8	of	of	ADP
fnp-4675	194	9	relapse	relapse	NOUN
fnp-4675	194	10	independent	independent	ADJ
fnp-4675	194	11	progression	progression	NOUN
fnp-4675	194	12	vs	vs	ADP
fnp-4675	194	13	relapse	relapse	NOUN
fnp-4675	194	14	associated	associate	VERB
fnp-4675	194	15	worsening	worsen	VERB
fnp-4675	194	16	to	to	ADP
fnp-4675	194	17	overall	overall	ADJ
fnp-4675	194	18	confirmed	confirm	VERB
fnp-4675	194	19	disability	disability	NOUN
fnp-4675	194	20	accumulation	accumulation	NOUN
fnp-4675	194	21	in	in	ADP
fnp-4675	194	22	typical	typical	ADJ
fnp-4675	194	23	relapsing	relapse	VERB
fnp-4675	194	24	multiple	multiple	ADJ
fnp-4675	194	25	sclerosis	sclerosis	NOUN
fnp-4675	194	26	in	in	ADP
fnp-4675	194	27	a	a	DET
fnp-4675	194	28	pooled	pooled	ADJ
fnp-4675	194	29	analysis	analysis	NOUN
fnp-4675	194	30	of	of	ADP
fnp-4675	194	31	2	2	NUM
fnp-4675	194	32	randomized	randomize	VERB
fnp-4675	194	33	clinical	clinical	ADJ
fnp-4675	194	34	trials	trial	NOUN
fnp-4675	194	35	.	.	PUNCT
fnp-4675	195	1	jama	jama	PROPN
fnp-4675	195	2	neurol	neurol	PROPN
fnp-4675	195	3	77	77	NUM
fnp-4675	195	4	,	,	PUNCT
fnp-4675	195	5	1132	1132	NUM
fnp-4675	195	6	1140	1140	NUM
fnp-4675	195	7	,	,	PUNCT
fnp-4675	195	8	https://doi.org/10.1001/jamaneurol.2020.1568	https://doi.org/10.1001/jamaneurol.2020.1568	PROPN
fnp-4675	195	9	(	(	PUNCT
fnp-4675	195	10	2020	2020	NUM
fnp-4675	195	11	)	)	PUNCT
fnp-4675	195	12	.	.	PUNCT
fnp-4675	196	1	2	2	X
fnp-4675	196	2	.	.	X
fnp-4675	196	3	university	university	PROPN
fnp-4675	196	4	of	of	ADP
fnp-4675	196	5	california	california	PROPN
fnp-4675	196	6	et	et	PROPN
fnp-4675	196	7	al	al	PROPN
fnp-4675	196	8	.	.	PROPN
fnp-4675	197	1	silent	silent	ADJ
fnp-4675	197	2	progression	progression	NOUN
fnp-4675	197	3	in	in	ADP
fnp-4675	197	4	disease	disease	NOUN
fnp-4675	197	5	activity	activity	NOUN
fnp-4675	197	6	free	free	ADJ
fnp-4675	197	7	relapsing	relapse	VERB
fnp-4675	197	8	multiple	multiple	ADJ
fnp-4675	197	9	sclerosis	sclerosis	NOUN
fnp-4675	197	10	.	.	PUNCT
fnp-4675	198	1	ann	ann	PROPN
fnp-4675	198	2	neurol	neurol	PROPN
fnp-4675	198	3	85	85	NUM
fnp-4675	198	4	,	,	PUNCT
fnp-4675	198	5	653	653	NUM
fnp-4675	198	6	666	666	NUM
fnp-4675	198	7	,	,	PUNCT
fnp-4675	198	8	https://doi.org/10.1002/ana.25463	https://doi.org/10.1002/ana.25463	PROPN
fnp-4675	198	9	(	(	PUNCT
fnp-4675	198	10	2019	2019	NUM
fnp-4675	198	11	)	)	PUNCT
fnp-4675	198	12	.	.	PUNCT
fnp-4675	199	1	3	3	X
fnp-4675	199	2	.	.	X
fnp-4675	199	3	kuhlmann	kuhlmann	PROPN
fnp-4675	199	4	,	,	PUNCT
fnp-4675	199	5	t.	t.	PROPN
fnp-4675	199	6	et	et	PROPN
fnp-4675	199	7	al	al	PROPN
fnp-4675	199	8	.	.	PROPN
fnp-4675	199	9	multiple	multiple	ADJ
fnp-4675	199	10	sclerosis	sclerosis	NOUN
fnp-4675	199	11	progression	progression	NOUN
fnp-4675	199	12	:	:	PUNCT
fnp-4675	199	13	time	time	NOUN
fnp-4675	199	14	for	for	ADP
fnp-4675	199	15	a	a	DET
fnp-4675	199	16	new	new	ADJ
fnp-4675	199	17	mechanism	mechanism	NOUN
fnp-4675	199	18	driven	drive	VERB
fnp-4675	199	19	framework	framework	NOUN
fnp-4675	199	20	.	.	PUNCT
fnp-4675	200	1	lancet	lancet	PROPN
fnp-4675	200	2	neurol	neurol	PROPN
fnp-4675	200	3	22	22	NUM
fnp-4675	200	4	,	,	PUNCT
fnp-4675	200	5	78	78	NUM
fnp-4675	200	6	88	88	NUM
fnp-4675	200	7	,	,	PUNCT
fnp-4675	200	8	https://doi.org/10.1016/s1474	https://doi.org/10.1016/s1474	NOUN
fnp-4675	200	9	4422(22)00289	4422(22)00289	NUM
fnp-4675	200	10	7	7	NUM
fnp-4675	200	11	(	(	PUNCT
fnp-4675	200	12	2023	2023	NUM
fnp-4675	200	13	)	)	PUNCT
fnp-4675	200	14	.	.	PUNCT
fnp-4675	201	1	4	4	X
fnp-4675	201	2	.	.	X
fnp-4675	201	3	macnair	macnair	PROPN
fnp-4675	201	4	,	,	PUNCT
fnp-4675	201	5	w.	w.	PROPN
fnp-4675	201	6	et	et	PROPN
fnp-4675	201	7	al	al	PROPN
fnp-4675	201	8	.	.	PROPN
fnp-4675	202	1	single	single	ADJ
fnp-4675	202	2	nuclei	nucleus	NOUN
fnp-4675	202	3	rnaseq	rnaseq	NOUN
fnp-4675	202	4	stratifies	stratify	VERB
fnp-4675	202	5	multiple	multiple	ADJ
fnp-4675	202	6	sclerosis	sclerosis	NOUN
fnp-4675	202	7	patients	patient	NOUN
fnp-4675	202	8	into	into	ADP
fnp-4675	202	9	three	three	NUM
fnp-4675	202	10	distinct	distinct	ADJ
fnp-4675	202	11	white	white	ADJ
fnp-4675	202	12	matter	matter	NOUN
fnp-4675	202	13	glia	glia	NOUN
fnp-4675	202	14	responses	response	NOUN
fnp-4675	202	15	.	.	PUNCT
fnp-4675	203	1	biorxiv	biorxiv	NOUN
fnp-4675	203	2	,	,	PUNCT
fnp-4675	203	3	https://doi.org/10.1101/2022.04.06.487263	https://doi.org/10.1101/2022.04.06.487263	PROPN
fnp-4675	203	4	(	(	PUNCT
fnp-4675	203	5	2022	2022	NUM
fnp-4675	203	6	)	)	PUNCT
fnp-4675	203	7	.	.	PUNCT
fnp-4675	204	1	5	5	X
fnp-4675	204	2	.	.	X
fnp-4675	204	3	tonietto	tonietto	NOUN
fnp-4675	204	4	,	,	PUNCT
fnp-4675	204	5	m.	m.	NOUN
fnp-4675	204	6	et	et	PROPN
fnp-4675	204	7	al	al	PROPN
fnp-4675	204	8	.	.	PROPN
fnp-4675	204	9	periventricular	periventricular	ADJ
fnp-4675	204	10	remyelination	remyelination	NOUN
fnp-4675	204	11	failure	failure	NOUN
fnp-4675	204	12	in	in	ADP
fnp-4675	204	13	multiple	multiple	ADJ
fnp-4675	204	14	sclerosis	sclerosis	NOUN
fnp-4675	204	15	:	:	PUNCT
fnp-4675	204	16	a	a	DET
fnp-4675	204	17	substrate	substrate	NOUN
fnp-4675	204	18	for	for	ADP
fnp-4675	204	19	neurodegeneration	neurodegeneration	NOUN
fnp-4675	204	20	.	.	PUNCT
fnp-4675	205	1	brain	brain	NOUN
fnp-4675	205	2	146	146	NUM
fnp-4675	205	3	,	,	PUNCT
fnp-4675	205	4	182	182	NUM
fnp-4675	205	5	194	194	NUM
fnp-4675	205	6	,	,	PUNCT
fnp-4675	205	7	https://doi.org/10.1093/brain/awac334	https://doi.org/10.1093/brain/awac334	X
fnp-4675	205	8	(	(	PUNCT
fnp-4675	205	9	2023	2023	NUM
fnp-4675	205	10	)	)	PUNCT
fnp-4675	205	11	.	.	PUNCT
fnp-4675	206	1	6	6	X
fnp-4675	206	2	.	.	X
fnp-4675	206	3	bjornevik	bjornevik	PROPN
fnp-4675	206	4	,	,	PUNCT
fnp-4675	206	5	k.	k.	PROPN
fnp-4675	206	6	et	et	PROPN
fnp-4675	207	1	al	al	PROPN
fnp-4675	207	2	.	.	PROPN
fnp-4675	208	1	longitudinal	longitudinal	ADJ
fnp-4675	208	2	analysis	analysis	NOUN
fnp-4675	208	3	reveals	reveal	VERB
fnp-4675	208	4	high	high	ADJ
fnp-4675	208	5	prevalence	prevalence	NOUN
fnp-4675	208	6	of	of	ADP
fnp-4675	208	7	epstein	epstein	PROPN
fnp-4675	208	8	barr	barr	PROPN
fnp-4675	208	9	virus	virus	PROPN
fnp-4675	208	10	associated	associate	VERB
fnp-4675	208	11	with	with	ADP
fnp-4675	208	12	multiple	multiple	ADJ
fnp-4675	208	13	sclerosis	sclerosis	NOUN
fnp-4675	208	14	.	.	PUNCT
fnp-4675	209	1	science	science	NOUN
fnp-4675	209	2	375	375	NUM
fnp-4675	209	3	,	,	PUNCT
fnp-4675	209	4	296	296	NUM
fnp-4675	209	5	301	301	NUM
fnp-4675	209	6	,	,	PUNCT
fnp-4675	209	7	https://doi.org/10.1126/science.abj8222	https://doi.org/10.1126/science.abj8222	NOUN
fnp-4675	209	8	(	(	PUNCT
fnp-4675	209	9	2022	2022	NUM
fnp-4675	209	10	)	)	PUNCT
fnp-4675	209	11	.	.	PUNCT
fnp-4675	210	1	7	7	X
fnp-4675	210	2	.	.	X
fnp-4675	210	3	rostgaard	rostgaard	NOUN
fnp-4675	210	4	,	,	PUNCT
fnp-4675	210	5	k.	k.	PROPN
fnp-4675	210	6	,	,	PUNCT
fnp-4675	210	7	nielsen	nielsen	PROPN
fnp-4675	210	8	,	,	PUNCT
fnp-4675	210	9	n.	n.	PROPN
fnp-4675	210	10	m.	m.	NOUN
fnp-4675	210	11	,	,	PUNCT
fnp-4675	210	12	melbye	melbye	ADV
fnp-4675	210	13	,	,	PUNCT
fnp-4675	210	14	m.	m.	NOUN
fnp-4675	210	15	,	,	PUNCT
fnp-4675	210	16	frisch	frisch	PROPN
fnp-4675	210	17	,	,	PUNCT
fnp-4675	210	18	m.	m.	NOUN
fnp-4675	210	19	&	&	CCONJ
fnp-4675	210	20	hjalgrim	hjalgrim	PROPN
fnp-4675	210	21	,	,	PUNCT
fnp-4675	210	22	h.	h.	PROPN
fnp-4675	210	23	siblings	sibling	NOUN
fnp-4675	210	24	reduce	reduce	VERB
fnp-4675	210	25	multiple	multiple	ADJ
fnp-4675	210	26	sclerosis	sclerosis	NOUN
fnp-4675	210	27	risk	risk	NOUN
fnp-4675	210	28	by	by	ADP
fnp-4675	210	29	preventing	prevent	VERB
fnp-4675	210	30	delayed	delay	VERB
fnp-4675	210	31	primary	primary	ADJ
fnp-4675	210	32	epstein	epstein	PROPN
fnp-4675	210	33	barr	barr	PROPN
fnp-4675	210	34	virus	virus	PROPN
fnp-4675	210	35	infection	infection	NOUN
fnp-4675	210	36	.	.	PUNCT
fnp-4675	211	1	brain	brain	NOUN
fnp-4675	211	2	,	,	PUNCT
fnp-4675	211	3	https://doi.org/10.1093/brain/awac401	https://doi.org/10.1093/brain/awac401	PROPN
fnp-4675	211	4	(	(	PUNCT
fnp-4675	211	5	2022	2022	NUM
fnp-4675	211	6	)	)	PUNCT
fnp-4675	211	7	.	.	PUNCT
fnp-4675	212	1	8	8	X
fnp-4675	212	2	.	.	PUNCT
fnp-4675	212	3	lanz	lanz	PROPN
fnp-4675	212	4	,	,	PUNCT
fnp-4675	212	5	t.	t.	PROPN
fnp-4675	212	6	v.	v.	PROPN
fnp-4675	212	7	et	et	PROPN
fnp-4675	212	8	al	al	PROPN
fnp-4675	212	9	.	.	PROPN
fnp-4675	212	10	clonally	clonally	ADV
fnp-4675	212	11	expanded	expand	VERB
fnp-4675	212	12	b	b	NOUN
fnp-4675	212	13	cells	cell	NOUN
fnp-4675	212	14	in	in	ADP
fnp-4675	212	15	multiple	multiple	ADJ
fnp-4675	212	16	sclerosis	sclerosis	NOUN
fnp-4675	212	17	bind	bind	VERB
fnp-4675	212	18	ebv	ebv	NOUN
fnp-4675	212	19	ebna1	ebna1	PROPN
fnp-4675	212	20	and	and	CCONJ
fnp-4675	212	21	glialcam	glialcam	PROPN
fnp-4675	212	22	.	.	PUNCT
fnp-4675	213	1	nature	nature	NOUN
fnp-4675	213	2	603	603	NUM
fnp-4675	213	3	,	,	PUNCT
fnp-4675	213	4	321	321	NUM
fnp-4675	213	5	327	327	NUM
fnp-4675	213	6	,	,	PUNCT
fnp-4675	213	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	PROPN
fnp-4675	213	8	022	022	NUM
fnp-4675	213	9	04432	04432	NUM
fnp-4675	213	10	7	7	NUM
fnp-4675	213	11	(	(	PUNCT
fnp-4675	213	12	2022	2022	NUM
fnp-4675	213	13	)	)	PUNCT
fnp-4675	213	14	.	.	PUNCT
fnp-4675	214	1	9	9	X
fnp-4675	214	2	.	.	X
fnp-4675	214	3	hoftberger	hoftberger	NOUN
fnp-4675	214	4	,	,	PUNCT
fnp-4675	214	5	r.	r.	PROPN
fnp-4675	214	6	&	&	CCONJ
fnp-4675	214	7	lassmann	lassmann	PROPN
fnp-4675	214	8	,	,	PUNCT
fnp-4675	214	9	h.	h.	PROPN
fnp-4675	214	10	immune	immune	ADJ
fnp-4675	214	11	mediated	mediate	VERB
fnp-4675	214	12	disorders	disorder	NOUN
fnp-4675	214	13	.	.	PUNCT
fnp-4675	215	1	handb	handb	PROPN
fnp-4675	215	2	clin	clin	PROPN
fnp-4675	215	3	neurol	neurol	PROPN
fnp-4675	215	4	145	145	NUM
fnp-4675	215	5	,	,	PUNCT
fnp-4675	215	6	285	285	NUM
fnp-4675	215	7	299	299	NUM
fnp-4675	215	8	,	,	PUNCT
fnp-4675	215	9	https://doi.org/10.1016/b978	https://doi.org/10.1016/b978	PROPN
fnp-4675	215	10	0	0	NUM
fnp-4675	215	11	12	12	NUM
fnp-4675	215	12	802395	802395	NUM
fnp-4675	215	13	2.00020	2.00020	NUM
fnp-4675	215	14	1	1	NUM
fnp-4675	215	15	(	(	PUNCT
fnp-4675	215	16	2017	2017	NUM
fnp-4675	215	17	)	)	PUNCT
fnp-4675	215	18	.	.	PUNCT
fnp-4675	216	1	10	10	NUM
fnp-4675	216	2	.	.	X
fnp-4675	216	3	wingerchuk	wingerchuk	NOUN
fnp-4675	216	4	,	,	PUNCT
fnp-4675	216	5	d.	d.	PROPN
fnp-4675	216	6	m.	m.	PROPN
fnp-4675	216	7	&	&	CCONJ
fnp-4675	216	8	lucchinetti	lucchinetti	PROPN
fnp-4675	216	9	,	,	PUNCT
fnp-4675	216	10	c.	c.	PROPN
fnp-4675	216	11	f.	f.	PROPN
fnp-4675	216	12	neuromyelitis	neuromyelitis	PROPN
fnp-4675	216	13	optica	optica	PROPN
fnp-4675	216	14	spectrum	spectrum	NOUN
fnp-4675	216	15	disorder	disorder	NOUN
fnp-4675	216	16	.	.	PUNCT
fnp-4675	217	1	n	n	PROPN
fnp-4675	217	2	engl	engl	PROPN
fnp-4675	217	3	j	j	PROPN
fnp-4675	217	4	med	me	VERB
fnp-4675	217	5	387	387	NUM
fnp-4675	217	6	,	,	PUNCT
fnp-4675	217	7	631	631	NUM
fnp-4675	217	8	639	639	NUM
fnp-4675	217	9	,	,	PUNCT
fnp-4675	217	10	https://doi.org/10.1056/nejmra1904655	https://doi.org/10.1056/nejmra1904655	PROPN
fnp-4675	217	11	(	(	PUNCT
fnp-4675	217	12	2022	2022	NUM
fnp-4675	217	13	)	)	PUNCT
fnp-4675	217	14	.	.	PUNCT
fnp-4675	218	1	11	11	NUM
fnp-4675	218	2	.	.	PUNCT
fnp-4675	219	1	schneider	schneider	PROPN
fnp-4675	219	2	hohendorf	hohendorf	PROPN
fnp-4675	219	3	,	,	PUNCT
fnp-4675	219	4	t.	t.	PROPN
fnp-4675	219	5	et	et	PROPN
fnp-4675	219	6	al	al	PROPN
fnp-4675	219	7	.	.	PROPN
fnp-4675	220	1	broader	broad	ADJ
fnp-4675	220	2	epstein	epstein	PROPN
fnp-4675	220	3	barr	barr	PROPN
fnp-4675	220	4	virus	virus	PROPN
fnp-4675	220	5	specific	specific	PROPN
fnp-4675	220	6	t	t	PROPN
fnp-4675	220	7	cell	cell	NOUN
fnp-4675	220	8	receptor	receptor	NOUN
fnp-4675	220	9	repertoire	repertoire	NOUN
fnp-4675	220	10	in	in	ADP
fnp-4675	220	11	patients	patient	NOUN
fnp-4675	220	12	with	with	ADP
fnp-4675	220	13	multiple	multiple	ADJ
fnp-4675	220	14	sclerosis	sclerosis	NOUN
fnp-4675	220	15	.	.	PUNCT
fnp-4675	221	1	j	j	PROPN
fnp-4675	221	2	exp	exp	NOUN
fnp-4675	221	3	med	med	PROPN
fnp-4675	221	4	219	219	NUM
fnp-4675	221	5	,	,	PUNCT
fnp-4675	221	6	https://doi.org/10.1084/jem.20220650	https://doi.org/10.1084/jem.20220650	PROPN
fnp-4675	221	7	(	(	PUNCT
fnp-4675	221	8	2022	2022	NUM
fnp-4675	221	9	)	)	PUNCT
fnp-4675	221	10	.	.	PUNCT
fnp-4675	222	1	12	12	NUM
fnp-4675	222	2	.	.	PUNCT
fnp-4675	223	1	ingelfinger	ingelfinger	PROPN
fnp-4675	223	2	,	,	PUNCT
fnp-4675	223	3	f.	f.	PROPN
fnp-4675	223	4	et	et	PROPN
fnp-4675	223	5	al	al	PROPN
fnp-4675	223	6	.	.	PROPN
fnp-4675	223	7	twin	twin	PROPN
fnp-4675	223	8	study	study	NOUN
fnp-4675	223	9	reveals	reveal	VERB
fnp-4675	223	10	non	non	PRON
fnp-4675	223	11	heritable	heritable	ADJ
fnp-4675	223	12	immune	immune	ADJ
fnp-4675	223	13	perturbations	perturbation	NOUN
fnp-4675	223	14	in	in	ADP
fnp-4675	223	15	multiple	multiple	ADJ
fnp-4675	223	16	sclerosis	sclerosis	NOUN
fnp-4675	223	17	.	.	PUNCT
fnp-4675	224	1	nature	nature	NOUN
fnp-4675	224	2	603	603	NUM
fnp-4675	224	3	,	,	PUNCT
fnp-4675	224	4	152	152	NUM
fnp-4675	224	5	158	158	NUM
fnp-4675	224	6	,	,	PUNCT
fnp-4675	224	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	VERB
fnp-4675	224	8	022	022	NUM
fnp-4675	224	9	04419	04419	NUM
fnp-4675	224	10	4	4	NUM
fnp-4675	224	11	(	(	PUNCT
fnp-4675	224	12	2022	2022	NUM
fnp-4675	224	13	)	)	PUNCT
fnp-4675	224	14	.	.	PUNCT
fnp-4675	225	1	13	13	NUM
fnp-4675	225	2	.	.	X
fnp-4675	225	3	imsm	imsm	PROPN
fnp-4675	225	4	consortium	consortium	PROPN
fnp-4675	225	5	.	.	PUNCT
fnp-4675	226	1	gut	gut	VERB
fnp-4675	226	2	microbiome	microbiome	NOUN
fnp-4675	226	3	of	of	ADP
fnp-4675	226	4	multiple	multiple	ADJ
fnp-4675	226	5	sclerosis	sclerosis	NOUN
fnp-4675	226	6	patients	patient	NOUN
fnp-4675	226	7	and	and	CCONJ
fnp-4675	226	8	paired	pair	VERB
fnp-4675	226	9	household	household	NOUN
fnp-4675	226	10	healthy	healthy	ADJ
fnp-4675	226	11	controls	control	NOUN
fnp-4675	226	12	reveal	reveal	VERB
fnp-4675	226	13	associations	association	NOUN
fnp-4675	226	14	with	with	ADP
fnp-4675	226	15	disease	disease	NOUN
fnp-4675	226	16	risk	risk	NOUN
fnp-4675	226	17	and	and	CCONJ
fnp-4675	226	18	course	course	NOUN
fnp-4675	226	19	.	.	PUNCT
fnp-4675	227	1	cell	cell	NOUN
fnp-4675	227	2	185	185	NUM
fnp-4675	227	3	,	,	PUNCT
fnp-4675	227	4	3467	3467	NUM
fnp-4675	227	5	3486	3486	NUM
fnp-4675	227	6	e3416	e3416	PROPN
fnp-4675	227	7	,	,	PUNCT
fnp-4675	227	8	https://doi.org/10.1016/j.cell.2022.08.021	https://doi.org/10.1016/j.cell.2022.08.021	NOUN
fnp-4675	227	9	(	(	PUNCT
fnp-4675	227	10	2022	2022	NUM
fnp-4675	227	11	)	)	PUNCT
fnp-4675	227	12	.	.	PUNCT
fnp-4675	228	1	14	14	NUM
fnp-4675	228	2	.	.	X
fnp-4675	228	3	hosang	hosang	PROPN
fnp-4675	228	4	,	,	PUNCT
fnp-4675	228	5	l.	l.	PROPN
fnp-4675	228	6	et	et	PROPN
fnp-4675	228	7	al	al	PROPN
fnp-4675	228	8	.	.	PUNCT
fnp-4675	229	1	the	the	DET
fnp-4675	229	2	lung	lung	NOUN
fnp-4675	229	3	microbiome	microbiome	NOUN
fnp-4675	229	4	regulates	regulate	VERB
fnp-4675	229	5	brain	brain	NOUN
fnp-4675	229	6	autoimmunity	autoimmunity	NOUN
fnp-4675	229	7	.	.	PUNCT
fnp-4675	230	1	nature	nature	NOUN
fnp-4675	230	2	603	603	NUM
fnp-4675	230	3	,	,	PUNCT
fnp-4675	230	4	138	138	NUM
fnp-4675	230	5	144	144	NUM
fnp-4675	230	6	,	,	PUNCT
fnp-4675	230	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	VERB
fnp-4675	230	8	022	022	NUM
fnp-4675	230	9	04427	04427	NUM
fnp-4675	230	10	4	4	NUM
fnp-4675	230	11	(	(	PUNCT
fnp-4675	230	12	2022	2022	NUM
fnp-4675	230	13	)	)	PUNCT
fnp-4675	230	14	.	.	PUNCT
fnp-4675	231	1	15	15	NUM
fnp-4675	231	2	.	.	PUNCT
fnp-4675	231	3	dorion	dorion	NOUN
fnp-4675	231	4	,	,	PUNCT
fnp-4675	231	5	m.	m.	PROPN
fnp-4675	231	6	f.	f.	PROPN
fnp-4675	231	7	et	et	PROPN
fnp-4675	231	8	al	al	PROPN
fnp-4675	231	9	.	.	PUNCT
fnp-4675	232	1	systematic	systematic	ADJ
fnp-4675	232	2	comparison	comparison	NOUN
fnp-4675	232	3	of	of	ADP
fnp-4675	232	4	culture	culture	NOUN
fnp-4675	232	5	media	medium	NOUN
fnp-4675	232	6	uncovers	uncover	NOUN
fnp-4675	232	7	phenotypic	phenotypic	ADJ
fnp-4675	232	8	shift	shift	NOUN
fnp-4675	232	9	of	of	ADP
fnp-4675	232	10	primary	primary	ADJ
fnp-4675	232	11	human	human	ADJ
fnp-4675	232	12	microglia	microglia	NOUN
fnp-4675	232	13	defined	define	VERB
fnp-4675	232	14	by	by	ADP
fnp-4675	232	15	reduced	reduced	ADJ
fnp-4675	232	16	reliance	reliance	NOUN
fnp-4675	232	17	to	to	ADP
fnp-4675	232	18	csf1r	csf1r	PROPN
fnp-4675	232	19	signaling	signal	VERB
fnp-4675	232	20	.	.	PUNCT
fnp-4675	233	1	glia	glia	NOUN
fnp-4675	233	2	,	,	PUNCT
fnp-4675	233	3	https://doi.org/10.1002/glia.24338	https://doi.org/10.1002/glia.24338	NOUN
fnp-4675	233	4	(	(	PUNCT
fnp-4675	233	5	2023	2023	NUM
fnp-4675	233	6	)	)	PUNCT
fnp-4675	233	7	.	.	PUNCT
fnp-4675	234	1	16	16	NUM
fnp-4675	234	2	.	.	PUNCT
fnp-4675	235	1	thompson	thompson	PROPN
fnp-4675	235	2	,	,	PUNCT
fnp-4675	235	3	a.	a.	PROPN
fnp-4675	235	4	j.	j.	PROPN
fnp-4675	235	5	et	et	PROPN
fnp-4675	235	6	al	al	PROPN
fnp-4675	235	7	.	.	PUNCT
fnp-4675	235	8	diagnosis	diagnosis	NOUN
fnp-4675	235	9	of	of	ADP
fnp-4675	235	10	multiple	multiple	ADJ
fnp-4675	235	11	sclerosis	sclerosis	NOUN
fnp-4675	235	12	:	:	PUNCT
fnp-4675	235	13	2017	2017	NUM
fnp-4675	235	14	revisions	revision	NOUN
fnp-4675	235	15	of	of	ADP
fnp-4675	235	16	the	the	DET
fnp-4675	235	17	mcdonald	mcdonald	PROPN
fnp-4675	235	18	criteria	criterion	NOUN
fnp-4675	235	19	.	.	PUNCT
fnp-4675	236	1	lancet	lancet	PROPN
fnp-4675	236	2	neurol	neurol	PROPN
fnp-4675	236	3	17	17	NUM
fnp-4675	236	4	,	,	PUNCT
fnp-4675	236	5	162	162	NUM
fnp-4675	236	6	173	173	NUM
fnp-4675	236	7	,	,	PUNCT
fnp-4675	236	8	https://doi.org/10.1016/s1474	https://doi.org/10.1016/s1474	PROPN
fnp-4675	236	9	4422(17)30470	4422(17)30470	NUM
fnp-4675	236	10	2	2	NUM
fnp-4675	236	11	(	(	PUNCT
fnp-4675	236	12	2018	2018	NUM
fnp-4675	236	13	)	)	PUNCT
fnp-4675	236	14	.	.	PUNCT
fnp-4675	237	1	17	17	NUM
fnp-4675	237	2	.	.	PUNCT
fnp-4675	238	1	lublin	lublin	PROPN
fnp-4675	238	2	,	,	PUNCT
fnp-4675	238	3	f.	f.	PROPN
fnp-4675	238	4	d.	d.	PROPN
fnp-4675	238	5	et	et	PROPN
fnp-4675	238	6	al	al	PROPN
fnp-4675	238	7	.	.	PUNCT
fnp-4675	238	8	defining	define	VERB
fnp-4675	238	9	the	the	DET
fnp-4675	238	10	clinical	clinical	ADJ
fnp-4675	238	11	course	course	NOUN
fnp-4675	238	12	of	of	ADP
fnp-4675	238	13	multiple	multiple	ADJ
fnp-4675	238	14	sclerosis	sclerosis	NOUN
fnp-4675	238	15	:	:	PUNCT
fnp-4675	238	16	the	the	DET
fnp-4675	238	17	2013	2013	NUM
fnp-4675	238	18	revisions	revision	NOUN
fnp-4675	238	19	.	.	PUNCT
fnp-4675	239	1	neurology	neurology	NOUN
fnp-4675	239	2	83	83	NUM
fnp-4675	239	3	,	,	PUNCT
fnp-4675	239	4	278	278	NUM
fnp-4675	239	5	286	286	NUM
fnp-4675	239	6	,	,	PUNCT
fnp-4675	239	7	https://doi.org/10.1212/wnl.0000000000000560	https://doi.org/10.1212/wnl.0000000000000560	PROPN
fnp-4675	239	8	(	(	PUNCT
fnp-4675	239	9	2014	2014	NUM
fnp-4675	239	10	)	)	PUNCT
fnp-4675	239	11	.	.	PUNCT
fnp-4675	240	1	18	18	NUM
fnp-4675	240	2	.	.	X
fnp-4675	241	1	lublin	lublin	PROPN
fnp-4675	241	2	,	,	PUNCT
fnp-4675	241	3	f.	f.	PROPN
fnp-4675	241	4	d.	d.	PROPN
fnp-4675	241	5	et	et	PROPN
fnp-4675	241	6	al	al	PROPN
fnp-4675	241	7	.	.	PUNCT
fnp-4675	242	1	how	how	SCONJ
fnp-4675	242	2	patients	patient	NOUN
fnp-4675	242	3	with	with	ADP
fnp-4675	242	4	multiple	multiple	ADJ
fnp-4675	242	5	sclerosis	sclerosis	NOUN
fnp-4675	242	6	acquire	acquire	VERB
fnp-4675	242	7	disability	disability	NOUN
fnp-4675	242	8	.	.	PUNCT
fnp-4675	243	1	brain	brain	NOUN
fnp-4675	243	2	145	145	NUM
fnp-4675	243	3	,	,	PUNCT
fnp-4675	243	4	3147	3147	NUM
fnp-4675	243	5	3161	3161	NUM
fnp-4675	243	6	,	,	PUNCT
fnp-4675	243	7	https://doi.org/10.1093/brain/awac016	https://doi.org/10.1093/brain/awac016	PROPN
fnp-4675	243	8	(	(	PUNCT
fnp-4675	243	9	2022	2022	NUM
fnp-4675	243	10	)	)	PUNCT
fnp-4675	243	11	.	.	PUNCT
fnp-4675	244	1	19	19	NUM
fnp-4675	244	2	.	.	X
fnp-4675	244	3	tur	tur	PROPN
fnp-4675	244	4	,	,	PUNCT
fnp-4675	244	5	c.	c.	PROPN
fnp-4675	244	6	et	et	PROPN
fnp-4675	244	7	al	al	PROPN
fnp-4675	244	8	.	.	PROPN
fnp-4675	244	9	association	association	PROPN
fnp-4675	244	10	of	of	ADP
fnp-4675	244	11	early	early	ADJ
fnp-4675	244	12	progression	progression	NOUN
fnp-4675	244	13	independent	independent	ADJ
fnp-4675	244	14	of	of	ADP
fnp-4675	244	15	relapse	relapse	NOUN
fnp-4675	244	16	activity	activity	NOUN
fnp-4675	244	17	with	with	ADP
fnp-4675	244	18	long	long	ADJ
fnp-4675	244	19	term	term	NOUN
fnp-4675	244	20	disability	disability	NOUN
fnp-4675	244	21	after	after	ADP
fnp-4675	244	22	a	a	DET
fnp-4675	244	23	first	first	ADJ
fnp-4675	244	24	demyelinating	demyelinate	VERB
fnp-4675	244	25	event	event	NOUN
fnp-4675	244	26	in	in	ADP
fnp-4675	244	27	multiple	multiple	ADJ
fnp-4675	244	28	sclerosis	sclerosis	NOUN
fnp-4675	244	29	.	.	PUNCT
fnp-4675	245	1	jama	jama	PROPN
fnp-4675	245	2	neurol	neurol	PROPN
fnp-4675	245	3	,	,	PUNCT
fnp-4675	245	4	https://doi.org/10.1001/jamaneurol.2022.4655	https://doi.org/10.1001/jamaneurol.2022.4655	PROPN
fnp-4675	245	5	(	(	PUNCT
fnp-4675	245	6	2022	2022	NUM
fnp-4675	245	7	)	)	PUNCT
fnp-4675	245	8	.	.	PUNCT
fnp-4675	246	1	20	20	NUM
fnp-4675	246	2	.	.	X
fnp-4675	247	1	beynon	beynon	PROPN
fnp-4675	247	2	,	,	PUNCT
fnp-4675	247	3	v.	v.	ADP
fnp-4675	247	4	et	et	PROPN
fnp-4675	247	5	al	al	PROPN
fnp-4675	247	6	.	.	PROPN
fnp-4675	247	7	chronic	chronic	ADJ
fnp-4675	247	8	lesion	lesion	NOUN
fnp-4675	247	9	activity	activity	NOUN
fnp-4675	247	10	and	and	CCONJ
fnp-4675	247	11	disability	disability	NOUN
fnp-4675	247	12	progression	progression	NOUN
fnp-4675	247	13	in	in	ADP
fnp-4675	247	14	secondary	secondary	ADJ
fnp-4675	247	15	progressive	progressive	ADJ
fnp-4675	247	16	multiple	multiple	ADJ
fnp-4675	247	17	sclerosis	sclerosis	NOUN
fnp-4675	247	18	.	.	PUNCT
fnp-4675	248	1	bmj	bmj	PROPN
fnp-4675	248	2	neurol	neurol	PROPN
fnp-4675	248	3	open	open	ADJ
fnp-4675	248	4	4	4	NUM
fnp-4675	248	5	,	,	PUNCT
fnp-4675	248	6	e000240	e000240	NOUN
fnp-4675	248	7	,	,	PUNCT
fnp-4675	248	8	https://doi.org/10.1136/bmjno	https://doi.org/10.1136/bmjno	PROPN
fnp-4675	248	9	2021	2021	NUM
fnp-4675	248	10	000240	000240	NUM
fnp-4675	248	11	(	(	PUNCT
fnp-4675	248	12	2022	2022	NUM
fnp-4675	248	13	)	)	PUNCT
fnp-4675	248	14	.	.	PUNCT
fnp-4675	249	1	21	21	NUM
fnp-4675	249	2	.	.	PUNCT
fnp-4675	250	1	bevan	bevan	PROPN
fnp-4675	250	2	,	,	PUNCT
fnp-4675	250	3	r.	r.	PROPN
fnp-4675	250	4	j.	j.	PROPN
fnp-4675	250	5	et	et	PROPN
fnp-4675	250	6	al	al	PROPN
fnp-4675	250	7	.	.	PROPN
fnp-4675	250	8	meningeal	meningeal	ADJ
fnp-4675	250	9	inflammation	inflammation	NOUN
fnp-4675	250	10	and	and	CCONJ
fnp-4675	250	11	cortical	cortical	ADJ
fnp-4675	250	12	demyelination	demyelination	NOUN
fnp-4675	250	13	in	in	ADP
fnp-4675	250	14	acute	acute	ADJ
fnp-4675	250	15	multiple	multiple	ADJ
fnp-4675	250	16	sclerosis	sclerosis	NOUN
fnp-4675	250	17	.	.	PUNCT
fnp-4675	251	1	ann	ann	PROPN
fnp-4675	251	2	neurol	neurol	PROPN
fnp-4675	251	3	84	84	NUM
fnp-4675	251	4	,	,	PUNCT
fnp-4675	251	5	829	829	NUM
fnp-4675	251	6	842	842	NUM
fnp-4675	251	7	,	,	PUNCT
fnp-4675	251	8	https://doi.org/10.1002/ana.25365	https://doi.org/10.1002/ana.25365	PROPN
fnp-4675	251	9	(	(	PUNCT
fnp-4675	251	10	2018	2018	NUM
fnp-4675	251	11	)	)	PUNCT
fnp-4675	251	12	.	.	PUNCT
fnp-4675	252	1	22	22	NUM
fnp-4675	252	2	.	.	PUNCT
fnp-4675	253	1	magliozzi	magliozzi	PROPN
fnp-4675	253	2	,	,	PUNCT
fnp-4675	253	3	r.	r.	PROPN
fnp-4675	253	4	et	et	PROPN
fnp-4675	253	5	al	al	PROPN
fnp-4675	253	6	.	.	PUNCT
fnp-4675	254	1	a	a	DET
fnp-4675	254	2	gradient	gradient	NOUN
fnp-4675	254	3	of	of	ADP
fnp-4675	254	4	neuronal	neuronal	ADJ
fnp-4675	254	5	loss	loss	NOUN
fnp-4675	254	6	and	and	CCONJ
fnp-4675	254	7	meningeal	meningeal	ADJ
fnp-4675	254	8	inflammation	inflammation	NOUN
fnp-4675	254	9	in	in	ADP
fnp-4675	254	10	multiple	multiple	ADJ
fnp-4675	254	11	sclerosis	sclerosis	NOUN
fnp-4675	254	12	.	.	PUNCT
fnp-4675	255	1	ann	ann	PROPN
fnp-4675	255	2	.	.	PUNCT
fnp-4675	256	1	neurol	neurol	PROPN
fnp-4675	256	2	68	68	NUM
fnp-4675	256	3	,	,	PUNCT
fnp-4675	256	4	477	477	NUM
fnp-4675	256	5	493	493	NUM
fnp-4675	256	6	,	,	PUNCT
fnp-4675	256	7	https://doi.org/10.1002/ana.22230	https://doi.org/10.1002/ana.22230	PROPN
fnp-4675	256	8	(	(	PUNCT
fnp-4675	256	9	2010	2010	NUM
fnp-4675	256	10	)	)	PUNCT
fnp-4675	256	11	.	.	PUNCT
fnp-4675	257	1	23	23	NUM
fnp-4675	257	2	.	.	PUNCT
fnp-4675	258	1	magliozzi	magliozzi	PROPN
fnp-4675	258	2	,	,	PUNCT
fnp-4675	258	3	r.	r.	PROPN
fnp-4675	258	4	et	et	PROPN
fnp-4675	258	5	al	al	PROPN
fnp-4675	258	6	.	.	PROPN
fnp-4675	258	7	meningeal	meningeal	PROPN
fnp-4675	259	1	b	b	NOUN
fnp-4675	259	2	cell	cell	NOUN
fnp-4675	259	3	follicles	follicle	VERB
fnp-4675	259	4	in	in	ADP
fnp-4675	259	5	secondary	secondary	ADJ
fnp-4675	259	6	progressive	progressive	ADJ
fnp-4675	259	7	multiple	multiple	ADJ
fnp-4675	259	8	sclerosis	sclerosis	NOUN
fnp-4675	259	9	associate	associate	NOUN
fnp-4675	259	10	with	with	ADP
fnp-4675	259	11	early	early	ADJ
fnp-4675	259	12	onset	onset	NOUN
fnp-4675	259	13	of	of	ADP
fnp-4675	259	14	disease	disease	NOUN
fnp-4675	259	15	and	and	CCONJ
fnp-4675	259	16	severe	severe	ADJ
fnp-4675	259	17	cortical	cortical	ADJ
fnp-4675	259	18	pathology	pathology	NOUN
fnp-4675	259	19	.	.	PUNCT
fnp-4675	260	1	brain	brain	NOUN
fnp-4675	260	2	130	130	NUM
fnp-4675	260	3	,	,	PUNCT
fnp-4675	260	4	1089	1089	NUM
fnp-4675	260	5	1104	1104	NUM
fnp-4675	260	6	,	,	PUNCT
fnp-4675	260	7	https://doi.org/10.1093/brain/awm038	https://doi.org/10.1093/brain/awm038	NOUN
fnp-4675	260	8	(	(	PUNCT
fnp-4675	260	9	2007	2007	NUM
fnp-4675	260	10	)	)	PUNCT
fnp-4675	260	11	.	.	PUNCT
fnp-4675	261	1	24	24	NUM
fnp-4675	261	2	.	.	PUNCT
fnp-4675	262	1	howell	howell	PROPN
fnp-4675	262	2	,	,	PUNCT
fnp-4675	262	3	o.	o.	PROPN
fnp-4675	262	4	w.	w.	PROPN
fnp-4675	262	5	et	et	PROPN
fnp-4675	262	6	al	al	PROPN
fnp-4675	262	7	.	.	PROPN
fnp-4675	263	1	meningeal	meningeal	PROPN
fnp-4675	263	2	inflammation	inflammation	NOUN
fnp-4675	263	3	is	be	AUX
fnp-4675	263	4	widespread	widespread	ADJ
fnp-4675	263	5	and	and	CCONJ
fnp-4675	263	6	linked	link	VERB
fnp-4675	263	7	to	to	ADP
fnp-4675	263	8	cortical	cortical	ADJ
fnp-4675	263	9	pathology	pathology	NOUN
fnp-4675	263	10	in	in	ADP
fnp-4675	263	11	multiple	multiple	ADJ
fnp-4675	263	12	sclerosis	sclerosis	NOUN
fnp-4675	263	13	.	.	PUNCT
fnp-4675	264	1	brain	brain	NOUN
fnp-4675	264	2	134	134	NUM
fnp-4675	264	3	,	,	PUNCT
fnp-4675	264	4	2755	2755	NUM
fnp-4675	264	5	2771	2771	NUM
fnp-4675	264	6	,	,	PUNCT
fnp-4675	264	7	https://doi.org/10.1093/brain/awr182	https://doi.org/10.1093/brain/awr182	NOUN
fnp-4675	264	8	(	(	PUNCT
fnp-4675	264	9	2011	2011	NUM
fnp-4675	264	10	)	)	PUNCT
fnp-4675	264	11	.	.	PUNCT
fnp-4675	265	1	25	25	NUM
fnp-4675	265	2	.	.	PUNCT
fnp-4675	266	1	ahmed	ahmed	PROPN
fnp-4675	266	2	,	,	PUNCT
fnp-4675	266	3	s.	s.	PROPN
fnp-4675	266	4	m.	m.	PROPN
fnp-4675	266	5	et	et	PROPN
fnp-4675	266	6	al	al	PROPN
fnp-4675	266	7	.	.	PROPN
fnp-4675	266	8	accumulation	accumulation	NOUN
fnp-4675	266	9	of	of	ADP
fnp-4675	266	10	meningeal	meningeal	NOUN
fnp-4675	266	11	lymphocytes	lymphocyte	NOUN
fnp-4675	266	12	correlates	correlate	VERB
fnp-4675	266	13	with	with	ADP
fnp-4675	266	14	white	white	ADJ
fnp-4675	266	15	matter	matter	NOUN
fnp-4675	266	16	lesion	lesion	NOUN
fnp-4675	266	17	activity	activity	NOUN
fnp-4675	266	18	in	in	ADP
fnp-4675	266	19	progressive	progressive	ADJ
fnp-4675	266	20	multiple	multiple	ADJ
fnp-4675	266	21	sclerosis	sclerosis	NOUN
fnp-4675	266	22	.	.	PUNCT
fnp-4675	267	1	jci	jci	PROPN
fnp-4675	267	2	insight	insight	PROPN
fnp-4675	267	3	7	7	NUM
fnp-4675	267	4	,	,	PUNCT
fnp-4675	267	5	https://doi.org/10.1172/jci.insight.151683	https://doi.org/10.1172/jci.insight.151683	PROPN
fnp-4675	267	6	(	(	PUNCT
fnp-4675	267	7	2022	2022	NUM
fnp-4675	267	8	)	)	PUNCT
fnp-4675	267	9	.	.	PUNCT
fnp-4675	268	1	26	26	NUM
fnp-4675	268	2	.	.	PUNCT
fnp-4675	269	1	howell	howell	PROPN
fnp-4675	269	2	,	,	PUNCT
fnp-4675	269	3	o.	o.	PROPN
fnp-4675	269	4	w.	w.	PROPN
fnp-4675	269	5	et	et	PROPN
fnp-4675	269	6	al	al	PROPN
fnp-4675	269	7	.	.	PROPN
fnp-4675	269	8	extensive	extensive	ADJ
fnp-4675	269	9	grey	grey	NOUN
fnp-4675	269	10	matter	matter	NOUN
fnp-4675	269	11	pathology	pathology	NOUN
fnp-4675	269	12	in	in	ADP
fnp-4675	269	13	the	the	DET
fnp-4675	269	14	cerebellum	cerebellum	NOUN
fnp-4675	269	15	in	in	ADP
fnp-4675	269	16	multiple	multiple	ADJ
fnp-4675	269	17	sclerosis	sclerosis	NOUN
fnp-4675	269	18	is	be	AUX
fnp-4675	269	19	linked	link	VERB
fnp-4675	269	20	to	to	ADP
fnp-4675	269	21	inflammation	inflammation	NOUN
fnp-4675	269	22	in	in	ADP
fnp-4675	269	23	the	the	DET
fnp-4675	269	24	subarachnoid	subarachnoid	ADJ
fnp-4675	269	25	space	space	NOUN
fnp-4675	269	26	.	.	PUNCT
fnp-4675	270	1	neuropathol	neuropathol	NOUN
fnp-4675	270	2	appl	appl	PROPN
fnp-4675	270	3	neurobiol	neurobiol	PROPN
fnp-4675	270	4	41	41	NUM
fnp-4675	270	5	,	,	PUNCT
fnp-4675	270	6	798	798	NUM
fnp-4675	270	7	813	813	NUM
fnp-4675	270	8	,	,	PUNCT
fnp-4675	270	9	https://doi.org/10.1111/nan.12199	https://doi.org/10.1111/nan.12199	PROPN
fnp-4675	270	10	(	(	PUNCT
fnp-4675	270	11	2015	2015	NUM
fnp-4675	270	12	)	)	PUNCT
fnp-4675	270	13	.	.	PUNCT
fnp-4675	271	1	27	27	NUM
fnp-4675	271	2	.	.	PUNCT
fnp-4675	271	3	fransen	fransen	PROPN
fnp-4675	271	4	,	,	PUNCT
fnp-4675	271	5	n.	n.	PROPN
fnp-4675	271	6	l.	l.	PROPN
fnp-4675	271	7	et	et	PROPN
fnp-4675	271	8	al	al	PROPN
fnp-4675	271	9	.	.	PROPN
fnp-4675	272	1	absence	absence	NOUN
fnp-4675	272	2	of	of	ADP
fnp-4675	272	3	b	b	NOUN
fnp-4675	272	4	cells	cell	NOUN
fnp-4675	272	5	in	in	ADP
fnp-4675	272	6	brainstem	brainstem	NOUN
fnp-4675	272	7	and	and	CCONJ
fnp-4675	272	8	white	white	ADJ
fnp-4675	272	9	matter	matter	NOUN
fnp-4675	272	10	lesions	lesion	NOUN
fnp-4675	272	11	associates	associate	NOUN
fnp-4675	272	12	with	with	ADP
fnp-4675	272	13	less	less	ADV
fnp-4675	272	14	severe	severe	ADJ
fnp-4675	272	15	disease	disease	NOUN
fnp-4675	272	16	and	and	CCONJ
fnp-4675	272	17	absence	absence	NOUN
fnp-4675	272	18	of	of	ADP
fnp-4675	272	19	oligoclonal	oligoclonal	ADJ
fnp-4675	272	20	bands	band	NOUN
fnp-4675	272	21	in	in	ADP
fnp-4675	272	22	ms	ms	PROPN
fnp-4675	272	23	.	.	PROPN
fnp-4675	272	24	neurol	neurol	PROPN
fnp-4675	272	25	neuroimmunol	neuroimmunol	PROPN
fnp-4675	272	26	neuroinflamm	neuroinflamm	PROPN
fnp-4675	272	27	8	8	NUM
fnp-4675	272	28	,	,	PUNCT
fnp-4675	272	29	https://doi.org/10.1212/nxi.0000000000000955	https://doi.org/10.1212/nxi.0000000000000955	NOUN
fnp-4675	272	30	(	(	PUNCT
fnp-4675	272	31	2021	2021	NUM
fnp-4675	272	32	)	)	PUNCT
fnp-4675	272	33	.	.	PUNCT
fnp-4675	273	1	28	28	NUM
fnp-4675	273	2	.	.	PUNCT
fnp-4675	274	1	reali	reali	PROPN
fnp-4675	274	2	,	,	PUNCT
fnp-4675	274	3	c.	c.	PROPN
fnp-4675	274	4	et	et	PROPN
fnp-4675	274	5	al	al	PROPN
fnp-4675	274	6	.	.	PUNCT
fnp-4675	275	1	b	b	PROPN
fnp-4675	275	2	cell	cell	NOUN
fnp-4675	275	3	rich	rich	ADJ
fnp-4675	275	4	meningeal	meningeal	ADJ
fnp-4675	275	5	inflammation	inflammation	NOUN
fnp-4675	275	6	associates	associate	NOUN
fnp-4675	275	7	with	with	ADP
fnp-4675	275	8	increased	increase	VERB
fnp-4675	275	9	spinal	spinal	ADJ
fnp-4675	275	10	cord	cord	NOUN
fnp-4675	275	11	pathology	pathology	NOUN
fnp-4675	275	12	in	in	ADP
fnp-4675	275	13	multiple	multiple	ADJ
fnp-4675	275	14	sclerosis	sclerosis	NOUN
fnp-4675	275	15	.	.	PUNCT
fnp-4675	276	1	brain	brain	NOUN
fnp-4675	276	2	pathol	pathol	NOUN
fnp-4675	276	3	30	30	NUM
fnp-4675	276	4	,	,	PUNCT
fnp-4675	276	5	779	779	NUM
fnp-4675	276	6	793	793	NUM
fnp-4675	276	7	,	,	PUNCT
fnp-4675	276	8	https://doi.org/10.1111/bpa.12841	https://doi.org/10.1111/bpa.12841	PROPN
fnp-4675	276	9	(	(	PUNCT
fnp-4675	276	10	2020	2020	NUM
fnp-4675	276	11	)	)	PUNCT
fnp-4675	276	12	.	.	PUNCT
fnp-4675	277	1	29	29	NUM
fnp-4675	277	2	.	.	X
fnp-4675	277	3	drieu	drieu	NOUN
fnp-4675	277	4	,	,	PUNCT
fnp-4675	277	5	a.	a.	PROPN
fnp-4675	277	6	et	et	PROPN
fnp-4675	277	7	al	al	PROPN
fnp-4675	277	8	.	.	PROPN
fnp-4675	277	9	parenchymal	parenchymal	ADJ
fnp-4675	277	10	border	border	NOUN
fnp-4675	277	11	macrophages	macrophage	NOUN
fnp-4675	277	12	regulate	regulate	VERB
fnp-4675	277	13	the	the	DET
fnp-4675	277	14	flow	flow	NOUN
fnp-4675	277	15	dynamics	dynamic	NOUN
fnp-4675	277	16	of	of	ADP
fnp-4675	277	17	the	the	DET
fnp-4675	277	18	cerebrospinal	cerebrospinal	ADJ
fnp-4675	277	19	fluid	fluid	NOUN
fnp-4675	277	20	.	.	PUNCT
fnp-4675	278	1	nature	nature	NOUN
fnp-4675	278	2	611	611	NUM
fnp-4675	278	3	,	,	PUNCT
fnp-4675	278	4	585	585	NUM
fnp-4675	278	5	593	593	NUM
fnp-4675	278	6	,	,	PUNCT
fnp-4675	278	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	PROPN
fnp-4675	278	8	022	022	NUM
fnp-4675	278	9	05397	05397	NUM
fnp-4675	278	10	3	3	NUM
fnp-4675	278	11	(	(	PUNCT
fnp-4675	278	12	2022	2022	NUM
fnp-4675	278	13	)	)	PUNCT
fnp-4675	278	14	.	.	PUNCT
fnp-4675	279	1	30	30	NUM
fnp-4675	279	2	.	.	PUNCT
fnp-4675	279	3	carotenuto	carotenuto	NOUN
fnp-4675	279	4	,	,	PUNCT
fnp-4675	279	5	a.	a.	PROPN
fnp-4675	279	6	et	et	PROPN
fnp-4675	279	7	al	al	PROPN
fnp-4675	279	8	.	.	PUNCT
fnp-4675	279	9	glymphatic	glymphatic	ADJ
fnp-4675	279	10	system	system	NOUN
fnp-4675	279	11	impairment	impairment	NOUN
fnp-4675	279	12	in	in	ADP
fnp-4675	279	13	multiple	multiple	ADJ
fnp-4675	279	14	sclerosis	sclerosis	NOUN
fnp-4675	279	15	:	:	PUNCT
fnp-4675	279	16	relation	relation	NOUN
fnp-4675	279	17	with	with	ADP
fnp-4675	279	18	brain	brain	NOUN
fnp-4675	279	19	damage	damage	NOUN
fnp-4675	279	20	and	and	CCONJ
fnp-4675	279	21	disability	disability	NOUN
fnp-4675	279	22	.	.	PUNCT
fnp-4675	280	1	brain	brain	PROPN
fnp-4675	280	2	145	145	NUM
fnp-4675	280	3	,	,	PUNCT
fnp-4675	280	4	2785	2785	NUM
fnp-4675	280	5	2795	2795	NUM
fnp-4675	280	6	,	,	PUNCT
fnp-4675	280	7	https://doi.org/10.1093/brain/awab454	https://doi.org/10.1093/brain/awab454	NOUN
fnp-4675	280	8	(	(	PUNCT
fnp-4675	280	9	2022	2022	NUM
fnp-4675	280	10	)	)	PUNCT
fnp-4675	280	11	.	.	PUNCT
fnp-4675	281	1	31	31	NUM
fnp-4675	281	2	.	.	X
fnp-4675	281	3	fabriek	fabriek	PROPN
fnp-4675	281	4	,	,	PUNCT
fnp-4675	281	5	b.	b.	PROPN
fnp-4675	282	1	o.	o.	PROPN
fnp-4675	282	2	et	et	PROPN
fnp-4675	282	3	al	al	PROPN
fnp-4675	282	4	.	.	PROPN
fnp-4675	283	1	in	in	ADP
fnp-4675	283	2	vivo	vivo	ADJ
fnp-4675	283	3	detection	detection	NOUN
fnp-4675	283	4	of	of	ADP
fnp-4675	283	5	myelin	myelin	ADJ
fnp-4675	283	6	proteins	protein	NOUN
fnp-4675	283	7	in	in	ADP
fnp-4675	283	8	cervical	cervical	ADJ
fnp-4675	283	9	lymph	lymph	NOUN
fnp-4675	283	10	nodes	node	NOUN
fnp-4675	283	11	of	of	ADP
fnp-4675	283	12	ms	ms	NOUN
fnp-4675	283	13	patients	patient	NOUN
fnp-4675	283	14	using	use	VERB
fnp-4675	283	15	ultrasound	ultrasound	NOUN
fnp-4675	283	16	guided	guide	VERB
fnp-4675	283	17	fine	fine	ADJ
fnp-4675	283	18	needle	needle	NOUN
fnp-4675	283	19	aspiration	aspiration	NOUN
fnp-4675	283	20	cytology	cytology	NOUN
fnp-4675	283	21	.	.	PUNCT
fnp-4675	284	1	j	j	PROPN
fnp-4675	284	2	neuroimmunol	neuroimmunol	PROPN
fnp-4675	284	3	161	161	NUM
fnp-4675	284	4	,	,	PUNCT
fnp-4675	284	5	190	190	NUM
fnp-4675	284	6	194	194	NUM
fnp-4675	284	7	,	,	PUNCT
fnp-4675	284	8	https://doi.org/10.1016/j.jneuroim.2004.12.018	https://doi.org/10.1016/j.jneuroim.2004.12.018	NOUN
fnp-4675	284	9	(	(	PUNCT
fnp-4675	284	10	2005	2005	NUM
fnp-4675	284	11	)	)	PUNCT
fnp-4675	284	12	.	.	PUNCT
fnp-4675	285	1	32	32	NUM
fnp-4675	285	2	.	.	PUNCT
fnp-4675	286	1	merlini	merlini	PROPN
fnp-4675	286	2	,	,	PUNCT
fnp-4675	286	3	a.	a.	PROPN
fnp-4675	286	4	et	et	PROPN
fnp-4675	286	5	al	al	PROPN
fnp-4675	286	6	.	.	PUNCT
fnp-4675	287	1	distinct	distinct	ADJ
fnp-4675	287	2	roles	role	NOUN
fnp-4675	287	3	of	of	ADP
fnp-4675	287	4	the	the	DET
fnp-4675	287	5	meningeal	meningeal	ADJ
fnp-4675	287	6	layers	layer	NOUN
fnp-4675	287	7	in	in	ADP
fnp-4675	287	8	cns	cns	NOUN
fnp-4675	287	9	autoimmunity	autoimmunity	NOUN
fnp-4675	287	10	.	.	PUNCT
fnp-4675	288	1	nat	nat	PROPN
fnp-4675	288	2	neurosci	neurosci	PROPN
fnp-4675	288	3	25	25	NUM
fnp-4675	288	4	,	,	PUNCT
fnp-4675	288	5	887	887	NUM
fnp-4675	288	6	899	899	NUM
fnp-4675	288	7	,	,	PUNCT
fnp-4675	288	8	https://doi.org/10.1038/s41593	https://doi.org/10.1038/s41593	NUM
fnp-4675	288	9	022	022	NUM
fnp-4675	288	10	01108	01108	NUM
fnp-4675	288	11	3	3	NUM
fnp-4675	288	12	(	(	PUNCT
fnp-4675	288	13	2022	2022	NUM
fnp-4675	288	14	)	)	PUNCT
fnp-4675	288	15	.	.	PUNCT
fnp-4675	289	1	33	33	NUM
fnp-4675	289	2	.	.	PUNCT
fnp-4675	290	1	van	van	PROPN
fnp-4675	290	2	den	den	PROPN
fnp-4675	290	3	bosch	bosch	PROPN
fnp-4675	290	4	,	,	PUNCT
fnp-4675	290	5	a.	a.	PROPN
fnp-4675	290	6	m.	m.	PROPN
fnp-4675	290	7	r.	r.	PROPN
fnp-4675	290	8	et	et	PROPN
fnp-4675	291	1	al	al	PROPN
fnp-4675	291	2	.	.	PUNCT
fnp-4675	292	1	ultrastructural	ultrastructural	ADJ
fnp-4675	292	2	axon	axon	PROPN
fnp-4675	292	3	myelin	myelin	NOUN
fnp-4675	292	4	unit	unit	NOUN
fnp-4675	292	5	alterations	alteration	NOUN
fnp-4675	292	6	in	in	ADP
fnp-4675	292	7	multiple	multiple	ADJ
fnp-4675	292	8	sclerosis	sclerosis	NOUN
fnp-4675	292	9	correlate	correlate	VERB
fnp-4675	292	10	with	with	ADP
fnp-4675	292	11	inflammation	inflammation	NOUN
fnp-4675	292	12	.	.	PUNCT
fnp-4675	293	1	ann	ann	PROPN
fnp-4675	293	2	neurol	neurol	PROPN
fnp-4675	293	3	,	,	PUNCT
fnp-4675	293	4	https://doi.org/10.1002/ana.26585	https://doi.org/10.1002/ana.26585	PROPN
fnp-4675	293	5	(	(	PUNCT
fnp-4675	293	6	2022	2022	NUM
fnp-4675	293	7	)	)	PUNCT
fnp-4675	293	8	.	.	PUNCT
fnp-4675	294	1	34	34	NUM
fnp-4675	294	2	.	.	X
fnp-4675	294	3	wolswijk	wolswijk	PROPN
fnp-4675	294	4	,	,	PUNCT
fnp-4675	294	5	g.	g.	PROPN
fnp-4675	294	6	&	&	CCONJ
fnp-4675	294	7	balesar	balesar	PROPN
fnp-4675	294	8	,	,	PUNCT
fnp-4675	294	9	r.	r.	PROPN
fnp-4675	294	10	changes	change	NOUN
fnp-4675	294	11	in	in	ADP
fnp-4675	294	12	the	the	DET
fnp-4675	294	13	expression	expression	NOUN
fnp-4675	294	14	and	and	CCONJ
fnp-4675	294	15	localization	localization	NOUN
fnp-4675	294	16	of	of	ADP
fnp-4675	294	17	the	the	DET
fnp-4675	294	18	paranodal	paranodal	ADJ
fnp-4675	294	19	protein	protein	NOUN
fnp-4675	294	20	caspr	caspr	NOUN
fnp-4675	294	21	on	on	ADP
fnp-4675	294	22	axons	axon	NOUN
fnp-4675	294	23	in	in	ADP
fnp-4675	294	24	chronic	chronic	ADJ
fnp-4675	294	25	multiple	multiple	ADJ
fnp-4675	294	26	sclerosis	sclerosis	NOUN
fnp-4675	294	27	.	.	PUNCT
fnp-4675	295	1	brain	brain	NOUN
fnp-4675	295	2	126	126	NUM
fnp-4675	295	3	,	,	PUNCT
fnp-4675	295	4	1638	1638	NUM
fnp-4675	295	5	1649	1649	NUM
fnp-4675	295	6	,	,	PUNCT
fnp-4675	295	7	https://doi.org/10.1093/brain/awg151	https://doi.org/10.1093/brain/awg151	PROPN
fnp-4675	295	8	(	(	PUNCT
fnp-4675	295	9	2003	2003	NUM
fnp-4675	295	10	)	)	PUNCT
fnp-4675	295	11	.	.	PUNCT
fnp-4675	296	1	35	35	NUM
fnp-4675	296	2	.	.	PUNCT
fnp-4675	296	3	gallego	gallego	PROPN
fnp-4675	296	4	delgado	delgado	PROPN
fnp-4675	296	5	,	,	PUNCT
fnp-4675	296	6	p.	p.	NOUN
fnp-4675	296	7	et	et	NOUN
fnp-4675	297	1	al	al	PROPN
fnp-4675	297	2	.	.	PROPN
fnp-4675	297	3	neuroinflammation	neuroinflammation	NOUN
fnp-4675	297	4	in	in	ADP
fnp-4675	297	5	the	the	DET
fnp-4675	297	6	normal	normal	ADJ
fnp-4675	297	7	appearing	appearing	ADJ
fnp-4675	297	8	white	white	ADJ
fnp-4675	297	9	matter	matter	NOUN
fnp-4675	297	10	(	(	PUNCT
fnp-4675	297	11	nawm	nawm	PROPN
fnp-4675	297	12	)	)	PUNCT
fnp-4675	297	13	of	of	ADP
fnp-4675	297	14	the	the	DET
fnp-4675	297	15	multiple	multiple	ADJ
fnp-4675	297	16	sclerosis	sclerosis	NOUN
fnp-4675	297	17	brain	brain	NOUN
fnp-4675	297	18	causes	cause	VERB
fnp-4675	297	19	abnormalities	abnormality	NOUN
fnp-4675	297	20	at	at	ADP
fnp-4675	297	21	the	the	DET
fnp-4675	297	22	nodes	node	NOUN
fnp-4675	297	23	of	of	ADP
fnp-4675	297	24	ranvier	ranvier	NOUN
fnp-4675	297	25	.	.	PUNCT
fnp-4675	298	1	plos	plos	PROPN
fnp-4675	298	2	biol	biol	PROPN
fnp-4675	298	3	18	18	NUM
fnp-4675	298	4	,	,	PUNCT
fnp-4675	298	5	e3001008	e3001008	PROPN
fnp-4675	298	6	,	,	PUNCT
fnp-4675	298	7	https://doi.org/10.1371/journal.pbio.3001008	https://doi.org/10.1371/journal.pbio.3001008	NOUN
fnp-4675	298	8	(	(	PUNCT
fnp-4675	298	9	2020	2020	NUM
fnp-4675	298	10	)	)	PUNCT
fnp-4675	298	11	.	.	PUNCT
fnp-4675	299	1	36	36	NUM
fnp-4675	299	2	.	.	PUNCT
fnp-4675	299	3	irvine	irvine	PROPN
fnp-4675	299	4	,	,	PUNCT
fnp-4675	299	5	k.	k.	PROPN
fnp-4675	299	6	a.	a.	PROPN
fnp-4675	299	7	&	&	CCONJ
fnp-4675	299	8	blakemore	blakemore	PROPN
fnp-4675	299	9	,	,	PUNCT
fnp-4675	299	10	w.	w.	PROPN
fnp-4675	299	11	f.	f.	PROPN
fnp-4675	299	12	remyelination	remyelination	PROPN
fnp-4675	299	13	protects	protect	VERB
fnp-4675	299	14	axons	axon	NOUN
fnp-4675	299	15	from	from	ADP
fnp-4675	299	16	demyelination	demyelination	NOUN
fnp-4675	299	17	associated	associate	VERB
fnp-4675	299	18	axon	axon	NOUN
fnp-4675	299	19	degeneration	degeneration	NOUN
fnp-4675	299	20	.	.	PUNCT
fnp-4675	300	1	brain	brain	NOUN
fnp-4675	300	2	131	131	NUM
fnp-4675	300	3	,	,	PUNCT
fnp-4675	300	4	1464	1464	NUM
fnp-4675	300	5	1477	1477	NUM
fnp-4675	300	6	,	,	PUNCT
fnp-4675	300	7	https://doi.org/10.1093/brain/awn080	https://doi.org/10.1093/brain/awn080	NOUN
fnp-4675	300	8	(	(	PUNCT
fnp-4675	300	9	2008	2008	NUM
fnp-4675	300	10	)	)	PUNCT
fnp-4675	300	11	.	.	PUNCT
fnp-4675	301	1	37	37	NUM
fnp-4675	301	2	.	.	X
fnp-4675	302	1	duncan	duncan	PROPN
fnp-4675	302	2	,	,	PUNCT
fnp-4675	302	3	i.	i.	PROPN
fnp-4675	302	4	d.	d.	PROPN
fnp-4675	302	5	,	,	PUNCT
fnp-4675	302	6	brower	brower	PROPN
fnp-4675	302	7	,	,	PUNCT
fnp-4675	302	8	a.	a.	PROPN
fnp-4675	302	9	,	,	PUNCT
fnp-4675	302	10	kondo	kondo	PROPN
fnp-4675	302	11	,	,	PUNCT
fnp-4675	302	12	y.	y.	PROPN
fnp-4675	302	13	,	,	PUNCT
fnp-4675	302	14	curlee	curlee	PROPN
fnp-4675	302	15	,	,	PUNCT
fnp-4675	302	16	j.	j.	PROPN
fnp-4675	302	17	f.	f.	PROPN
fnp-4675	302	18	,	,	PUNCT
fnp-4675	302	19	jr	jr	PROPN
fnp-4675	302	20	.	.	PROPN
fnp-4675	302	21	&	&	CCONJ
fnp-4675	302	22	schultz	schultz	PROPN
fnp-4675	302	23	,	,	PUNCT
fnp-4675	302	24	r.	r.	PROPN
fnp-4675	302	25	d.	d.	PROPN
fnp-4675	302	26	extensive	extensive	ADJ
fnp-4675	302	27	remyelination	remyelination	NOUN
fnp-4675	302	28	of	of	ADP
fnp-4675	302	29	the	the	DET
fnp-4675	302	30	cns	cns	NOUN
fnp-4675	302	31	leads	lead	VERB
fnp-4675	302	32	to	to	ADP
fnp-4675	302	33	functional	functional	ADJ
fnp-4675	302	34	recovery	recovery	NOUN
fnp-4675	302	35	.	.	PUNCT
fnp-4675	303	1	proc	proc	NOUN
fnp-4675	303	2	.	.	PUNCT
fnp-4675	304	1	natl	natl	PROPN
fnp-4675	304	2	.	.	PUNCT
fnp-4675	305	1	acad	acad	PROPN
fnp-4675	305	2	.	.	PUNCT
fnp-4675	306	1	sci	sci	PROPN
fnp-4675	306	2	.	.	PUNCT
fnp-4675	306	3	u.	u.	PROPN
fnp-4675	306	4	s.	s.	PROPN
fnp-4675	306	5	a	a	DET
fnp-4675	306	6	106	106	NUM
fnp-4675	306	7	,	,	PUNCT
fnp-4675	306	8	6832	6832	NUM
fnp-4675	306	9	6836	6836	NUM
fnp-4675	306	10	,	,	PUNCT
fnp-4675	306	11	https://doi.org/10.1073/pnas.0812500106	https://doi.org/10.1073/pnas.0812500106	NOUN
fnp-4675	306	12	(	(	PUNCT
fnp-4675	306	13	2009	2009	NUM
fnp-4675	306	14	)	)	PUNCT
fnp-4675	306	15	.	.	PUNCT
fnp-4675	307	1	38	38	NUM
fnp-4675	307	2	.	.	PUNCT
fnp-4675	308	1	sarrazin	sarrazin	PROPN
fnp-4675	308	2	,	,	PUNCT
fnp-4675	308	3	n.	n.	PROPN
fnp-4675	308	4	et	et	PROPN
fnp-4675	308	5	al	al	PROPN
fnp-4675	308	6	.	.	PROPN
fnp-4675	308	7	failed	fail	VERB
fnp-4675	308	8	remyelination	remyelination	NOUN
fnp-4675	308	9	of	of	ADP
fnp-4675	308	10	the	the	DET
fnp-4675	308	11	nonhuman	nonhuman	ADJ
fnp-4675	308	12	primate	primate	NOUN
fnp-4675	308	13	optic	optic	ADJ
fnp-4675	308	14	nerve	nerve	NOUN
fnp-4675	308	15	leads	lead	VERB
fnp-4675	308	16	to	to	ADP
fnp-4675	308	17	axon	axon	VERB
fnp-4675	308	18	degeneration	degeneration	NOUN
fnp-4675	308	19	,	,	PUNCT
fnp-4675	308	20	retinal	retinal	ADJ
fnp-4675	308	21	damages	damage	NOUN
fnp-4675	308	22	,	,	PUNCT
fnp-4675	308	23	and	and	CCONJ
fnp-4675	308	24	visual	visual	ADJ
fnp-4675	308	25	dysfunction	dysfunction	NOUN
fnp-4675	308	26	.	.	PUNCT
fnp-4675	309	1	proc	proc	PROPN
fnp-4675	309	2	natl	natl	PROPN
fnp-4675	309	3	acad	acad	PROPN
fnp-4675	309	4	sci	sci	PROPN
fnp-4675	309	5	u	u	PROPN
fnp-4675	309	6	s	s	PROPN
fnp-4675	309	7	a	a	DET
fnp-4675	309	8	119	119	NUM
fnp-4675	309	9	,	,	PUNCT
fnp-4675	309	10	e2115973119	e2115973119	PROPN
fnp-4675	309	11	,	,	PUNCT
fnp-4675	309	12	https://doi.org/10.1073/pnas.2115973119	https://doi.org/10.1073/pnas.2115973119	ADV
fnp-4675	309	13	(	(	PUNCT
fnp-4675	309	14	2022	2022	NUM
fnp-4675	309	15	)	)	PUNCT
fnp-4675	309	16	.	.	PUNCT
fnp-4675	310	1	39	39	NUM
fnp-4675	310	2	.	.	PUNCT
fnp-4675	311	1	patrikios	patrikio	NOUN
fnp-4675	311	2	,	,	PUNCT
fnp-4675	311	3	p.	p.	NOUN
fnp-4675	311	4	et	et	NOUN
fnp-4675	312	1	al	al	PROPN
fnp-4675	312	2	.	.	PROPN
fnp-4675	312	3	remyelination	remyelination	NOUN
fnp-4675	312	4	is	be	AUX
fnp-4675	312	5	extensive	extensive	ADJ
fnp-4675	312	6	in	in	ADP
fnp-4675	312	7	a	a	DET
fnp-4675	312	8	subset	subset	NOUN
fnp-4675	312	9	of	of	ADP
fnp-4675	312	10	multiple	multiple	ADJ
fnp-4675	312	11	sclerosis	sclerosis	NOUN
fnp-4675	312	12	patients	patient	NOUN
fnp-4675	312	13	.	.	PUNCT
fnp-4675	313	1	brain	brain	NOUN
fnp-4675	313	2	129	129	NUM
fnp-4675	313	3	,	,	PUNCT
fnp-4675	313	4	3165	3165	NUM
fnp-4675	313	5	3172	3172	NUM
fnp-4675	313	6	,	,	PUNCT
fnp-4675	313	7	https://doi.org/10.1093/brain/awl217	https://doi.org/10.1093/brain/awl217	NOUN
fnp-4675	313	8	(	(	PUNCT
fnp-4675	313	9	2006	2006	NUM
fnp-4675	313	10	)	)	PUNCT
fnp-4675	313	11	.	.	PUNCT
fnp-4675	314	1	40	40	NUM
fnp-4675	314	2	.	.	PUNCT
fnp-4675	315	1	goldschmidt	goldschmidt	PROPN
fnp-4675	315	2	,	,	PUNCT
fnp-4675	315	3	t.	t.	PROPN
fnp-4675	315	4	,	,	PUNCT
fnp-4675	315	5	antel	antel	PROPN
fnp-4675	315	6	,	,	PUNCT
fnp-4675	315	7	j.	j.	PROPN
fnp-4675	315	8	,	,	PUNCT
fnp-4675	315	9	konig	konig	PROPN
fnp-4675	315	10	,	,	PUNCT
fnp-4675	315	11	f.	f.	PROPN
fnp-4675	315	12	b.	b.	PROPN
fnp-4675	315	13	,	,	PUNCT
fnp-4675	315	14	brück	brück	PROPN
fnp-4675	315	15	,	,	PUNCT
fnp-4675	315	16	w.	w.	PROPN
fnp-4675	315	17	&	&	CCONJ
fnp-4675	315	18	kuhlmann	kuhlmann	PROPN
fnp-4675	315	19	,	,	PUNCT
fnp-4675	315	20	t.	t.	NOUN
fnp-4675	315	21	remyelination	remyelination	NOUN
fnp-4675	315	22	capacity	capacity	NOUN
fnp-4675	315	23	of	of	ADP
fnp-4675	315	24	the	the	DET
fnp-4675	315	25	ms	ms	PROPN
fnp-4675	315	26	brain	brain	NOUN
fnp-4675	315	27	decreases	decrease	VERB
fnp-4675	315	28	with	with	ADP
fnp-4675	315	29	disease	disease	NOUN
fnp-4675	315	30	chronicity	chronicity	NOUN
fnp-4675	315	31	.	.	PUNCT
fnp-4675	316	1	neurology	neurology	NOUN
fnp-4675	316	2	72	72	NUM
fnp-4675	316	3	,	,	PUNCT
fnp-4675	316	4	1914	1914	NUM
fnp-4675	316	5	1921	1921	NUM
fnp-4675	316	6	,	,	PUNCT
fnp-4675	316	7	https://doi.org/10.1212/wnl.0b013e3181a8260a	https://doi.org/10.1212/wnl.0b013e3181a8260a	NOUN
fnp-4675	316	8	(	(	PUNCT
fnp-4675	316	9	2009	2009	NUM
fnp-4675	316	10	)	)	PUNCT
fnp-4675	316	11	.	.	PUNCT
fnp-4675	317	1	41	41	NUM
fnp-4675	317	2	.	.	PUNCT
fnp-4675	318	1	arnold	arnold	PROPN
fnp-4675	318	2	,	,	PUNCT
fnp-4675	318	3	d.	d.	PROPN
fnp-4675	318	4	l.	l.	PROPN
fnp-4675	318	5	et	et	PROPN
fnp-4675	318	6	al	al	PROPN
fnp-4675	318	7	.	.	PROPN
fnp-4675	318	8	effect	effect	NOUN
fnp-4675	318	9	of	of	ADP
fnp-4675	318	10	siponimod	siponimod	PROPN
fnp-4675	318	11	on	on	ADP
fnp-4675	318	12	magnetic	magnetic	ADJ
fnp-4675	318	13	resonance	resonance	NOUN
fnp-4675	318	14	imaging	imaging	NOUN
fnp-4675	318	15	measures	measure	NOUN
fnp-4675	318	16	of	of	ADP
fnp-4675	318	17	neurodegeneration	neurodegeneration	NOUN
fnp-4675	318	18	and	and	CCONJ
fnp-4675	318	19	myelination	myelination	NOUN
fnp-4675	318	20	in	in	ADP
fnp-4675	318	21	secondary	secondary	ADJ
fnp-4675	318	22	progressive	progressive	ADJ
fnp-4675	318	23	multiple	multiple	ADJ
fnp-4675	318	24	sclerosis	sclerosis	NOUN
fnp-4675	318	25	:	:	PUNCT
fnp-4675	318	26	gray	gray	ADJ
fnp-4675	318	27	matter	matter	NOUN
fnp-4675	318	28	atrophy	atrophy	NOUN
fnp-4675	318	29	and	and	CCONJ
fnp-4675	318	30	magnetization	magnetization	NOUN
fnp-4675	318	31	transfer	transfer	NOUN
fnp-4675	318	32	ratio	ratio	NOUN
fnp-4675	318	33	analyses	analysis	NOUN
fnp-4675	318	34	from	from	ADP
fnp-4675	318	35	the	the	DET
fnp-4675	318	36	expand	expand	NOUN
fnp-4675	318	37	phase	phase	NOUN
fnp-4675	318	38	3	3	NUM
fnp-4675	318	39	trial	trial	NOUN
fnp-4675	318	40	.	.	PUNCT
fnp-4675	319	1	mult	mult	PROPN
fnp-4675	319	2	scler	scler	PROPN
fnp-4675	319	3	28	28	NUM
fnp-4675	319	4	,	,	PUNCT
fnp-4675	319	5	1526	1526	NUM
fnp-4675	319	6	1540	1540	NUM
fnp-4675	319	7	,	,	PUNCT
fnp-4675	319	8	https://doi.org/10.1177/13524585221076717	https://doi.org/10.1177/13524585221076717	NOUN
fnp-4675	319	9	(	(	PUNCT
fnp-4675	319	10	2022	2022	NUM
fnp-4675	319	11	)	)	PUNCT
fnp-4675	319	12	.	.	PUNCT
fnp-4675	320	1	42	42	NUM
fnp-4675	320	2	.	.	PUNCT
fnp-4675	321	1	rahmanzadeh	rahmanzadeh	PROPN
fnp-4675	321	2	,	,	PUNCT
fnp-4675	321	3	r.	r.	PROPN
fnp-4675	321	4	et	et	PROPN
fnp-4675	321	5	al	al	PROPN
fnp-4675	321	6	.	.	PUNCT
fnp-4675	322	1	a	a	DET
fnp-4675	322	2	new	new	ADJ
fnp-4675	322	3	advanced	advanced	ADJ
fnp-4675	322	4	mri	mri	NOUN
fnp-4675	322	5	biomarker	biomarker	NOUN
fnp-4675	322	6	for	for	ADP
fnp-4675	322	7	remyelinated	remyelinate	VERB
fnp-4675	322	8	lesions	lesion	NOUN
fnp-4675	322	9	in	in	ADP
fnp-4675	322	10	multiple	multiple	ADJ
fnp-4675	322	11	sclerosis	sclerosis	NOUN
fnp-4675	322	12	.	.	PUNCT
fnp-4675	323	1	ann	ann	PROPN
fnp-4675	323	2	neurol	neurol	PROPN
fnp-4675	323	3	92	92	NUM
fnp-4675	323	4	,	,	PUNCT
fnp-4675	323	5	486	486	NUM
fnp-4675	323	6	502	502	NUM
fnp-4675	323	7	,	,	PUNCT
fnp-4675	323	8	https://doi.org/10.1002/ana.26441	https://doi.org/10.1002/ana.26441	PROPN
fnp-4675	323	9	(	(	PUNCT
fnp-4675	323	10	2022	2022	NUM
fnp-4675	323	11	)	)	PUNCT
fnp-4675	323	12	.	.	PUNCT
fnp-4675	324	1	43	43	NUM
fnp-4675	324	2	.	.	PUNCT
fnp-4675	325	1	absinta	absinta	PROPN
fnp-4675	325	2	,	,	PUNCT
fnp-4675	325	3	m.	m.	NOUN
fnp-4675	325	4	et	et	PROPN
fnp-4675	325	5	al	al	PROPN
fnp-4675	325	6	.	.	PUNCT
fnp-4675	325	7	persistent	persistent	ADJ
fnp-4675	325	8	7	7	NUM
fnp-4675	325	9	tesla	tesla	PROPN
fnp-4675	325	10	phase	phase	NOUN
fnp-4675	325	11	rim	rim	NOUN
fnp-4675	325	12	predicts	predict	VERB
fnp-4675	325	13	poor	poor	ADJ
fnp-4675	325	14	outcome	outcome	NOUN
fnp-4675	325	15	in	in	ADP
fnp-4675	325	16	new	new	ADJ
fnp-4675	325	17	multiple	multiple	ADJ
fnp-4675	325	18	sclerosis	sclerosis	NOUN
fnp-4675	325	19	patient	patient	NOUN
fnp-4675	325	20	lesions	lesion	NOUN
fnp-4675	325	21	.	.	PUNCT
fnp-4675	326	1	j	j	PROPN
fnp-4675	326	2	clin	clin	PROPN
fnp-4675	326	3	invest	invest	VERB
fnp-4675	326	4	126	126	NUM
fnp-4675	326	5	,	,	PUNCT
fnp-4675	326	6	2597	2597	NUM
fnp-4675	326	7	2609	2609	NUM
fnp-4675	326	8	,	,	PUNCT
fnp-4675	326	9	https://doi.org/10.1172/jci86198	https://doi.org/10.1172/jci86198	PROPN
fnp-4675	326	10	(	(	PUNCT
fnp-4675	326	11	2016	2016	NUM
fnp-4675	326	12	)	)	PUNCT
fnp-4675	326	13	.	.	PUNCT
fnp-4675	327	1	44	44	NUM
fnp-4675	327	2	.	.	PUNCT
fnp-4675	328	1	chen	chen	PROPN
fnp-4675	328	2	,	,	PUNCT
fnp-4675	328	3	w.	w.	PROPN
fnp-4675	328	4	et	et	PROPN
fnp-4675	328	5	al	al	PROPN
fnp-4675	328	6	.	.	PROPN
fnp-4675	329	1	quantitative	quantitative	ADJ
fnp-4675	329	2	susceptibility	susceptibility	NOUN
fnp-4675	329	3	mapping	mapping	NOUN
fnp-4675	329	4	of	of	ADP
fnp-4675	329	5	multiple	multiple	ADJ
fnp-4675	329	6	sclerosis	sclerosis	NOUN
fnp-4675	329	7	lesions	lesion	NOUN
fnp-4675	329	8	at	at	ADP
fnp-4675	329	9	various	various	ADJ
fnp-4675	329	10	ages	age	NOUN
fnp-4675	329	11	.	.	PUNCT
fnp-4675	330	1	radiology	radiology	NOUN
fnp-4675	330	2	271	271	NUM
fnp-4675	330	3	,	,	PUNCT
fnp-4675	330	4	183	183	NUM
fnp-4675	330	5	192	192	NUM
fnp-4675	330	6	,	,	PUNCT
fnp-4675	330	7	https://doi.org/10.1148/radiol.13130353	https://doi.org/10.1148/radiol.13130353	X
fnp-4675	330	8	(	(	PUNCT
fnp-4675	330	9	2014	2014	NUM
fnp-4675	330	10	)	)	PUNCT
fnp-4675	330	11	.	.	PUNCT
fnp-4675	331	1	45	45	NUM
fnp-4675	331	2	.	.	PUNCT
fnp-4675	332	1	chen	chen	PROPN
fnp-4675	332	2	,	,	PUNCT
fnp-4675	332	3	j.	j.	PROPN
fnp-4675	332	4	t.	t.	PROPN
fnp-4675	332	5	,	,	PUNCT
fnp-4675	332	6	collins	collins	PROPN
fnp-4675	332	7	,	,	PUNCT
fnp-4675	332	8	d.	d.	PROPN
fnp-4675	332	9	l.	l.	PROPN
fnp-4675	332	10	,	,	PUNCT
fnp-4675	332	11	atkins	atkins	PROPN
fnp-4675	332	12	,	,	PUNCT
fnp-4675	332	13	h.	h.	PROPN
fnp-4675	332	14	l.	l.	PROPN
fnp-4675	332	15	,	,	PUNCT
fnp-4675	332	16	freedman	freedman	PROPN
fnp-4675	332	17	,	,	PUNCT
fnp-4675	332	18	m.	m.	PROPN
fnp-4675	332	19	s.	s.	PROPN
fnp-4675	332	20	&	&	CCONJ
fnp-4675	332	21	arnold	arnold	PROPN
fnp-4675	332	22	,	,	PUNCT
fnp-4675	332	23	d.	d.	PROPN
fnp-4675	332	24	l.	l.	PROPN
fnp-4675	332	25	magnetization	magnetization	PROPN
fnp-4675	332	26	transfer	transfer	NOUN
fnp-4675	332	27	ratio	ratio	NOUN
fnp-4675	332	28	evolution	evolution	NOUN
fnp-4675	332	29	with	with	ADP
fnp-4675	332	30	demyelination	demyelination	NOUN
fnp-4675	332	31	and	and	CCONJ
fnp-4675	332	32	remyelination	remyelination	NOUN
fnp-4675	332	33	in	in	ADP
fnp-4675	332	34	multiple	multiple	ADJ
fnp-4675	332	35	sclerosis	sclerosis	NOUN
fnp-4675	332	36	lesions	lesion	NOUN
fnp-4675	332	37	.	.	PUNCT
fnp-4675	333	1	ann	ann	PROPN
fnp-4675	333	2	.	.	PUNCT
fnp-4675	334	1	neurol	neurol	PROPN
fnp-4675	334	2	63	63	NUM
fnp-4675	334	3	,	,	PUNCT
fnp-4675	334	4	254	254	NUM
fnp-4675	334	5	262	262	NUM
fnp-4675	334	6	,	,	PUNCT
fnp-4675	334	7	https://doi.org/10.1002/ana.21302	https://doi.org/10.1002/ana.21302	PROPN
fnp-4675	334	8	(	(	PUNCT
fnp-4675	334	9	2008	2008	NUM
fnp-4675	334	10	)	)	PUNCT
fnp-4675	334	11	.	.	PUNCT
fnp-4675	335	1	46	46	NUM
fnp-4675	335	2	.	.	PUNCT
fnp-4675	336	1	jakel	jakel	PROPN
fnp-4675	336	2	,	,	PUNCT
fnp-4675	336	3	s.	s.	PROPN
fnp-4675	336	4	et	et	PROPN
fnp-4675	336	5	al	al	PROPN
fnp-4675	336	6	.	.	PROPN
fnp-4675	336	7	altered	alter	VERB
fnp-4675	336	8	human	human	ADJ
fnp-4675	336	9	oligodendrocyte	oligodendrocyte	PROPN
fnp-4675	336	10	heterogeneity	heterogeneity	NOUN
fnp-4675	336	11	in	in	ADP
fnp-4675	336	12	multiple	multiple	ADJ
fnp-4675	336	13	sclerosis	sclerosis	NOUN
fnp-4675	336	14	.	.	PUNCT
fnp-4675	337	1	nature	nature	NOUN
fnp-4675	337	2	566	566	NUM
fnp-4675	337	3	,	,	PUNCT
fnp-4675	337	4	543	543	NUM
fnp-4675	337	5	547	547	NUM
fnp-4675	337	6	,	,	PUNCT
fnp-4675	337	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	VERB
fnp-4675	337	8	019	019	NUM
fnp-4675	337	9	0903	0903	NUM
fnp-4675	337	10	2	2	NUM
fnp-4675	337	11	(	(	PUNCT
fnp-4675	337	12	2019	2019	NUM
fnp-4675	337	13	)	)	PUNCT
fnp-4675	337	14	.	.	PUNCT
fnp-4675	338	1	47	47	NUM
fnp-4675	338	2	.	.	PUNCT
fnp-4675	339	1	schirmer	schirmer	PROPN
fnp-4675	339	2	,	,	PUNCT
fnp-4675	339	3	l.	l.	PROPN
fnp-4675	339	4	et	et	PROPN
fnp-4675	339	5	al	al	PROPN
fnp-4675	339	6	.	.	PUNCT
fnp-4675	339	7	neuronal	neuronal	ADJ
fnp-4675	339	8	vulnerability	vulnerability	NOUN
fnp-4675	339	9	and	and	CCONJ
fnp-4675	339	10	multilineage	multilineage	NOUN
fnp-4675	339	11	diversity	diversity	NOUN
fnp-4675	339	12	in	in	ADP
fnp-4675	339	13	multiple	multiple	ADJ
fnp-4675	339	14	sclerosis	sclerosis	NOUN
fnp-4675	339	15	.	.	PUNCT
fnp-4675	340	1	nature	nature	NOUN
fnp-4675	340	2	573	573	NUM
fnp-4675	340	3	,	,	PUNCT
fnp-4675	340	4	75	75	NUM
fnp-4675	340	5	82	82	NUM
fnp-4675	340	6	,	,	PUNCT
fnp-4675	340	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	VERB
fnp-4675	340	8	019	019	NUM
fnp-4675	340	9	1404	1404	NUM
fnp-4675	340	10	z	z	NOUN
fnp-4675	340	11	(	(	PUNCT
fnp-4675	340	12	2019	2019	NUM
fnp-4675	340	13	)	)	PUNCT
fnp-4675	340	14	.	.	PUNCT
fnp-4675	341	1	48	48	NUM
fnp-4675	341	2	.	.	PUNCT
fnp-4675	342	1	absinta	absinta	PROPN
fnp-4675	342	2	,	,	PUNCT
fnp-4675	342	3	m.	m.	NOUN
fnp-4675	342	4	et	et	PROPN
fnp-4675	342	5	al	al	PROPN
fnp-4675	342	6	.	.	PUNCT
fnp-4675	343	1	a	a	DET
fnp-4675	343	2	lymphocyte	lymphocyte	ADJ
fnp-4675	343	3	microglia	microglia	ADJ
fnp-4675	343	4	astrocyte	astrocyte	NOUN
fnp-4675	343	5	axis	axis	NOUN
fnp-4675	343	6	in	in	ADP
fnp-4675	343	7	chronic	chronic	ADJ
fnp-4675	343	8	active	active	ADJ
fnp-4675	343	9	multiple	multiple	ADJ
fnp-4675	343	10	sclerosis	sclerosis	NOUN
fnp-4675	343	11	.	.	PUNCT
fnp-4675	344	1	nature	nature	NOUN
fnp-4675	344	2	597	597	NUM
fnp-4675	344	3	,	,	PUNCT
fnp-4675	344	4	709	709	NUM
fnp-4675	344	5	714	714	NUM
fnp-4675	344	6	,	,	PUNCT
fnp-4675	344	7	https://doi.org/10.1038/s41586	https://doi.org/10.1038/s41586	PROPN
fnp-4675	344	8	021	021	NUM
fnp-4675	344	9	03892	03892	NUM
fnp-4675	344	10	7	7	NUM
fnp-4675	344	11	(	(	PUNCT
fnp-4675	344	12	2021	2021	NUM
fnp-4675	344	13	)	)	PUNCT
fnp-4675	344	14	.	.	PUNCT
fnp-4675	345	1	49	49	NUM
fnp-4675	345	2	.	.	PUNCT
fnp-4675	346	1	kaufmann	kaufmann	PROPN
fnp-4675	346	2	,	,	PUNCT
fnp-4675	346	3	m.	m.	NOUN
fnp-4675	346	4	et	et	PROPN
fnp-4675	346	5	al	al	PROPN
fnp-4675	346	6	.	.	PUNCT
fnp-4675	346	7	identification	identification	NOUN
fnp-4675	346	8	of	of	ADP
fnp-4675	346	9	early	early	ADJ
fnp-4675	346	10	neurodegenerative	neurodegenerative	ADJ
fnp-4675	346	11	pathways	pathway	NOUN
fnp-4675	346	12	in	in	ADP
fnp-4675	346	13	progressive	progressive	ADJ
fnp-4675	346	14	multiple	multiple	ADJ
fnp-4675	346	15	sclerosis	sclerosis	NOUN
fnp-4675	346	16	.	.	PUNCT
fnp-4675	347	1	nat	nat	PROPN
fnp-4675	347	2	neurosci	neurosci	PROPN
fnp-4675	347	3	25	25	NUM
fnp-4675	347	4	,	,	PUNCT
fnp-4675	347	5	944	944	NUM
fnp-4675	347	6	955	955	NUM
fnp-4675	347	7	,	,	PUNCT
fnp-4675	347	8	https://doi.org/10.1038/s41593	https://doi.org/10.1038/s41593	NUM
fnp-4675	347	9	022	022	NUM
fnp-4675	347	10	01097	01097	NUM
fnp-4675	347	11	3	3	NUM
fnp-4675	347	12	(	(	PUNCT
fnp-4675	347	13	2022	2022	NUM
fnp-4675	347	14	)	)	PUNCT
fnp-4675	347	15	.	.	PUNCT
fnp-4675	348	1	50	50	NUM
fnp-4675	348	2	.	.	PUNCT
fnp-4675	348	3	jurgens	jurgens	PROPN
fnp-4675	348	4	,	,	PUNCT
fnp-4675	348	5	t.	t.	PROPN
fnp-4675	348	6	et	et	PROPN
fnp-4675	348	7	al	al	PROPN
fnp-4675	348	8	.	.	PROPN
fnp-4675	348	9	reconstruction	reconstruction	NOUN
fnp-4675	348	10	of	of	ADP
fnp-4675	348	11	single	single	ADJ
fnp-4675	348	12	cortical	cortical	ADJ
fnp-4675	348	13	projection	projection	NOUN
fnp-4675	348	14	neurons	neuron	NOUN
fnp-4675	348	15	reveals	reveal	VERB
fnp-4675	348	16	primary	primary	ADJ
fnp-4675	348	17	spine	spine	ADJ
fnp-4675	348	18	loss	loss	NOUN
fnp-4675	348	19	in	in	ADP
fnp-4675	348	20	multiple	multiple	ADJ
fnp-4675	348	21	sclerosis	sclerosis	NOUN
fnp-4675	348	22	.	.	PUNCT
fnp-4675	349	1	brain	brain	NOUN
fnp-4675	349	2	139	139	NUM
fnp-4675	349	3	,	,	PUNCT
fnp-4675	349	4	39	39	NUM
fnp-4675	349	5	46	46	NUM
fnp-4675	349	6	,	,	PUNCT
fnp-4675	349	7	https://doi.org/10.1093/brain/awv353	https://doi.org/10.1093/brain/awv353	NOUN
fnp-4675	349	8	(	(	PUNCT
fnp-4675	349	9	2016	2016	NUM
fnp-4675	349	10	)	)	PUNCT
fnp-4675	349	11	.	.	PUNCT
fnp-4675	350	1	51	51	NUM
fnp-4675	350	2	.	.	PUNCT
fnp-4675	350	3	wingerchuk	wingerchuk	PROPN
fnp-4675	350	4	,	,	PUNCT
fnp-4675	350	5	d.	d.	PROPN
fnp-4675	350	6	m.	m.	PROPN
fnp-4675	350	7	et	et	PROPN
fnp-4675	351	1	al	al	PROPN
fnp-4675	351	2	.	.	PUNCT
fnp-4675	352	1	international	international	ADJ
fnp-4675	352	2	consensus	consensus	NOUN
fnp-4675	352	3	diagnostic	diagnostic	ADJ
fnp-4675	352	4	criteria	criterion	NOUN
fnp-4675	352	5	for	for	ADP
fnp-4675	352	6	neuromyelitis	neuromyelitis	PROPN
fnp-4675	352	7	optica	optica	PROPN
fnp-4675	352	8	spectrum	spectrum	PROPN
fnp-4675	352	9	disorders	disorder	NOUN
fnp-4675	352	10	.	.	PUNCT
fnp-4675	353	1	neurology	neurology	NOUN
fnp-4675	353	2	85	85	NUM
fnp-4675	353	3	,	,	PUNCT
fnp-4675	353	4	177	177	NUM
fnp-4675	353	5	189,https://doi.org/10.1212	189,https://doi.org/10.1212	NUM
fnp-4675	353	6	/	/	SYM
fnp-4675	353	7	wnl.0000000000001729	wnl.0000000000001729	NUM
fnp-4675	353	8	(	(	PUNCT
fnp-4675	353	9	2015	2015	NUM
fnp-4675	353	10	)	)	PUNCT
fnp-4675	353	11	.	.	PUNCT
fnp-4675	354	1	52	52	NUM
fnp-4675	354	2	.	.	PUNCT
fnp-4675	354	3	marignier	marignier	NOUN
fnp-4675	354	4	,	,	PUNCT
fnp-4675	354	5	r.	r.	PROPN
fnp-4675	354	6	et	et	PROPN
fnp-4675	354	7	al	al	PROPN
fnp-4675	354	8	.	.	PROPN
fnp-4675	354	9	myelin	myelin	PROPN
fnp-4675	354	10	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	354	11	glycoprotein	glycoprotein	NOUN
fnp-4675	354	12	antibody	antibody	NOUN
fnp-4675	354	13	associated	associate	VERB
fnp-4675	354	14	disease	disease	NOUN
fnp-4675	354	15	.	.	PUNCT
fnp-4675	355	1	lancet	lancet	PROPN
fnp-4675	355	2	neurol	neurol	PROPN
fnp-4675	355	3	20	20	NUM
fnp-4675	355	4	,	,	PUNCT
fnp-4675	355	5	762	762	NUM
fnp-4675	355	6	772	772	NUM
fnp-4675	355	7	,	,	PUNCT
fnp-4675	355	8	https://doi.org/10.1016/s1474	https://doi.org/10.1016/s1474	PROPN
fnp-4675	355	9	4422(21)00218	4422(21)00218	NOUN
fnp-4675	355	10	0	0	PUNCT
fnp-4675	355	11	(	(	PUNCT
fnp-4675	355	12	2021	2021	NUM
fnp-4675	355	13	)	)	PUNCT
fnp-4675	355	14	.	.	PUNCT
fnp-4675	356	1	53	53	NUM
fnp-4675	356	2	.	.	PUNCT
fnp-4675	356	3	gaudioso	gaudioso	PROPN
fnp-4675	356	4	,	,	PUNCT
fnp-4675	356	5	c.	c.	PROPN
fnp-4675	356	6	m.	m.	PROPN
fnp-4675	356	7	et	et	PROPN
fnp-4675	356	8	al	al	PROPN
fnp-4675	356	9	.	.	PUNCT
fnp-4675	356	10	mog	mog	PROPN
fnp-4675	356	11	and	and	CCONJ
fnp-4675	356	12	aqp4	aqp4	PROPN
fnp-4675	356	13	antibodies	antibodie	VERB
fnp-4675	356	14	among	among	ADP
fnp-4675	356	15	children	child	NOUN
fnp-4675	356	16	with	with	ADP
fnp-4675	356	17	multiple	multiple	ADJ
fnp-4675	356	18	sclerosis	sclerosis	NOUN
fnp-4675	356	19	and	and	CCONJ
fnp-4675	356	20	controls	control	NOUN
fnp-4675	356	21	.	.	PUNCT
fnp-4675	357	1	ann	ann	PROPN
fnp-4675	357	2	neurol	neurol	PROPN
fnp-4675	357	3	,	,	PUNCT
fnp-4675	357	4	https://doi.org/10.1002/ana.26502	https://doi.org/10.1002/ana.26502	INTJ
fnp-4675	357	5	(	(	PUNCT
fnp-4675	357	6	2022	2022	NUM
fnp-4675	357	7	)	)	PUNCT
fnp-4675	357	8	.	.	PUNCT
fnp-4675	358	1	54	54	NUM
fnp-4675	358	2	.	.	PUNCT
fnp-4675	359	1	ogawa	ogawa	PROPN
fnp-4675	359	2	,	,	PUNCT
fnp-4675	359	3	r.	r.	PROPN
fnp-4675	359	4	et	et	PROPN
fnp-4675	359	5	al	al	PROPN
fnp-4675	359	6	.	.	PUNCT
fnp-4675	359	7	mog	mog	NOUN
fnp-4675	359	8	antibody	antibody	NOUN
fnp-4675	359	9	positive	positive	ADJ
fnp-4675	359	10	,	,	PUNCT
fnp-4675	359	11	benign	benign	ADJ
fnp-4675	359	12	,	,	PUNCT
fnp-4675	359	13	unilateral	unilateral	ADJ
fnp-4675	359	14	,	,	PUNCT
fnp-4675	359	15	cerebral	cerebral	ADJ
fnp-4675	359	16	cortical	cortical	ADJ
fnp-4675	359	17	encephalitis	encephalitis	NOUN
fnp-4675	359	18	with	with	ADP
fnp-4675	359	19	epilepsy	epilepsy	NOUN
fnp-4675	359	20	.	.	PUNCT
fnp-4675	360	1	neurol	neurol	PROPN
fnp-4675	360	2	neuroimmunol	neuroimmunol	PROPN
fnp-4675	360	3	neuroinflamm	neuroinflamm	PROPN
fnp-4675	360	4	4	4	NUM
fnp-4675	360	5	,	,	PUNCT
fnp-4675	360	6	e322	e322	PROPN
fnp-4675	360	7	,	,	PUNCT
fnp-4675	360	8	https://doi.org/10.1212/nxi.0000000000000322	https://doi.org/10.1212/nxi.0000000000000322	PROPN
fnp-4675	360	9	(	(	PUNCT
fnp-4675	360	10	2017	2017	NUM
fnp-4675	360	11	)	)	PUNCT
fnp-4675	360	12	.	.	PUNCT
fnp-4675	361	1	55	55	NUM
fnp-4675	361	2	.	.	PUNCT
fnp-4675	362	1	valencia	valencia	PROPN
fnp-4675	362	2	sanchez	sanchez	PROPN
fnp-4675	362	3	,	,	PUNCT
fnp-4675	362	4	c.	c.	PROPN
fnp-4675	362	5	et	et	PROPN
fnp-4675	362	6	al	al	PROPN
fnp-4675	362	7	.	.	PROPN
fnp-4675	362	8	cerebral	cerebral	ADJ
fnp-4675	362	9	cortical	cortical	ADJ
fnp-4675	362	10	encephalitis	encephalitis	NOUN
fnp-4675	362	11	in	in	ADP
fnp-4675	362	12	myelin	myelin	ADJ
fnp-4675	362	13	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	362	14	glycoprotein	glycoprotein	NOUN
fnp-4675	362	15	antibody	antibody	NOUN
fnp-4675	362	16	associated	associate	VERB
fnp-4675	362	17	disease	disease	NOUN
fnp-4675	362	18	.	.	PUNCT
fnp-4675	363	1	ann	ann	PROPN
fnp-4675	363	2	neurol	neurol	PROPN
fnp-4675	363	3	,	,	PUNCT
fnp-4675	363	4	https://doi.org/10.1002/ana.26549	https://doi.org/10.1002/ana.26549	PROPN
fnp-4675	363	5	(	(	PUNCT
fnp-4675	363	6	2022	2022	NUM
fnp-4675	363	7	)	)	PUNCT
fnp-4675	363	8	.	.	PUNCT
fnp-4675	364	1	56	56	NUM
fnp-4675	364	2	.	.	PUNCT
fnp-4675	364	3	junker	junker	PROPN
fnp-4675	364	4	,	,	PUNCT
fnp-4675	364	5	a.	a.	PROPN
fnp-4675	364	6	et	et	PROPN
fnp-4675	364	7	al	al	PROPN
fnp-4675	364	8	.	.	PROPN
fnp-4675	365	1	extensive	extensive	ADJ
fnp-4675	365	2	subpial	subpial	ADJ
fnp-4675	365	3	cortical	cortical	ADJ
fnp-4675	365	4	demyelination	demyelination	NOUN
fnp-4675	365	5	is	be	AUX
fnp-4675	365	6	specific	specific	ADJ
fnp-4675	365	7	to	to	ADP
fnp-4675	365	8	multiple	multiple	ADJ
fnp-4675	365	9	sclerosis	sclerosis	NOUN
fnp-4675	365	10	.	.	PUNCT
fnp-4675	366	1	brain	brain	NOUN
fnp-4675	366	2	pathol	pathol	NOUN
fnp-4675	366	3	30	30	NUM
fnp-4675	366	4	,	,	PUNCT
fnp-4675	366	5	641	641	NUM
fnp-4675	366	6	652	652	NUM
fnp-4675	366	7	,	,	PUNCT
fnp-4675	366	8	https://doi.org/10.1111/bpa.12813	https://doi.org/10.1111/bpa.12813	PROPN
fnp-4675	366	9	(	(	PUNCT
fnp-4675	366	10	2020	2020	NUM
fnp-4675	366	11	)	)	PUNCT
fnp-4675	366	12	.	.	PUNCT
fnp-4675	367	1	57	57	NUM
fnp-4675	367	2	.	.	X
fnp-4675	367	3	hoftberger	hoftberger	NOUN
fnp-4675	367	4	,	,	PUNCT
fnp-4675	367	5	r.	r.	PROPN
fnp-4675	367	6	et	et	PROPN
fnp-4675	367	7	al	al	PROPN
fnp-4675	367	8	.	.	PUNCT
fnp-4675	368	1	the	the	DET
fnp-4675	368	2	pathology	pathology	NOUN
fnp-4675	368	3	of	of	ADP
fnp-4675	368	4	central	central	ADJ
fnp-4675	368	5	nervous	nervous	ADJ
fnp-4675	368	6	system	system	NOUN
fnp-4675	368	7	inflammatory	inflammatory	ADJ
fnp-4675	368	8	demyelinating	demyelinate	VERB
fnp-4675	368	9	disease	disease	NOUN
fnp-4675	368	10	accompanying	accompany	VERB
fnp-4675	368	11	myelin	myelin	NOUN
fnp-4675	368	12	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	368	13	glycoprotein	glycoprotein	NOUN
fnp-4675	368	14	autoantibody	autoantibody	NOUN
fnp-4675	368	15	.	.	PUNCT
fnp-4675	369	1	acta	acta	PROPN
fnp-4675	369	2	neuropathol	neuropathol	PROPN
fnp-4675	369	3	139	139	NUM
fnp-4675	369	4	,	,	PUNCT
fnp-4675	369	5	875	875	NUM
fnp-4675	369	6	892	892	NUM
fnp-4675	369	7	,	,	PUNCT
fnp-4675	369	8	https://doi.org/10.1007/s00401	https://doi.org/10.1007/s00401	PROPN
fnp-4675	369	9	020	020	NUM
fnp-4675	369	10	02132	02132	NUM
fnp-4675	369	11	y	y	PROPN
fnp-4675	369	12	(	(	PUNCT
fnp-4675	369	13	2020	2020	NUM
fnp-4675	369	14	)	)	PUNCT
fnp-4675	369	15	.	.	PUNCT
fnp-4675	370	1	58	58	NUM
fnp-4675	370	2	.	.	PUNCT
fnp-4675	371	1	takai	takai	PROPN
fnp-4675	371	2	,	,	PUNCT
fnp-4675	371	3	y.	y.	PROPN
fnp-4675	371	4	et	et	PROPN
fnp-4675	371	5	al	al	PROPN
fnp-4675	371	6	.	.	PROPN
fnp-4675	371	7	myelin	myelin	PROPN
fnp-4675	371	8	oligodendrocyte	oligodendrocyte	ADJ
fnp-4675	371	9	glycoprotein	glycoprotein	NOUN
fnp-4675	371	10	antibody	antibody	NOUN
fnp-4675	371	11	associated	associate	VERB
fnp-4675	371	12	disease	disease	NOUN
fnp-4675	371	13	:	:	PUNCT
fnp-4675	371	14	an	an	DET
fnp-4675	371	15	immunopathological	immunopathological	ADJ
fnp-4675	371	16	study	study	NOUN
fnp-4675	371	17	.	.	PUNCT
fnp-4675	372	1	brain	brain	NOUN
fnp-4675	372	2	143	143	NUM
fnp-4675	372	3	,	,	PUNCT
fnp-4675	372	4	1431	1431	NUM
fnp-4675	372	5	1446	1446	NUM
fnp-4675	372	6	,	,	PUNCT
fnp-4675	372	7	https://doi.org/10.1093/brain/awaa102	https://doi.org/10.1093/brain/awaa102	X
fnp-4675	372	8	(	(	PUNCT
fnp-4675	372	9	2020	2020	NUM
fnp-4675	372	10	)	)	PUNCT
fnp-4675	372	11	.	.	PUNCT
fnp-4675	373	1	59	59	NUM
fnp-4675	373	2	.	.	X
fnp-4675	373	3	francis	francis	PROPN
fnp-4675	373	4	,	,	PUNCT
fnp-4675	373	5	a.	a.	PROPN
fnp-4675	373	6	g.	g.	PROPN
fnp-4675	373	7	et	et	PROPN
fnp-4675	374	1	al	al	PROPN
fnp-4675	374	2	.	.	PROPN
fnp-4675	374	3	acute	acute	ADJ
fnp-4675	374	4	inflammatory	inflammatory	ADJ
fnp-4675	374	5	diseases	disease	NOUN
fnp-4675	374	6	of	of	ADP
fnp-4675	374	7	the	the	DET
fnp-4675	374	8	central	central	ADJ
fnp-4675	374	9	nervous	nervous	ADJ
fnp-4675	374	10	system	system	NOUN
fnp-4675	374	11	after	after	SCONJ
fnp-4675	374	12	sars	sars	PROPN
fnp-4675	374	13	cov	cov	PROPN
fnp-4675	374	14	2	2	NUM
fnp-4675	374	15	vaccination	vaccination	NOUN
fnp-4675	374	16	.	.	PUNCT
fnp-4675	375	1	neurol	neurol	PROPN
fnp-4675	375	2	neuroimmunol	neuroimmunol	PROPN
fnp-4675	375	3	neuroinflamm	neuroinflamm	PROPN
fnp-4675	375	4	10	10	NUM
fnp-4675	375	5	,	,	PUNCT
fnp-4675	375	6	https://doi.org/10.1212/nxi.0000000000200063	https://doi.org/10.1212/nxi.0000000000200063	VERB
fnp-4675	375	7	(	(	PUNCT
fnp-4675	375	8	2023	2023	NUM
fnp-4675	375	9	)	)	PUNCT
fnp-4675	375	10	.	.	PUNCT
fnp-4675	376	1	copyright	copyright	NOUN
fnp-4675	376	2	:	:	PUNCT
fnp-4675	376	3	©	©	PROPN
fnp-4675	376	4	2023	2023	NUM
fnp-4675	376	5	the	the	DET
fnp-4675	376	6	author(s	author(s	NOUN
fnp-4675	376	7	)	)	PUNCT
fnp-4675	376	8	.	.	PUNCT
fnp-4675	377	1	this	this	PRON
fnp-4675	377	2	is	be	AUX
fnp-4675	377	3	an	an	DET
fnp-4675	377	4	open	open	ADJ
fnp-4675	377	5	access	access	NOUN
fnp-4675	377	6	article	article	NOUN
fnp-4675	377	7	distributed	distribute	VERB
fnp-4675	377	8	under	under	ADP
fnp-4675	377	9	the	the	DET
fnp-4675	377	10	terms	term	NOUN
fnp-4675	377	11	of	of	ADP
fnp-4675	377	12	the	the	DET
fnp-4675	377	13	creative	creative	ADJ
fnp-4675	377	14	commons	common	NOUN
fnp-4675	377	15	attribution	attribution	NOUN
fnp-4675	377	16	4.0	4.0	NUM
fnp-4675	377	17	international	international	ADJ
fnp-4675	377	18	license	license	NOUN
fnp-4675	377	19	(	(	PUNCT
fnp-4675	377	20	https://creativecommons.org/licenses/by/4.0/	https://creativecommons.org/licenses/by/4.0/	PROPN
fnp-4675	377	21	)	)	PUNCT
fnp-4675	377	22	,	,	PUNCT
fnp-4675	377	23	which	which	PRON
fnp-4675	377	24	permits	permit	VERB
fnp-4675	377	25	unrestricted	unrestricted	ADJ
fnp-4675	377	26	use	use	NOUN
fnp-4675	377	27	,	,	PUNCT
fnp-4675	377	28	distribution	distribution	NOUN
fnp-4675	377	29	,	,	PUNCT
fnp-4675	377	30	and	and	CCONJ
fnp-4675	377	31	reproduction	reproduction	NOUN
fnp-4675	377	32	in	in	ADP
fnp-4675	377	33	any	any	DET
fnp-4675	377	34	medium	medium	NOUN
fnp-4675	377	35	,	,	PUNCT
fnp-4675	377	36	provided	provide	VERB
fnp-4675	377	37	the	the	DET
fnp-4675	377	38	original	original	ADJ
fnp-4675	377	39	author	author	NOUN
fnp-4675	377	40	and	and	CCONJ
fnp-4675	377	41	source	source	NOUN
fnp-4675	377	42	are	be	AUX
fnp-4675	377	43	credited	credit	VERB
fnp-4675	377	44	,	,	PUNCT
fnp-4675	377	45	a	a	DET
fnp-4675	377	46	link	link	NOUN
fnp-4675	377	47	to	to	ADP
fnp-4675	377	48	the	the	DET
fnp-4675	377	49	creative	creative	ADJ
fnp-4675	377	50	commons	common	NOUN
fnp-4675	377	51	license	license	NOUN
fnp-4675	377	52	is	be	AUX
fnp-4675	377	53	provided	provide	VERB
fnp-4675	377	54	,	,	PUNCT
fnp-4675	377	55	and	and	CCONJ
fnp-4675	377	56	any	any	DET
fnp-4675	377	57	changes	change	NOUN
fnp-4675	377	58	are	be	AUX
fnp-4675	377	59	indicated	indicate	VERB
fnp-4675	377	60	.	.	PUNCT
fnp-4675	378	1	the	the	DET
fnp-4675	378	2	creative	creative	ADJ
fnp-4675	378	3	commons	common	NOUN
fnp-4675	378	4	public	public	ADJ
fnp-4675	378	5	domain	domain	NOUN
fnp-4675	378	6	dedication	dedication	NOUN
fnp-4675	378	7	waiver	waiver	NOUN
fnp-4675	378	8	(	(	PUNCT
fnp-4675	378	9	https://creativecommons.org/publicdomain/zero/1.0/	https://creativecommons.org/publicdomain/zero/1.0/	PROPN
fnp-4675	378	10	)	)	PUNCT
fnp-4675	378	11	applies	apply	VERB
fnp-4675	378	12	to	to	ADP
fnp-4675	378	13	the	the	DET
fnp-4675	378	14	data	datum	NOUN
fnp-4675	378	15	made	make	VERB
fnp-4675	378	16	available	available	ADJ
fnp-4675	378	17	in	in	ADP
fnp-4675	378	18	this	this	DET
fnp-4675	378	19	article	article	NOUN
fnp-4675	378	20	,	,	PUNCT
fnp-4675	378	21	unless	unless	SCONJ
fnp-4675	378	22	otherwise	otherwise	ADV
fnp-4675	378	23	stated	state	VERB
fnp-4675	378	24	.	.	PUNCT